13. 多発性硬化症/視神経脊髄炎 [臨床試験数:1,398,薬物数:1,426(DrugBank:306),標的遺伝子数:216,標的パスウェイ数:210]
Searched query = "Multiple sclerosis", "Neuromyelitis optica", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02912897 | September 2020 | 22 October 2019 | Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy With Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients With a First Clinical Episode Highly Suggestive of Multiple Sclerosis | An Open Single-center, Phase I Proof of Concept Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy With Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients With a First Clinical Episode Highly Suggestive of Multiple Sclerosis | Multiple Sclerosis | Biological: Cellular therapy with EBV specific autologous CTL infusion | Nantes University Hospital | Not recruiting | 18 Years | 45 Years | All | 7 | Phase 1 | France | |
2 | NCT03404388 | April 1, 2020 | 29 July 2019 | Brain and Behavioral Influences on Motor Skill Learning in Multiple Sclerosis | Brain and Behavioral Influences on Motor Skill Learning in Multiple Sclerosis | Multiple Sclerosis | Behavioral: Balance Training | Wayne State University | Recruiting | 18 Years | 65 Years | All | 150 | N/A | United States | |
3 | NCT04150549 | February 2020 | 11 November 2019 | FMT for MS Patients | Fecal Microbial Transplantation for Relapsing Multiple Sclerosis Patients - a Placebo-controlled, Double-blinded, Randomized Trial | Multiple Sclerosis | Biological: Fecal Microbial Transplants | Lawson Health Research Institute | Not recruiting | 18 Years | 55 Years | All | 34 | Phase 2 | ||
4 | NCT04140305 | January 5, 2020 | 4 November 2019 | Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) | A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) | Multiple Sclerosis | Drug: RPC-1063 | Celgene | Not recruiting | 18 Years | 65 Years | All | 250 | Phase 3 | ||
5 | NCT04079088 | December 23, 2019 | 7 October 2019 | Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-ß1) in Relapsing Multiple Sclerosis (RMS) | A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Oral BIIB061 as Add-On Therapy to Interferon-Beta 1 Therapies in Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | Drug: Placebo;Drug: BIIB061;Biological: Interferon-beta1 | Biogen | Not recruiting | 18 Years | 55 Years | All | 300 | Phase 2 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT04075266 | December 11, 2019 | 4 November 2019 | A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis | An Open-Label, Parallel-Group Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Ocrelizumab | Hoffmann-La Roche | Not recruiting | 10 Years | 18 Years | All | 12 | Phase 2 | United States;Italy | |
7 | NCT04130997 | December 2019 | 11 November 2019 | An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis | TG1101-RMS303 is an Open-label, Single-arm Extension Study Designed to Evaluate Long-term Safety and Efficacy of Ublituximab in Subjects With Relapsing Multiple Sclerosis. Subjects Who Complete the 96-week, Double-blind Treatment Period o TG1101-RMS301 or TG1101-RMS302 Are Eligible for Participation in This Open Label Extension (OLE) Study. | Relapsing Multiple Sclerosis (RMS) | Biological: Ublituximab | TG Therapeutics, Inc. | Not recruiting | 18 Years | N/A | All | 1000 | Phase 3 | ||
8 | NCT04025554 | November 13, 2019 | 11 November 2019 | Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis | Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis | Multiple Sclerosis | Drug: Anakinra | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | 18 Years | 100 Years | All | 10 | Phase 1/Phase 2 | United States | |
9 | NCT04146285 | November 5, 2019 | 4 November 2019 | A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders | A Phase I Clinical Trial of BAT4406F Injection on the Safety, Tolerability, and Pharmacokinetics in Patients With Neuromyelitis Optica Spectrum Disorders | Neuromyelitis Optica Spectrum Disorders | Drug: BAT4406F | Bio-Thera Solutions | Not recruiting | 18 Years | 65 Years | All | 48 | Phase 1 | China | |
10 | NCT03829566 | November 2019 | 11 November 2019 | Autologous Transplant To End NMO Spectrum Disorder | Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD) | Neuromyelitis Optica;Devic's Disease;NMO Spectrum Disorder | Drug: Rituximab;Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;Biological: IVIg;Biological: Autologous Stem Cells | Northwestern University | Not recruiting | 18 Years | 65 Years | All | 0 | Phase 2/Phase 3 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
11 | NCT03983720 | November 2019 | 28 October 2019 | Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis? | Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis? | Sclerosis, Multiple | Other: Evaluation of degree chronic fatigue.;Other: Questionnaires;Biological: Blood sample;Other: Cardiopulmonary evaluation;Device: Capacity of muscular oxygen extraction;Device: Sleep assessment;Device: Metabolic fatigue;Other: Neuromuscular evaluation | Centre Hospitalier Universitaire de Saint Etienne | Not recruiting | 18 Years | 70 Years | All | 60 | Phase 2 | France | |
12 | NCT04038541 | November 2019 | 28 October 2019 | Prebiotic vs Probiotic in Multiple Sclerosis | Prebiotic and Probiotic Treatment Trial in Multiple Sclerosis | Multiple Sclerosis;Clinically Isolated Syndrome (CIS) | Dietary Supplement: Prebiotics (Prebiotin Prebiotic Fiber Stick Pac);Dietary Supplement: Probiotics (Visbiome®) | Columbia University | Recruiting | 18 Years | N/A | All | 20 | N/A | United States | |
13 | NCT04047628 | November 2019 | 4 November 2019 | Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) | A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI) | Relapsing Multiple Sclerosis;Relapsing Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis | Procedure: Autologous Hematopoietic Stem Cell Transplantation;Biological: Best Available Therapy (BAT) | National Institute of Allergy and Infectious Diseases (NIAID) | Immune Tolerance Network (ITN) | Not recruiting | 18 Years | 55 Years | All | 156 | Phase 3 | United States;United Kingdom |
14 | NCT04155424 | November 2019 | 11 November 2019 | A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder | A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients With Relapsing Neuromyelitis Optica Spectrum Disorder | Neuromyelitis Optica;Neuromyelitis Optica Spectrum Disorder | Drug: Eculizumab | Alexion Pharmaceuticals | Not recruiting | 2 Years | 17 Years | All | 15 | Phase 2/Phase 3 | United States;Canada;Germany;Italy;Japan;Korea, Republic of;Spain | |
15 | NCT03958877 | October 31, 2019 | 22 October 2019 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension | Multiple Sclerosis, Relapsing-Remitting | Drug: BIIB017 (peginterferon beta-1a);Drug: Interferon beta type 1a | Biogen | Recruiting | 10 Years | 18 Years | All | 142 | Phase 3 | United States;Bulgaria;Czechia;France;Italy;Spain;Greece | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
16 | NCT04096443 | October 14, 2019 | 30 September 2019 | Oral FMT (Fecal Microbial Transplant) in Subjects With Multiple Sclerosis | A Pilot Study of Oral FMT (Fecal Microbial Transplant) in Subjects With Multiple Sclerosis | Multiple Sclerosis | Biological: Fecal microbial transplant (FMT) | Griffin Hospital | Yale-Griffin Prevention Research Center;Multiple Sclerosis Treatment Center, Derby, Connecticut | Recruiting | 18 Years | 40 Years | All | 15 | Early Phase 1 | United States |
17 | NCT04129736 | October 10, 2019 | 28 October 2019 | Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis | Determination of Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis Treated With Teriflunomide 14 mg Daily. | Multiple Sclerosis, Pharmacokinetics | Drug: Teriflunomide 14 MG | Jan Lycke | Recruiting | 18 Years | 65 Years | All | 20 | Phase 4 | Sweden | |
18 | NCT04115488 | October 1, 2019 | 11 November 2019 | Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® | Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) | Relapsing-Remitting Multiple Sclerosis (RRMS) | Biological: Intravenous (IV) infusions | Polpharma Biologics S.A. | Recruiting | 18 Years | 60 Years | All | 260 | Phase 3 | Poland | |
19 | NCT03963375 | October 2019 | 14 October 2019 | Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis | Cladribine Tablets: Collaborative Study to Evaluate the Impact On Central Nervous System Biomarkers in Multiple Sclerosis | Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting | Drug: Cladribine | Washington University School of Medicine | EMD Serono | Recruiting | 18 Years | 65 Years | All | 50 | Phase 4 | United States |
20 | NCT04121403 | October 2019 | 22 October 2019 | Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) | Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) A Prospective Randomized Open-label Blinded Endpoint (PROBE) Multicenter Non-inferiority Study | Relapsing Multiple Sclerosis;Multiple Sclerosis | Biological: Rituximab;Drug: Cladribine | Oslo University Hospital | University of Oslo;Göteborg University;Sykehuset Ostfold;Sykehuset Telemark;Vestre Viken Hospital Trust;Sorlandet Hospital HF;Helse Stavanger HF;Sykehuset Innlandet HF;Sykehuset i Vestfold HF;Helse Forde;University Hospital of North Norway | Recruiting | 18 Years | 65 Years | All | 264 | Phase 3 | Norway |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
21 | NCT04121468 | October 2019 | 22 October 2019 | A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis | A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis | Multiple Sclerosis (MS) | Drug: Metformin;Other: Placebo | The Hospital for Sick Children | Queen's University;Ontario Institute for Regenerative Medicine | Not recruiting | 10 Years | 18 Years | All | 30 | Phase 1/Phase 2 | |
22 | NCT04144257 | October 2019 | 4 November 2019 | Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue | Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue | Multiple Sclerosis | Drug: [F-18]PBR06;Drug: [C-11]Methylreboxetine | Brigham and Women's Hospital | United States Department of Defense | Not recruiting | 18 Years | 60 Years | All | 12 | Phase 1/Phase 2 | United States |
23 | NCT03807973 | September 30, 2019 | 30 September 2019 | Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes. | Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes. | Fibromyalgia;Chronic Fatigue Syndrome;Multiple Sclerosis;Healthy | Drug: [Zr-89]Oxine-labeled leukocytes PET/MR | University of Alabama at Birmingham | Not recruiting | 18 Years | 65 Years | All | 120 | Phase 1 | ||
24 | NCT03996291 | September 23, 2019 | 14 October 2019 | Long Term Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis | Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | Drug: SAR442168 | Sanofi | Recruiting | 18 Years | 55 Years | All | 105 | Phase 2 | United States | |
25 | NCT04035889 | September 23, 2019 | 7 October 2019 | Melatonin for Sleep in MS | A Randomized, Crossover Pilot Trial of Melatonin for Sleep Disturbance in Adults With Multiple Sclerosis (MS) | Multiple Sclerosis | Dietary Supplement: Placebo;Dietary Supplement: Melatonin | University of California, San Francisco | Recruiting | 20 Years | 70 Years | All | 30 | N/A | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
26 | NCT04121221 | September 19, 2019 | 22 October 2019 | A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS | A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Safety and Tolerability of GA Depot, a Long Acting IM Injection of Glatiramer Acetate, Once Monthly Compared to Placebo | Multiple Sclerosis, Relapsing-Remitting | Drug: GA Depot;Other: Placebo | Mapi Pharma Ltd. | Recruiting | 18 Years | 55 Years | All | 960 | Phase 3 | United States | |
27 | NCT04002934 | September 10, 2019 | 11 November 2019 | Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis | A Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Delayed-Start Trial to Assess the Efficacy, Safety, and Tolerability of Bazedoxifene Acetate (BZA) as a Remyelinating Agent in Patients With Multiple Sclerosis | Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting | Drug: Bazedoxifene Acetate | Riley Bove, MD | Recruiting | 40 Years | 65 Years | Female | 50 | Phase 2 | United States | |
28 | ChiCTR1900025744 | 2019-09-01 | 30 September 2019 | Clinical effectiveness and safety of Rituximab (Henlius) for optic neuritis secondary to neuromyelitis optica spectrum disorder: a pilot clinical trial | Clinical effectiveness and safety Rituximab (Henlius) for optic neuritis secondary to neuromyelitis optica spectrum disorder: a pilot clinical trial | neuromyelitis optica spectrum disorder (NMOSD) | 1:Intravenous 200mg Rituximab, 1/week*2, if the proportion of CD19+ B lymphocytes in peripheral blood is above 1% then repeat administration (200mg);2:Oral azathioprine (2.5-3 mg/kg bodyweight/day) or mycophenolate mofetil (750~3000mg/day); | The Ophthalmology Department of the Chinese Peoples Liberation Army Hospital | Recruiting | 18 | 70 | Both | 1:30;2:30; | Phase 4 | China | |
29 | NCT03993171 | September 2019 | 16 September 2019 | 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis (REPAIR-MS) | A Phase 2, Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: gold nanocrystals | Clene Nanomedicine | University of Texas Southwestern Medical Center | Not recruiting | 18 Years | 55 Years | All | 24 | Phase 2 | United States |
30 | NCT04032158 | August 26, 2019 | 11 November 2019 | Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS) | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety | Relapsing-remitting Multiple Sclerosis | Drug: Evobrutinib;Drug: Avonex®;Drug: Placebo | EMD Serono Research & Development Institute, Inc. | Merck KGaA, Darmstadt, Germany | Recruiting | 18 Years | 55 Years | All | 950 | Phase 3 | United States;Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Montenegro;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
31 | NCT04032171 | August 19, 2019 | 29 July 2019 | Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety | Relapsing-remitting Multiple Sclerosis | Drug: Evobrutinib;Drug: Avonex®;Drug: Placebo | EMD Serono Research & Development Institute, Inc. | Merck KGaA, Darmstadt, Germany | Not recruiting | 18 Years | 55 Years | All | 950 | Phase 3 | United States;Germany |
32 | NCT03961204 | August 15, 2019 | 22 October 2019 | Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for Multiple Sclerosis (MS) | Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials | Multiple Sclerosis | Drug: Cladribine | EMD Serono Research & Development Institute, Inc. | Merck KGaA, Darmstadt, Germany | Recruiting | 18 Years | 65 Years | All | 971 | Phase 4 | United States;Georgia;Korea, Republic of;Germany |
33 | NCT03972306 | August 12, 2019 | 28 October 2019 | A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis | A Phase Ib, Open-Label, Multicenter Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis | Multiple Sclerosis (MS) | Drug: Ocrelizumab;Drug: rHuPH20 | Hoffmann-La Roche | Recruiting | 18 Years | 65 Years | All | 135 | Phase 1 | United States | |
34 | NCT04035005 | August 12, 2019 | 22 October 2019 | A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Drug: Ocrelizumab;Drug: Placebo | Hoffmann-La Roche | Recruiting | 18 Years | 65 Years | All | 1000 | Phase 3 | United States;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom | |
35 | JPRN-JapicCTI-194838 | 31/7/2019 | 10 September 2019 | Investigation for immune response against JC virus in Multiple Sclerosis patients on treatment with fingolimod | A 18-month, multicenter, two-cohort, prospective, observational study to investigate immune response against JC virus in Multiple Sclerosis patients on treatment with 0.5 mg fingolimod (FTY720) | Multiple Sclerosis | Intervention name : Gilenya / Imusera INN of the intervention : Fingolimod Dosage And administration of the intervention : 0.5mg/day Fingolimod orally Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | Novartis Pharma K.K. | Mitsubishi Tanabe Pharma Corporation | Recruiting | 18 | BOTH | 280 | NA | Japan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
36 | NCT03933202 | July 22, 2019 | 22 October 2019 | A Study of Suboptimally Controlled Participants Previously Taking Oral Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) | Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Oral Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) (MASTER-2) | Multiple Sclerosis | Drug: Cladribine Tablets | EMD Serono Research & Development Institute, Inc. | Merck KGaA, Darmstadt, Germany | Recruiting | 18 Years | N/A | All | 200 | N/A | United States |
37 | NCT04022473 | July 7, 2019 | 29 July 2019 | Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers | A Randomized, Double-Blind Study to Compare Gastrointestinal Tolerability Following Oral Administration of Bafiertam™ (Monomethyl Fumarate) or Tecfidera® (Dimethyl Fumarate) to Healthy Male and Female Volunteers | Multiple Sclerosis | Drug: Bafiertam;Drug: Tecfidera | Banner Life Sciences LLC | Recruiting | 18 Years | 65 Years | All | 200 | Phase 1 | United States | |
38 | NCT03983252 | July 2019 | 24 June 2019 | Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis | Effect of Alemtuzumab on Microglial Activation Assessed Using Novel [F-18]-Based Positron Emission Tomography (PET) Ligand in Multiple Sclerosis | Multiple Sclerosis | Drug: [F-18]PBR06 | Brigham and Women's Hospital | Genzyme, a Sanofi Company | Not recruiting | 18 Years | 60 Years | All | 10 | Phase 1/Phase 2 | United States |
39 | NCT03656627 | June 27, 2019 | 22 October 2019 | Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease | Safety, Activity, and Pharmacology of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease | Autoimmune Diseases;Non-small Cell Lung Cancer;Rheumatoid Arthritis;Psoriasis;Giant Cell Arteritis;Polymyalgia Rheumatica;Systemic Lupus Erythematosus;Crohn Disease;Multiple Sclerosis;Ulcerative Colitis | Drug: Nivolumab | Alliance Foundation Trials, LLC. | Bristol-Myers Squibb | Recruiting | 18 Years | N/A | All | 72 | Phase 1 | United States |
40 | NCT03774407 | June 20, 2019 | 2 September 2019 | Vaginal Estriol in Multiple Sclerosis | Dual Benefits of Vaginal Estriol: Improved Urogenital Health and Re-myelination in Relapsing Remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis;Neurogenic Bladder | Drug: vaginal estriol | Texas Tech University Health Sciences Center | Recruiting | 40 Years | 65 Years | Female | 20 | Phase 2/Phase 3 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
41 | NCT03887065 | June 15, 2019 | 20 May 2019 | Magnetic Resonance Imaging Study of JM-4 in Multiple Sclerosis/Clinically Patients | Magnetic Resonance Imaging 12 Day Study for Multiple Sclerosis/Clinically Isolated Syndrome Trial of JM-4 Novel Human Peptide | Multiple Sclerosis | Drug: JM-4 | Cook, Stuart, MD | Not recruiting | 18 Years | 55 Years | All | 15 | Early Phase 1 | ||
42 | NCT03995810 | June 15, 2019 | 15 July 2019 | Oral Carnosine for Neuromuscular Performance in Multiple Sclerosis | Oral Carnosine for Neuromuscular Performance, Brain Biomarkers of Carnosine Metabolism and Health-related Quality of Life in Multiple Sclerosis | Multiple Sclerosis | Dietary Supplement: Carnosine, capsulle, 2 g/day, 8 weeks | University of Novi Sad, Faculty of Sport and Physical Education | CarnoMed | Recruiting | 18 Years | 65 Years | All | 3 | N/A | Serbia |
43 | NCT03873389 | June 12, 2019 | 15 July 2019 | Ocrelizumab Effects on the Metabolome in MS | Evaluating the Effects of Ocrelizumab on the Circulating Metabolome in Multiple Sclerosis (MS) | Multiple Sclerosis | Drug: Ocrelizumab | Johns Hopkins University | Genentech, Inc. | Recruiting | 18 Years | 75 Years | All | 50 | Phase 1 | United States |
44 | NCT03783416 | June 1, 2019 | 21 January 2019 | SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis | Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis: A Phase 1b Randomised, Double-blind, Placebo-controlled Trial. | Relapsing Remitting Multiple Sclerosis;Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis | Drug: Ixazomib (NINLARO®) capsules / Matching placebo capsules | Queen Mary University of London | Takeda Pharmaceuticals International, Inc. | Not recruiting | 18 Years | 65 Years | All | 72 | Phase 1 | United Kingdom |
45 | NCT03910738 | June 2019 | 23 April 2019 | TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis | TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection;Drug: Placebo 4 mL Solution for Injection;Procedure: MRI;Behavioral: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities;Behavioral: Assessment of disability | University Hospital, Strasbourg, France | Bayer;Fédération Hospitalo-Universitaire NEUROGENYCS | Not recruiting | 18 Years | 55 Years | Male | 40 | Phase 2 | France |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
46 | NCT03933215 | May 21, 2019 | 22 October 2019 | A Study of Suboptimally Controlled Participants Previously Taking Injectable Disease-modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) | Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Injectable Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) (CLICK-MS) | Multiple Sclerosis | Drug: Cladribine Tablets | EMD Serono Research & Development Institute, Inc. | Merck KGaA, Darmstadt, Germany | Recruiting | 18 Years | N/A | All | 200 | N/A | United States |
47 | NCT03824938 | April 30, 2019 | 15 July 2019 | Aspirin for Exercise in Multiple Sclerosis (ASPIRE) | Aspirin for Exercise in Multiple Sclerosis (ASPIRE): A Double-Blind RCT of Aspirin or Acetaminophen Pretreatment to Improve Exercise Performance in Multiple Sclerosis (MS) | Multiple Sclerosis | Drug: Aspirin 650mg Oral Capsule;Drug: Acetaminophen Tab 650mg;Other: Placebo | Columbia University | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Recruiting | 18 Years | 65 Years | All | 60 | Phase 1/Phase 2 | United States |
48 | NCT03816345 | April 4, 2019 | 11 November 2019 | Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer | A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO) | Advanced Malignant Neoplasm;Autoimmune Disease;Crohn Disease;Dermatomyositis;Inflammatory Bowel Disease;Metastatic Malignant Neoplasm;Multiple Sclerosis;Rheumatoid Arthritis;Sjogren Syndrome;Systemic Lupus Erythematosus;Systemic Scleroderma;Ulcerative Colitis;Unresectable Malignant Neoplasm | Biological: Nivolumab | National Cancer Institute (NCI) | Recruiting | 18 Years | N/A | All | 264 | Phase 1 | United States | |
49 | NCT03025269 | April 2, 2019 | 29 April 2019 | Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis | Effect of Ocrelizumab on Gray Matter Pathology, Leptomeningeal Inflammation and Cognitive Dysfunction in Multiple Sclerosis | Multiple Sclerosis | Drug: Ocrelizumab | University at Buffalo | Recruiting | 18 Years | 60 Years | All | 30 | N/A | United States | |
50 | NCT03853746 | April 1, 2019 | 27 May 2019 | Short-term B-cell Depletion in Relapsing Multiple Sclerosis | Evaluating the Effects of Short-term B-cell Depletion on Long-term Disease Activity and Immune Tolerance in Relapsing Multiple Sclerosis | Multiple Sclerosis | Drug: Ocrelizumab | Johns Hopkins University | National Multiple Sclerosis Society | Recruiting | 18 Years | 99 Years | All | 10 | Phase 4 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
51 | NCT03888924 | April 1, 2019 | 1 April 2019 | Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS) | Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS) | Multiple Sclerosis | Drug: Placebo;Drug: Bacille Calmette-Guerin vaccine | S. Andrea Hospital | Not recruiting | 18 Years | N/A | All | 100 | Phase 2 | Italy | |
52 | NCT02466074 | April 2019 | 19 November 2018 | Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis | Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis | Multiple Sclerosis | Drug: Acetazolamide;Drug: Placebo | The University of Texas Health Science Center, Houston | Not recruiting | 18 Years | 55 Years | All | 60 | Phase 2 | United States | |
53 | NCT03856619 | March 27, 2019 | 15 April 2019 | To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis | A Single Arm Phase IV Clinical Trial to Describe the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis | Relapsing Multiple Sclerosis | Drug: TERIFLUNOMIDE HMR1726 | Sanofi | Recruiting | 18 Years | N/A | All | 193 | Phase 4 | India | |
54 | NCT03945006 | March 25, 2019 | 20 May 2019 | Balance, Trunk Impairment and Fear of Falling in Multiple Sclerosis Patients With Incontinence | An Investigation of Balance, Trunk Impairment, and Fear of Falling in Multiple Sclerosis Patients With Incontinence | Multiple Sclerosis;Physical Therapy;Incontinence | Other: Incontinence Severity;Other: Balance;Other: Trunk impairment;Other: Fear of falling | Ankara Yildirim Beyazit University | Not recruiting | 24 Years | 58 Years | All | 36 | N/A | Turkey | |
55 | NCT03870763 | March 19, 2019 | 28 October 2019 | Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants | A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Dimethyl Fumarate;Drug: Peginterferon Beta-1a;Drug: Placebo | Biogen | Recruiting | 10 Years | 17 Years | All | 340 | Phase 3 | United States;Colombia;Estonia;Hungary;Korea, Republic of;Taiwan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
56 | EUCTR2018-003927-12-SK | 18/03/2019 | 30 April 2019 | Dose-finding study for SAR442168 in relapsing multiple sclerosis | A Phase 2b dose-finding study for SAR442168, a Bruton's tyrosine kinase inhibitor, in participants with relapsing multiple sclerosis | Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10067063 Term: Progressive relapsing multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: SAR442168 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Not available CAS Number: 1971920-73-6 Current Sponsor code: SAR442168 Other descriptive name: PRN2246 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- INN or Proposed INN: Not available CAS Number: 1971920-73-6 Current Sponsor code: SAR442168 Other descriptive name: PRN2246 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Genzyme Corporation | Authorised | Female: yes Male: yes | 160 | Phase 2 | France;United States;Estonia;Czech Republic;Slovakia;Canada;Spain;Ukraine;Russian Federation;Norway;Netherlands;Sweden | |||
57 | NCT03799718 | March 13, 2019 | 26 August 2019 | Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS | A Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn® [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MS | Multiple Sclerosis, Chronic Progressive | Biological: NurOwn (MSC-NTF cells) | Brainstorm-Cell Therapeutics | Recruiting | 18 Years | 65 Years | All | 20 | Phase 2 | United States | |
58 | EUCTR2018-000516-22-HU | 04/03/2019 | 30 April 2019 | Study to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants | A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: TECFIDERA Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Plegridy Product Name: PEGylated Interferon Beta-1a Product Code: BIIB017 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: PEGINTERFERON BETA-1A CAS Number: 1211327-92-2 Current Sponsor code: BIIB017 Other descriptive name: PEGINTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: up to Concentration number: 125- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use | Biogen Idec Research Limited | Authorised | Female: yes Male: yes | 340 | Phase 3 | Serbia;Portugal;United States;Saudi Arabia;Taiwan;Estonia;Greece;Thailand;Turkey;Russian Federation;Israel;Colombia;Italy;Hungary;Mexico;Jordan;Malaysia;Croatia;Bulgaria;Tunisia;Korea, Republic of | |||
59 | NCT03896217 | March 2019 | 8 April 2019 | Simvastatin in Secondary Progressive Multiple Sclerosis | A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis: Impact on Vascular Perfusion and Oxidative Damage | Secondary Progressive Multiple Sclerosis | Drug: Simvastatin | University College, London | MS Society | Not recruiting | 18 Years | 65 Years | All | 40 | Phase 2 | United Kingdom |
60 | NCT03737812 | February 27, 2019 | 4 November 2019 | A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis | A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis | Multiple Sclerosis (MS) | Drug: elezanumab;Drug: placebo | AbbVie | Recruiting | 18 Years | 65 Years | All | 90 | Phase 2 | United States;Canada | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
61 | NCT03808142 | February 20, 2019 | 4 November 2019 | PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon | PROmyBETAappGame: Ascertaining Medication Usage & Patient Reported Outcomes Via the myBETAapp and Exploring Gamification in Patients With Multiple Sclerosis Treated With Betaferon | Multiple Sclerosis | Other: myBETAapp;Other: PEAK;Drug: Betaferon, BAY 86-5046;Device: BETACONNECT | Bayer | Recruiting | 18 Years | N/A | All | 200 | Phase 2 | Germany | |
62 | NCT03756974 | February 18, 2019 | 11 November 2019 | BX-1 in Spasticity Due to Multiple Sclerosis | A Phase III, Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Investigate the Efficacy and Safety of BX-1 for the Symptomatic Relief of Spasticity in Patients With Multiple Sclerosis (MS) | Spasticity Due to Multiple Sclerosis | Drug: BX-1;Drug: Placebo | Bionorica SE | Recruiting | 18 Years | 65 Years | All | 384 | Phase 3 | Czechia;Germany;Hungary;Poland;Spain | |
63 | NCT03752307 | February 15, 2019 | 13 May 2019 | Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses | Double-blind, Placebo-controlled, Randomized Study of the Safety and Tolerability of Isoxsuprine HCL Combined With High Dose Steroid Treatment of Multiple Sclerosis (MS) Relapse | Multiple Sclerosis | Drug: Isoxsuprine Hydrochloride;Drug: Placebo;Drug: Corticosteroid | University of New Mexico | Recruiting | 18 Years | 50 Years | All | 20 | Phase 1/Phase 2 | United States | |
64 | NCT03623243 | February 14, 2019 | 8 April 2019 | Safety and Tolerability of Conversion From Oral or Injectable Disease Modifying Therapies to Dose-titrated Oral Siponimod in Advancing RMS Patients. | Exploring the Safety and Tolerability of Conversion From Oral or Injectable Disease Modifying Therapies to Dose-titrated Oral Siponimod in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi- Center Phase IIIb Study | Multiple Sclerosis, Relapsing MS, Advancing Multiple Sclerosis | Drug: Siponimod | Novartis Pharmaceuticals | Recruiting | 18 Years | 65 Years | All | 300 | Phase 3 | United States | |
65 | NCT03822858 | February 12, 2019 | 30 September 2019 | Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis | Autologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered Intrathecally | Multiple Sclerosis | Drug: Intrathecal MSC-NP injection | Tisch Multiple Sclerosis Research Center of New York | Not recruiting | 18 Years | 70 Years | All | Phase 2 | United States | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
66 | NCT03759522 | February 3, 2019 | 8 April 2019 | Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714. | Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714. | Fibromyalgia;Chronic Fatigue Syndrome;Multiple Sclerosis;Healthy | Drug: DPA-714 PET/MRI | University of Alabama at Birmingham | Recruiting | 18 Years | 65 Years | All | 120 | Phase 1 | United States | |
67 | NCT03784547 | February 1, 2019 | 26 August 2019 | Real-world Data of Ocrelizumab in Multiple Sclerosis in LATAM | Real-world Patient Profile and Treatment Persistence of Ocrelizumab in Multiple Sclerosis: A Retrospective Analysis in Latin America | Multiple Sclerosis | Drug: Ocrelizumab | Hospital Italiano de Buenos Aires | Recruiting | N/A | N/A | All | 100 | N/A | Argentina | |
68 | NCT03825601 | February 1, 2019 | 11 February 2019 | PET With [18F]Flumazenil as an Index of Neurodegeneration in MS | PET With [18F]Flumazenil as an Index of Neurodegeneration in MS: Sensitivity at an Early Disease Stage and Pathophysiological Meaning | Multiple Sclerosis;Relapsing-Remitting Multiple Sclerosis | Diagnostic Test: PET with [11C]Flumazenil | Institut National de la Santé Et de la Recherche Médicale, France | Not recruiting | 18 Years | 55 Years | All | 45 | N/A | ||
69 | NCT03846219 | January 28, 2019 | 4 March 2019 | MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) | Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial Assessing the Effect of IMU-838 on Disease Activity, as Measured by Magnetic Resonance Imaging (MRI), as Well as Safety and Tolerability in Patients With Relapsing-remitting Multiple Sclerosis (RRMS) | Relapsing-Remitting Multiple Sclerosis (RRMS) | Drug: IMU-838 (30 mg/day);Drug: IMU-838 (45 mg/day);Drug: Placebo | Immunic AG | Recruiting | 18 Years | 55 Years | All | 195 | Phase 2 | Bulgaria | |
70 | NCT03653273 | January 24, 2019 | 18 March 2019 | Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP) | Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years | Multiple Sclerosis | Drug: DMT continuation;Other: DMT withdrawal | Rennes University Hospital | Recruiting | 50 Years | N/A | All | 250 | Phase 3 | France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
71 | NCT03745144 | January 17, 2019 | 28 October 2019 | Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon® | A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the Pharmacokinetics of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With Relapsing Multiple Sclerosis (RMS). | Relapsing Multiple Sclerosis (RMS) | Drug: Cladribine;Drug: Placebo;Drug: Microgynon® | Merck KGaA, Darmstadt, Germany | Recruiting | 18 Years | 45 Years | Female | 34 | Phase 1 | Germany;Poland | |
72 | NCT04086225 | January 17, 2019 | 16 September 2019 | Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon® | A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the Pharmacokinetics of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With Relapsing Multiple Sclerosis (RMS). | Relapsing Multiple Sclerosis (RMS) | Drug: Cladribine;Drug: Placebo;Drug: Microgynon® | Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Recruiting | 18 Years | 45 Years | Female | 34 | Phase 1 | Germany;Poland | |
73 | EUCTR2018-000516-22-EE | 14/01/2019 | 28 February 2019 | Study to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants | A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3- Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: TECFIDERA Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Plegridy Product Name: PEGylated Interferon Beta-1a Product Code: BIIB017 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: PEGINTERFERON BETA-1A CAS Number: 1211327-92-2 Current Sponsor code: BIIB017 Other descriptive name: PEGINTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: up to Concentration number: 125- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use | Biogen Idec Research Limited | Authorised | Female: yes Male: yes | 340 | Phase 3 | Serbia;Portugal;United States;Saudi Arabia;Estonia;Taiwan;Greece;Thailand;Turkey;Russian Federation;Israel;Colombia;Italy;Hungary;Mexico;Jordan;Malaysia;Croatia;Bulgaria;Tunisia;Korea, Republic of | |||
74 | EUCTR2017-004886-29-IE | 11/01/2019 | 28 February 2019 | A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la Roche Sponsored Ocrelizumab Clinical Trial | A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED OCRELIZUMAB PHASE IIIb/IV CLINICAL TRIAL | Multiple sclerosis (MS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- | F. Hoffmann-La Roche Ltd | Authorised | Female: yes Male: yes | 750 | Phase 3 | Estonia;Finland;Spain;Ireland;Turkey;United Kingdom;Italy;France;Czech Republic;Denmark;Netherlands;Norway;Sweden | |||
75 | NCT03803800 | January 9, 2019 | 28 January 2019 | Periodized Rehabilitation and Beta-alanine Supplementation in Multiple Sclerosis | Periodized Rehabilitation and Beta-alanine Supplementation in Multiple Sclerosis | Multiple Sclerosis | Other: Classic, progressive endurance training;Other: Periodized exercise training;Dietary Supplement: beta-alanine | Hasselt University | Recruiting | 18 Years | 75 Years | All | 80 | N/A | Belgium | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
76 | NCT03535298 | January 3, 2019 | 26 August 2019 | Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS | Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Early Highly Effective Therapies Group;Drug: Escalation Therapies Group | The Cleveland Clinic | University of Nottingham | Recruiting | 18 Years | 60 Years | All | 800 | Phase 4 | United States;United Kingdom |
77 | NCT04106830 | January 1, 2019 | 22 October 2019 | Clinical and Imaging Patterns of Neuroinflammation Diseases in China (CLUE) | Prospective Cohort Study of Clinical and Imaging Patterns of Neuroinflammation Diseases (CLUE) | NMO Spectrum Disorder;MRI;Multiple Sclerosis | Drug: Intravenous steroid | Beijing Tiantan Hospital | Recruiting | 16 Years | 80 Years | All | 1000 | N/A | China | |
78 | NCT03650114 | December 28, 2018 | 14 October 2019 | Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS | An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | Biological: Ofatumumab;Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap);Biological: 13-valent pneumococcal conjugate vaccine (13-PCV);Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV);Biological: Seasonal Quadrivalent influenza vaccine;Biological: Keyhole limpet hemocyanin (KLH) neo-antigen | Novartis Pharmaceuticals | Recruiting | 18 Years | N/A | All | 2010 | Phase 3 | United States;Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Japan;Latvia;Lithuania;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom | |
79 | NCT03847545 | December 12, 2018 | 11 March 2019 | Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Speckle Tracking Technique | Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Speckle Tracking | Multiple Sclerosis | Drug: Fampridine | University of Southern Denmark | Odense University Hospital;Sygehus Lillebaelt;University of Miami;Region of Southern Denmark;The Augustinus Foundation, Denmark.;The Lounkaer Foundation;Fonden for scleroseramte paa Fyn;The Danish Multiple Sclerosis Society;The Lily Benthine Lunds Foundation | Recruiting | 18 Years | 100 Years | All | 60 | N/A | Denmark |
80 | NCT03737851 | December 11, 2018 | 4 November 2019 | A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis | A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis (MS) | Drug: elezanumab;Drug: placebo | AbbVie | Recruiting | 18 Years | 65 Years | All | 165 | Phase 2 | United States;Canada | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
81 | EUCTR2018-002315-98-DK | 06/12/2018 | 30 April 2019 | The effect of cannabis products on nerve pain and muscle stiffness in patients with multiple sclerosis and in patients with spinal cord injury. | The effect of medical cannabis on neuropathic pain and spasticity in patients with Multiple Sclerosis and in patients with spinal cord injury. A multicenter national placebo-controlled trial - The effect of medical cannabis on neuropathic pain and spasticity in patients with MS and SCI | Central neuropathic pain and spasticity MedDRA version: 20.0 Level: PT Classification code 10028335 Term: Muscle spasticity System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10077975 Term: Central neuropathic pain System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Cannabidiol capsule 5 mg Product Code: N/A Pharmaceutical Form: Capsule INN or Proposed INN: Cannabidiol CAS Number: 13956-29-1 Other descriptive name: CBD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Dronabinol capsule 2,5 mg Product Code: N/A Pharmaceutical Form: Capsule INN or Proposed INN: DRONABINOL CAS Number: 1972-08-3 Other descriptive name: THC Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Cannabidiol / Dronabinol capsule 5 mg+2,5 mg Product Code: N/A Pharmaceutical Form: Capsule INN or Proposed INN: DRONABINOL CAS Number: 1972-08-3 Other descriptive name: THC Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- INN or Proposed INN: Cannabidiol CAS Number: 13956-29-1 Other descriptive name: CBD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Aarhus Universitetshospital | Authorised | Female: yes Male: yes | 448 | Phase 2 | Denmark | |||
82 | NCT03944447 | December 1, 2018 | 7 October 2019 | Outcomes Mandate National Integration With Cannabis as Medicine | Outcomes Mandate National Integration With Cannabis as Medicine | Chronic Pain;Chronic Pain Syndrome;Chronic Pain Due to Injury;Chronic Pain Due to Trauma;Fibromyalgia;Seizures;Hepatitis C;Cancer;Crohn Disease;HIV/AIDS;Multiple Sclerosis;Traumatic Brain Injury;Sickle Cell Disease;Post Traumatic Stress Disorder;Tourette Syndrome;Ulcerative Colitis;Glaucoma;Epilepsy;Inflammatory Bowel Diseases;Parkinson Disease;Amyotrophic Lateral Sclerosis;Chronic Traumatic Encephalopathy;Anxiety;Depression;Insomnia;Autism;Opioid-use Disorder;Bipolar Disorder | Drug: Cannabis, Medical | OMNI Medical Services, LLC | Recruiting | 7 Years | N/A | All | 100000 | Phase 2 | United States | |
83 | NCT03689972 | November 28, 2018 | 7 October 2019 | A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment | A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment | Multiple Sclerosis, Relapsing-Remitting | Drug: Natalizumab | Biogen | Not recruiting | 18 Years | 60 Years | All | 480 | Phase 3 | United States;Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom | |
84 | NCT03536559 | November 23, 2018 | 28 January 2019 | Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis | A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis;Optic Neuropathy;Optic; Neuritis, With Demyelination | Drug: CNM-Au8;Drug: Placebo | Clene Nanomedicine | Clene Australia Pty Ltd | Recruiting | 18 Years | 50 Years | All | 150 | Phase 2 | Australia |
85 | EUCTR2017-004703-51-SK | 21/11/2018 | 14 January 2019 | Long-term safety, tolerability and effectiveness study of ofatumumab in subjects with relapsing multiple sclerosis | An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis | Multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use | Novartis Pharma AG | Authorised | Female: yes Male: yes | 2233 | Phase 3 | Portugal;United States;Taiwan;Estonia;Slovakia;Greece;Thailand;Spain;Russian Federation;Israel;Italy;Switzerland;India;France;Peru;Australia;Denmark;South Africa;Netherlands;Latvia;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Croatia;Bulgaria;Norway;Germany;Japan;Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
86 | NCT03594487 | November 16, 2018 | 18 December 2018 | Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis | Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis: A Phase 1b Clinical Trial to Evaluate Feasibility, Safety, Tolerability and Effects on Immune Function | Relapsing Remitting Multiple Sclerosis | Drug: FMP30 Donor Stool;Procedure: Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool;Other: Observational Control | University of California, San Francisco | Recruiting | 18 Years | 60 Years | All | 30 | Phase 1 | United States | |
87 | NCT03621761 | November 15, 2018 | 4 November 2019 | Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue | A Randomized Controlled Trial of Telephone-delivered Cognitive Behavioral-therapy, Modafinil, and Combination Therapy of Both Interventions for Fatigue in Multiple Sclerosis | Multiple Sclerosis | Behavioral: Telephone-based Cognitive Behavioral Therapy;Drug: Modafinil | University of Michigan | University of Washington;Patient-Centered Outcomes Research Institute;National Multiple Sclerosis Society | Recruiting | 18 Years | N/A | All | 330 | Phase 4 | United States |
88 | NCT03691077 | November 11, 2018 | 18 December 2018 | Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714 | A Prospective Study Evaluating the Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in Multiple Sclerosis Using PET-MRI With 18F-DPA714 | Multiple Sclerosis;Relapse;Primary Progressive Multiple Sclerosis | Drug: Ocrelizumab | Assistance Publique - Hôpitaux de Paris | Roche Pharma AG;Institut du Cerveau et de la Moelle épinière | Recruiting | 18 Years | 60 Years | All | 51 | Phase 3 | France |
89 | NCT04120675 | November 9, 2018 | 22 October 2019 | Efficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis | Randomized, Double Blind, Controlled Prospective Study, to Evaluate the Therapeutic Effects of Early Harvest Olive Oil in Cognitive Functions of Patients With Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis. | Progressive Multiple Sclerosis | Dietary Supplement: Freshly-Pressed Extra Virgin Olive Oil | Aristotle University Of Thessaloniki | Greek Alzheimer's Association and Related Disorders;YANNI'S OLIVE GROVE | Recruiting | 18 Years | 65 Years | All | 150 | N/A | Greece |
90 | EUCTR2018-000001-23-ES | 06/11/2018 | 7 January 2019 | Clinical study to investigate the efficacy and safety of the test substance BX-1 (dronabinol) for the symptomatic relief of spasticity in patients with multiple sclerosis | A phase III, multi-centre, randomised, double-blind, placebo-controlled, parallel-group clinical trial to investigate the efficacy and safety of BX-1 for the symptomatic relief of spasticity in patients with multiple sclerosis - BX-1 in spasticity due to MS | Symptomatic relief of spasticity in patients with multiple sclerosis MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dronabinol Product Code: BX-1 Pharmaceutical Form: Oral solution INN or Proposed INN: Dronabinol CAS Number: 1972-08-3 Current Sponsor code: BX-1 Other descriptive name: Dronabinol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use | Bionorica SE | Authorised | Female: yes Male: yes | 548 | Phase 3 | Hungary;Spain | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
91 | NCT03283397 | November 4, 2018 | 16 December 2017 | A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS | A Phase IIIb, Multi-center, International, Randomized, Assessor-blind, Active-controlled Parallel Arm Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Neuropeptide Combination of Metenkefalin and Tridecactide (EK-12) in Comparison to Interferon Beta-1a (REBIF®) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis, Relapsing-Remitting | Drug: EK-12;Drug: INF beta-1a | Bosnalijek D.D | MonitorCRO | Not recruiting | 18 Years | 55 Years | All | 400 | Phase 3 | |
92 | NCT03593590 | November 2, 2018 | 11 November 2019 | Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis | A Multicentre Non-interventional Study to Assess the Real-world Effectiveness of Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis - The MuSicalE STUDY | Multiple Sclerosis | Drug: Ocrelizumab | Hoffmann-La Roche | Recruiting | 18 Years | N/A | All | 1250 | Phase 3 | Austria;Belgium;Bulgaria;Colombia;Dominican Republic;Egypt;Italy;Kuwait;Montenegro;Netherlands;Panama;Paraguay;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Slovakia;Spain;Turkey;United Arab Emirates;United Kingdom;Israel | |
93 | EUCTR2018-000001-23-HU | 25/10/2018 | 6 November 2018 | Clinical study to investigate the efficacy and safety of the test substance BX-1 (dronabinol) for the symptomatic relief of spasticity in patients with multiple sclerosis | A phase III, multi-centre, randomised, double-blind, placebo-controlled, parallel-group clinical trial to investigate the efficacy and safety of BX-1 for the symptomatic relief of spasticity in patients with multiple sclerosis - BX-1 in spasticity due to MS | Symptomatic relief of spasticity in patients with multiple sclerosis MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dronabinol Product Code: BX-1 Pharmaceutical Form: Oral solution INN or Proposed INN: Dronabinol CAS Number: 1972-08-3 Current Sponsor code: BX-1 Other descriptive name: Dronabinol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use | Bionorica SE | Authorised | Female: yes Male: yes | 548 | Phase 3 | Hungary | |||
94 | EUCTR2017-004702-17-CZ | 23/10/2018 | 28 February 2019 | A 12 week study to evaluate bioequivalence of ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients. | A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20 mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients | Multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- | Novartis Pharma AG | Authorised | Female: yes Male: yes | 284 | Phase 2 | United States;Estonia;Czech Republic;Poland;Spain;Lithuania;Austria;Russian Federation;Bulgaria;Latvia;Germany;Italy | |||
95 | EUCTR2018-003231-30-ES | 19/10/2018 | 7 January 2019 | EFFECTIVENESS OF REPEATED INJECTIONS OF BOTULINUM TOXIN IN THE GAIT AND QUALITY OF LIFE OF ADULT PATIENTS WITH WEAKNESS AND MUSCLE RIGIDITY DUE TO MULTIPLE ESCLEROSIS | EFFECTIVENESS OF THE REPEATED INFILTRATIONS OF BOTULINUM TOXIN A IN THE GAIT AND QUALITY OF LIFE IN ADULTS WITH SPASTIC PARAPARESIA SECONDARY TO MULTIPLE SCLEROSIS - BOTULINUM TOXIN IN PATIENTS WITH SPASTIC PARAPARESIA ASSOCIATED WITH ESCLEROSIS MULTIPLE | Multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Dysport Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: BOTULINUM TOXIN TYPE A CAS Number: 93384-43-1 Current Sponsor code: Dysport Other descriptive name: BOTULINUM TOXIN TYPE A Concentration unit: U unit(s) Concentration type: range Concentration number: 250-1000 | Aránzazu Vázquez Doce | Authorised | Female: yes Male: yes | 84 | Phase 3 | Spain | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
96 | NCT03740295 | October 5, 2018 | 11 November 2019 | Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis | Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis | Multiple Sclerosis | Dietary Supplement: Coconut oil and epigallocatechin gallate;Other: Placebo | Fundación Universidad Católica de Valencia San Vicente Mártir | Valencian Institute of Neurorehabilitation Foundation | Not recruiting | 19 Years | 65 Years | All | 60 | Phase 2 | Spain |
97 | NCT03674099 | October 1, 2018 | 26 August 2019 | Imatinib for Multiple Sclerosis (MS) Relapses | Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study | Multiple Sclerosis | Drug: Imatinib Mesylate;Drug: Methylprednisolone | Tomas Olsson | The Swedish Research Council | Recruiting | 18 Years | 55 Years | All | 200 | Phase 2 | Denmark;Norway;Sweden |
98 | NCT03396822 | September 24, 2018 | 7 October 2019 | Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis | Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis | Multiple Sclerosis | Drug: Gadoteridol | University of Maryland, Baltimore | Genentech, Inc. | Recruiting | 18 Years | 65 Years | All | 22 | Phase 1 | United States |
99 | NCT03355365 | September 21, 2018 | 11 June 2019 | Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis | Autologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered Intrathecally | Multiple Sclerosis | Biological: Intrathecal MSC-NP injection;Other: Intrathecal saline injection | Tisch Multiple Sclerosis Research Center of New York | Recruiting | 18 Years | 65 Years | All | 50 | Phase 2 | United States | |
100 | EUCTR2017-004702-17-EE | 17/09/2018 | 1 October 2018 | A 12 week study to evaluate bioequivalence of ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients. | A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20 mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients | Multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- | Novartis Pharma AG | Authorised | Female: yes Male: yes | 284 | Phase 2 | United States;Czech Republic;Estonia;Poland;Spain;Lithuania;Austria;Russian Federation;Bulgaria;Latvia;Germany;Italy | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
101 | NCT03166800 | September 15, 2018 | 15 July 2019 | MitoQ for Fatigue in Multiple Sclerosis | MitoQ for Fatigue in Multiple Sclerosis: a Placebo Controlled Trial | Multiple Sclerosis;Fatigue | Drug: Mitoquinone | Oregon Health and Science University | MitoQ Ltd | Recruiting | 18 Years | 70 Years | All | 60 | Phase 1/Phase 2 | United States |
102 | NCT03606460 | September 14, 2018 | 30 September 2019 | A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS) | A Phase IIIb, Open-Label Study To Evaluate The Safety And Tolerability Of Shorter Infusions Of Ocrelizumab In Patients With Primary Progressive And Relapsing Multiple Sclerosis | Multiple Sclerosis | Drug: Ocrelizumab Dose 1;Drug: Ocrelizumab Dose 2 and Dose 3 | Genentech, Inc. | Not recruiting | 18 Years | 55 Years | All | 140 | Phase 3 | United States | |
103 | EUCTR2017-004158-40-FR | 11/09/2018 | 30 April 2019 | NA | A Prospective study evaluating the effect of ocrelizumab on brain innate immune Microglial cells Activation in Multiple Sclerosis using PET-MRI with 18F-DPA714 - INN-MS | Patients with Relapsing MS or primary progressive MS MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ocrevus Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab Other descriptive name: ocrelizumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Authorised | Female: yes Male: yes | 71 | Phase 3 | France | |||
104 | EUCTR2017-004702-17-AT | 01/09/2018 | 19 November 2018 | A 12 week study to evaluate bioequivalence of ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients. | A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20 mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients | Multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- | Novartis Pharma AG | Authorised | Female: yes Male: yes | 284 | Phase 2 | United States;Estonia;Czech Republic;Poland;Spain;Lithuania;Austria;Russian Federation;Bulgaria;Latvia;Germany;Italy | |||
105 | NCT03605238 | August 15, 2018 | 30 September 2019 | Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20 | Clinical Study of CD19/CD20 tanCAR T Cells in Relapsed and/or Refractory AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders (NMOSD) | Neuromyelitis Optica Spectrum Disorder | Biological: Corticosteroids & tanCART19/20 | Chinese PLA General Hospital | Not recruiting | 12 Years | 75 Years | All | 0 | Phase 1 | China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
106 | NCT03500289 | August 10, 2018 | 16 September 2019 | Ketamine for Treatment of MS Fatigue | Ketamine for Treatment of Multiple Sclerosis-related Fatigue | Multiple Sclerosis;Fatigue | Drug: Ketamine;Drug: Midazolam | Johns Hopkins University | National Multiple Sclerosis Society | Not recruiting | 18 Years | 65 Years | All | 18 | Phase 1/Phase 2 | United States |
107 | EUCTR2017-004886-29-CZ | 08/08/2018 | 7 January 2019 | A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la Roche Sponsored Ocrelizumab Clinical Trial | A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED OCRELIZUMAB PHASE IIIb/IV CLINICAL TRIAL | Multiple sclerosis (MS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- | F. Hoffmann-La Roche Ltd | Authorised | Female: yes Male: yes | 750 | Phase 3 | Estonia;Finland;Spain;Ireland;Turkey;United Kingdom;Italy;France;Czech Republic;Denmark;Netherlands;Norway;Sweden | |||
108 | NCT03589105 | August 6, 2018 | 30 September 2019 | A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting | An Open-Label, Single-Arm Phase IV Study To Assess Ocrelizumab Efficacy, Safety, And Impact On Patient Reported Outcomes (PROS) In Patients With Active Relapsing Multiple Sclerosis | Multiple Sclerosis | Drug: Ocrelizumab 300 mg;Drug: Ocrelizumab 600 mg | Hoffmann-La Roche | Not recruiting | 18 Years | N/A | All | 423 | Phase 4 | France | |
109 | NCT03584672 | August 5, 2018 | 23 July 2018 | The Reliability, Validity, and Responsiveness of the Static Balance Test in Patients With Multiple Sclerosis. | The Reliability, Validity, and Responsiveness of the Static Balance Test in Patients With Multiple Sclerosis. | Multiple Sclerosis | Other: One-leg Stance Test;Other: Functional Reach Test;Other: Four Square Step Test;Other: Timed Up an Go Test;Other: Berg Balance Scale;Other: Static Balance Test | Gazi University | Not recruiting | 18 Years | N/A | All | 30 | N/A | ||
110 | NCT03562975 | July 23, 2018 | 4 November 2019 | Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus | A Single-center Prospective Measurement of Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus™ | Multiple Sclerosis;Pathologic Processes;Demyelinating Diseases;Nervous System Diseases;Autoimmune Diseases;Immune System Diseases;Primary Progressive Multiple Sclerosis;Relapsing Remitting Multiple Sclerosis | Drug: Ocrelizumab | University of South Florida | Genentech, Inc. | Recruiting | 18 Years | 70 Years | All | 35 | Phase 3 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
111 | NCT03567057 | July 18, 2018 | 10 September 2018 | A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment | A Multicenter, Open-Label Safety and Efficacy Study of ADS-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment | Multiple Sclerosis;Walking Impairment | Drug: ADS-5102 | Adamas Pharmaceuticals, Inc. | Recruiting | 18 Years | 70 Years | All | 540 | Phase 3 | United States | |
112 | NCT03979456 | July 4, 2018 | 24 June 2019 | RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS | RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS. A Randomized Trial of Long-term Dosage of Rituximab in Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Rituximab | Karolinska Institutet | Recruiting | 20 Years | 52 Years | All | 200 | Phase 3 | Sweden | |
113 | NCT03000127 | July 1, 2018 | 11 November 2019 | Testosterone for Fatigue in Men With MS | A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis | Multiple Sclerosis | Drug: AndroGel 1 % Topical Gel;Drug: Placebos | University of California, Los Angeles | Washington University School of Medicine | Not recruiting | 18 Years | 60 Years | Male | 0 | Phase 2 | United States |
114 | NCT03161028 | July 1, 2018 | 11 November 2019 | Lipoic Acid for Progressive Multiple Sclerosis (MS) | Lipoic Acid for the Treatment of Progressive Multiple Sclerosis | Multiple Sclerosis | Drug: Lipoic acid;Drug: Placebo | VA Office of Research and Development | Recruiting | 18 Years | 70 Years | All | 118 | Phase 2 | United States;Canada | |
115 | EUCTR2017-004886-29-DK | 21/06/2018 | 19 November 2018 | A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la Roche Sponsored Ocrelizumab Clinical Trial | A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED OCRELIZUMAB PHASE IIIb/IV CLINICAL TRIAL | Multiple sclerosis (MS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 300- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 300- | F. Hoffmann-La Roche Ltd | Authorised | Female: yes Male: yes | 750 | Phase 3 | Estonia;Finland;Spain;Ireland;Turkey;United Kingdom;Italy;France;Czech Republic;Denmark;Netherlands;Norway;Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
116 | NCT03369665 | June 20, 2018 | 22 October 2019 | Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) | A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad® | Multiple Sclerosis | Drug: Mavenclad® | Merck KGaA, Darmstadt, Germany | Not recruiting | 18 Years | N/A | All | 486 | Phase 4 | Austria;Belgium;Czechia;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;Germany | |
117 | NCT03423121 | June 19, 2018 | 26 August 2019 | A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis | A Phase 1/2 Trial of Tauroursodeoxycholic Acid Supplementation in Progressive MS Patients | Progressive Multiple Sclerosis | Drug: Tauroursodeoxycholic Acid;Drug: Placebo oral capsule | Johns Hopkins University | Recruiting | 18 Years | N/A | All | 60 | Phase 1/Phase 2 | United States | |
118 | EUCTR2017-000635-13-DE | 08/06/2018 | 30 April 2019 | Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption | Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption | Multiple Sclerosis (MS), acute episode MedDRA version: 20.0 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Pharmaceutical Form: Powder and solution for solution for injection INN or Proposed INN: Methylprednisolone Other descriptive name: METHYLPREDNISOLONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2000- | Universität Leipzig | Authorised | Female: yes Male: yes | 140 | Phase 3 | Germany | |||
119 | NCT03493841 | June 8, 2018 | 1 April 2019 | Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis | Comparing Gastrointestinal Tolerability and Absorption of Racemic Lipoic Acid and R-lipoic Acid in Progressive Multiple Sclerosis: a Randomized Crossover Trial | Multiple Sclerosis;Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis | Drug: Alpha Lipoic Acid | Rebecca Spain | Not recruiting | 18 Years | N/A | All | 20 | Phase 1 | United States | |
120 | NCT03526224 | June 4, 2018 | 22 October 2018 | Teriflunomide Tecfidera LMCE | Effect of Teriflunomide on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective Observational Case-control Pilot Study | Tecfidera;Teriflunomide | Drug: Dimethyl Fumarate;Drug: Teriflunomide | University at Buffalo | Not recruiting | 18 Years | 65 Years | All | 120 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
121 | NCT03364036 | May 28, 2018 | 2 September 2019 | Evaluation of the Onset of Action in Highly Active Multiple Sclerosis (MS) | A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis | Multiple Sclerosis | Drug: Mavenclad® | Merck KGaA, Darmstadt, Germany | Not recruiting | 18 Years | N/A | All | 270 | Phase 4 | Australia;Austria;Canada;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;Belgium | |
122 | NCT03523858 | May 28, 2018 | 22 October 2019 | A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis | An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis | Progressive Multiple Sclerosis (PMS) | Drug: Ocrelizumab | Hoffmann-La Roche | Recruiting | 18 Years | 65 Years | All | 600 | Phase 3 | United States;Algeria;Bosnia and Herzegovina;Brazil;Canada;Colombia;Costa Rica;Czechia;Denmark;Egypt;France;Guatemala;Hungary;Ireland;Italy;Lebanon;Mexico;Morocco;Netherlands;Panama;Poland;Russian Federation;Saudi Arabia;Spain;United Arab Emirates | |
123 | NCT03610139 | May 21, 2018 | 24 September 2018 | Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients | Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients: A Single-Blind Randomized Clinical Trial | Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting;Clinically Isolated Syndrome;Clinically Isolated Syndrome, CNS Demyelinating;Vitamin D3 Deficiency | Dietary Supplement: Vitamin D3 | American University of Beirut Medical Center | Recruiting | 18 Years | N/A | All | 162 | N/A | Lebanon | |
124 | EUCTR2017-001313-93-ES | 11/05/2018 | 18 June 2018 | A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis | AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS | Progressive multiple sclerosis (PMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- | Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD | Authorised | Female: yes Male: yes | 600 | Phase 3 | United Arab Emirates;Saudi Arabia;Morocco;Costa Rica;Spain;Ireland;Lebanon;Russian Federation;Colombia;Italy;France;Denmark;Kuwait;Netherlands;Bosnia and Herzegovina;Panama;Guatemala;Egypt;Czech Republic;Hungary;Mexico;Canada;Brazil;Poland;Algeria | |||
125 | NCT03498131 | May 9, 2018 | 7 October 2019 | Melatonin in Patients With Multiple Sclerosis (MS). | Evaluating the Potential Role of Melatonin in Subjects With Relapsing Multiple Sclerosis (MS) | Relapsing Remitting Multiple Sclerosis | Drug: 3 mg Melatonin;Drug: 5 mg Melatonin | Providence Health & Services | Recruiting | 18 Years | 65 Years | All | 30 | Early Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
126 | NCT03574428 | May 8, 2018 | 3 June 2019 | Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers | A Randomised, Double-Blind, Placebo Controlled, Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers | Multiple Sclerosis | Drug: GNbAC1;Other: GNbAC1 Placebo | GeNeuro Australia PTY Ltd | Not recruiting | 18 Years | 55 Years | Male | 24 | Phase 1 | Australia | |
127 | EUCTR2017-001313-93-IE | 03/05/2018 | 7 January 2019 | A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis | AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS | Progressive multiple sclerosis (PMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ocrelizumab Product Code: RO4964913/F07-01 (development) Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913/F07-01 (commercial) Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- | F. Hoffmann-La Roche Ltd | Authorised | Female: yes Male: yes | 600 | Phase 3 | United Arab Emirates;Saudi Arabia;Morocco;Costa Rica;Spain;Ireland;Lebanon;Russian Federation;Colombia;Italy;France;Denmark;Kuwait;Netherlands;Bosnia and Herzegovina;Panama;Guatemala;Egypt;Czech Republic;Hungary;Mexico;Canada;Brazil;Poland;Algeria | |||
128 | NCT03585569 | May 1, 2018 | 23 July 2018 | Treating MS Patients With Lower Extremity Spasticity Using Dysport | A Prospective, Open Label, Single Center Study of Patients With Multiple Sclerosis With Lower Extremity Spasticity Who Are Treated With Dysport | Multiple Sclerosis;Spasticity, Muscle | Biological: Abobotulinumtoxin A | Neurology Center of New England P.C. | Ipsen | Recruiting | N/A | N/A | All | 30 | Phase 3 | United States |
129 | EUCTR2018-000620-34-SE | 24/04/2018 | 3 September 2018 | Imatinib treatment for Multiple Sclerosis (MS) Relapses | Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study - Imatinib MS | Patients with clinically definite Multiple Sclerosis (MS) according to the McDonald Criteria, or possible MS (also named clinically isolated syndrome-CIS, as a first manifestation of MS, where there are radiological and/or cerebrospinal fluid signs consistent with MS), which display an acute relapse MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10028247 Term: Multiple sclerosis like syndrome System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Pharmaceutical Form: Film-coated tablet INN or Proposed INN: IMATINIB MESILATE CAS Number: 220127-57-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Trade Name: Solu-Medrol Product Name: Solu-Medrol Pharmaceutical Form: Injection INN or Proposed INN: Methylprednisolone Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE Concentration unit: g gram(s) Concentration type: equal Concentration number: 1- | Department of Clinical Neuroscience, Karolinska Institutet | Authorised | Female: yes Male: yes | 200 | Phase 2 | Sweden | |||
130 | EUCTR2017-000426-35-AT | 17/04/2018 | 10 September 2018 | The efficacy of treatment of patients with multiple sclerosis, a chronic, inflammatory, autoimmune, disease that leads to neurologic deficits and aggravates with flairs, with low doses of rituximab, an antibody directed against the CD20 epitope on B Lymphocytes, specific cells of the immune system contributing to the progression of the disease - a pilot trial | Efficacy of Rituximab at low doses in Multiple Sclerosis – A prospective, randomized, double-blind, active controlled, pilo trial - Low-dose Rituximab in MS | Relapse Remitting Multiple Sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Mabthera or biosimilar rituximab product Product Name: Rituximab Product Code: Rituximab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: Rituximab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: Mabthera or biosimilar rituximab product Product Name: Rituximab Product Code: Rituximab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: Rituximab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- | Medical University of Vienna - Department of Neurology | Authorised | Female: yes Male: yes | 70 | Phase 2 | Austria | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
131 | NCT03464448 | April 17, 2018 | 16 September 2019 | Mechanistic Studies of Teriflunomide in RRMS | Mechanistic Studies of Teriflunomide in Relapsing Remitting Multiple Sclerosis: Regulatory B Lymphocytes as Central Mediators of the Therapeutic Effects of Teriflunomide in MS | Relapsing Remitting Multiple Sclerosis | Drug: Teriflunomide | University of Michigan | Recruiting | 18 Years | 65 Years | All | 30 | Phase 3 | United States | |
132 | NCT03501342 | April 9, 2018 | 22 October 2018 | Effects of Immersive Virtual Reality on Balance, Mobility, and Fatigue in Patients With Multiple Sclerosis | Effects of Immersive Virtual Reality on Balance, Mobility, and Fatigue in Patients With Multiple Sclerosis | Multiple Sclerosis | Other: Dynamic Balance Training;Other: Virtual reality group | Gazi University | Not recruiting | 18 Years | 65 Years | All | 39 | N/A | Turkey | |
133 | EUCTR2017-001313-93-DK | 04/04/2018 | 30 April 2019 | A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis | AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS | Progressive multiple sclerosis (PMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- | F. Hoffmann-La Roche Ltd | Authorised | Female: yes Male: yes | 600 | Phase 3 | United Arab Emirates;Saudi Arabia;Morocco;Costa Rica;Spain;Ireland;Lebanon;Russian Federation;Colombia;Italy;France;Denmark;Kuwait;Netherlands;Bosnia and Herzegovina;Panama;Guatemala;Egypt;Czech Republic;Hungary;Mexico;Canada;Brazil;Poland;Algeria | |||
134 | NCT03319732 | April 3, 2018 | 28 January 2019 | A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS | An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity (Study OS440-3005) | Multiple Sclerosis;Spasticity, Muscle | Drug: Arbaclofen | Osmotica Pharmaceutical US LLC | Not recruiting | 18 Years | 65 Years | All | 323 | Phase 3 | United States | |
135 | JPRN-UMIN000031135 | 2018/04/01 | 2 April 2019 | Treatment of Neuromyelitis Optica with Mycophenolate Mofetil in Japanese Patients | Neuromyelitis Optica | Mycophenolate mofetil treatment for 1 year | Kobe University Hospital | Recruiting | 20years-old | 80years-old | Male and Female | 10 | Not selected | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
136 | NCT03850301 | April 1, 2018 | 18 March 2019 | Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target | An Experimental Medicine Study to Validate the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target in Multiple Sclerosis | Multiple Sclerosis | Drug: XBD173;Drug: Etifoxine | Imperial College London | Recruiting | 35 Years | 65 Years | All | 44 | N/A | United Kingdom | |
137 | NCT03436199 | March 29, 2018 | 20 August 2018 | Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment | A 3-arm, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment | Walking Impairment;Multiple Sclerosis | Other: Placebo;Drug: ADS-5102, 274 mg;Drug: ADS-5102, 137 mg | Adamas Pharmaceuticals, Inc. | Recruiting | 18 Years | 70 Years | All | 540 | Phase 3 | United States | |
138 | NCT03387046 | March 26, 2018 | 26 August 2019 | A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS) | Evaluation of clINical reCovery After a Relapse: a Pilot Study assEssing the Neuronal Effects of D-Aspartate in RR-MS Subjects Treated With IntErferon Beta 1a 44 mcg TIW (INCREASE) | Multiple Sclerosis, Relapsing-Remitting | Dietary Supplement: D-aspartate;Drug: Placebo;Biological: IFN beta-1a;Drug: Methylprednisolone | Merck KGaA, Darmstadt, Germany | Not recruiting | 18 Years | 55 Years | All | 7 | Phase 2 | Italy;Germany | |
139 | NCT03266965 | March 23, 2018 | 2 September 2019 | Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach | Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach | Multiple Sclerosis | Drug: Carbidopa;Dietary Supplement: L-Histidine | University of Miami | United States Department of Defense | Recruiting | 18 Years | 60 Years | All | 15 | Phase 1 | United States |
140 | EUCTR2017-004100-22-PL | 21/03/2018 | 28 February 2019 | Arbaclofen Extended-Release Tablets for Treatment of Spasticity in Patients with Multiple Sclerosis | A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients with Multiple Sclerosis (Study OS440-3004) | Spasticity in patients with multiple sclerosis MedDRA version: 20.0 Level: LLT Classification code 10041416 Term: Spasticity System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Arbaclofen Extended Release Tablets Product Code: OS440 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Arbaclofen CAS Number: 69308-37-8 Current Sponsor code: OS440 Other descriptive name: AERT, (R)-Baclofen Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use | Osmotica Pharmaceutical US LLC | Not Recruiting | Female: yes Male: yes | 510 | Phase 3 | Serbia;Belarus;United States;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of;Bosnia and Herzegovina | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
141 | EUCTR2017-004101-40-PL | 21/03/2018 | 28 February 2019 | Long-Term Study of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity | An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity (Study OS440-3005). | Spasticity in patients with multiple sclerosis MedDRA version: 20.0 Level: LLT Classification code 10041416 Term: Spasticity System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Arbaclofen Extended Release Tablets Product Code: OS440 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Arbaclofen CAS Number: 69308-37-8 Current Sponsor code: OS440 Other descriptive name: AERT, (R)-Baclofen Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- | Osmotica Pharmaceutical US LLC | Authorised | Female: yes Male: yes | 300 | Phase 3 | Serbia;Belarus;United States;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of;Bosnia and Herzegovina | |||
142 | NCT03477500 | March 21, 2018 | 17 June 2019 | RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab in MS | Randomized Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab for Patients With Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Cyclophosphamide and ATG;Drug: Alemtuzumab | Haukeland University Hospital | Recruiting | 18 Years | 50 Years | All | 100 | Phase 3 | Denmark;Netherlands;Norway;Sweden | |
143 | EUCTR2017-004100-22-BG | 16/03/2018 | 7 January 2019 | Arbaclofen Extended-Release Tablets for Treatment of Spasticity in Patients with Multiple Sclerosis | A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients with Multiple Sclerosis (Study OS440-3004) | Spasticity in patients with multiple sclerosis MedDRA version: 20.0 Level: LLT Classification code 10041416 Term: Spasticity System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Arbaclofen Extended Release Tablets Product Code: OS440 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Arbaclofen CAS Number: 69308-37-8 Current Sponsor code: OS440 Other descriptive name: AERT, (R)-Baclofen Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use | Osmotica Pharmaceutical US LLC | Not Recruiting | Female: yes Male: yes | 510 | Phase 3 | Serbia;Belarus;United States;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of;Bosnia and Herzegovina | |||
144 | JPRN-JapicCTI-173711 | 15/3/2018 | 10 September 2019 | Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab | A 24-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Ofatumumab in Patients With Relapsing Multiple Sclerosis Followed by an Extended Treatment of at Least 24 Weeks With Open-label Ofatumumab | Relapsing Multiple Sclerosis | Intervention name : Ofatumumab INN of the intervention : - Dosage And administration of the intervention : Ofatumumab 20 mg subcutaneous injections every 4 weeks Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Placebo subcutaneous injection matching to ofatumumab every 4 weeks | Novartis Pharma K.K. | Not Recruiting | 18 | 55 | BOTH | 30 | Phase 2 | Japan, Russia | |
145 | NCT03249714 | March 15, 2018 | 4 November 2019 | Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab | A 24-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Ofatumumab in Patients With Relapsing Multiple Sclerosis Followed by an Extended Treatment of at Least 24 Weeks With Open-label Ofatumumab | Relapsing Multiple Sclerosis | Drug: Ofatumumab subcutaneous injection;Drug: Placebo subcutaneous injection matching ofatumumab | Novartis Pharmaceuticals | Not recruiting | 18 Years | 55 Years | All | 64 | Phase 2 | Japan;Russian Federation | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
146 | NCT03005119 | March 1, 2018 | 16 December 2017 | Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms | A Phase II, Double-blind, Randomized, Placebocontrolled, Parallel-group, Single-center Study to Evaluate the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in Multiple Sclerosis (MS) Patients With Spasticity-related Symptoms | Multiple Sclerosis | Drug: PTL201;Drug: Placebo Oral Capsule | PhytoTech Therapeutics, Ltd. | Not recruiting | 18 Years | 65 Years | All | 70 | Phase 2 | Israel | |
147 | EUCTR2016-004414-10-SE | 23/02/2018 | 12 March 2018 | Determination of the concentration of Teriflunomide in serum and cerebrospinal fluid from patients with multiple sclerosis who are treated with Teriflunomide 14 mg daily. | Determination of the concentration of Teriflunomide in serum and cerebrospinal fluid from patients with multiple sclerosis who are treated with Teriflunomide 14 mg daily. | Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Aubagio Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- | MS Centrum, Department of Neurology, Sshlgrenska University Hospital | Authorised | Female: yes Male: yes | 20 | Phase 4 | Sweden | |||
148 | NCT03551275 | February 22, 2018 | 20 August 2018 | Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis | A Multicenter Open-Label Non-Comparative Dose Escalation Study (Phase 1) of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 (JSC BIOCAD, Russia) in Patients With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis | Biological: BCD-132 | Biocad | Not recruiting | 18 Years | 60 Years | All | 48 | Phase 1 | Russian Federation | |
149 | EUCTR2017-001224-22-BE | 02/02/2018 | 28 February 2019 | Efficacy and Safety of BIIB033 as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies - Efficacy and Safety of BIIB033 as an Add-on Therapy to DMTs in RMS | Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10067063 Term: Progressive relapsing multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Opicinumab Product Code: BIIB033 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Opicinumab Other descriptive name: BIIB033 (ANTI-LINGO) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | Biogen Idec Research Limited | Authorised | Female: yes Male: yes | 240 | Phase 2 | United States;Spain;Israel;Italy;Switzerland;United Kingdom;France;Czech Republic;Hungary;Canada;Poland;Belgium;Australia;Netherlands;Germany;Sweden | |||
150 | EUCTR2017-003008-30-GB | 31/01/2018 | 21 May 2018 | Simvastatin in Secondary Progressive Multiple Sclerosis | A double-blind, randomised, placebo-controlled single-site study of high dose simvastatin treatment for secondary progressive multiple sclerosis: impact on vascular perfusion and oxidative damage - MS-OPT Version 1.0 dated 12/10/17 | Multiple Sclerosis (Secondary Progressive) MedDRA version: 20.0 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Simvastatin 40 mg film-coated tablets Product Name: Simvastatin 40 mg film-coated tablets Product Code: Not applicable Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | University College London | Authorised | Female: yes Male: yes | 40 | Phase 2 | United Kingdom | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
151 | NCT03290131 | January 28, 2018 | 9 September 2019 | A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS | A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis | Multiple Sclerosis;Spasticity, Muscle | Drug: Arbaclofen;Drug: Placebo | Osmotica Pharmaceutical US LLC | Not recruiting | 18 Years | 65 Years | All | 536 | Phase 3 | Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Serbia;United States | |
152 | NCT03399981 | January 24, 2018 | 24 June 2019 | Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries | An Observational Study Utilising Data From the US Tysabri TOUCH Programme and Select EU MS Registries to Estimate the Risk of Progressive Multifocal Leukoencephalopathy (PML) and Other Serious Opportunistic Infections Among Patients Who Were Exposed to an MS Disease Modifying Treatment Prior to Treatment With Tysabri | Progressive Multifocal Leukoencephalopathy | Biological: Tysabri | Biogen | Not recruiting | N/A | N/A | All | 72600 | N/A | United States | |
153 | NCT03560739 | January 18, 2018 | 11 November 2019 | A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients | A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients | Multiple Sclerosis | Drug: OMB157 | Novartis Pharmaceuticals | Not recruiting | 18 Years | 55 Years | All | 284 | Phase 2 | United States;Austria;Bulgaria;Czechia;Estonia;Latvia;Lithuania;Russian Federation;Spain | |
154 | NCT03135249 | January 1, 2018 | 22 October 2019 | Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis | Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis (SUPPRESS) | Multiple Sclerosis (MS) | Drug: Alemtuzumab | University of Texas Southwestern Medical Center | Genzyme, a Sanofi Company | Not recruiting | 18 Years | 60 Years | All | 40 | Phase 4 | United States |
155 | EUCTR2018-000516-22-PT | 30 April 2019 | Study to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants | A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3- Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: TECFIDERA Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Plegridy Product Name: PEGylated Interferon Beta-1a Product Code: BIIB017 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: PEGINTERFERON BETA-1A CAS Number: 1211327-92-2 Current Sponsor code: BIIB017 Other descriptive name: PEGINTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: up to Concentration number: 125- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use | Biogen Idec Research Limited | Not Available | Female: yes Male: yes | 340 | Phase 3 | Serbia;Portugal;United States;Saudi Arabia;Taiwan;Estonia;Greece;Thailand;Turkey;Russian Federation;Israel;Colombia;Italy;Hungary;Mexico;Jordan;Malaysia;Croatia;Bulgaria;Tunisia;Korea, Republic of | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
156 | NCT03670459 | December 31, 2017 | 24 September 2018 | Forty Five Patients With Multiple Sclerosis Recieved Vestibular Rehabilitation and Balance Training | Cawthorne Cooksey Versus Vestibular Habituation Exercises on Trunk Kinetics and Velocity of Gait in Patients With Multiple Sclerosis | Neurologic Disorder | Other: Cawthorne Cooksey exercises;Other: Vestibular habituation exercises;Other: Balance exercises | October 6 University | Not recruiting | 35 Years | 55 Years | All | 45 | N/A | Egypt | |
157 | EUCTR2017-003328-56-GB | 19/12/2017 | 26 November 2018 | MS-STAT2 - Multiple Sclerosis – Simvastatin Trial 2 | A phase 3 randomised, double blind, clinical trial investigating the effectiveness of repurposed simvastatin compared to placebo, in secondary progressive multiple sclerosis, in slowing the progression of disability - MS-STAT2 | Multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Simvastatin 40 mg film-coated tablets Product Name: Simvastatin 40 mg film-coated tablets Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Simvastatine Sandoz 40 mg filmomhulde tabletten Product Name: Simvastatine Sandoz 40 mg filmomhulde tabletten Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: SimvaHEXAL® 40 mg Filmtabletten Product Name: SimvaHEXAL® 40 mg Filmtabletten Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Simvastatina Sandoz 40 mg comprimidos recubiertos con película EFG Product Name: Simvastatina Sandoz 40 mg comprimidos recubiertos con película EFG Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Sinvastatina Sandoz 40 mg comprimidos revestidos por película Product Name: Sinvastatina Sandoz 40 mg comprimidos revestidos por película Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Sivatin 40 mg film-coated tablets Product Name: Sivatin 40 mg film-coated tablets Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Simvastatine Sandoz 40mg deelbare filmomhulde tabletten Product Name: Simvastatine Sandoz 40mg deelbare filmomhulde tabletten Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal | University College London Comprehensive Clinical Trials Unit | Authorised | Female: yes Male: yes | 1180 | Phase 3 | United Kingdom | |||
158 | NCT03385356 | December 19, 2017 | 1 April 2019 | Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis | Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting;Vitamin D Deficiency | Drug: Vitamin D | University Medical Centre Maribor | Medical Faculty Maribor | Not recruiting | 18 Years | 60 Years | All | 89 | Phase 4 | Slovenia |
159 | EUCTR2017-004846-31-SI | 14/12/2017 | 8 January 2018 | Vitamin D supplementation in patients with multiple sclerosis | Impact of vitamin D supplementation in patients with multiple sclerosis | Relapsing remitting multiple sclerosis MedDRA version: 20.1 Level: LLT Classification code 10064137 Term: Progression of multiple sclerosis System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Oleovit D3 14.400 IU/ml oral drops, solution | University medical centre Maribor | Authorised | Female: yes Male: yes | 95 | Phase 4 | Slovenia | |||
160 | EUCTR2017-000638-75-PL | 13/12/2017 | 23 July 2018 | UbLiTuximab In Multiple Sclerosis Treatment Effects | Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY) - ULTIMATE I STUDY | Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10029202 Term: Nervous system disorder System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ublituximab Product Code: TG-1101 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: UBLITUXIMAB Current Sponsor code: TGTX 1101 Other descriptive name: LFB-R603 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: Teriflunomide Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | TG Therapeutics, Inc. | Authorised | Female: yes Male: yes | 440 | Phase 3 | United Kingdom;Georgia;Russian Federation;Ukraine;Poland;Spain;United States;Belarus;Serbia | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
161 | NCT03362294 | December 11, 2017 | 16 September 2019 | Safety and Efficacy of Monthly Long-acting IM Injection of 40 mg GA Depot in Subjects With PPMS | A Prospective, Multicenter, Single Arm, Open Label, Phase IIa Study to Assess the Safety and Efficacy of Once-a-month Long-acting Intramuscular Injection of 40mg Glatiramer Acetate (GA Depot) in Subjects With Primary Progressive Multiple Sclerosis (PPMS) | Primary Progressive Multiple Sclerosis | Drug: GA Depot 40mg once monthly | Mapi Pharma Ltd. | Recruiting | 18 Years | 65 Years | All | 24 | Phase 2 | Israel | |
162 | EUCTR2017-000638-75-ES | 05/12/2017 | 26 March 2018 | UbLiTuximab In Multiple Sclerosis Treatment Effects | Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY) - ULTIMATE I STUDY | Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10029202 Term: Nervous system disorder System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ublituximab Product Code: TG-1101 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: UBLITUXIMAB Current Sponsor code: TGTX 1101 Other descriptive name: LFB-R603 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Product Name: Teriflunomide Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | TG Therapeutics | Authorised | Female: yes Male: yes | 440 | Phase 3 | Serbia;Belarus;United States;Poland;Spain;Ukraine;Russian Federation;Georgia;United Kingdom | |||
163 | EUCTR2017-000639-15-ES | 05/12/2017 | 26 March 2018 | UbLiTuximab In Multiple Sclerosis Treatment Effects | Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY) - ULTIMATE II STUDY | Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10029202 Term: Nervous system disorder System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ublituximab Product Code: TG-1101 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: UBLITUXIMAB Current Sponsor code: TGTX 1101 Other descriptive name: LFB-R603 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Product Name: Teriflunomide Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | TG Therapeutics | Authorised | Female: yes Male: yes | 440 | Phase 3 | Belarus;United States;Poland;Spain;Ukraine;Romania;Croatia;Russian Federation;United Kingdom | |||
164 | NCT02988401 | December 1, 2017 | 25 February 2019 | Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis | Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis, Primary Progressive | Drug: Insulin;Drug: Placebo (Sterile diluent) | Johns Hopkins University | United States Department of Defense | Recruiting | 18 Years | 70 Years | All | 105 | Phase 1/Phase 2 | United States |
165 | NCT03315923 | December 1, 2017 | 3 June 2019 | Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients | Comparison of Expanded Disability Status Scale, Gad-enhanced Brain Lesions, Annualized Relapse Rate, and Side Effects Between Active Secondary Progressive Multiple Sclerosis Patients on Rituximab and Glatiramer Acetate | Secondary Progressive Multiple Sclerosis | Drug: Glatiramer Acetate;Drug: Rituximab | Isfahan University of Medical Sciences | Not recruiting | 18 Years | 55 Years | All | 84 | Phase 2/Phase 3 | Iran, Islamic Republic of | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
166 | NCT03353974 | December 1, 2017 | 22 October 2018 | Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients. | The Role of Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients. A Pilot Randomized Controlled Trial. | Multiple Sclerosis | Device: Video game therapy;Device: Balance platform therapy | University Hospital of Ferrara | Recruiting | 18 Years | 80 Years | All | 40 | N/A | Italy | |
167 | NCT03347370 | November 27, 2017 | 7 October 2019 | A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis | Subcutaneous (SC) Interferon Beta Therapy in Multiple Sclerosis Patients and Characterization of Injection Site Reactions and Flu-Like Symptoms Under Daily Practice Setting | Multiple Sclerosis, Relapsing-Remitting | Drug: SC Peginterferon beta-1a;Drug: SC interferon beta-1a;Drug: SC interferon beta-1b | Biogen | AMS Advanced Medical Services GmbH | Not recruiting | 18 Years | N/A | All | 626 | N/A | Germany |
168 | NCT03222973 | November 14, 2017 | 13 May 2019 | Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies | Multiple Sclerosis | Drug: BIIB033 (opicinumab);Drug: Placebo | Biogen | Not recruiting | 18 Years | 58 Years | All | 263 | Phase 2 | United States;Australia;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom | |
169 | NCT03342638 | November 8, 2017 | 26 August 2019 | Maximizing Outcome of Multiple Sclerosis Transplantation | Maximizing Outcome of Multiple Sclerosis Transplantation: MOST Trial | Multiple Sclerosis, Relapsing-Remitting | Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;Biological: IVIg;Biological: Autologous Stem Cells | Northwestern University | Not recruiting | 18 Years | 58 Years | All | 200 | Phase 3 | United States | |
170 | EUCTR2017-001176-31-GB | 06/11/2017 | 28 February 2019 | A long term follow up study to look at the progress of patients with symptoms suggestive of MS who took part in previous studies with Betaferon®/Betaseron® | BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies | Clinically-isolated syndrome (CIS) and multiple sclerosis (MS) MedDRA version: 20.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10071068 Term: Clinically isolated syndrome System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Betaferon 250 microgram/ml, powder and solvent for solution for injection Product Name: Betaferon Product Code: BAY86-5046 Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: RECOMBINANT INTERFERON BETA-1B CAS Number: 145155-23-3 Current Sponsor code: BAY86-5046 Other descriptive name: RECOMBINANT INTERFERON BETA-1B Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- | Bayer AG, | Not Recruiting | Female: yes Male: yes | 300 | Phase 4 | Portugal;Slovenia;Finland;Spain;Austria;Israel;Italy;United Kingdom;Switzerland;France;Czech Republic;Hungary;Canada;Poland;Belgium;Denmark;Norway;Germany;Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
171 | NCT03244696 | November 2, 2017 | 11 February 2019 | Behavior and Activity Monitoring in MS | Behavior and Activity Monitoring in Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Behavioral: Step Tracking;Behavioral: Water Tracking | Ohio State University | National Multiple Sclerosis Society | Recruiting | 30 Years | 59 Years | All | 200 | N/A | United States |
172 | NCT03350633 | November 1, 2017 | 4 November 2019 | Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders | Safety and Efficacy of Tocilizumab Versus Azathioprine in Neuromyelitis Optica Spectrum Disorders: a Randomized, Controlled, Open-label, Phase 2 Trial | Neuromyelitis Optica Spectrum Disorders;Neuromyelitis Optica | Drug: Tocilizumab Injection;Drug: Azathioprine | Tianjin Medical University General Hospital | Not recruiting | 18 Years | N/A | All | 118 | Phase 2/Phase 3 | China | |
173 | NCT02200718 | November 2017 | 14 March 2016 | A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis | A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis | Multiple Sclerosis | Biological: NeuroVax;Biological: IFA Incomplete Freund's Adjuvant | Immune Response BioPharma, Inc. | Oregon Health and Science University | Not recruiting | 5 Years | 17 Years | Both | 12 | Phase 1 | United States |
174 | EUCTR2017-002838-23-ES | 27/10/2017 | 13 November 2017 | Randomized, double-blind, placebo-controlled, 3-arm, 36 weeks parallel-group study to evaluate the safety and tolerability of ORY-2001 in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS) | Randomized, double-blind, placebo-controlled, 3-arm, 36 weeks parallel-group study to evaluate the safety and tolerability of ORY-2001 in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS) | patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS) MedDRA version: 20.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ORY2001 Product Code: ORY2001 Pharmaceutical Form: Capsule INN or Proposed INN: Not yet requested Current Sponsor code: ORY2001 Other descriptive name: PHENYLCYCLOPROPYLAMINE DERIVATIVES AND DUAL LSD1/MAO-B (LYSINE-SPECIFIC DEMETHYLASE 1 AND MONOAMINE OXIDASE-B) INHIBITOR Concentration unit: mg milligram(s) Concentration type: range Concentration number: 0.6-1.2 Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Oryzon Genomics S. A | Authorised | Female: yes Male: yes | 24 | Phase 2 | Spain | |||
175 | NCT03368664 | October 24, 2017 | 28 October 2019 | A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT | A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT) | Multiple Sclerosis | Drug: Alemtuzumab GZ402673;Drug: Glatiramer acetate;Drug: Beta-Interferon;Drug: Methylprednisolone;Drug: Ranitidine;Drug: Ceterizine;Drug: Dexchlorpheniramine;Drug: Paracetamol;Drug: Acyclovir;Drug: Prednisolone;Drug: Diphenydramine;Drug: Other H1 antagonist | Genzyme, a Sanofi Company | Recruiting | 10 Years | 17 Years | All | 50 | Phase 3 | Austria;Belgium;Bulgaria;Czechia;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;Switzerland | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
176 | NCT03283826 | October 19, 2017 | 14 October 2019 | Phase 1 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis | A Phase 1, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study With an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis | Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis | Biological: ATA188;Drug: Placebo | Atara Biotherapeutics | Recruiting | 18 Years | 65 Years | All | 72 | Phase 1 | United States;Australia | |
177 | EUCTR2015-005431-41-PL | 16/10/2017 | 10 October 2018 | A late stage clinical trial to investigate the efficacy and safety of SA237 monotherapy in patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) | Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD) MedDRA version: 20.0 Level: LLT Classification code 10029322 Term: Neuromyelitis optica System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: SA237 Product Code: SA237-120/vial Pharmaceutical Form: Solution for injection INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: FULLY HUMANIZED ANTI-HUMAN IL-6 RECEPTOR (IL-6R) NEUTRALIZING MONOCLONAL ANTIBODY Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: SA237 Product Code: SA237-120 PFS with NSD Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: FULLY HUMANIZED ANTI-HUMAN IL-6 RECEPTOR (IL-6R) NEUTRALIZING MONOCLONAL ANTIBODY Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120- | Chugai Pharmaceutical Co. Ltd | Authorised | Female: yes Male: yes | 90 | Phase 3 | United States;Taiwan;Ukraine;Turkey;Russian Federation;Italy;Canada;Poland;Malaysia;Croatia;Romania;Bulgaria;Georgia;Korea, Republic of | |||
178 | NCT03344094 | October 12, 2017 | 16 December 2017 | Mechanism of Action of Ocrelizumab in Multiple Sclerosis | Mechanism of Action of Ocrelizumab in Multiple Sclerosis | Multiple Sclerosis;Immune System Diseases | Drug: ocrelizumab | University of Chicago | Recruiting | 18 Years | 65 Years | All | 30 | N/A | United States | |
179 | NCT03207464 | October 10, 2017 | 16 July 2018 | Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis | Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis | Multiple Sclerosis | Drug: [C-11]Methylreboxetine | Brigham and Women's Hospital | Recruiting | 18 Years | 60 Years | All | 19 | Phase 1/Phase 2 | United States | |
180 | EUCTR2017-002636-16-NL | 09/10/2017 | 23 October 2017 | Understanding problems with attention, memory and concentration in persons with multiple sclerosis | Cognitive impairment and functional reorganization in multiple sclerosis: The role of GABA and glutamate - GABA and glutamate in cognitive impairment in MS | Multiple Sclerosis (MS). And specifically cognitive problems in MS.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: [11C]flumazenil Pharmaceutical Form: Solution for injection in administration system | VU University medical center Amsterdam | Authorised | Female: yes Male: yes | Phase 4 | Netherlands | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
181 | NCT03185065 | October 4, 2017 | 1 April 2019 | Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis | Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis | Fatigue in Multiple Sclerosis | Drug: Amantadine;Drug: Modafinil;Drug: Methylphenidate;Drug: Placebos | Johns Hopkins University | Patient-Centered Outcomes Research Institute | Not recruiting | 18 Years | N/A | All | 140 | Phase 3 | United States |
182 | EUCTR2016-004719-10-ES | 02/10/2017 | 16 October 2017 | A research study to look at the long term benefits and risks of ponesimod 20 mg treatment for patients with relapsing multiple sclerosis. | Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis - OPTIMUM LT | relapsing multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 6- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 8- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9- Product Name: Ponesimod Product Code: ACT-128800 | Actelion Pharmaceuticals Ltd. | Authorised | Female: yes Male: yes | 800 | Phase 3 | Bulgaria;Georgia;Germany;Sweden;Croatia;Romania;Poland;Canada;Mexico;Hungary;Czech Republic;United Kingdom;Lithuania;Turkey;Finland;Bosnia and Herzegovina;Latvia;France;Italy;Israel;Russian Federation;Ukraine;Spain;Greece;Portugal;United States;Belarus;Serbia | |||
183 | EUCTR2017-002634-24-SE | 29/09/2017 | 6 November 2017 | MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. | MultipleMS – Multiple-omics approach to accelerate personalised medicine in a prospective cohort of newly diagnosed MS and CIS patients. - MultipleMS | Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Mabthera Pharmaceutical Form: Infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 500-1000 Trade Name: Tysabri Pharmaceutical Form: Infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Trade Name: Tecfidera Pharmaceutical Form: Capsule INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- Trade Name: Gilenya Pharmaceutical Form: Tablet INN or Proposed INN: FINGOLIMOD CAS Number: 162359-55-9 Other descriptive name: FINGOLIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Trade Name: Copaxone Pharmaceutical Form: Injection INN or Proposed INN: GLATIRAMER ACETATE CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg milligram(s) Concentration type: range Concentration number: 20-40 Trade Name: Betaferon Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1B CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Trade Name: Extavia Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1B CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Trade Name: Avonex Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30- Trade Name: Rebif Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 | Karolinska Institutet | Authorised | Female: yes Male: yes | 150 | Phase 4 | Sweden | |||
184 | NCT03122652 | September 25, 2017 | 23 April 2019 | Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome | Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study | Multiple Sclerosis | Drug: Teriflunomide 14 MG Oral Tablet [Aubagio];Drug: Placebo Oral Tablet | Centre Hospitalier Universitaire de Nice | Genzyme, a Sanofi Company | Recruiting | 18 Years | N/A | All | 200 | Phase 3 | France;Germany;Martinique;Switzerland;Turkey;United Kingdom;Sweden |
185 | NCT03326505 | September 25, 2017 | 16 December 2017 | Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment | The Effect of Stem Cell Therapy and Comprehensive Physical Therapy in Motor and Non-Motor Symptoms in Patients With Multiple Sclerosis: A Comparative Study. | Multiple Sclerosis | Biological: Umbilical cord derived Mesenchymal Stem Cells;Other: Supervised physical therapy | University of Jordan | Recruiting | 18 Years | 65 Years | All | 60 | Phase 1/Phase 2 | Jordan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
186 | NCT03424733 | September 25, 2017 | 26 August 2019 | Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects | A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms From Pegylated Interferon Beta-1a | Multiple Sclerosis | Drug: Plegridy;Drug: Prednisone;Drug: Tylenol Pill | Holy Name Medical Center, Inc. | Biogen | Recruiting | 18 Years | N/A | All | 50 | Phase 4 | United States |
187 | EUCTR2017-001294-16-PL | 22/09/2017 | 30 April 2019 | A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate | A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate | Relapsing-Remitting Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: N/A Product Code: ALKS 8700 Delayed Release (DR) Pharmaceutical Form: Capsule INN or Proposed INN: Not available Current Sponsor code: RDC-5108-00, ALKS8700 Other descriptive name: Diroximel Fumarate (DRF) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 231- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Tecfidera® 120 mg Product Name: Tecfidera® 120 mg Pharmaceutical Form: Capsule INN or Proposed INN: Tecfidera CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Tecfidera® 240 mg Product Name: Tecfidera® 240 mg Pharmaceutical Form: Capsule INN or Proposed INN: Tecfidera CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Alkermes, Inc. | Authorised | Female: yes Male: yes | 420 | Phase 3 | United States;Poland;Germany | |||
188 | NCT03330418 | September 21, 2017 | 28 January 2019 | A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders | A Phase III Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Neuromyelitis Optica Spectrum Disorders. | Neuromyelitis Optica Spectrum Disorders | Biological: Placebo;Biological: RC18 160 mg | RemeGen | Recruiting | 18 Years | 65 Years | All | 118 | Phase 3 | China | |
189 | EUCTR2016-003622-16-FI | 19/09/2017 | 2 October 2017 | The effect of teriflunomide on brain microglial cell activation in multiple sclerosis. | Targeting SPMS: Effect of teriflunomide treatment on microglial activation in an MS patient cohort at risk of progression. A [11C]PK11195 Brain PET study. | Multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: AUBAGIO Product Name: Teriflunomide Product Code: L04AA31 Pharmaceutical Form: Film-coated tablet | Turku University Hospital | Authorised | Female: yes Male: yes | Phase 4 | Finland | ||||
190 | NCT03257358 | September 19, 2017 | 2 September 2019 | A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod | A 12-Month, Prospective, Multicenter, Two-cohort, Nonrandomized, Open-label Study in Adult Patients With Relapsing Multiple Sclerosis (RMS), to Investigate Changes in Immune Phenotype Biomarkers After Treatment With 0.5mg Fingolimod [FLUENT] | Relapsing Multiple Sclerosis | Drug: Fingolimod | Novartis Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 370 | Phase 4 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
191 | NCT03134573 | September 15, 2017 | 8 April 2019 | Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study | PROmyBETAapp: Ascertaining Medication Usage & Documentation of Patient Reported Outcomes Utilizing the myBETAapp® in Patients With Multiple Sclerosis Treated With Betaferon®: a Pilot Study | Multiple Sclerosis | Drug: Interferon beta-1b (Betaferon, BAY86-5046);Device: Betaconnect auto-injector;Device: myBETAapp | Bayer | Not recruiting | 18 Years | N/A | All | 96 | Phase 2 | Germany | |
192 | NCT03282760 | September 9, 2017 | 28 January 2019 | Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients | A Phase I Multicenter Study of Allogenic, Intracerebroventricular Human Neural Stem Cells Transplantation for the Experimental Treatment of Secondary Progressive Multiple Sclerosis Patients | Secondary-progressive Multiple Sclerosis | Biological: Human Neural Stem Cells | Casa Sollievo della Sofferenza IRCCS | Associazione Revert ONLUS;Neurocenter of Southern Switzerland;Fondazione Cellule Staminali | Not recruiting | 18 Years | 60 Years | All | 24 | Phase 1 | Italy;Switzerland |
193 | NCT03183869 | August 24, 2017 | 16 December 2017 | Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients | Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients | Autoimmune Diseases;Relapsing Multiple Sclerosis | Drug: Fecal microbiota | Lawson Health Research Institute | Recruiting | 18 Years | N/A | All | 40 | Phase 2 | Canada | |
194 | EUCTR2017-001253-13-BE | 23/08/2017 | 20 August 2018 | Does decresaed perfusion of the brain play a role in the reduced function of axons and the clinical disability and fatigue in patients with multiple sclerosis ? | Does cerebral hypoperfusion play a role in reduced axonal metabolism and clinical disability in patients with multiple sclerosis ? - ROCHIMS (Role of Cerebral Hypoperfusion In Multiple Sclerosis) | Patients suffering relapsing- remitting multiple sclerosis will be investigated in this study, with an EDSS score less or equal to 4.0. Patients must be older than 18 years old. There must not be any clinical evidence of an MS relpase within the 3 months prior to inclusion.;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Tracleer Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | UZ Brussel | Authorised | Female: yes Male: yes | 30 | Phase 2 | Belgium | |||
195 | NCT03109288 | August 11, 2017 | 4 November 2019 | Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) | Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) | Multiple Sclerosis | Drug: Pioglitazone;Drug: Montelukast;Drug: Losartan;Drug: Hydroxychloroquine | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | 18 Years | 99 Years | All | 250 | Phase 1/Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
196 | NCT02744222 | August 10, 2017 | 20 August 2018 | Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis | An International Multicenter Double-blind Placebo-controlled Randomized Study to Compare the Efficacy, Safety and Tolerability of BCD-054 (JSC BIOCAD, Russia), 180 µg and 240 µg, Versus Avonex® (Biogen Idec Ltd., UK) in Patients With Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Biological: BCD-054 180 mcg;Biological: Avonex®;Biological: BCD-054 240 mcg;Other: Placebo | Biocad | Not recruiting | 18 Years | 60 Years | All | 399 | Phase 2/Phase 3 | Russian Federation | |
197 | EUCTR2016-000700-29-SE | 07/08/2017 | 28 February 2019 | Effect of MD1003 in progressive multiple sclerosis with walking impairment | Effect of MD1003 in progressive multiple sclerosis: a randomized-double blind placebo-controlled study. - SPI2 | Multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: D-Biotin Product Code: MD1003 Pharmaceutical Form: Capsule, hard INN or Proposed INN: D-BIOTIN CAS Number: 58-85-5 Current Sponsor code: MD1003 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | MEDDAY PHARMACEUTICALS SA | Authorised | Female: yes Male: yes | 754 | Phase 3 | United States;Spain;Turkey;United Kingdom;Italy;Czech Republic;Hungary;Canada;Poland;Belgium;Australia;Germany;Netherlands;Sweden | |||
198 | NCT03138421 | August 1, 2017 | 4 February 2019 | Central Pain Study for ABX-1431 | A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of ABX-1431 in Patients With Central Pain | Neuromyelitis Optica Spectrum Disorder;Transverse Myelitis;Multiple Sclerosis;Longitudinally Extensive Transverse Myelitis | Drug: ABX-1431 HCl;Drug: Placebo | Abide Therapeutics | Not recruiting | 18 Years | N/A | All | 9 | Phase 1 | United Kingdom | |
199 | NCT03277248 | August 1, 2017 | 11 November 2019 | A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2) | ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY) | Relapsing Multiple Sclerosis (RMS) | Biological: Ublituximab;Drug: Teriflunomide | TG Therapeutics, Inc. | Not recruiting | 18 Years | 55 Years | All | 500 | Phase 3 | United States | |
200 | NCT03277261 | August 1, 2017 | 11 November 2019 | A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) | UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY) | Relapsing Multiple Sclerosis (RMS) | Biological: Ublituximab;Drug: Teriflunomide | TG Therapeutics, Inc. | Not recruiting | 18 Years | 55 Years | All | 500 | Phase 3 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
201 | NCT03232073 | July 17, 2017 | 14 October 2019 | Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis | Multicenter, Non-comparative Extension to Study AC-058B301, to Investigate the Long-term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis | Multiple Sclerosis | Drug: Ponesimod | Actelion | Not recruiting | 18 Years | 65 Years | All | 800 | Phase 3 | United States;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom | |
202 | EUCTR2016-002937-31-BE | 10/07/2017 | 28 February 2019 | A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis | An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis | Relapsing remitting multiple sclerosis (RRMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ocrelizumab Product Code: RO4964913/F07-01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913/F07-01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- | F. Hoffmann-La Roche Ltd | Authorised | Female: yes Male: yes | 1078 | Phase 3 | Portugal;United States;Slovakia;Spain;Lebanon;Switzerland;Italy;France;Australia;Denmark;Kuwait;Netherlands;Slovenia;Turkey;Austria;United Kingdom;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Belgium;Romania;Croatia;Bulgaria;Norway;Germany;Sweden | |||
203 | NCT02903537 | July 6, 2017 | 11 June 2018 | Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS) | Tolerance-Induction With Dendritic Cells Treated With Vitamin-D3 and Loaded With Myelin Peptides, in Multiple Sclerosis Patients (TOLERVIT-MS) | Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Chronic Progressive | Drug: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3);Drug: Interferon-beta | Fundació Institut Germans Trias i Pujol | Clinica Universidad de Navarra, Universidad de Navarra | Recruiting | 18 Years | 60 Years | All | 16 | Phase 1 | Spain |
204 | NCT03250169 | July 1, 2017 | 16 December 2017 | Neurofilaments for NEDA Assessing in MS | Neurofilament Heavy and Light Chain Testing for NEDA (No Evidence of Disease Activity) Assessing in Multiple Sclerosis: a Longitudinal Biomarker Study | Multiple Sclerosis | Drug: Alemtuzumab | Queen Mary University of London | Recruiting | 18 Years | 55 Years | All | 60 | N/A | United Kingdom | |
205 | EUCTR2016-002937-31-SE | 19/06/2017 | 28 February 2019 | A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis | An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis | Relapsing remitting multiple sclerosis (RRMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ocrelizumab Product Code: RO4964913/F07-01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913/F07-01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- | F. Hoffmann-La Roche Ltd | Authorised | Female: yes Male: yes | 1078 | Phase 3 | Portugal;United States;Slovakia;Spain;Lebanon;Switzerland;Italy;France;Australia;Denmark;Kuwait;Netherlands;Slovenia;Turkey;Austria;United Kingdom;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Belgium;Romania;Croatia;Bulgaria;Norway;Germany;Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
206 | NCT03239860 | June 6, 2017 | 18 December 2018 | Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis | A Long-Term International, Extension of Study GNC-003 With GNbAC1 in Patients With Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: GNbAC1 Monoclonal Antibody | GeNeuro SA | Les Laboratoires Servier;Worldwide Clinical Trials;Institut de Recherches Internationales Servier | Not recruiting | 18 Years | 55 Years | All | 220 | Phase 2 | Bulgaria;Croatia;Czechia;Estonia;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine |
207 | NCT03381170 | June 1, 2017 | 11 November 2019 | An Extension of the TG1101-RMS201 Trial | An Open Label Extension of the TG1101-RMS201 Trial, for Subjects Currently Enrolled in TG1101-RMS201Treated With Ublituximab for Relapsing Forms of Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Biological: Ublituximab | TG Therapeutics, Inc. | Not recruiting | 18 Years | 55 Years | All | 48 | Phase 2 | United States | |
208 | NCT02618902 | May 30, 2017 | 11 June 2018 | A NegativeDendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial | A NegativeDendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial | Multiple Sclerosis | Biological: tolerogenic dendritic cells (tolDC) | University Hospital, Antwerp | Recruiting | 18 Years | 60 Years | All | 9 | Phase 1 | Belgium | |
209 | NCT02901106 | May 23, 2017 | 21 January 2019 | Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate | Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate SURV-SEP | Multiple Sclerosis, Relapsing-Remitting | Drug: Dimethyl fumarate | Fondation Ophtalmologique Adolphe de Rothschild | Not recruiting | 18 Years | N/A | All | 11 | Phase 4 | France | |
210 | EUCTR2016-003587-39-SE | 22/05/2017 | 4 December 2018 | This is a long-term study of the safety, efficacy and patient satisfaction of the drug rituximab in comparison with other immunomodulatory treatments for multiple sclerosis. The study will use a national registry for both retrospective and prospective data retrieval. | COMBAT-MS (COMparison Between All immunoTherapies for Multiple Sclerosis) A prospective long-term cohort study of safety, efficacy and patient’s satisfaction of MS disease modulatory treatments in relapsing-remitting multiple sclerosis - COMparison Between All immunoTherapies for Multiple Sclerosis (COMBAT-MS) | Relapsing-remitting multiple sclerosis (RRMS) that has started on their first or second immunomodulatory drug at the earliest 2011-01-01 and at the latest 2018-06-30. The clinical course and response to treatment is thereafter followed until 2021-06-30;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Mabthera Pharmaceutical Form: Infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 500-1000 Trade Name: Tysabri Pharmaceutical Form: Infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Trade Name: Tecfidera Pharmaceutical Form: Capsule INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- Trade Name: Gilenya Pharmaceutical Form: Tablet INN or Proposed INN: FINGOLIMOD CAS Number: 162359-55-9 Other descriptive name: FINGOLIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Trade Name: Copaxone Pharmaceutical Form: Injection INN or Proposed INN: GLATIRAMER ACETATE CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg milligram(s) Concentration type: range Concentration number: 20-40 Trade Name: Betaferon Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1B CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Trade Name: Extavia Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1B CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Trade Name: Avonex Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30- Trade Name: Rebif Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 | Karolinska Institutet | Authorised | Female: yes Male: yes | 3700 | Phase 4 | Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
211 | NCT03126760 | May 22, 2017 | 18 March 2019 | Pilot Study to Assess the Efficacy & Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis | A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis | Relapsing, Remitting Multiple Sclerosis | Drug: Repository Corticotropin Injection;Drug: Placebo | Mallinckrodt | Recruiting | 18 Years | N/A | All | 66 | Phase 4 | United States | |
212 | NCT03269071 | May 17, 2017 | 11 March 2019 | Neural Stem Cell Transplantation in Multiple Sclerosis Patients | Neural Stem Cell Transplantation in Multiple Sclerosis Patient: a Phase I Study | Progressive Multiple Sclerosis | Drug: human fetal-derived Neural Stem Cells (hNSCs) | IRCCS San Raffaele | Fondazione Italiana Sclerosi Multipla | Recruiting | 18 Years | 55 Years | All | 4 | Phase 1 | Italy |
213 | NCT03028675 | May 1, 2017 | 22 October 2019 | pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress | pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress | Multiple Sclerosis | Drug: Gd-DTPA-ST;Drug: Control | NYU Langone Health | Not recruiting | 18 Years | 65 Years | All | 4 | Phase 4 | United States | |
214 | NCT03345940 | April 30, 2017 | 4 November 2019 | Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis | A Multicentric Randomized PRAGmatic Trial to Compare the Effectiveness of Fingolimod Versus Dimethyl-Fumarate on Patient Overall Disease Experience in Relapsing Remitting Multiple Sclerosis: Novel Data to Inform Decision-makers | Relapsing Remitting Multiple Sclerosis | Drug: Fingolimod;Drug: Dimethyl Fumarate | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Patient-Centered Outcomes Research Institute;Universita degli Studi di Genova | Not recruiting | 18 Years | N/A | All | 55 | Phase 4 | Italy |
215 | NCT03073603 | April 20, 2017 | 22 July 2019 | Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS) | Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS) | Multiple Sclerosis | Drug: Discontinuation of disease modifying therapy;Drug: Standard of Care | University of Colorado, Denver | Patient-Centered Outcomes Research Institute;National Multiple Sclerosis Society;University of Alabama at Birmingham | Recruiting | 55 Years | N/A | All | 250 | Phase 4 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
216 | NCT02881567 | April 18, 2017 | 7 October 2019 | Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab | A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab (SUSTAIN) | Relapsing-Remitting Multiple Sclerosis (RRMS) | Drug: Daclizumab | Biogen | AbbVie | Not recruiting | 18 Years | 55 Years | All | 41 | Phase 3 | United States;Canada;Germany;Italy;Puerto Rico;France;United Kingdom |
217 | EUCTR2016-004935-18-HU | 12/04/2017 | 23 October 2017 | A clinical study to assess the long-term safety of GNbAC1 in patients with Multiple Sclerosis | A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis - ANGEL-MS | Multiple Sclerosis (MS) MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: GNbAC1 Product Code: GNbAC1 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Not Available CAS Number: 1393641-34-3 Current Sponsor code: GNbAC1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- | GeNeuro SA | Authorised | Female: yes Male: yes | 240 | Phase 2 | Serbia;Estonia;Czech Republic;Hungary;Poland;Spain;Ukraine;Croatia;Russian Federation;Bulgaria;Germany;Italy | |||
218 | EUCTR2016-003100-30-ES | 04/04/2017 | 10 April 2017 | A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients with RRMS with Disease Activity on Prior DMT | A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclerosis (RRMS) with Disease Activity on Prior Disease Modifying Therapy (DMT) | Multiple Sclerosis MedDRA version: 19.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Lemtrada Product Name: Lemtrada Product Code: GZ402673 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: alemtuzumab CAS Number: 216503-57-0 Current Sponsor code: GZ402673 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- | Genzyme Corporation | Authorised | Female: yes Male: yes | 65 | Phase 3 | Portugal;Greece;Spain;Turkey;Austria;Russian Federation;Switzerland;United Kingdom;Italy;France;Czech Republic;Poland;Belgium;Bulgaria;Norway;Netherlands;Germany;Sweden | |||
219 | NCT03085810 | April 4, 2017 | 11 November 2019 | Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) | An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Ocrelizumab | Hoffmann-La Roche | Not recruiting | 18 Years | 55 Years | All | 1233 | Phase 3 | United States;Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;Finland | |
220 | NCT02907177 | March 30, 2017 | 30 September 2019 | Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) | Multicenter, Randomized, Double-blind, Parallel-group, add-on, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) | Multiple Sclerosis | Drug: Ponesimod;Other: Placebo | Actelion | Recruiting | 18 Years | 55 Years | All | 600 | Phase 3 | United States;Australia;Austria;Belgium;Bulgaria;Canada;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Mexico;Poland;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;Croatia;Czech Republic;Norway | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
221 | NCT03091400 | March 28, 2017 | 25 June 2018 | Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS) | Phase Two Randomized Controlled Crossover Trial of Atomoxetine to Treat Memory Impairment Due to Multiple Sclerosis | Memory Disorders;Multiple Sclerosis | Drug: Atomoxetine;Drug: Placebo | Icahn School of Medicine at Mount Sinai | Not recruiting | 21 Years | 60 Years | All | 11 | Phase 2 | United States | |
222 | NCT03110315 | March 28, 2017 | 29 April 2019 | A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia | A Double-blind, Crossover, Placebo-controlled Study to Compare the Effects of Nighttime Administration of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia | Multiple Sclerosis;Fatigue;Insomnia | Drug: Suvorexant;Drug: Placebo | Theodore R. Brown, MD MPH | Merck Sharp & Dohme Corp. | Recruiting | 18 Years | 75 Years | All | 30 | Phase 4 | United States |
223 | NCT03093324 | March 15, 2017 | 2 September 2019 | A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 | A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate | Relapsing Remitting Multiple Sclerosis | Drug: ALKS 8700;Drug: Dimethyl Fumarate | Alkermes, Inc. | Not recruiting | 18 Years | 65 Years | All | 506 | Phase 3 | United States;Germany;Poland | |
224 | NCT03091569 | March 10, 2017 | 11 June 2018 | Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy | Effects of VITAmin K in Lessening Erythema Grade Associated to Injection Site Reactions in Patients Treated With PlegridY (VITALITY) | Relapsing-Remitting Multiple Sclerosis | Other: Vitamin K Cream;Other: Placebo Cream | Biogen | Not recruiting | 18 Years | N/A | All | 23 | Phase 4 | Italy | |
225 | EUCTR2016-000700-29-DE | 08/03/2017 | 28 February 2019 | Effect of MD1003 in progressive multiple sclerosis with walking impairment | Effect of MD1003 in progressive multiple sclerosis: a randomized double-blind placebo-controlled study. - SPI2 | Multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: D-Biotin Product Code: MD1003 Pharmaceutical Form: Capsule, hard INN or Proposed INN: D-BIOTIN CAS Number: 58-85-5 Current Sponsor code: MD1003 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | MEDDAY PHARMACEUTICALS SA | Authorised | Female: yes Male: yes | 754 | Phase 3 | United States;Spain;Turkey;United Kingdom;Italy;Czech Republic;Hungary;Canada;Poland;Belgium;Australia;Germany;Netherlands;Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
226 | NCT02975349 | March 7, 2017 | 28 January 2019 | A Study of Efficacy and Safety of M2951 in Subjects With Relapsing Multiple Sclerosis | A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 With a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients With Relapsing Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity. | Relapsing-remitting Multiple Sclerosis | Drug: M2951;Drug: Placebo;Drug: Tecfidera | EMD Serono Research & Development Institute, Inc. | Merck KGaA, Darmstadt, Germany | Not recruiting | 18 Years | 65 Years | All | 267 | Phase 2 | Bulgaria;Czechia;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;Germany;United States |
227 | NCT03164018 | March 7, 2017 | 25 February 2019 | Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis | Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis | Multiple Sclerosis | Drug: Fampridine | Genesis Pharma CNS & Specialty | Not recruiting | 18 Years | N/A | All | 111 | Phase 2 | Greece | |
228 | NCT03806387 | March 1, 2017 | 28 January 2019 | Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment | Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment - a Prospective Observational Study | Multiple Sclerosis | Drug: Alemtuzumab | University of Aarhus | Genzyme, a Sanofi Company | Recruiting | 18 Years | 65 Years | All | 60 | N/A | Denmark |
229 | NCT02149706 | March 2017 | 14 March 2016 | A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis | A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination | Multiple Sclerosis | Biological: NeuroVax;Biological: IFA Incomplete Freund's Adjuvant | Immune Response BioPharma, Inc. | Oregon Health and Science University | Not recruiting | 18 Years | 70 Years | Both | 150 | Phase 2 | United States |
230 | EUCTR2016-001448-21-SK | 16/02/2017 | 28 February 2019 | A Study of Efficacy and Safety of M2951 in Relapsing Multiple Sclerosis | A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 with a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients with Relapsing Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity. | Relapsing Multiple Sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: M2951 Product Code: M2951 Pharmaceutical Form: Tablet INN or Proposed INN: M2951 Current Sponsor code: M2951 Other descriptive name: M2951 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Tecfidera Product Name: Tecfidera Pharmaceutical Form: Capsule, hard INN or Proposed INN: Tecfidera CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Trade Name: Tecfidera Product Name: Tecfidera Pharmaceutical Form: Capsule, hard INN or Proposed INN: Tecfidera CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- | Merck KGaA | Authorised | Female: yes Male: yes | 250 | Phase 2 | Serbia;United States;Czech Republic;Slovakia;Poland;Spain;Ukraine;Croatia;Turkey;Russian Federation;Bulgaria;United Kingdom | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
231 | NCT02949908 | February 9, 2017 | 16 December 2017 | MEasuring Satisfaction of Treatment With REbif After Initial Treatment of MS (MESTRE-MS) | A Phase IV, Prospective, Multicenter, Open Label, Uncontrolled, Non-interventional, Single Arm Study to Measure Treatment Satisfaction of Multiple Sclerosis (MS) Patients on Rebif® After Discontinuing Initial First-line Treatment | Multiple Sclerosis | Drug: Rebif (IFNß-1b) | Merck KGaA | Merck B.V., Netherlands | Not recruiting | 18 Years | 65 Years | All | 2 | N/A | Germany |
232 | NCT03193866 | February 1, 2017 | 29 April 2019 | COMparison Between All immunoTherapies for Multiple Sclerosis. | COMparison Between All immunoTherapies for Multiple Sclerosis. An Observational Long-term Prospective Cohort Study of Safety, Efficacy and Patient's Satisfaction of MS Disease Modulatory Treatments in Relapsing-remitting Multiple Sclerosis | Relapsing-remitting Multiple Sclerosis | Drug: Rituximab | Karolinska Institutet | Patient-Centered Outcomes Research Institute;Kaiser Foundation Research Institute | Recruiting | 18 Years | N/A | All | 3700 | N/A | Sweden |
233 | NCT03418376 | February 1, 2017 | 21 January 2019 | Carnosine Loading in MS and HC | The Impact of Carnosine Loading and Rehabilitation Therapy on Exercise Capacity in Multiple Sclerosis. | Multiple Sclerosis;Exercise Therapy;Dietary Supplement | Dietary Supplement: Beta-alanine supplementation;Other: Exercise intervention | Hasselt University | Not recruiting | 18 Years | 75 Years | All | 45 | N/A | Belgium | |
234 | NCT02057159 | February 2017 | 14 March 2016 | A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis | A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis | Secondary Progress Multiple Sclerosis;Multiple Sclerosis | Biological: NeuroVax;Biological: IFA Placebo | Immune Response BioPharma, Inc. | Oregon Health and Science University | Not recruiting | 18 Years | 50 Years | Both | 200 | Phase 2/Phase 3 | United States |
235 | NCT03021317 | February 2017 | 16 December 2017 | Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses | Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses | Multiple Sclerosis | Drug: ACTHar | University of Chicago | Not recruiting | 18 Years | N/A | All | 18 | Phase 4 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
236 | NCT03177083 | January 30, 2017 | 24 September 2018 | Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy | Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients With Relapsing Remitting Multiple Sclerosis (MS) Transitioning From Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™) | Relapsing Remitting Multiple Sclerosis | Drug: peginterferon beta-1a;Drug: interferon beta-1a;Drug: interferon beta-1b | Biogen | Recruiting | 18 Years | 65 Years | All | 140 | Phase 4 | Portugal | |
237 | NCT03051646 | January 13, 2017 | 26 November 2018 | Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis | A Placebo-controlled Double Blind Crossover Trial of Acetylsalicylic Acid as a Pre-treatment for Exercise in Multiple Sclerosis | Overheating;Fatigue | Drug: Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit;Drug: Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit | Columbia University | National Multiple Sclerosis Society | Not recruiting | 18 Years | 60 Years | All | 12 | Early Phase 1 | United States |
238 | NCT03032601 | January 5, 2017 | 23 April 2019 | Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis | Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis | Multiple Sclerosis | Dietary Supplement: N-acetyl Cysteine | Thomas Jefferson University | Not recruiting | 30 Years | 80 Years | All | 25 | N/A | United States | |
239 | NCT03193086 | January 1, 2017 | 16 December 2017 | The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients | The Effect of Alemtuzumab on the Blood-brain-barrier and Cerebral Metabolism in Multiple Sclerosis Patients; a New MRI Method for Treatment Response Evaluation in Multiple Sclerosis | Multiple Sclerosis | Drug: Alemtuzumab | Glostrup University Hospital, Copenhagen | Genzyme, a Sanofi Company | Recruiting | 18 Years | 60 Years | All | 35 | N/A | Denmark |
240 | NCT02481882 | January 2017 | 22 October 2018 | Baseline Cortical Haemodynamics in MS | Investigating Baseline Cortical Haemodynamics in Multiple Sclerosis | Multiple Sclerosis | Device: Magnetic Resonance Imaging;Drug: Prohance (Gadoteridol) | University of Nottingham | Recruiting | 21 Years | 80 Years | All | 80 | N/A | United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
241 | NCT02980042 | January 2017 | 29 April 2019 | Tolerability and Safety of Switching From Rituximab to Ocrelizumab in Patients With Relapsing Forms of Multiple Sclerosis | Evaluating the Tolerability and Safety Profile of Switching From Rituximab to Ocrelizumab: A Real World Evaluation of Patients With Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis | Drug: Ocrelizumab;Drug: Rituximab | University of Colorado, Denver | Recruiting | 18 Years | 65 Years | All | 200 | Phase 3 | United States | |
242 | NCT03172741 | January 2017 | 20 August 2018 | The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis | The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis | Multiple Sclerosis | Drug: Medical Marijuana;Drug: Placebo | Colorado State University | Not recruiting | 21 Years | 74 Years | All | 0 | Phase 2/Phase 3 | ||
243 | NCT04082260 | January 2017 | 30 September 2019 | Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response | Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response | Multiple Sclerosis | Drug: Alemtuzumab Injection [Lemtrada] | University Hospital Muenster | Recruiting | 18 Years | N/A | All | 150 | N/A | Germany | |
244 | EUCTR2017-005129-18-IT | 17 September 2018 | Clinical trial to evaluate the effectiveness and safety of IFN beta-1a (IFN beta-1a), injected once a week via intramuscolar (i.m.), and glatiramer-acetate (GA) in children/adolescent patients with multiple sclerosis. | Multi-centre, randomised, open label pragmatic trial to compare the effectiveness and safety of interferon beta-1a (IFN-beta-1a) weekly i.m. and glatiramer-acetate (GA) in paediatric patients affected by multiple sclerosis. | Relapsing-remitting multiple sclerosis with paediatric onset MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Copaxone 40 mg/ml solution for injection, pre-filled syringe Pharmaceutical Form: Suspension for injection in pre-filled syringe INN or Proposed INN: Glatiramer Acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40- Trade Name: AVONEX 30 µg/0,5 ml solution for injection Pharmaceutical Form: Suspension for injection in pre-filled syringe INN or Proposed INN: Interferon beta-1a CAS Number: 145258-61-3 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 30- | Università degli Studi Aldo Moro | Not Available | Female: yes Male: yes | 142 | Phase 3 | Italy | ||||
245 | NCT02969304 | December 30, 2016 | 16 December 2017 | Study of Utilization Patterns of Dimethyl Fumarate in Germany | Claims Database Study of Utilization Patterns of Dimethyl Fumarate in Germany | Multiple Sclerosis | Drug: dimethyl fumarate | Biogen | Not recruiting | N/A | N/A | All | 930 | N/A | Germany | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
246 | NCT03186664 | December 28, 2016 | 26 August 2019 | The Role of SAtivex® in Robotic-Rehabilitation | The Role of SAtivex® Associated With Robotic-Rehabilitation in Improving the Motor Performances of Multiple Sclerosis Patients (SARR) | Rehabilitation | Device: Lokomat training;Drug: Sativex | IRCCS Centro Neurolesi Bonino-Pulejo | Not recruiting | 18 Years | 65 Years | All | 40 | N/A | Italy | |
247 | NCT02977533 | December 1, 2016 | 11 June 2018 | A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis | A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of GZ402668 in Men and Women With Progressive Multiple Sclerosis | Progressive Multiple Sclerosis | Drug: GZ402668;Drug: Placebo;Drug: Acyclovir | Sanofi | Not recruiting | 18 Years | 65 Years | All | 20 | Phase 1 | Germany | |
248 | NCT03561402 | December 1, 2016 | 20 August 2018 | Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio) | Association of Possible Biomarkers With Disease Activity in Patients Treated With Teriflunomide (Aubagio) | Multiple Sclerosis, Relapsing-Remitting | Drug: Teriflunomide | McGill University | Recruiting | 18 Years | 55 Years | All | 75 | Early Phase 1 | Canada | |
249 | NCT02936037 | December 2016 | 20 May 2019 | Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) | Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study | Multiple Sclerosis | Drug: MD1003 100mg capsule;Drug: PLACEBO | MedDay Pharmaceuticals SA | Not recruiting | 18 Years | 65 Years | All | 642 | Phase 3 | United States;Australia;Belgium;Canada;Czechia;Germany;Hungary;Italy;Poland;Spain;Sweden;Turkey;United Kingdom;Czech Republic;Netherlands | |
250 | NCT02959658 | December 2016 | 4 March 2019 | Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis | Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Drug: Dimethyl Fumarate;Drug: Placebo Oral Capsule | Rigshospitalet, Denmark | Biogen | Not recruiting | 18 Years | 65 Years | All | 90 | Phase 2 | Denmark |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
251 | EUCTR2015-005431-41-HR | 30/11/2016 | 7 January 2019 | A late stage clinical trial to investigate the efficacy and safety of SA237 monotherapy in patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) | Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD) MedDRA version: 20.0 Level: LLT Classification code 10029322 Term: Neuromyelitis optica System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: SA237 Product Code: SA237-120/vial Pharmaceutical Form: Solution for injection INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: SA237-120 PFS with NSD Product Code: L04AX01 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120- | Chugai Pharmaceutical Co. Ltd | Authorised | Female: yes Male: yes | 90 | Phase 3 | United States;Taiwan;Ukraine;Turkey;Italy;Canada;Malaysia;Poland;Croatia;Romania;Bulgaria;Georgia;Korea, Republic of | |||
252 | EUCTR2016-002180-33-PL | 16/11/2016 | 29 January 2018 | Multiple sclerosis therapy with transdermal myelin peptide stimulation. | Multiple sclerosis therapy with transdermal myelin peptide stimulation. | relapsing-remitting multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: SMderpept Pharmaceutical Form: Powder for cutaneous solution INN or Proposed INN: PLP peptide Current Sponsor code: PLP peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- INN or Proposed INN: MBP peptide Current Sponsor code: MBP peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- INN or Proposed INN: MOG peptide Current Sponsor code: MOG peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Product Name: SMderpept Pharmaceutical Form: Powder for cutaneous solution INN or Proposed INN: PLP peptide Current Sponsor code: PLP peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- INN or Proposed INN: MBP peptide Current Sponsor code: MBP peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- INN or Proposed INN: MOG peptide Current Sponsor code: MOG peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Product Name: Avonex Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta 1-A CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30- | Centrum Neurologii Krzysztof Selmaj | Authorised | Female: yes Male: yes | 220 | Phase 2 | Poland | |||
253 | EUCTR2012-000541-12-DE | 15/11/2016 | 6 November 2018 | Clinical study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera®) | Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera®) - POINT | Relapsing multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) | Actelion Pharmaceuticals Ltd. | Authorised | Female: yes Male: yes | 600 | Phase 3 | Greece;Finland;United States;Portugal;Spain;Austria;Israel;Italy;France;Czech Republic;Hungary;Canada;Belgium;Poland;Australia;Denmark;Bulgaria;Germany | |||
254 | EUCTR2016-000434-21-PT | 14/11/2016 | 30 April 2019 | PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™) | PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™) | Relapsing-remitting multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Plegridy 125 micrograms Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: Peginterferon beta-1a CAS Number: 1211327-92-2 Other descriptive name: PEGINTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 125- Trade Name: Rebif 22 micrograms Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: Interferon beta-1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- Trade Name: Rebif 44 micrograms Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: Interferon beta-1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Trade Name: Betaferon 250 microgram/ml Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Recombinant Interferon Beta-1b Other descriptive name: RECOMBINANT INTERFERON BETA-1B Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: Extavia 250 micrograms/ml Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Recombinant Interferon Beta-1b Other descriptive name: RECOMBINANT INTERFERON BETA-1B | Biogen Portugal | Authorised | Female: yes Male: yes | 140 | Phase 4 | Portugal | |||
255 | NCT03516526 | November 3, 2016 | 22 July 2019 | Towards Personalized Dosing of Natalizumab in Multiple Sclerosis | Towards Personalized Dosing of Natalizumab in Multiple Sclerosis | Multiple Sclerosis | Drug: Natalizumab | VU University Medical Center | Sanquin Plasma Products BV;Erasmus Medical Center;St. Antonius Hospital;OLVG;Rijnstate Hospital | Not recruiting | 18 Years | N/A | All | 61 | Phase 4 | Netherlands |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
256 | NCT02913157 | November 2016 | 29 April 2019 | Hydroxychloroquine in Primary Progressive Multiple Sclerosis | Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Hydroxychloroquine 200mg BID for Reducing Progression of Disability in Patients With Primary Progressive Multiple Sclerosis (PPMS) | Multiple Sclerosis, Primary Progressive | Drug: Hydroxychloroquine | University of Calgary | Recruiting | 18 Years | 65 Years | All | 35 | Phase 2 | Canada | |
257 | EUCTR2016-001515-20-IT | 20/10/2016 | 12 February 2018 | nd | EFFECT OF TERIFLUNOMIDE ON T CELL SUBPOPULATIONS IN PERIPHERAL BLOOD FROM RRMS PATIENTS - nd | RELAPSING-REMITTING MULTIPLE SCLEROSIS MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 28 COMPRESSE Product Name: teriflunomide Product Code: nd Pharmaceutical Form: Film-coated tablet | UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI | Authorised | Female: yes Male: yes | 30 | Phase 4 | Italy | |||
258 | NCT02587065 | October 19, 2016 | 11 June 2018 | Plegridy Satisfaction Study in Participants | Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Plegridy (Pre-filled Pen) in Subjects With Relapsing-remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM) | Relapsing-Remitting Multiple Sclerosis (RRMS) | Drug: peginterferon beta-1a | Biogen | Not recruiting | 18 Years | 65 Years | All | 199 | Phase 4 | Italy | |
259 | NCT02601885 | October 18, 2016 | 11 June 2018 | A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis | An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis | Drug: ABT-555;Other: Placebo | AbbVie | Not recruiting | 18 Years | 60 Years | All | 20 | Phase 1 | United States | |
260 | NCT01649050 | October 2016 | 16 December 2017 | Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis | A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Assess the Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis | Muscle Spasticity Due to Multiple Sclerosis | Drug: BGG492;Drug: Placebo | Novartis Pharmaceuticals | Not recruiting | 18 Years | 65 Years | All | 0 | Phase 2 | Germany;Russian Federation | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
261 | NCT02807285 | October 2016 | 16 December 2017 | Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | An Open Label, MultiCenter, Expanded-Access Program for Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis | Multiple Sclerosis | Drug: Ocrelizumab | Genentech, Inc. | Not recruiting | 18 Years | 55 Years | All | N/A | United States | ||
262 | EUCTR2016-000345-31-NL | 30/09/2016 | 10 October 2016 | Reduce the number of natalizumab infusions in patients with multiple sclerosis | Towards personalized dosing of natalizumab in multiple sclerosis - Personalised Dosing of Natalizumab in Multiple Sclerosis (The PDNMS trial) | multiple sclerosis MedDRA version: 18.1 Level: LLT Classification code 10070425 Term: Multiple sclerosis exacerbation System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: tysabri Product Name: natalizumab Pharmaceutical Form: Solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- | VU medical center | Authorised | Female: yes Male: yes | 60 | Phase 4 | Netherlands | |||
263 | EUCTR2016-003073-18-GB | 29/09/2016 | 3 April 2017 | A study designed to investigate how radiolabelled RPC1063 is taken up, broken down and removed from the body | A Phase I, Single-Centre, Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults - ADME study of [14C]-RPC1063 in healthy male subjects (QCL117686) | The drug is a potential treatment for adult patients with relapsing multiple sclerosis (RMS) and for adult patients with moderately to severely active inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). MedDRA version: 19.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.0 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856 MedDRA version: 19.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: [14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration Pharmaceutical Form: Oral solution INN or Proposed INN: Ozanimod hydrochloride CAS Number: 1618636-37-5 Current Sponsor code: RPC1063HCL Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 0.1- | Celgene International II Sàrl | Authorised | Female: no Male: yes | 6 | Phase 1 | United Kingdom | |||
264 | NCT03101735 | September 23, 2016 | 20 August 2018 | Study to Assess Resource Utilization and Quality of Life of Patients With RRMS Treated With Tecfidera in Greece | A Real Life, Non-interventional, Multicentre Study to Assess Resource Utilization and Quality of Life of Patients With Relapsing Forms of Multiple Sclerosis Treated With Dimethyl Fumarate in Greece - the FIDELITY Study | RRMS | Drug: Dimethyl Fumarate (DMF) | Genesis Pharma CNS & Specialty | Not recruiting | 18 Years | 65 Years | All | 455 | N/A | Greece | |
265 | JPRN-UMIN000024312 | 2016/09/20 | 2 April 2019 | Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds. | Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis | Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks | Tsukuba International Clinical Pharmacology Clinic | Not Recruiting | 20years-old | 80years-old | Male and Female | 12 | Not selected | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
266 | NCT02792218 | September 20, 2016 | 16 September 2019 | Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis | A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | Drug: Placebo subcutanous injection matching to ofatumumab;Drug: Teriflunomide orally;Drug: Placebo orally matching to teriflunomide;Drug: Ofatumumab subcutaneous injection | Novartis Pharmaceuticals | Not recruiting | 18 Years | 55 Years | All | 929 | Phase 3 | Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Puerto Rico;Russian Federation;Slovakia;Spain | |
267 | EUCTR2015-005418-31-EE | 12/09/2016 | 28 February 2019 | Study of efficacy and safety of ofatumumab compared to teriflunomide in patients with relapsing forms of multiple sclerosis | A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis | multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Current Sponsor code: OMB157 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Trade Name: Aubagio Product Name: Teriflunomide Pharmaceutical Form: Capsule, hard INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Novartis Pharma Services AG | Authorised | Female: yes Male: yes | 900 | Phase 3 | United States;Estonia;Slovakia;Greece;Thailand;Spain;Russian Federation;Israel;Switzerland;India;France;Australia;Denmark;Netherlands;Turkey;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Argentina;Belgium;Poland;Croatia;Bulgaria;Germany;Sweden | |||
268 | EUCTR2016-000283-41-DK | 12/09/2016 | 6 November 2018 | Treatment with dimethyl fumarate in patients with primary progressive multiple sclerosis | Dimethyl fumarate treatment of primary progressive multiple sclerosis - FUMAPMS | Primary progressive multiple sclerosis (PPMS) MedDRA version: 20.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Tecfidera Product Name: dimethyl fumarate Product Code: dimethyl fumarate Pharmaceutical Form: Capsule, hard INN or Proposed INN: dimethyl fumarate CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Finn Sellebjerg | Authorised | Female: yes Male: yes | 90 | Phase 2 | Denmark | |||
269 | NCT02861014 | September 9, 2016 | 22 October 2019 | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) | An Open-Label Study To Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Multiple Sclerosis Who Have A Suboptimal Response to an Adequate Course of Disease-Modifying Treatment | Multiple Sclerosis, Relapsing-Remitting | Biological: Ocrelizumab | Hoffmann-La Roche | Not recruiting | 18 Years | 55 Years | All | 681 | Phase 3 | Australia;Belgium;Czechia;Denmark;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;Czech Republic;Hong Kong | |
270 | NCT02898974 | September 2016 | 22 January 2018 | Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis | Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis: An Observational Case-control Study | Multiple Sclerosis | Behavioral: Medical Marijuana | Colorado State University | William R. Shaffer, M.D. | Not recruiting | 30 Years | 60 Years | All | 19 | N/A | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
271 | NCT02792231 | August 26, 2016 | 16 September 2019 | Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. | A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis. | Relapsing Multiple Scelrosis | Drug: Ofatumumab subcutaneous injection;Drug: Placebo orally matching to teriflunomide;Drug: Teriflunomide orally;Drug: Placebo subcutaneous injection matching to ofatumumab | Novartis Pharmaceuticals | Not recruiting | 18 Years | 55 Years | All | 900 | Phase 3 | United States;Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Finland;France;Germany;Hungary;India;Italy;Latvia;Lithuania;Mexico;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom | |
272 | EUCTR2015-003147-19-GR | 18/07/2016 | 8 August 2016 | To confirm the safety and efficacy of NEUROASPIS PLP10® in the treatment of individuals, who have been diagnosed with relapsing remitting multiple sclerosis (MS). | Novel Oral Nutraceutical Intervention NEUROASPIS PLP10® for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Multicenter, Parallel-group, Phase III, Double-blind, Randomized, Placebo-Controlled, Add-on with Interferon Beta, Trial of Efficacy and Safety. - Efficacy and Safety study of NEUROASPIS PLP10® versus placebo | Relapsing-Remitting Multiple Sclerosis (RRMS) MedDRA version: 19.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: NEUROASPIS PLP10® Pharmaceutical Form: Oral liquid INN or Proposed INN: FISH OIL,RICH IN OMEGA 3 ACIDS Other descriptive name: FISH OIL, RICH IN OMEGA-3-ACIDS Concentration unit: % (W/W) percent weight/weight Concentration type: equal Concentration number: 42.1- INN or Proposed INN: BORAGE OIL 20% GLA CAS Number: 8000051-62-9 Other descriptive name: BORAGE OIL Concentration unit: % (W/W) percent weight/weight Concentration type: equal Concentration number: 43.7- INN or Proposed INN: beta-Carotene Other descriptive name: BETACAROTENE Concentration unit: % (W/W) percent weight/weight Concentration type: equal Concentration number: 0.04- INN or Proposed INN: Gamma-tocopherol CAS Number: 54 28 4 Concentration unit: % (W/W) percent weight/weight Concentration type: equal Concentration number: 4.2- Pharmaceutical form of the placebo: Oral liquid Route of administration of the placebo: Oral use | PALUPA Medical Ltd | Authorised | Female: yes Male: yes | 220 | Phase 3 | Greece | |||
273 | NCT03436927 | July 15, 2016 | 26 February 2018 | Comparison of Two Different Virtual Reality Methods in Patients With Multiple Sclerosis | Comparison of the Effects of Two Different Virtual Reality Treatment Methods in Patients With Multiple Sclerosis: A Randomized Controlled Trial | Multiple Sclerosis | Other: Nintendo Wii Fit Balance exercises;Other: Balance Trainer Balance Exercises | Biruni University | Istanbul University | Not recruiting | 25 Years | 60 Years | All | 51 | N/A | |
274 | NCT02660359 | July 8, 2016 | 11 November 2019 | Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 | A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis | Urinary Incontinence;Overactive Bladder | Biological: Botulinum toxin type A;Drug: Placebo | Ipsen | Not recruiting | 18 Years | 80 Years | All | 258 | Phase 3 | Argentina;Australia;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;Peru;Russian Federation;Spain;Ukraine;United Kingdom;New Zealand | |
275 | NCT02760056 | July 2016 | 5 September 2016 | Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study | Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study | Multiple Sclerosis | Drug: Liothyronine sodium;Drug: Placebo | Oregon Health and Science University | Recruiting | 18 Years | 50 Years | Both | 24 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
276 | NCT02833142 | July 2016 | 9 January 2017 | Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes | A Randomized, Blinded, Parallel-Group, Phase 1 Study of Pharmacokinetics, Safety and Tolerability of Single Intravenous Doses of BIIB033 (Opicinumab ) Produced by 2 Manufacturing Processes, in Healthy Volunteers | Multiple Sclerosis;Acute Optic Neuritis | Drug: BIIB033 (opicinumab) | Biogen | Not recruiting | 18 Years | 55 Years | Both | 28 | Phase 1 | United States | |
277 | NCT02869425 | July 2016 | 9 September 2019 | To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS | A Randomized, Double-Blind, Parallel-Group Study to Assess the Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With Multiple Sclerosis | Multiple Sclerosis;Sperm | Drug: arbaclofen ER Tablets;Drug: Placebo for arbaclofen ER tablets | Osmotica Pharmaceutical US LLC | Not recruiting | 18 Years | 55 Years | Male | 0 | Phase 3 | United States | |
278 | NCT03069170 | July 2016 | 18 June 2018 | Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis. | Safety and Efficacy of Immuno-modulation and Autologous Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Multiple Sclerosis. | Multiple Sclerosis | Biological: Stem Cell Transplantation | Stem Cells Arabia | Not recruiting | N/A | N/A | All | 50 | Phase 1 | Jordan | |
279 | NCT02921035 | June 30, 2016 | 30 September 2019 | Non-interventional Study to Assess Adherence to Treatment for Patients With Relapsing Multiple Sclerosis | A Multicenter, Prospective, Non-interventional Study to Assess Adherence to Treatment for patIeNts With Relapsing Multiple Sclerosis (RMS) Who Are Prescribed Subcutaneous (sc) Interferon Beta-1a | Relapsing Multiple Sclerosis | Drug: Rebif (Interferon beta-1a) | Merck KGaA, Darmstadt, Germany | Merck Serono Middle East FZ LLC | Not recruiting | 18 Years | 60 Years | All | 594 | N/A | Algeria;Argentina;Bahrain;Bulgaria;Egypt;Hungary;Iran, Islamic Republic of;Korea, Republic of;Kuwait;Lebanon;Morocco;Poland;Saudi Arabia;Germany;Tunisia;United Arab Emirates |
280 | EUCTR2015-000507-44-DE | 29/06/2016 | 21 May 2018 | A study to investigate DYSPORT® for the treatment of subjects with loss of bladder control and involuntary urination as a result of spinal cord injury or multiple sclerosis | A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT® FOR THE TREATMENT OF URINARY INCONTINENCE IN SUBJECTS WITH NEUROGENIC DETRUSOR OVERACTIVITY DUE TO SPINAL CORD INJURY OR MULTIPLE SCLEROSIS | Urinary incontinence caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10046543 Term: Urinary incontinence System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Not possible to specify | Trade Name: Dysport® Product Name: Dysport® Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: CLOSTRIDIUM BOTULINUM TOXIN TYPE A CAS Number: 93384-43-1 Current Sponsor code: 52120 Other descriptive name: BOTULINUM TOXIN A - HAEMAGGLUTININ COMPLEX Concentration unit: U unit(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Intravesical use Trade Name: Dysport® Product Name: Dysport® Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: CLOSTRIDIUM BOTULINUM TOXIN TYPE A CAS Number: 93384-43-1 Current Sponsor code: 52120 Other descriptive name: BOTULINUM TOXIN A - HAEMAGGLUTININ COMPLEX Concentration unit: U unit(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Intravesical use | Ipsen Innovation | Authorised | Female: yes Male: yes | 330 | Phase 3 | Spain;Ukraine;Lithuania;Russian Federation;Chile;Israel;Colombia;United Kingdom;France;Mexico;Argentina;Belgium;Brazil;Peru;Germany;New Zealand | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
281 | NCT02797015 | June 23, 2016 | 11 June 2018 | Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS | A Phase I, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics and Pharmacodynamics of RPC 1063 in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis | Drug: RPC1063 | Celgene | Not recruiting | 18 Years | 55 Years | All | 22 | Phase 1 | United States | |
282 | EUCTR2016-000464-42-DE | 13/06/2016 | 11 June 2018 | The Effectiveness of an Additional Course of Alemtuzumab in Relapsing Remitting Multiple Sclerosis Patients After 2 Courses of Alemtuzumab | A Prospective, Open-label, Interventional Phase IIIb Clinical Trial to Investigate the Effectiveness of an Additional Course of Alemtuzumab in Relapsing Remitting Multiple Sclerosis Patients After 2 Courses of Alemtuzumab - LemCourse | Relapsing-remitting multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Lemtrada Product Name: Lemtrada Product Code: GZ402673 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: alemtuzumab CAS Number: 216503-57-0 Current Sponsor code: GZ402673 Other descriptive name: ALEMTUZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- | Genzyme GmbH | Authorised | Female: yes Male: yes | 100 | Phase 3 | Germany | |||
283 | NCT02424396 | June 13, 2016 | 11 February 2019 | Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis | Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis. Multicentric Randomized Study | Relapsing Remitting Multiple Sclerosis | Drug: IL2;Drug: Placebo | Assistance Publique - Hôpitaux de Paris | Fondation ARSEP/AFM | Recruiting | 18 Years | 65 Years | All | 30 | Phase 2 | France |
284 | NCT03150966 | June 8, 2016 | 24 September 2018 | The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients | The Effects of Oral Nanocurcumin on Expression Levels of microRNAs and Treg Cells and Th17 Cells Development Factors in Multiple Sclerosis Patients | Multiple Sclerosis | Drug: Nanocurcumin;Drug: Placebo | Tabriz University of Medical Sciences | Not recruiting | 18 Years | 65 Years | All | 41 | Phase 2 | Iran, Islamic Republic of | |
285 | EUCTR2015-005160-41-PL | 07/06/2016 | 28 February 2019 | an Open Label Study of ALKS 8700 in Adults with Multiple Sclerosis | A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis - EVOLVE-MS-1 | Relapsing Remitting Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: N/A Product Code: ALKS 8700 Delayed Release (DR) Capsule Pharmaceutical Form: Capsule INN or Proposed INN: Not available CAS Number: Not availabl Current Sponsor code: RDC-5108-00, ALKS 8700 Other descriptive name: ALKS 8700 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 231- | Alkermes, Inc. | Authorised | Female: yes Male: yes | 800 | Phase 3 | Serbia;United States;Canada;Belgium;Spain;Poland;Ukraine;Russian Federation;Bulgaria;Germany | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
286 | NCT02446886 | June 2016 | 14 January 2019 | Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS | Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS | Multiple Sclerosis | Drug: Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®) | Weill Medical College of Cornell University | Mallinckrodt | Recruiting | 18 Years | N/A | All | 30 | Phase 4 | United States |
287 | NCT02609607 | June 2016 | 18 December 2018 | Treating Anorectal Dysfunction in MS | Treating Anorectal Dysfunction Associated With Multiple Sclerosis | Constipation;Fecal Incontinence;Multiple Sclerosis | Drug: Bisacodyl;Other: Placebo | David Levinthal | Consortium of Multiple Sclerosis Centers | Not recruiting | 18 Years | 80 Years | All | 11 | Phase 2 | United States |
288 | NCT02870023 | June 2016 | 4 March 2019 | How Does Strength Training and Balance Training Affect Gait Function and Fatigue in Patients With Multiple Sclerosis? | How Does Strength Training and Balance Training Affect Gait Function and Fatigue in Patients With Multiple Sclerosis? | Multiple Sclerosis | Other: Balance training;Other: Strength training | University of Aarhus | VIA University College;TrygFonden, Denmark;Fondazione Don Carlo Gnocchi Onlus | Not recruiting | 18 Years | N/A | All | 71 | N/A | Denmark |
289 | NCT02784210 | May 26, 2016 | 23 April 2019 | Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques | The Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques: An Investigator-Blinded Study | Multiple Sclerosis | Drug: Methylprednisolone | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | 25 Years | 55 Years | All | 10 | Phase 2 | United States | |
290 | NCT02676739 | May 20, 2016 | 1 April 2019 | Adderall XR and Cognitive Impairment in MS | A Double-blind Placebo Controlled Study of Mixed-amphetamine Salts, Extended Release (Adderall XR) for Cognitive Impairment in MS | Multiple Sclerosis | Drug: Adderall XR | Sarah Morrow | Recruiting | 18 Years | 59 Years | All | 180 | Phase 2/Phase 3 | Canada | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
291 | EUCTR2015-005597-38-GB | 19/05/2016 | 7 January 2019 | A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis | An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment - CASTING | Relapsing remitting multiple sclerosis (RRMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ocrelizumab Product Code: RO4964913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- | F. Hoffmann-La Roche Ltd | Authorised | Female: yes Male: yes | 750 | Phase 3 | Estonia;Greece;Finland;Spain;Ireland;Turkey;Italy;United Kingdom;Switzerland;France;Czech Republic;Belgium;Denmark;Norway;Netherlands;Germany;Sweden | |||
292 | NCT03237832 | May 16, 2016 | 16 December 2017 | A Phase 1 Study of ARN-6039 | A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Oral Doses of ARN-6039 in Healthy Adult Subjects. | Multiple Sclerosis | Drug: ARN-6039;Other: Placebo | Arrien Pharmaceuticals | Worldwide Clinical Trials | Not recruiting | 18 Years | 50 Years | All | 60 | Phase 1 | |
293 | EUCTR2015-004059-29-HU | 04/05/2016 | 19 February 2018 | Clinical study to assess efficacy, safety and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis | An international, double-blind, randomised, placebo-controlled phase IIb trial to assess the efficacy, safety, and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis - CHANGE-MS | Multiple Sclerosis (MS) MedDRA version: 19.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: GNbAC1 Product Code: GNbAC1 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Not available CAS Number: 1393641-34-3 Current Sponsor code: GNbAC1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: GNbAC1 Product Code: GNbAC1 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Not available CAS Number: 1393641-34-3 Current Sponsor code: GNBAC1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: GNbAC1 Product Code: GNbAC1 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Not available CAS Number: 1393641-34-3 Current Sponsor code: GNBAC1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | GeNeuro SA | Not Recruiting | Female: yes Male: yes | 260 | Phase 2 | Serbia;Estonia;Spain;Ukraine;Russian Federation;Italy;France;Hungary;Czech Republic;Poland;Croatia;Bulgaria;Germany | |||
294 | NCT02749396 | May 2, 2016 | 26 August 2019 | EPID Multiple Sclerosis Pregnancy Study | Pregnancy Outcomes in Multiple Sclerosis Populations Exposed and Unexposed to Interferon ß - a Register-based Study in the Nordic Countries | Multiple Sclerosis | Drug: Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG;Drug: Extavia (interferon beta-1b), Novartis Pharma AG;Drug: Rebif (interferon beta-1a), Merck Serono Europe Ltd;Drug: Plegridy (peginterferon beta-1a), Biogen Idec Ltd;Drug: Avonex (interferon beta-1a), Biogen Idec Ltd;Drug: MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046);Other: No MSDMDs therapy (control) | Bayer | EPID Research;Biogen;Merck Serono Europe Ltd;Novartis Pharmaceuticals | Not recruiting | N/A | N/A | Female | 2089 | Early Phase 1 | Finland |
295 | NCT03566251 | May 1, 2016 | 2 July 2018 | Core Stability, Trunk Position Sense, Balance and Functional Mobility in Patients With Multiple Sclerosis | The Investigation of the Relationship Between Core Stability and Trunk Position Sense With Balance and Functional Mobility in Patients With Multiple Sclerosis | Physical Therapy | Other: Balance;Other: Functional mobility;Other: Core stability;Other: Trunk position sense | Ankara Yildirim Beyazit University | Not recruiting | 18 Years | 65 Years | All | 74 | N/A | Turkey | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
296 | NCT02428218 | May 2016 | 25 April 2016 | Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) | A Randomized, Placebo-Controlled, Parallel-Group Study in Pediatric Subjects Ages 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 for the Treatment of Relapsing-Remitting Forms of Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis;Relapsing Forms of Multiple Sclerosis | Drug: Placebo;Drug: dimethyl fumarate | Biogen | Not recruiting | 10 Years | 17 Years | Both | 0 | Phase 3 | ||
297 | NCT02670161 | May 2016 | 26 August 2019 | Quality Improvement and Practice Based Research in Neurology Using the EMR | Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record | Brain Tumors;Epilepsy;Migraine;Mild Cognitive Impairment;Concussion;Multiple Sclerosis;Neuropathy;Parkinson's;Restless Legs Syndrome;Stroke | Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) | NorthShore University HealthSystem | Recruiting | 18 Years | 100 Years | All | 3300 | Phase 4 | ||
298 | NCT02746744 | May 2016 | 17 June 2019 | RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. | RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. A Randomized Phase 3 Study Comparing Rituximab With Dimethyl Fumarate in Early Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome. | Multiple Sclerosis, Relapsing-Remitting | Drug: Rituximab;Drug: Dimethyl fumarate;Drug: Sodium Chloride solution | Anders Svenningsson | Not recruiting | 18 Years | 50 Years | All | 200 | Phase 3 | Sweden | |
299 | NCT02688985 | April 29, 2016 | 11 November 2019 | Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) | An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis | Relapsing Multiple Sclerorsis;Multiple Sclerosis, Primary Progressive | Drug: Ocrelizumab;Procedure: Lumbar Puncture;Drug: Methyloprednisolone;Drug: Antihistamine | Genentech, Inc. | Recruiting | 18 Years | 55 Years | All | 120 | Phase 3 | United States;Canada;Germany;Sweden | |
300 | NCT02675413 | April 2016 | 8 August 2016 | Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS | Mechanisms of Action of Dimethyl Fumarate in Relapsing MS | Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting | Drug: Dimethyl Fumarate | Washington University School of Medicine | Biogen | Not recruiting | 18 Years | N/A | Both | 0 | Phase 4 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
301 | NCT02769689 | April 2016 | 23 May 2016 | Methylprednisolone During the Switch Between Natalizumab and Fingolimod | Once a Month High-dose Methylprednisolone During Wash-out Period Between Natalizumab and Fingolimod Treatments in Patients With Multiple Sclerosis: a Randomised, Controlled, Double-blind Trial (NTZ2FTY) | Multiple Sclerosis | Drug: Methylprednisolone;Drug: Placebo;Drug: natalizumab (NTZ);Drug: fingolimob (FTY) | University Hospital, Clermont-Ferrand | Recruiting | 18 Years | 65 Years | Both | 56 | Phase 4 | France | |
302 | NCT02739542 | March 19, 2016 | 27 May 2019 | Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS) | Multi-center, Randomized, Double-blinded Assessment of Tecfidera® in Extending the Time to a First Attack in Radiologically Isolated Syndrome (RIS) (ARISE) | Multiple Sclerosis (MS) | Drug: Tecfidera;Drug: Placebo | University of Texas Southwestern Medical Center | Biogen | Recruiting | 18 Years | N/A | All | 90 | Phase 4 | United States |
303 | NCT02738775 | March 18, 2016 | 11 November 2019 | Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis | A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis. | Multiple Sclerosis | Biological: Ublituximab;Drug: Placebo | TG Therapeutics, Inc. | Not recruiting | 18 Years | 55 Years | All | 48 | Phase 2 | United States | |
304 | NCT02636829 | March 2016 | 26 September 2016 | Validation of Self-administered Questionnaire for Assessing Calcium Intake in Patients With Multiple Sclerosis or Chronic Inflammatory Arthritis | Validation of Self-administered Questionnaire Specifically for Assessing Calcium Intake (QALCIMUM®) in Patients With Multiple Sclerosis (MS) or Chronic Inflammatory Arthritis | Multiple Sclerosis;Rheumatoid Arthritis | Other: QALCIMUM questionnaire;Other: Determination of calcium intake by a dietician interview | Centre Hospitalier Universitaire de Nimes | Not recruiting | 18 Years | 69 Years | Both | 100 | N/A | France | |
305 | NCT02660138 | March 2016 | 11 November 2019 | Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 | A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis | Urinary Incontinence;Overactive Bladder | Biological: Botulinum toxin type A;Drug: Placebo | Ipsen | Not recruiting | 18 Years | 80 Years | All | 227 | Phase 3 | United States;Canada;Czechia;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Turkey;Czech Republic;Malaysia | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
306 | NCT02555215 | February 22, 2016 | 18 December 2018 | Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) | A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: dimethyl fumarate | Biogen | Not recruiting | 10 Years | 17 Years | All | 20 | Phase 3 | United States;Belgium;Bulgaria;Czechia;Germany;Kuwait;Latvia;Lebanon;Poland;Turkey;Czech Republic | |
307 | EUCTR2015-004451-40-CZ | 17/02/2016 | 3 July 2017 | SATIVEX® AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS | SATIVEX® AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS THE S A V A N T TRIAL - SAVANT | Moderate to severe spasticity due to MS (multiple sclerosis). MedDRA version: 19.0 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: SATIVEX Pharmaceutical Form: Oromucosal spray Pharmaceutical form of the placebo: Oromucosal spray Route of administration of the placebo: Oromucosal use | Almirall Hermal GmbH | Not Recruiting | Female: yes Male: yes | 228 | Phase 4 | Czech Republic;Austria | |||
308 | NCT02575365 | February 16, 2016 | 16 December 2017 | Effect of Fingolimod on Neurodegeneration | Effect of Fingolimod on Neurodegeneration, Brain Atrophy and Cognitive Impairment in Relapsing Remitting Multiple Sclerosis Patients | Cognition;Brain Volume Loss | Drug: 0,5 mg Fingolimod | Novartis Pharmaceuticals | Not recruiting | 18 Years | 65 Years | All | 4 | Phase 4 | Turkey | |
309 | NCT02637856 | February 11, 2016 | 30 September 2019 | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) | An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment | Multiple Sclerosis, Relapsing-Remitting | Drug: Ocrelizumab | Genentech, Inc. | Not recruiting | 18 Years | 55 Years | All | 611 | Phase 3 | United States;Canada | |
310 | NCT02652091 | February 5, 2016 | 17 September 2018 | Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction | Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction | Multiple Sclerosis, Relapsing-Remitting | Drug: Interferon beta-1b (Betaseron, BAY86-5046);Device: BETACONNECT device | Bayer | Not recruiting | 18 Years | N/A | All | 146 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
311 | EUCTR2015-002820-20-NL | 03/02/2016 | 7 January 2019 | Are alpha blockers effective in the treatment of bladder elimination problems in female patients with Multiple Sclerosis? | Are alpha blockers effective in the treatment of bladder elimination problems in female patients with Multiple Sclerosis? - Alpha blockers and Multiple Sclerosis (MS) | Bladder dysfunction in Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10069632 Term: Bladder dysfunction System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Silodyx Pharmaceutical Form: Capsule, hard Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Erasmus MC Dept. Urology | Authorised | Female: yes Male: no | 30 | Phase 3 | Netherlands | |||
312 | NCT02601131 | February 2016 | 12 December 2016 | Post-transfusion Platelet Count | Post-transfusion Platelet Count | Leukemia;Multiple Sclerosis | Biological: Platelet transfusion | Region Skane | Not recruiting | 18 Years | N/A | Both | 80 | N/A | Sweden | |
313 | NCT02641041 | February 2016 | 17 October 2016 | Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants | A Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Japanese Subjects | Central Nervous System (CNS) Demyelinating Disease;Multiple Sclerosis | Biological: BIIB033;Other: Placebo | Biogen | Not recruiting | 20 Years | 55 Years | Both | 24 | Phase 1 | United Kingdom | |
314 | NCT02644083 | February 2016 | 10 September 2018 | Tecfidera and MRI for Brain Energy in MS | Modulation of Cerebral Grey Matter High Energy Phosphate Metabolites in Multiple Sclerosis by Dimethyl Fumarate | Multiple Sclerosis | Drug: Dimethyl fumarate | Oregon Health and Science University | Biogen | Not recruiting | 18 Years | 55 Years | All | 4 | N/A | United States |
315 | NCT02710214 | February 2016 | 15 July 2019 | A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis | Effect of a Tissue Selective Estrogen Complex on Menopausal Symptoms in Women With MS: A Pilot Trial. | Menopause;Multiple Sclerosis | Drug: Tissue Selective Estrogen Complex;Drug: Placebo | University of California, San Francisco | National Multiple Sclerosis Society | Not recruiting | 18 Years | 62 Years | Female | 24 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
316 | NCT02823951 | February 2016 | 12 March 2018 | Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif® | Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®: A Retrospective Study (PROTRACT) | Relapsing-remitting Multiple Sclerosis | Drug: Rebif;Drug: Tecfidera | IMS HEALTH GmbH & Co. OHG | EMD Serono | Not recruiting | 18 Years | 55 Years | All | 479 | N/A | United States;Canada |
317 | JPRN-UMIN000022201 | 2016/01/10 | 2 April 2019 | The efficacy and safety of tocilizumab in patients with neuromyelitis optica | neuromyelitis optica | Tocilizumab it to be infused every 4weeks at 8mg/kg of body weight for 2 years. | Department of Neurology, Shimane University Hospital | Recruiting | 20years-old | 74years-old | Male and Female | 3 | Not selected | Japan | ||
318 | ChiCTR-OPB-16007730 | 2016-01-01 | 18 April 2017 | Mycophenolate Mofetil Treatment of Neuromyelitis Optica in Chinese Patients (MONICA) | Mycophenolate Mofetil Treatment of Neuromyelitis Optica in Chinese Patients (MONICA) | Neuromyelitis optica | Case series:Mycophenolate Mofetil; | The third affiliated hospital,Sun Yat-sen university | Recruiting | 18 | 65 | Both | Case series:100; | Post-market | China | |
319 | NCT02276963 | January 2016 | 17 June 2019 | Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses | Phase I, Single-Center, Open Label Trial of Ublituximab + Glucocorticoids for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) | Neuromyelitis Optica;Neuromyelitis Optica Spectrum Disorder | Drug: Ublituximab | Johns Hopkins University | Not recruiting | 18 Years | 100 Years | All | 6 | Phase 1 | United States | |
320 | NCT02644044 | January 2016 | 18 January 2016 | Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study | Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study | To Evaluate the Effect of Therapy With IT MTX on the Disease Course of Patients With Progressive MS | Drug: Intrathecal methotrexate | Tel-Aviv Sourasky Medical Center | Not recruiting | 18 Years | 75 Years | Both | 30 | Phase 0 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
321 | NCT02649985 | January 2016 | 11 June 2018 | Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease | Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease | Multiple Sclerosis;Alzheimer's Disease | Drug: [F-18]PBR06 | Brigham and Women's Hospital | Recruiting | 18 Years | 70 Years | All | 50 | Phase 1/Phase 2 | United States | |
322 | NCT02809079 | January 2016 | 27 June 2016 | Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients | Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients | Neuromyelitis Optica Spectrum Disorders;Mycophenolate Mofetil;Efficacy and Safety | Drug: Mycophenolate mofetil;Drug: Prednisone | Third Affiliated Hospital, Sun Yat-Sen University | Zhongshan Ophthalmic Centre, Sun Yat-sen University;Nangfang Hospital, Southern Medical University | Recruiting | 18 Years | 65 Years | Both | 100 | Phase 4 | |
323 | EUCTR2016-003100-30-BG | 28 February 2019 | A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients with RRMS with Disease Activity on Prior DMT | A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclerosis (RRMS) with Disease Activity on Prior Disease Modifying Therapy (DMT) | Multiple Sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Lemtrada Product Name: Lemtrada Product Code: GZ402673 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: alemtuzumab CAS Number: 216503-57-0 Current Sponsor code: GZ402673 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- | Genzyme Corporation | Not Available | Female: yes Male: yes | 65 | Phase 3 | Norway;Netherlands;Germany;Bulgaria;Poland;Belgium;France;Italy;United Kingdom;Switzerland;Russian Federation;Austria;Turkey;Spain;Greece;Portugal | ||||
324 | NCT02677077 | December 31, 2015 | 14 January 2019 | Clinical Disease Activity With Long Term Natalizumab Treatment | MRI and Clinical Disease Activity in Patients Treated Long Term With Natalizumab | Relapsing-Remitting Multiple Sclerosis | Drug: natalizumab | Biogen | Not recruiting | 18 Years | 65 Years | All | 277 | Phase 2 | Belgium;Czechia;Czech Republic | |
325 | EUCTR2015-004116-38-SE | 18/12/2015 | 22 January 2018 | A clincial study comparing the effectiveness of two drugs, named Rituximab and Dimethyl Fumarate (Tecfidera®), for the neurological disease Multiple Sclerosis. | RItuximab versus FUmarate in Newly Diagnosed Multiple Sclerosis – RIFUND-MS A randomized phase 3 study comparing Rituximab with Dimethyl Fumarate in early Relapsing-Remitting Multiple Sclerosis Objective: To compare the efficacy of rituximab on the ability to prevent relapses in early RRMS and CIS compared with dimethyl fumarate (DMF), which is an approved first-line medication for RRMS today, using a phase 3 design. Population: Patients with newly diagnosed RRMS or CIS with no more than 10 years disease duration (since diagnosis), 18 – 50 years of age and previously not treated with immunomodulating drugs OR treated with first-line injectables. Patients should display protocol-defined clinical or radiological disease activity during the preceding year before screening for inclusion. Intervention: Treatment with rituximab (Mabthera®) with an initial dose of 1000 mg intravenously (iv) followed by 500 mg iv every six months. Control: Treatment with DMF (Tecfidera®) 240 mg twice daily. The two treatments are randomised in a 1:1 proportion. Outcome: Primary outcome is the relative risk of experiencing a relapse during the two–year period for either compound. As secondary endpoints worsening on neurological disability, magnetic-resonance imaging-defined disease activity and effect on cerebrospinal fluid biomarkers will be analysed. In addition, health-economic evaluations of using rituximab as first-line treatment for RRMS will be performed. | Patients with multiple sclerosis (MS) or patients presenting with symptoms highly suspicious of MS while not completely fulfilling diagnostic criteria, 18 - 50 years of age and no more than 10 years of disease duration (from diagnosis). Patients treated with immunomodulatory drugs or treated with first-line injectable therapies (eg interferons or glatiramer acetate) may be included.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Mabthera Pharmaceutical Form: Infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 500-1000 Pharmaceutical form of the placebo: Infusion Route of administration of the placebo: Intravenous use Trade Name: Tecfidera Pharmaceutical Form: Capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 480- | Department of Clinical Sciences, Danderyd Hospital | Authorised | Female: yes Male: yes | 200 | Phase 3 | Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
326 | NCT02587195 | December 18, 2015 | 11 June 2018 | A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period | A National, Multi-center Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period | Multiple Sclerosis | Drug: Teriflunomide | Centre Hospitalier Universitaire de Nice | Not recruiting | 18 Years | 55 Years | All | 5 | Phase 3 | France | |
327 | NCT02583594 | December 6, 2015 | 5 November 2018 | A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis | A Phase 1, Exploratory, Randomized, Open-label, 2-Arm Study to Characterize the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Alemtuzumab 12mg Administered Subcutaneously or Intravenously in Patients With Progressive Multiple Sclerosis | Progressive Multiple Sclerosis | Drug: Acyclovir;Drug: Methylprednisolone;Drug: alemtuzumab GZ402673;Drug: Paracetamol;Drug: Loratadine;Drug: Ceterizine;Drug: Dexchlorpheniramine | Genzyme, a Sanofi Company | Not recruiting | 18 Years | N/A | All | 24 | Phase 1 | Spain | |
328 | NCT02011451 | December 2015 | 3 October 2016 | Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis | Safety and Neuroprotective Effects of Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis | Multiple Sclerosis | Drug: 95% Pure ECGC capsules 200mg;Drug: Placebo Comparator: | Louisiana State University Health Sciences Center in New Orleans | National Multiple Sclerosis Society | Not recruiting | 18 Years | 65 Years | Both | 0 | Phase 2 | United States |
329 | NCT02634307 | December 2015 | 14 October 2019 | A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 | A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis | Drug: ALKS 8700 | Alkermes, Inc. | Not recruiting | 18 Years | 65 Years | All | 1057 | Phase 3 | United States;Belgium;Bulgaria;Germany;Poland;Russian Federation;Serbia;Spain;Ukraine | |
330 | NCT02471560 | November 30, 2015 | 12 February 2018 | Tecfidera and the Gut Microbiota | The Effect of Tecfidera® (Dimethyl Fumarate, BG00012) on the Gut Microbiota as a Causal Factor for Gastro Intestinal Associated Adverse Events. | Multiple Sclerosis, Relapsing-Remitting | Drug: dimethyl fumarate;Drug: injectable MS DMT | Biogen | Not recruiting | 18 Years | N/A | All | 37 | Phase 4 | Norway | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
331 | NCT02545959 | November 30, 2015 | 14 October 2019 | Intrathecal Rituximab in Progressive Multiple Sclerosis | Intrathecal Rituximab in Progressive Multiple Sclerosis | Multiple Sclerosis, Chronic Progressive;Nervous System Diseases | Drug: Rituximab IT;Drug: methylprednisolone IV;Drug: Rituximab IV | Centre Hospitalier de PAU | University Hospital, Bordeaux | Not recruiting | 45 Years | N/A | All | 10 | Phase 2 | France |
332 | JPRN-JapicCTI-153058 | 24/11/2015 | 16 July 2019 | Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) Prevention of Relapse of Multiple Sclerosis | Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) Prevention of Relapse of Multiple Sclerosis | Multiple sclerosis | Intervention name : Copaxone subcutaneous injection syringe Dosage And administration of the intervention : For adults, a 20 mg dose of glatiramer acetate will be subcutaneously administered once daily.Participants will receive interventions as part of routine medical care. | TAKEDA PHARMACEUTICAL COMPANY LTD. | Recruiting | BOTH | 1000 | NA | ||||
333 | NCT02633033 | November 24, 2015 | 4 February 2019 | Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse | A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse | Multiple Sclerosis, Relapsing-Remitting | Drug: H.P. Acthar® Gel (repository corticotropin injection) | Mallinckrodt | Not recruiting | 18 Years | N/A | All | 160 | Phase 3 | United States;Puerto Rico | |
334 | EUCTR2012-003735-32-GR | 19/11/2015 | 23 July 2018 | Study to compare the efficacy and/or safety of masitinib to interferon beta-1a, interferon beta-1b, peginterferon beta-1a or glatiramer acetate in patients with relapsing remitting multiple sclerosis with unsatisfactory response to these first line treatments. | A 96-weeks, prospective, multicentre, randomised, open label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to first line treatment, in patients with relapsing remitting multiple sclerosis with unsatisfactory response to first line treatment | Relapsing-remitting multiple sclerosis (RR MS) MedDRA version: 18.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: mastinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: masitinib mesylate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Product Name: mastinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinb mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: masitinib mesylate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- | AB Science | Not Recruiting | Female: yes Male: yes | 450 | Phase 3 | Slovakia;Greece;Spain;United Kingdom;Italy;Czech Republic;Hungary;Mexico;Argentina;Belgium;Brazil;Bulgaria;Germany | |||
335 | EUCTR2015-002500-91-BE | 10/11/2015 | 28 February 2019 | A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis | A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Label Extension (OLE) study | Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: 0.25mg RPC1063 Product Code: RPC1063 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Current Sponsor code: RPC1063 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Product Name: 1.0mg RPC1063 Product Code: RPC1063 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Current Sponsor code: RPC1063 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0- | Celgene International II Sàrl (CIS II) | Authorised | Female: yes Male: yes | 2496 | Phase 3 | Serbia;Belarus;United States;Portugal;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy;South Africa;Latvia;Moldova, Republic of;Bosnia and Herzegovina;Lithuania;United Kingdom;Hungary;Belgium;Poland;Croatia;Romania;Bulgaria;Georgia;Germany;New Zealand;Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
336 | NCT02490982 | November 2015 | 16 December 2017 | Teriflunomide Observational Effectiveness Study | Teriflunomide Observational Effectiveness Study | Relapsing Remitting Multiple Sclerosis | Drug: Teriflunomide | Centre hospitalier de l'Université de Montréal (CHUM) | Genzyme, a Sanofi Company;Montreal Neurological Institute and Hospital | Recruiting | 18 Years | N/A | All | 300 | N/A | Canada |
337 | NCT02686684 | November 2015 | 7 November 2016 | Tecfidera Diffusion Tensor Imaging | An Open-label, Observational, Single-blinded, Longitudinal Study to Evaluate the Effect of Dimethyl Fumarate on Gray and White Matter Pathology in Subjects With Relapsing Multiple Sclerosis | Multiple Sclerosis, Dimethyl Fumarate, Diffusion Tensor Imaging Magnetic Resonance Imaging | Drug: Dimethyl fumarate | University at Buffalo | Not recruiting | 18 Years | N/A | Both | 115 | N/A | ||
338 | NCT02743312 | November 2015 | 24 October 2016 | Long-Term Effects of Torso-Weighting | Long-Term Effects of Balance-Based Torso-Weighting: Pilot Study | Multiple Sclerosis | Device: Balance-Based Torso-Weighting (WT);Device: Sham Weights (SW);Device: Fitbit Flex | San Francisco State University | Samuel Merritt University;Samuel Merritt University | Not recruiting | 18 Years | N/A | Both | 5 | N/A | United States |
339 | NCT02545868 | October 27, 2015 | 11 November 2019 | A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis | A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Patients With Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Biological: 23-PPV;Biological: 13-PCV Booster;Biological: Influenza Vaccine;Biological: KLH;Drug: OCR;Biological: TT Vaccine | Hoffmann-La Roche | Not recruiting | 18 Years | 55 Years | All | 102 | Phase 3 | United States;Canada | |
340 | EUCTR2015-002500-91-HU | 12/10/2015 | 28 February 2019 | A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis | A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Label Extension (OLE) study | Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: 0.25mg RPC1063 Product Code: RPC1063 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Current Sponsor code: RPC1063 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Product Name: 1.0mg RPC1063 Product Code: RPC1063 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Current Sponsor code: RPC1063 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0- | Celgene International II Sàrl (CIS II) | Authorised | Female: yes Male: yes | 2496 | Phase 3 | Belgium;Serbia;Belarus;United States;Portugal;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy;South Africa;Latvia;Moldova, Republic of;Bosnia and Herzegovina;Lithuania;United Kingdom;Hungary;Poland;Croatia;Romania;Bulgaria;Georgia;Germany;New Zealand;Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
341 | NCT02529839 | October 2015 | 31 August 2015 | Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS) | Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation in Patients With Multiple Sclerosis | Multiple Sclerosis | Procedure: Autologous bone marrow transplantation;Drug: Fludarabine;Drug: Cyclophosphamide;Drug: Alemtuzumab | Hadassah Medical Organization | Not recruiting | 18 Years | 65 Years | Both | 20 | N/A | ||
342 | NCT02606630 | October 2015 | 16 December 2017 | [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis | A [C-11]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT-555 on Central Nervous System Inflammation in Subjects With Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis | Drug: ABT-555 | AbbVie | Not recruiting | 18 Years | 60 Years | All | 4 | Phase 1 | United Kingdom | |
343 | EUCTR2012-000540-10-DE | 23/09/2015 | 25 June 2018 | International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis | Multicenter, randomized, double-blind, parallel-group, active-controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis - OPTIMUM | relapsing multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Capsule INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod CAS Number: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Aubagio® Product Name: Aubagio® Pharmaceutical Form: Tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod CAS Number: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod CAS Number: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod CAS Number: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod | Actelion Pharmaceuticals Ltd | Authorised | Female: yes Male: yes | 1100 | Phase 3 | Serbia;Portugal;Belarus;United States;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;France;Latvia;Bosnia and Herzegovina;Finland;Turkey;Lithuania;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Romania;Croatia;Bulgaria;Georgia;Germany;Sweden | |||
344 | EUCTR2014-003498-41-AT | 22/09/2015 | 28 September 2015 | Effects of dalfampridine on mobility in the context of daily life | Effects of dalfampridine on mobility in the context of daily life - Fampridine Study in Activities of Daily Living | Motor behaviour and cognition in multiple sclerosis patients;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Fampyra Pharmaceutical Form: Tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- | Medical University of Vienna | Authorised | Female: yes Male: yes | Austria | |||||
345 | NCT02486640 | September 8, 2015 | 11 November 2019 | Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon | BETAPREDICT - MS Patients Treated With BETAferon®: PREDICTors of Treatment Adherence | Multiple Sclerosis | Drug: Interferon beta-1b (Betaferon, BAY86-5046);Device: Betaconnect Autoinjector | Bayer | Not recruiting | 18 Years | N/A | All | 162 | N/A | Germany | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
346 | NCT03774914 | September 1, 2015 | 26 August 2019 | LEMTRADA Pregnancy Registry in Multiple Sclerosis | International LEMTRADA Pregnancy Exposure Cohort in Multiple Sclerosis | Multiple Sclerosis | Drug: Alemtuzumab (GZ402673) | Genzyme, a Sanofi Company | Recruiting | 18 Years | 55 Years | Female | 204 | Phase 2 | United States;Austria;Belgium;Canada;Denmark;Germany;Italy;Spain;Sweden;United Kingdom | |
347 | NCT02283671 | September 2015 | 25 February 2019 | Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B | Multiple Sclerosis;Neuromyelitis Optica | Biological: Tolerogenic Dendritic cells loaded with myelin peptides | Sara Varea | Recruiting | 18 Years | 65 Years | All | 22 | Phase 1 | Spain | ||
348 | NCT03002038 | September 2015 | 9 January 2017 | Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients | Comparison of Annual Relapse Rate, Expanded Disability Status Scale, and Side Effects Between Azathioprine and Rituximab in Patients With Neuromyelitis Optica Spectrum Disorders | Neuromyelitis Optica Spectrum Disorder | Drug: Azathioprine;Drug: Rituximab | Isfahan University of Medical Sciences | Not recruiting | 18 Years | 50 Years | Both | 76 | Phase 2/Phase 3 | Iran, Islamic Republic of | |
349 | NCT02499900 | August 31, 2015 | 16 December 2017 | Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® | A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone® (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily | Multiple Sclerosis | Drug: Copaxone® | Teva Pharmaceutical Industries, Ltd. | Not recruiting | 18 Years | N/A | All | 861 | Phase 4 | United States;Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Italy;Mexico;Poland;Puerto Rico;Russian Federation;Spain;Turkey | |
350 | NCT02525874 | August 31, 2015 | 3 December 2018 | Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). | An Open-Label Study to Assess the Effects of BG00012 on Lymphocyte Subsets in Subjects With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis | Drug: dimethyl fumarate | Biogen | Not recruiting | 18 Years | 65 Years | All | 218 | Phase 3 | United States;Belgium;Bulgaria;Kuwait;Lithuania;Poland;Turkey;Croatia | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
351 | EUCTR2014-000395-26-DE | 07/08/2015 | 30 October 2017 | Description ofchanges in that part of the nervous sstem that is processing visual information over an extended perion of time in patients with relapsing remitting multiple sclerosis who take Tecfidera | A 3-year open-label, exploratory, single arm study to describe long term changes in the visual system of patients with relapsing remitting multiple sclerosis (RRMS) on oral dimethyl fumarate - VISION | Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 18.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Tecfidera Pharmaceutical Form: Capsule, hard INN or Proposed INN: Dimethyl fumarate CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- | Biogen GmbH | Not Recruiting | Female: yes Male: yes | 600 | Phase 4 | Germany | |||
352 | NCT01532154 | August 2015 | 31 October 2016 | Fampridine Pregnancy Exposure Registry | Fampridine Pregnancy Exposure Registry | Multiple Sclerosis;Pregnancy | Drug: Fampridine | Biogen | Not recruiting | N/A | N/A | Female | 1 | N/A | France;Germany;United Kingdom;United States | |
353 | NCT02493049 | August 2015 | 22 October 2019 | Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS) | Randomized, Controlled Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Domperidone | University of Calgary | Alberta Innovates Health Solutions | Not recruiting | 18 Years | 60 Years | All | 17 | Phase 2 | Canada |
354 | NCT02542787 | August 2015 | 12 March 2018 | Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis | A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects With Multiple Sclerosis | Spasticity in People With Multiple Sclerosis | Drug: VSN16R;Other: Placebo | Canbex Therapeutics Ltd | Not recruiting | 18 Years | 70 Years | All | 160 | Phase 2 | United Kingdom | |
355 | NCT02632591 | August 2015 | 28 December 2015 | Use on Human Beings of Mix of Known Drugs for New Destination - MS Treatment | Use on Human Being of a Mix Between Very Well Known Drugs, Tested Upon Registered Trial n° NCT02606929, to Consider Effectiveness of Improvement After 45 Days | Multiple Sclerosis;Autoimmune Disease;Disseminated or Multiple Sclerosis Nos;Multiple Sclerosis, Acute Relapsing;Multiple Sclerosis, Primary Progressive;Multiple Sclerosis, Chronic Progressive | Drug: Tetracycline;Drug: statin;Drug: antimycotic;Drug: Fingolimod;Drug: copaxone | Università Popolare Homo & Natura | Not recruiting | 18 Years | 65 Years | Both | 90 | Phase 1 | Italy | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
356 | NCT02683863 | August 2015 | 16 December 2017 | Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers | An Open Label Study of the Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers in Subjects With Secondary Progressive Multiple Sclerosis | Multiple Sclerosis | Drug: BG00012 (DMF) (Tecfidera®.) | Multiple Sclerosis Center of Northeastern New York | Biogen | Not recruiting | 25 Years | 65 Years | All | 20 | Phase 4 | United States |
357 | NCT02686788 | August 2015 | 3 December 2018 | TMP001 in Relapsing-remitting Multiple Sclerosis | TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial | Remitting-Relapsing Multiple Sclerosis | Drug: TMP001 | Dr. Frank Behrens | SocraMetrics GmbH | Not recruiting | 18 Years | 55 Years | All | 9 | Phase 2 | Germany |
358 | NCT03046251 | August 2015 | 26 August 2019 | Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis | Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis | Multiple Sclerosis | Drug: Natalizumab | State University of New York at Buffalo | Recruiting | 18 Years | N/A | Female | 100 | Phase 4 | United States | |
359 | NCT02511028 | July 28, 2015 | 1 April 2019 | In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging | In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging | Multiple Sclerosis | Other: Ferumoxytol | National Institutes of Health Clinical Center (CC) | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | 70 Years | All | 14 | Early Phase 1 | United States |
360 | EUCTR2014-004483-38-DE | 16/07/2015 | 7 May 2018 | TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trial | TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trial | Patients with defined diagnosis of relapsing-remitting multiple sclerosis and at least 1 documented relapse during the previous year OR at least 2 documented relapses during the previous 2 years. MedDRA version: 19.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Tarenflurbil Product Code: TMP001 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Tarenflurbil CAS Number: 5104-49-4 Other descriptive name: FLURBIPROFEN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- | Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME) | Not Recruiting | Female: yes Male: yes | 55 | Phase 2 | Germany | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
361 | JPRN-UMIN000018154 | 2015/07/01 | 2 April 2019 | 11C-acetate PET for Multiple sclerosis | 11C-acetate PET for Multiple sclerosis - 11C-acetate PET for Multiple sclerosis | Multiple Sclerosis, NMO | Withdraw blood before and after the injection of 11C-acetate | department of neurology, Osaka university school of medicine | Recruiting | 20years-old | 75years-old | Male and Female | 30 | Not applicable | Japan | |
362 | NCT02472938 | July 2015 | 4 January 2016 | Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis | Phase IV, Interventional, multicenteR, Double-blind, Randomized, Placebo-controlled Study tO Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With relapsingremitTing Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: dimethyl fumarate;Other: Placebo | Biogen | GB Pharma Services & Consulting S.r.l. Unipersonale | Not recruiting | 18 Years | 50 Years | Both | 0 | Phase 4 | |
363 | NCT02506751 | July 2015 | 19 February 2018 | Open-label Study of Liothyronine in MS | A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals With MS | Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis, Primary Progressive | Drug: liothyronine | Johns Hopkins University | Not recruiting | 18 Years | 58 Years | All | 20 | Phase 1 | United States | |
364 | NCT02519413 | July 2015 | 5 September 2016 | Tecfidera Lymphocyte Chart Review | A Retrospective, Multi-Center, Observational Study to Assess the Effect of Tecfidera® Delayed-Release Capsules on Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis (REALIZE) | Multiple Sclerosis | Drug: dimethyl fumarate | Biogen | Not recruiting | 18 Years | N/A | Both | 483 | N/A | United States | |
365 | NCT02521545 | July 2015 | 14 September 2015 | Single-Dose Study of a New Formulation of BIIB061 | A Single-Dose Study in Healthy Volunteers to Assess the Pharmacokinetic Profile of a New Formulation of BIIB061 | Multiple Sclerosis | Drug: BIIB061 | Biogen | Not recruiting | 20 Years | 55 Years | Both | 8 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
366 | NCT02665221 | July 2015 | 16 December 2017 | Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY | Single Center, Randomized, Open Label Study in Relapsing MS Patients on PLEGRIDY to Assess Topical Application of Preparation H (Phenylephrine) on Mitigation of Erythema Severity and Size. | Multiple Sclerosis | Other: No Treatment Arm;Drug: Topical Preparation H arm | New York University School of Medicine | Not recruiting | 18 Years | 70 Years | All | 32 | Phase 4 | United States | |
367 | NCT02696590 | July 2015 | 11 April 2016 | High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients | Isfahan University of Medical Sciences | Relapsing Remitting Multiple Sclerosis | Dietary Supplement: Vitamin D3 | Isfahan University of Medical Sciences | Not recruiting | 23 Years | 59 Years | Both | 200 | N/A | Iran, Islamic Republic of | |
368 | NCT02410278 | June 29, 2015 | 11 June 2018 | Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera | A Multicenter, Double- Blind, Placebo- Controlled Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera® (Dimethyl Fumarate) Delayed Release Capsules | Multiple Sclerosis | Drug: dimethyl fumarate;Drug: montelukast;Drug: Placebo | Biogen | Not recruiting | 18 Years | N/A | All | 63 | Phase 4 | United States | |
369 | EUCTR2015-000303-21-IT | 24/06/2015 | 11 April 2016 | Experimental clinical trial regarding relapsing-remitTing Multiple Sclerosis newly diagnosed patients, not yet treated for the evaluation of the onset, the efficacy and speed of action of the treatment with BG00012 | A Phase IV, interventional, multicenteR, double-blind, randomized, placebo-controlled study tO explore the onset of efficacy on Magnetic resonance disease activity of BG00012 (dimethyl fumarate) in Patients with relapsing-remitTing Multiple Sclerosis (PROMPT) - PROMPT | Relapsing-remitting Multiple Sclerosis patients MedDRA version: 17.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Tecfidera® Product Name: Tecfidera® Product Code: BG00012 Pharmaceutical Form: Capsule INN or Proposed INN: Dimethyl fumarate CAS Number: 624-49-7 Current Sponsor code: BG00012 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Biogen Idec Italia S.r.l. | Not Recruiting | Female: yes Male: yes | Phase 4 | Italy | ||||
370 | EUCTR2014-004562-22-BE | 10/06/2015 | 30 April 2018 | Study to evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients with Multiple Sclerosis | A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients with Multiple Sclerosis | Multiple Sclerosis MedDRA version: 17.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Biogen Idec Research Limited | Not Recruiting | Female: yes Male: yes | 300 | Phase 3 | France;United States;Hungary;Czech Republic;Canada;Spain;Belgium;Australia;Germany;Italy | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
371 | NCT02425644 | June 4, 2015 | 16 September 2019 | Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis | Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis | Multiple Sclerosis | Drug: ponesimod;Drug: teriflunomide | Actelion | Not recruiting | 18 Years | 55 Years | All | 1133 | Phase 3 | United States;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;Argentina;Czech Republic | |
372 | EUCTR2014-005003-24-LV | 01/06/2015 | 24 October 2016 | A study of BG00012 on MRI lesions and Pharmacokinetics in children from 10 to less than 18 years old with a type of Multiple Sclerosis called 'Relapsing, Remitting Multiple Sclerosis' | Open-Label, Multicenter, Multiple-Dose Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis Aged 10 to 17 Years | Relapsing-Remitting Multiple Sclerosis MedDRA version: 17.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- | Biogen Idec Research Limited | Not Recruiting | Female: yes Male: yes | 20 | Phase 2 | Finland;Lebanon;Lithuania;Turkey;Israel;United Kingdom;Italy;France;Czech Republic;Belgium;Poland;Australia;Bulgaria;Latvia;Germany;Kuwait | |||
373 | NCT02090348 | June 2015 | 14 September 2015 | Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate | A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing-Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsules (TECNERGY) | Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis | Drug: dimethyl fumarate | Biogen | Not recruiting | 18 Years | N/A | Both | 0 | Phase 4 | ||
374 | NCT02239393 | June 2015 | 1 April 2019 | Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study | MEsenchymal Stem Cell Therapy for CAnadian MS Patients | Multiple Sclerosis | Biological: Mesenchymal Stem Cells | Ottawa Hospital Research Institute | Not recruiting | 18 Years | 50 Years | All | 40 | Phase 2 | Canada | |
375 | NCT03113162 | May 29, 2015 | 16 December 2017 | Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis | Evaluation of the Safety and Efficacy of Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Multiple Sclerosis | Multiple Sclerosis | Biological: Autologous Hematopoietic Stem Cell;Drug: BEAM Regimen | Makati Medical Center | Recruiting | 18 Years | 60 Years | All | 15 | Phase 1 | Philippines | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
376 | EUCTR2013-001055-12-IT | 28/05/2015 | 10 July 2015 | Study to evaluate the efficacy of cetirizine in the treatment of Flu-like syndrome (FLS) in patients with multiple sclerosis treated with interferoneß. | Flu-like syndrome Inhibition Giving anti-histaminic Therapy. Randomized cross-over, single-center, randomized, placebo-controlled, double-blind study to evaluate the efficacy of cetirizine on Flu-like syndrome (FLS) in patients with multiple sclerosis treated with interferoneß. - FLU-LIGHT | Patients with relapsing remitting multiple sclerosis (RRMS) treated with interferoneß, suffering from flu-like syndrome (FLS). MedDRA version: 16.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Cetirizina Mylan Generics Product Name: Cetirizina Mylan Generics Pharmaceutical Form: Tablet INN or Proposed INN: Cetirizina CAS Number: 83881-52-1 Other descriptive name: CETIRIZINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Biogen Idec Italia S.r.l. | Not Recruiting | Female: yes Male: yes | Italy | |||||
377 | NCT02315872 | May 22, 2015 | 9 September 2019 | ACTH for Fatigue in Multiple Sclerosis Patients | The Effect of ACTH (Acthar) on Measures of Chronic Fatigue in Patients With Relapsing Multiple Sclerosis. | Multiple Sclerosis, Relapsing-Remitting | Drug: ACTH;Drug: Placebo | Providence Health & Services | Mallinckrodt | Not recruiting | 18 Years | 65 Years | All | 8 | Phase 3 | United States |
378 | EUCTR2015-001197-18-NO | 20/05/2015 | 25 June 2018 | The effect of Tecfidera® (Dimethyl Fumarate) on the gut microbiota as a causal factor for GI associated adverse events. | The effect of Tecfidera® (Dimethyl Fumarate) on the gut microbiota as a causal factor for GI associated adverse events. | multiple sclerosis;Therapeutic area: Diseases [C] - Injuries, poisonings, and occupational diseases [C21] | Trade Name: Tecfidera Product Name: Tecfidera Pharmaceutical Form: Capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: IU/mg international unit(s)/milligram Concentration type: range Concentration number: 240-480 | Biogen Idec Norway | Authorised | Female: yes Male: yes | 70 | Phase 4 | Norway | |||
379 | EUCTR2014-003481-25-DE | 13/05/2015 | 20 August 2018 | Investigation of the effect of Dimethyl fumarate on T cells in patients with relapsing remitting Multiple Sclerosis | A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis - DIMAT-MS | relapsing remitting multiple sclerosis MedDRA version: 19.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Tecfidera® 120mg magensaftresistente Hartkapseln Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: Dimethyl fumarate CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Trade Name: Tecfidera® 240mg magensaftresistente Hartkapseln Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: Dimethyl fumarate CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- | Universitätsklinikum Münster | Not Recruiting | Female: yes Male: yes | 67 | Phase 4 | Germany | |||
380 | NCT02495766 | May 11, 2015 | 22 July 2019 | Autologous Mesenchymal Stromal Cells for Multiple Sclerosis | Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis | Drug: XCEL-MC-ALPHA;Drug: Placebo | Banc de Sang i Teixits | Vall d'Hebron Research Institute (VHIR) | Not recruiting | 18 Years | 60 Years | All | 8 | Phase 1/Phase 2 | Spain |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
381 | NCT02461069 | May 6, 2015 | 22 October 2018 | Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis | A 24-week, Multicenter, Exploratory, Two Arm Study to Assess the Effect of Dimethyl Fumarate on Immune-Modulatory Action on T Cells in Patients With Relapsing Remitting Multiple Sclerosis (DIMAT-MS) | Multiple Sclerosis, Relapsing-Remitting | Drug: Dimethyl fumarate | University Hospital Muenster | Biogen | Not recruiting | 18 Years | 60 Years | All | 67 | Phase 4 | Germany |
382 | NCT02323269 | May 2015 | 18 April 2016 | Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve) | A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing-Remitting Multiple Sclerosis, Who Are Either Treatment-Naïve or Switching From an Interferon or Glatiramer Acetate After Suboptimal Response (ImPROve) | Multiple Sclerosis, Relapsing-Remitting;Relapsing-Remitting Multiple Sclerosis | Drug: dimethyl fumarate | Biogen | Not recruiting | 18 Years | N/A | Both | 24 | N/A | Canada | |
383 | NCT02419378 | May 2015 | 27 June 2016 | Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential | Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential | Multiple Sclerosis, Relapsing-Remitting | Drug: Alemtuzumab | University Hospital Muenster | Genzyme, a Sanofi Company | Recruiting | 18 Years | 55 Years | Both | 15 | Phase 4 | Germany |
384 | NCT02419638 | May 2015 | 14 March 2016 | Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS | Multiple Sclerosis | Drug: Rebif (IFN ß-1a subcutaneous three times per week);Drug: Tecifdera (dimethyl fumarate) | Brigham and Women's Hospital | EMD Serono | Not recruiting | 18 Years | 65 Years | Both | 0 | N/A | United States | |
385 | NCT02471222 | May 2015 | 16 December 2017 | Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment | Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment | Walking Impairment;Multiple Sclerosis | Drug: ADS-5102;Other: Placebo | Adamas Pharmaceuticals, Inc. | Not recruiting | 18 Years | 70 Years | All | 60 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
386 | NCT02736279 | May 2015 | 14 November 2016 | Impact of Tecfidera on Gut Microbiota | Measuring the Impact of Tecfidera on the Gut Microbiota: Does a Change in the Gut Flora Correlate With Gastrointestinal Disturbances Following Therapy Initiation? | Multiple Sclerosis | Drug: Dimethyl fumarate | Virginia Simnad | Biogen | Recruiting | 18 Years | N/A | Both | 25 | N/A | United States |
387 | EUCTR2014-005548-17-FR | 28/04/2015 | 3 April 2017 | TREATMENT OF PENDULAR NYSTAGMUS WITH GABAPENTIN AND MEMANTINE IN PATIENTS WITH MULTIPLE SCLEROSIS or OCULOPALATAL TREMOR: A CONTROLED OPEN-LABEL STUDY | TREATMENT OF PENDULAR NYSTAGMUS WITH GABAPENTIN AND MEMANTINE IN PATIENTS WITH MULTIPLE SCLEROSIS or OCULOPALATAL TREMOR: A CONTROLED OPEN-LABEL STUDY | PENDULAR NYSTAGMUS IN PATIENTS WITH MULTIPLE SCLEROSIS OR OCULOPALATAL TREMOR MedDRA version: 18.0 Level: PT Classification code 10029864 Term: Nystagmus System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: NEURONTIN Product Name: Gabapentine Product Code: N03AX12 Pharmaceutical Form: Capsule CAS Number: 60142-96-3 Other descriptive name: GABAPENTIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Trade Name: EBIXA Product Name: MEMANTINE Product Code: N06DX01 Pharmaceutical Form: Coated tablet INN or Proposed INN: MEMANTINE CAS Number: 19982-08-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- | HOSPICES CIVILS DE LYON | Not Recruiting | Female: yes Male: yes | Phase 2 | France | ||||
388 | JPRN-UMIN000017217 | 2015/04/21 | 23 April 2019 | An open-label extension study following the RIN-1 study to investigate the efficacy of rituximab against a relapse of neuromyelitis optica | An open-label extension study following the RIN-1 study to investigate the efficacy of rituximab against a relapse of neuromyelitis optica - RIN-2 | Neuromyelitis optica | Rituximab intravenous infusion | Clinical Research Center, Utano National Hospital, National Hospital Organization | Zenyaku Kogyo Co., Ltd. | Not Recruiting | 16years-old | 80years-old | Male and Female | 40 | Phase 2,3 | Japan |
389 | NCT02423083 | April 21, 2015 | 11 November 2019 | Oral Guanabenz for Multiple Sclerosis | Phase I Study of Oral Guanabenz for Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis | Drug: Guanabenz | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | 55 Years | All | 2 | Phase 1 | United States | |
390 | EUCTR2014-002592-29-CZ | 17/04/2015 | 17 May 2016 | Administration of Mirabegron 50mg in patients with neurogenic bladder | A randomized, double blind, placebo controlled study to evaluate the efficacy and safety of mirabegron 50 mg versus placebo in patients with neurogenic detrusor overactivity - MIRAGE | Spinal cord injury Multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Betmiga Product Name: Betmiga Pharmaceutical Form: Coated tablet INN or Proposed INN: mirabegron CAS Number: 223673-61-8 Other descriptive name: MIRABEGRON Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use | Fakultní nemocnice Ostrava | Authorised | Female: yes Male: yes | Phase 3 | Czech Republic | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
391 | EUCTR2012-003735-32-SK | 01/04/2015 | 12 November 2018 | Study to compare the efficacy and/or safety of masitinib at 3 mg/kg/day with switch to 4.5 then to 6 mg/kg/day to interferon beta-1a, interferon beta-1b, peginterferon beta-1a or glatiramer acetate in patients with relapsing remitting multiple sclerosis with unsatisfactory response to these first line treatments. | A 96-weeks, prospective, multicentre, randomised, open label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to first line treatment, in patients with relapsing remitting multiple sclerosis with unsatisfactory response to first line treatment | Prospective, multicentre, randomised, open-label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib at 3 mg/kg/day with switch to 4.5 then 6 mg/kg/day as single agent first line treatment.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: mastinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: masitinib mesylate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Product Name: mastinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: masitinib mesylate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- | AB Science | Not Recruiting | Female: yes Male: yes | 450 | Phase 3 | Slovakia;Greece;Spain;Colombia;Switzerland;United Kingdom;Italy;Mexico;Canada;Argentina;Belgium;Brazil;Bulgaria;Germany | |||
392 | NCT02391961 | April 1, 2015 | 29 April 2019 | Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis | Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis | Multiple Sclerosis;Internuclear Ophthalmoplegia;Fatigue | Drug: Dalfampridine;Drug: Placebo | VA Office of Research and Development | Not recruiting | 18 Years | 65 Years | All | 20 | Phase 2 | United States | |
393 | NCT02398461 | April 2015 | 3 September 2018 | An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse | A Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse | Multiple Sclerosis, Acute Relapsing | Drug: rHIgM22;Drug: Placebo | Acorda Therapeutics | PRA Health Sciences | Not recruiting | 18 Years | 70 Years | All | 27 | Phase 1 | United States |
394 | NCT02939079 | April 2015 | 31 October 2016 | Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients | Evaluating the Effect of Fingolimod With Fish Oil Compared to Fingolimod With Placebo on Tumor Necrosis Factor-a , Interleukin1b , Interleukin6, and Interferon-gamma in Patients With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Fingolimod;Dietary Supplement: Fish Oil;Drug: Placebo (for Fish Oil) | Isfahan University of Medical Sciences | Shiraz University of Medical Sciences | Not recruiting | 18 Years | 45 Years | Both | 50 | Phase 2/Phase 3 | |
395 | NCT02373098 | March 31, 2015 | 16 December 2017 | Fingolimod Effect on Cytokine and Chemokine Levels | Effects of Fingolimod (Gilenya®) on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients | Relapsing Remitting Multiple Sclerosis | Drug: Fingolimod 0.5 mg | Novartis Pharmaceuticals | Not recruiting | 18 Years | 65 Years | All | 66 | Phase 4 | Turkey | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
396 | EUCTR2014-003021-18-SE | 25/03/2015 | 7 December 2015 | A safety and efficacy study of BG00012 in slowing the progression of disability in patients with Secondary Progressive Multiple Sclerosis. | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis MedDRA version: 17.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: Dimethyl Fumarate CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: Dimethyl Fumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Biogen Idec Research Limited | Not Recruiting | Female: yes Male: yes | 1170 | Serbia;United States;Slovakia;Finland;Spain;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Argentina;Poland;Belgium;Denmark;Australia;Bulgaria;Norway;Netherlands;Germany;Sweden | ||||
397 | NCT02386566 | March 20, 2015 | 24 September 2018 | Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab | A Prospective, Multicenter, Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Patients Treated With Natalizumab | Multiple Sclerosis | Drug: natalizumab | Biogen | Not recruiting | 18 Years | 65 Years | All | 48 | Phase 1 | Switzerland | |
398 | EUCTR2014-003145-99-GB | 19/03/2015 | 17 August 2015 | A trial to determine bexarotene's safety and tolerability and it's ability to promote brain repair in patients with multiple sclerosis. | A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on interferon-beta therapy: a phase 2a trial - CCMR One | Relapsing-remitting multiple sclerosis already on interferon-beta therapy MedDRA version: 17.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Targretin Product Name: Bexarotene Pharmaceutical Form: Capsule, hard INN or Proposed INN: Bexarotene CAS Number: 153559-49-0 Concentration unit: mg/m2 milligram(s)/square meter Concentration type: range Concentration number: 100-300 Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge | Authorised | Female: yes Male: yes | 50 | Phase 2a | United Kingdom | |||
399 | NCT02474134 | March 2015 | 23 November 2015 | Comparison Study of PF530 and Betaferon in Healthy Subjects | A Phase 1 Double-Blind, Randomised, Two-Treatment Cross-over Study Comparing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF530 and Betaferon Administered by Subcutaneous Injection in Healthy Adult Volunteers | Multiple Sclerosis | Drug: Interferon beta-1b (PF530, Betaferon) | Pfenex, Inc | Not recruiting | 18 Years | 50 Years | Both | 12 | Phase 1 | Australia | |
400 | NCT02097849 | February 28, 2015 | 16 December 2017 | Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. | An Open-Label Study to Assess the Immune Response to Vaccination in Tecfidera® (BG00012)-Treated Versus Interferon-Treated Subjects With Relapsing Forms of Multiple Sclerosis. | Relapsing Forms of Multiple Sclerosis | Drug: dimethyl fumarate;Biological: tetanus diphtheria toxoids vaccine;Biological: 23-valent pneumococcal polysaccharide vaccine;Biological: meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent);Drug: non-pegylated interferon | Biogen | Not recruiting | 18 Years | 55 Years | All | 71 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
401 | NCT02343159 | February 28, 2015 | 16 December 2017 | Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients. | A Multicenter, Open-label Phase IV Study to Evaluate Whether a Medication Event Monitoring System (MEMS®) Can Improve Adherence to Tecfidera® (Delayed-release Dimethyl Fumarate) Treatment in Multiple Sclerosis Patients. | Multiple Sclerosis | Drug: dimethyl fumarate;Device: Medication Event Monitoring System (MEMS);Behavioral: Adherence counseling | Biogen | Not recruiting | 18 Years | 65 Years | All | 84 | Phase 4 | United States | |
402 | EUCTR2015-000182-31-NL | 11/02/2015 | 23 February 2015 | Study to evaluate the effects of fampridine in patients with multiple sclerosis and eye movement abnormality | A randomized, double-blind, placebo-controlled, cross-over study to assess the effects of fampridine on eye movements and nerve conduction in patients with multiple sclerosis (MS) and a unilateral or bilateral internuclear ophthalmoplegia (INO) | Multiple sclerosis (MS) and a unilateral or bilateral internuclear ophthalmoplegia (INO);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Fampyra 10 mg prolonged-release tablets Pharmaceutical Form: Tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | CHDR | Authorised | Female: yes Male: yes | Netherlands | |||||
403 | EUCTR2014-001643-20-DE | 10/02/2015 | 13 February 2017 | Efficacy and Safety of Vatelizumab in Patients with Relapsing Remitting Multiple Sclerosis | A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) | Nervous System Diseases MedDRA version: 18.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: SAR339658 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Vatelizumab CAS Number: 1238217-55-4 Current Sponsor code: SAR339658 Other descriptive name: CHR-1103 / GBR500 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Vatelizumab CAS Number: 1238217-55-4 Current Sponsor code: SAR339658 Other descriptive name: CHR-1103 / GBR500 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Vatelizumab CAS Number: 1238217-55-4 Current Sponsor code: SAR339658 Other descriptive name: CHR-1103 / GBR500 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | Genzyme Corporation | Not Recruiting | Female: yes Male: yes | 168 | Phase 2 | United States;Czech Republic;Mexico;Canada;Poland;Russian Federation;Germany;Italy;Switzerland;Sweden | |||
404 | EUCTR2013-003884-71-BE | 05/02/2015 | 10 July 2015 | Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409 | A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409) - TOPAZ | Relapsing-remitting multiple sclerosis MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Lemtrada Product Name: Lemtrada Product Code: GZ402673 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: alemtuzumab CAS Number: 216503-57-0 Current Sponsor code: GZ402673 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- | Genzyme Corporation | Authorised | Female: yes Male: yes | 799 | Phase 3B | Serbia;Spain;Ukraine;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Croatia;Australia;Denmark;Netherlands;Germany;Sweden | |||
405 | NCT02306811 | February 2015 | 9 January 2017 | Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839 | A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839 | Relapsing-remitting Multiple Sclerosis | Drug: Vatelizumab | Genzyme, a Sanofi Company | Not recruiting | 18 Years | N/A | Both | 62 | Phase 2 | United States;Canada;Poland;Russian Federation | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
406 | NCT02308137 | February 2015 | 29 April 2019 | Domperidone in Secondary Progressive Multiple Sclerosis (SPMS) | Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS) | Multiple Sclerosis, Secondary Progressive | Drug: Domperidone | University of Calgary | Alberta Innovates Health Solutions | Recruiting | 18 Years | 60 Years | All | 62 | Phase 2 | Canada |
407 | NCT02403947 | February 2015 | 10 December 2018 | MEsenchymal StEm Cells for Multiple Sclerosis | Treatment of Multiple Sclerosis With Mesenchymal Stem Cells: Phase I/II Study | Multiple Sclerosis | Drug: Mesenchymal stem cells;Drug: Suspension media | University Hospital, Toulouse | Not recruiting | 18 Years | 50 Years | All | 1 | Phase 1/Phase 2 | France | |
408 | NCT02418325 | February 2015 | 17 November 2015 | A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis, Relapsing-Remitting | Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells;Other: Liberation therapy | Genesis Limited | Not recruiting | 18 Years | 60 Years | Both | 69 | Phase 1/Phase 2 | Trinidad and Tobago | |
409 | NCT02418351 | February 2015 | 17 November 2015 | A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | Multiple Sclerosis, Relapsing-Remitting | Biological: Autologous Bone Marrow-Derived Mononuclear Stem Cells;Other: Liberation therapy | Genesis Limited | Not recruiting | 18 Years | 60 Years | Both | 69 | Phase 1/Phase 2 | India;Trinidad and Tobago | |
410 | NCT02490046 | February 2015 | 3 August 2015 | D-mannose for the Prevention of UTIs in Multiple Sclerosis | Single Centre Open-label Feasibility Study Evaluating the Use of D-mannose in Multiple Sclerosis | Multiple Sclerosis;Recurrent Urinary Tract Infections | Dietary Supplement: D Mannose | University College, London | UCLH | Recruiting | 18 Years | 65 Years | Both | 20 | Phase 1 | United Kingdom |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
411 | NCT02587715 | February 2015 | 17 November 2015 | A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis, Relapsing-Remitting | Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells;Other: Liberation therapy | Novo Cellular Medicine Institute LLP | Recruiting | 18 Years | 60 Years | Both | 69 | Phase 1/Phase 2 | Trinidad and Tobago | |
412 | NCT02587806 | February 2015 | 17 November 2015 | A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | Multiple Sclerosis, Relapsing-Remitting | Biological: Autologous Bone Marrow-Derived Mononuclear Stem Cells;Other: Liberation therapy | Novo Cellular Medicine Institute LLP | Recruiting | 18 Years | 60 Years | Both | 69 | Phase 1/Phase 2 | India;Trinidad and Tobago | |
413 | NCT02638038 | February 2015 | 12 March 2018 | This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for = 3 Years | A 6-month, Double-blind, Randomized, Parallel-group, Multicenter Study Comparing Safety and Efficacy of Monotherapy With INT131 1 mg or 3 mg or Placebo Administered Orally Once Daily in Treatment Naïve Patients (Who Never Received Disease Modifying Treatment) With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing Remitting | Drug: INT131 | InteKrin Therapeutics, Inc. | Not recruiting | 18 Years | 50 Years | All | 228 | Phase 2 | ||
414 | NCT03092544 | February 2015 | 11 June 2018 | Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients | Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients | Multiple Sclerosis | Drug: dimethyl fumarate | Multiple Sclerosis Center of Northeastern New York | Icahn School of Medicine at Mount Sinai;Biogen | Not recruiting | 18 Years | 65 Years | All | 57 | Phase 4 | United States |
415 | EUCTR2013-005586-39-DE | 29/01/2015 | 16 November 2015 | Natalizumab (BG00002) as an Efficacy Switch in Subjects with Relapsing Multiple Sclerosis (MS) after Failure on Other Therapies | A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya® to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis (MS) | Multiple Sclerosis (MS) MedDRA version: 17.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Tysabri® Product Name: AN100226, BG00002 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 300- | Biogen Idec Research Limited | Not Recruiting | Female: yes Male: yes | 200 | Phase 4 | United States;Germany;Italy | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
416 | NCT02166021 | January 29, 2015 | 26 August 2019 | Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis | Phase 2 Trial to Investigate the Clinical Efficacy & the Optimal Administration (Based on the Immunological, Clinical & Neuroradiological Effects) of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis | Multiple Sclerosis (MS) | Biological: Mesenchymal stem cells | Dimitrios Karussis | Not recruiting | 18 Years | 65 Years | All | 48 | Phase 2 | Israel | |
417 | EUCTR2014-005129-10-FI | 27/01/2015 | 2 February 2015 | Multiple Sclerosis, menopause and hormone replacement therapy | Multiple Sclerosis and Menopause: the effect of hormone replacement therapy on clinical picture and immunology of multiple sclerosis | Multiple sclerosis MedDRA version: 17.1 Level: LLT Classification code 10064137 Term: Progression of multiple sclerosis System Organ Class: 100000004852 MedDRA version: 17.1 Level: LLT Classification code 10070425 Term: Multiple sclerosis exacerbation System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Femoston 2/10 Product Name: Femoston 2/10 Pharmaceutical Form: Tablet INN or Proposed INN: ESTRADIOL HEMIHYDRATE CAS Number: 35380-71-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- INN or Proposed INN: DYDROGESTERONE CAS Number: 152-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Trade Name: Femoston 1/10 Product Name: Femoston 1/10 Pharmaceutical Form: Tablet INN or Proposed INN: ESTRADIOL HEMIHYDRATE CAS Number: 35380-71-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- INN or Proposed INN: DYDROGESTERONE CAS Number: 152-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- | Irina Elovaara | Authorised | Female: yes Male: no | Finland | |||||
418 | EUCTR2014-004412-11-GB | 16/01/2015 | 23 May 2016 | The purpose of this study is to examine the safety and efficacy of VSN16R and the performance in treating spasticity (tightness, stiffness or pull of muscles) in patients with Multiple Sclerosis (MS). | A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects with Multiple Sclerosis | Multiple Sclerosis MedDRA version: 19.0 Level: LLT Classification code 10041416 Term: Spasticity System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: VSN16R 100mg Product Code: VSN16R Pharmaceutical Form: Capsule INN or Proposed INN: VSN16R Other descriptive name: (R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Canbex Therapeutics Ltd | Authorised | Female: yes Male: yes | Phase 2 | United Kingdom | ||||
419 | NCT02284568 | January 12, 2015 | 11 June 2018 | A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo | A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS) | Primary Progressive Multiple Sclerosis | Drug: Laquinimod;Drug: Placebo | Teva Branded Pharmaceutical Products, R&D Inc. | Not recruiting | 25 Years | 55 Years | All | 374 | Phase 2 | United States;Canada;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom | |
420 | NCT02255656 | January 7, 2015 | 15 April 2019 | Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 | A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) | Relapsing Remitting Multiple Sclerosis | Drug: alemtuzumab GZ402673 | Genzyme, a Sanofi Company | Not recruiting | 18 Years | N/A | All | 812 | Phase 4 | United States;Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;Sweden;Ukraine;United Kingdom;Czech Republic | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
421 | NCT02200770 | January 6, 2015 | 24 June 2019 | A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders | A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders | Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders | Biological: MEDI-551;Other: Placebo | MedImmune LLC | Not recruiting | 18 Years | N/A | All | 231 | Phase 2/Phase 3 | United States;Australia;Bulgaria;Canada;Colombia;Czechia;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;China;Czech Republic;India;Netherlands;Portugal;Ukraine | |
422 | NCT02335450 | January 2015 | 11 April 2016 | Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series | Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series | Multiple Sclerosis | Behavioral: Motivational Interviewing;Device: Wristband physical activity monitor | Oakland University | Not recruiting | 19 Years | N/A | Both | 5 | N/A | United States | |
423 | NCT02364986 | January 2015 | 13 June 2016 | Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis | Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis | Relapsing-remitting Multiple Sclerosis | Drug: Rebif®;Drug: Avonex | PD Dr. Marcus Müller | BfARM, Bonn;DZNE, Bonn | Recruiting | 18 Years | 65 Years | Both | 50 | Phase 1 | Germany |
424 | NCT02427776 | January 2015 | 16 December 2017 | A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis | A Clinical Trial to Document Safety and Radiological Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis Treated With Autologous CD4+ T Cells, Stimulated and Expanded ex Vivo by a Myelin Oligodendrocyte Glycoprotein Peptide Modified by the Introduction of a Thioreductase Motif Into the Flanking Residues of the Cell Epitope - A First-in-human Trial (SCLEROLYM TRIAL) | Multiple Sclerosis, Relapsing-Remitting | Biological: Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope | Imcyse SA | Not recruiting | 18 Years | 50 Years | All | 2 | Phase 1/Phase 2 | Belgium | |
425 | NCT02606929 | January 2015 | 23 November 2015 | Use of Well Known Drugs for New Destination - MS Improvement (MSNT) | Expanded Access Retrospective Study About the Use of Well Known Drugs in Combination to Obtain a New Drug to Improve Quality of Life/Health in Patient With Diagnosed Multiple Sclerosis Not Responding With Commonly Used Treatments | Multiple Sclerosis;Autoimmune Diseases;Disseminated or Multiple Sclerosis Nos;Multiple Sclerosis, Acute Relapsing;Multiple Sclerosis, Primary Progressive;Multiple Sclerosis, Chronic Progressive | Drug: Tetracycline - Statin - Antimycotic | Università Popolare Homo & Natura | Not recruiting | 18 Years | 65 Years | Both | Phase 0 | Italy | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
426 | EUCTR2015-000137-78-AT | 14 March 2016 | Mesenchymal stem cells therapy for patients with multiple sclerosis | Randomised, double-blind, cross-over phase II study with intravenous autologous mesenchymal stem cells vs. placebo for multiple sclerosis patients in Austria (MESEMS Austria) | multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Human autologous mesenchymal stem cells Pharmaceutical Form: Infusion INN or Proposed INN: MSC2015 Other descriptive name: UNDIFFERENTIATED AUTOLOGOUS MESENCHYMAL STEM CELLS Concentration unit: Other Concentration type: equal Concentration number: 2 mio cells /kg - Pharmaceutical form of the placebo: Infusion Route of administration of the placebo: Intravenous use | SALK - Gemeinnützige Salzburger Landeskliniken Betriebsges. m.b.H., Christian-Doppler-Klinik, UK für Neurologie der PMU | Authorised | Female: yes Male: yes | Phase 2 | Austria | |||||
427 | NCT02254304 | December 31, 2014 | 11 June 2018 | Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ | Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in Romania Using Electronic Device RebiSmart™ | Relapsing Multiple Sclerosis;Clinically Isolated Syndrome | Drug: Rebif | Merck KGaA | Merck Romania SRL, an affiliate of Merck KGaA, Darmstadt, Germany | Not recruiting | 18 Years | 65 Years | All | 106 | Phase 4 | Germany |
428 | EUCTR2014-000709-10-DE | 19/12/2014 | 18 June 2018 | Investigation on how alemtuzumab acts in patients with relapsing remitting multiple sclerosis. | Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential - ALAIN01 | relapsing-remitting multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: LEMTRADA 12 mg Konzentrat zur Herstellung einer Infusionslösung Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Alemtuzumab CAS Number: 216503-57-0 Other descriptive name: ALEMTUZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- | Universitätsklinikum Münster | Authorised | Female: yes Male: yes | 15 | Phase 4 | Germany | |||
429 | EUCTR2014-002547-17-NL | 18/12/2014 | 14 March 2016 | Imaging of inflammation in the cortex of the brain in progressive MS patients | Grey matter microglial imaging with [18F]DPA-714 in progressive MS patients - [18F]DPA-714 PET in MS | Progressive multiple sclerosis, both primary and secondary progressive MedDRA version: 17.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: [18F]DPA-714 Pharmaceutical Form: Radiopharmaceutical precursor INN or Proposed INN: [18F]DPA-714 Other descriptive name: [18F]DPA-714 Concentration unit: MBq megabecquerel(s) Concentration type: equal Concentration number: 250- | VU University Medical Center | Not Recruiting | Female: yes Male: yes | Netherlands | |||||
430 | NCT01910259 | December 18, 2014 | 16 December 2017 | MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial | A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis. | Secondary Progressive Multiple Sclerosis | Drug: Amiloride;Drug: Riluzole;Drug: Fluoxetine;Drug: Placebo | University College, London | Medical Research Council;National Institute for Health Research, United Kingdom;MS Society;University of Edinburgh;Queen Mary University of London;Keele University;University of Sheffield;University of Leeds;University of Warwick | Not recruiting | 25 Years | 65 Years | All | 445 | Phase 2 | United Kingdom |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
431 | EUCTR2014-001012-19-NL | 17/12/2014 | 12 January 2015 | Effects of fingolimod on advanced brain measures and clinical measures in multiple sclerosis | Effects of fingolimod on functional brain adaptation and clinical measures in multiple sclerosis - Effect of fingolimod on brain and cognition | Relapsing-remitting (RR) multiple sclerosis (MS);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya Pharmaceutical Form: Capsule INN or Proposed INN: fingolimod CAS Number: 162359-56-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Product Name: Interferon Beta Pharmaceutical Form: INN or Proposed INN: interferon beta-1b CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: mg milligram(s) Concentration type: range Concentration number: 0-0.25 INN or Proposed INN: interferon beta-1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: mg milligram(s) Concentration type: range Concentration number: 0-0.044 Trade Name: Copaxone Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Concentration unit: mg/l milligram(s)/litre Concentration type: equal Concentration number: 20- | VU University Medical Center | Authorised | Female: yes Male: yes | Netherlands | |||||
432 | EUCTR2014-001081-99-BE | 16/12/2014 | 8 August 2016 | A first in human trial for evaluating both safety and preliminary efficacy of a single infusion of stimulated autologous CD4+ cells in patients with Relapsing- Remitting multiple sclerosis | A clinical trial to document safety and radiological disease activity in patients with relapsing-remitting multiple sclerosis treated with autologous CD4+ cells, stimulated and expanded ex vivo by a myelin oligodendrocyte glycoprotein (MOG) peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope (SCLEROLYM trial). First-in-human trial - SCLEROLYM Trial | Multiple sclerosis is an immune-mediated inflammatory disease that attacks myelinated axons in the central nervous system. MS is characterized initially by episodes of reversible neurologic deficits. In most patients, these episodes are followed by progressive neurologic deterioration over time. Relapsing-remitting multiple sclerosis is characterized by recurrent attacks of neurologic dysfunction (relapses) followed by periods of complete or incomplete recovery (remission) MedDRA version: 18.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: SCLEROLYM Pharmaceutical Form: Suspension for injection INN or Proposed INN: Cytolytic CD4+ T cells Other descriptive name: AUTOLOGOUS T-LYMPHOCYTES Concentration unit: million organisms/ml million organisms/millilitre Concentration type: range Concentration number: 5-50 | ImCyse S.A | Not Recruiting | Female: yes Male: yes | Phase 1;Phase 2 | Belgium | ||||
433 | NCT02294058 | December 3, 2014 | 16 December 2017 | Phase 3 Study of RPC1063 in Relapsing MS | A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients | Multiple Sclerosis | Drug: RPC1063;Drug: Beta interferon | Celgene | Not recruiting | 18 Years | 55 Years | All | 1346 | Phase 3 | United States;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;Argentina;Austria;Colombia;Czech Republic;Mexico;Peru | |
434 | NCT02087631 | December 2014 | 22 October 2019 | Safety and Tolerability of Quetiapine in Multiple Sclerosis | A Dose-finding, Safety and Tolerability Trial of Extended-release Quetiapine in Relapsing-remitting and Progressive Multiple Sclerosis | Multiple Sclerosis | Drug: Extended-release quetiapine fumarate | University of Calgary | Multiple Sclerosis Society of Canada | Not recruiting | 18 Years | 65 Years | All | 14 | Phase 1/Phase 2 | Canada |
435 | NCT02142192 | December 2014 | 10 October 2016 | Natalizumab Subcutaneous Immunogenicity and Safety Study | A Multicenter, Open-Label Immunogenicity and Safety Study of Subcutaneous Natalizumab 300 mg Administered to Subjects With Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | Drug: natalizumab | Biogen | Not recruiting | 18 Years | 65 Years | Both | 2 | Phase 2 | Belgium;Denmark;Germany;Italy | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
436 | NCT02317263 | December 2014 | 15 August 2016 | A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis | Multiple Sclerosis | Drug: testosterone;Drug: placebo gel | University of California, Los Angeles | Not recruiting | 18 Years | 60 Years | Male | 0 | Phase 2 | |||
437 | NCT02389426 | December 2014 | 28 April 2015 | Transcranial Doppler in Multiple Sclerosis | Evaluation of Cerebrovascular Hemodynamics With Transcranial Doppler and Near-infrared Spectroscopy in Patients With Multiple Sclerosis | Multiple Sclerosis | Device: TCD baseline;Device: TCD after bosentan administration;Device: NIRS baseline;Device: NIRS after bosentan administration | Universitair Ziekenhuis Brussel | Not recruiting | 18 Years | N/A | Both | 30 | N/A | Belgium | |
438 | EUCTR2014-001579-30-GB | 27/11/2014 | 24 October 2016 | A Phase 2 clinical study in subjects with Progressive Multiple Sclerosis to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.5mg/day (experimental drug) as compared to placebo | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients with Primary Progressive Multiple Sclerosis (PPMS) - ARPEGGIO | Primary Progressive Multiple Sclerosis MedDRA version: 19.0 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Laquinimod Product Code: TV-5600 Pharmaceutical Form: Capsule, hard INN or Proposed INN: LAQUINIMOD CAS Number: 248282-07-7 Current Sponsor code: TV-5600 Other descriptive name: Laquinimod Sodium (USAN) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Laquinimod Product Code: TV-5600 Pharmaceutical Form: Capsule, hard INN or Proposed INN: LAQUINIMOD CAS Number: 248282-07-7 Current Sponsor code: TV-5600 Other descriptive name: Laquinimod Sodium (USAN) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- | Teva Pharmaceutical Industries Ltd. | Authorised | Female: yes Male: yes | 375 | Phase 2 | United States;Canada;Poland;Spain;Ukraine;Russian Federation;Netherlands;Germany;Italy;United Kingdom | |||
439 | EUCTR2013-002378-26-SE | 13/11/2014 | 25 June 2018 | Switch To RItuXimab in MS extension An extension study of an ongoing clinical trial where people with multiple sclerosis switch therapy from interferon or glatiramere injections to rituximab, a monoclonal antibody that eliminate B lymphocytes | Switch To RItuXimab in MS extension An extension study of STRIX-MS - a phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy approach - STRIX-MSext | The original trial (EudraCT 2010-023021-38) recruited 74 patients with relapsing-remitting multiple sclerosis in stable condition while treated with first line injectible disease-modifying drugs (DMDs), eg beta-interferons or glatiramere acetate. This extension study involves the same patients, those that consent to participate in this extension trial. MedDRA version: 16.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Mabthera® Product Name: Mabthera Pharmaceutical Form: Concentrate for solution for infusion | Västerbottens Läns Landsting | Not Recruiting | Female: yes Male: yes | 74 | Phase 2 | Sweden | |||
440 | NCT02230969 | November 12, 2014 | 6 May 2019 | Plegridy Observational Program | Plegridy™ (Peginterferon ß-1a) Real World Effectiveness and Safety Observational Program | Relapsing Forms of Multiple Sclerosis | Drug: peginterferon beta-1a | Biogen | Not recruiting | 18 Years | N/A | All | 1210 | N/A | United States;Australia;Austria;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;Switzerland;United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
441 | EUCTR2013-004622-29-IT | 10/11/2014 | 11 April 2016 | Impact of Natalizumab versus Fingolimod on Central Nervous System (CNS) Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis (RRMS) Subjects | A Multicenter, Randomized, Open-Label Study to Assess the Impact of Natalizumab versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects | Multiple Sclerosis (MS) MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Tysabri® Product Name: AN100226, BG00002 Pharmaceutical Form: Concentrate and solvent for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 300- Trade Name: Gilenya Product Name: Fingolimod Pharmaceutical Form: Capsule, hard INN or Proposed INN: fingolimod CAS Number: 162359-56-0 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- | Biogen Idec Research Limited | Not Recruiting | Female: yes Male: yes | 540 | France;United States;Czech Republic;Canada;Spain;Denmark;Australia;Germany;United Kingdom;Italy;Sweden | ||||
442 | NCT02142764 | November 2014 | 9 January 2017 | Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients | Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients (MS). | Multiple Sclerosis | Biological: Blood samples | University Hospital, Bordeaux | Merck Serono International SA;ADERA | Not recruiting | 18 Years | N/A | Both | 30 | N/A | France |
443 | NCT02253264 | November 2014 | 16 December 2017 | A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients | A Phase 1 Open-label Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients With Magnetic Resonance Imaging Evidence of Leptomeningeal Enhancement | Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis | Drug: Rituximab | Johns Hopkins University | Not recruiting | 18 Years | N/A | All | 8 | Phase 1 | United States | |
444 | NCT02259361 | November 2014 | 19 February 2015 | Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS | Efficacy of Sustained-release Oral Dalfampridine on Upper Extremity Function in Patients With Multiple Sclerosis: a Pilot Study | Multiple Sclerosis | Drug: Sustained-release oral dalfampridine;Drug: Placebo | Sheba Medical Center | Not recruiting | 18 Years | 70 Years | Both | 30 | Phase 4 | Israel | |
445 | NCT02310048 | November 2014 | 23 March 2015 | Comparative Oral Bioavailability Study of MT-1303 | A Randomised, Open-Label, Single-Dose, Parallel Group Study to Assess the Comparative Oral Bioavailability of Two Capsule Formulations of MT-1303 in Healthy Male Subjects | Relapsing-remitting Multiple Sclerosis | Drug: MT-1303-FormA;Drug: MT-1303-FormB | Mitsubishi Tanabe Pharma Corporation | Not recruiting | 18 Years | 55 Years | Male | 34 | Phase 1 | United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
446 | NCT02326935 | November 2014 | 11 June 2018 | Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis | Proposal for a Non-randomized, Patient Sponsored, Multi-center Study Studying the Impact and Safety of the Utilization of Culture Expanded Autologous, Adipose-derived Mesenchymal Stem Cells Deployed Via Intravenous Injection for the Treatment of Multiple Sclerosis | Multiple Sclerosis | Biological: Autologous adipose derived mesenchymal cells | American CryoStem Corporation | Not recruiting | 18 Years | 65 Years | All | 2 | Phase 1 | Cayman Islands | |
447 | EUCTR2014-002335-34-GB | 30/10/2014 | 22 May 2017 | Intravenous immunoglobulin vs standard therapy for treatment of transverse myelitis | A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin (IVIg) versus standard therapy for the treatment of transverse myelitis in adults and children - STRiVE | Transverse myelitis (TM) (acute, first onset cases), including first presentation of neuromyelitis optica (NMO) MedDRA version: 17.1 Level: PT Classification code 10028527 Term: Myelitis transverse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1 Level: PT Classification code 10029322 Term: Neuromyelitis optica System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Body processes [G] - Immune system processes [G12] | Trade Name: Intratect Product Name: Intratect Pharmaceutical Form: Solution for infusion | Guy's and St Thomas NHS Foundation Trust | Not Recruiting | Female: yes Male: yes | 0 | Phase 3 | United Kingdom | |||
448 | EUCTR2014-003669-97-BE | 27/10/2014 | 30 April 2018 | A safety study for patients with Relapsing Forms of Multiple Sclerosis who participated STRATA. | A Multicenter, Open-Label Safety Study of Natalizumab administered to Subjects with Relapsing Forms of Multiple Sclerosis who participated in STRATA. | Relapsing Forms of Multiple Sclerosis MedDRA version: 17.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Tysabri Product Name: Tysabri Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- | Biogen Idec | Not Recruiting | Female: yes Male: yes | 10 | Phase 4 | Belgium | |||
449 | EUCTR2014-000221-20-AT | 23/10/2014 | 23 July 2018 | Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical Trial | Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical Trial | Clinically Isolated Syndrome and Relapsing-remitting Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: RNS60 Product Code: RNS60 Pharmaceutical Form: Infusion | University Hospital Zürich | Not Recruiting | Female: yes Male: yes | 16 | Phase 2 | Austria;Switzerland | |||
450 | NCT02247310 | October 20, 2014 | 16 December 2017 | BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon | BETAEVAL_Global- The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon® | Multiple Sclerosis, Relapsing Remitting | Drug: Interferon beta-1b (Betaferon®, BAY 86-5046);Device: BETACONNECT | Bayer | Not recruiting | N/A | N/A | All | 498 | N/A | Austria;Belgium;Bosnia and Herzegovina;Croatia;Czechia;France;Greece;Hungary;Italy;Spain;Switzerland;Czech Republic;Netherlands | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
451 | NCT02096133 | October 13, 2014 | 16 December 2017 | Vitamin D3 and the Stress-axis in MS | Regulation of the Stress-axis by Vitamin D3 in Subjects With Multiple Sclerosis; a Double-blinded, Randomized, Placebo-controlled Study | Multiple Sclerosis | Drug: Cholecalciferol;Other: Placebo comparator | Academic MS Center Limburg | Not recruiting | 18 Years | N/A | Female | 54 | Phase 2 | Netherlands | |
452 | NCT02104661 | October 2014 | 11 June 2018 | Protective Role of Oxcarbazepine in Multiple Sclerosis | OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial | Multiple Sclerosis | Drug: Oxcarbazepine;Drug: Placebo | Queen Mary University of London | National Multiple Sclerosis Society;Novartis Pharmaceuticals;Barts & The London NHS Trust;University College, London;Royal Free Hospital NHS Foundation Trust;Southend University Hospital;Basildon and Thurrock University Hospitals NHS Foundation Trust;St George's Healthcare NHS Trust;Barnet and Chase Farm Hospitals NHS Trust | Not recruiting | 18 Years | 60 Years | All | 30 | Phase 2 | United Kingdom |
453 | NCT02212886 | October 2014 | 1 April 2019 | Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS | A Prospective 1-year, Open-label, Two Arms, Multicenter, Phase IIa Study to Assess Safety, Tolerability and Efficacy of Once a Month Long-acting Intramuscular Injection of 80 or 40 mg Glatiramer Acetate (GA Depot) in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis | Drug: GA Depot 80 mg;Drug: GA Depot 40 mg | Mapi Pharma Ltd. | Not recruiting | 18 Years | 70 Years | All | 25 | Phase 1/Phase 2 | Israel | |
454 | NCT02228213 | October 2014 | 16 December 2017 | Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis | A Phase 2B Randomised, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of MIS416 in the Treatment of Subjects With Secondary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Biological: MIS416;Drug: Saline | Innate Immunotherapeutics | INC Research | Not recruiting | 18 Years | 70 Years | All | 93 | Phase 2 | Australia;New Zealand |
455 | NCT02234869 | October 2014 | 19 February 2015 | Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy | Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Patients With Relapsing Multiple Sclerosis Transitioning From Standard-of-care Subcutaneous Interferon Therapy to Peginterferon Beta-1a (BIIB017) | Relapsing Multiple Sclerosis | Drug: Interferon Beta;Drug: BIIB017 (Peginterferon beta-1a) | Biogen Idec | Not recruiting | 18 Years | 65 Years | Both | 0 | Phase 4 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
456 | NCT02269930 | October 2014 | 19 February 2015 | Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers | An Open-label Crossover Phase 1 Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers | Multiple Sclerosis | Drug: peginterferon beta-1a;Drug: Rebif | Biogen Idec | Not recruiting | 18 Years | 45 Years | Both | 30 | Phase 1 | United States | |
457 | NCT02280096 | October 2014 | 28 December 2015 | Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis | Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis. Randomized, Blinded, Placebo-controlled Clinical Trial. | Multiple Sclerosis | Drug: 4-aminopyridine;Drug: Placebo | Coordinación de Investigación en Salud, Mexico | Not recruiting | 18 Years | 60 Years | Both | 24 | Phase 2 | Mexico | |
458 | NCT02282826 | October 2014 | 25 April 2016 | A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis | A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Intravenous and Subcutaneous Doses of GZ402668 in Men and Women With Progressive Multiple Sclerosis | Progressive Multiple Sclerosis | Drug: GZ402668;Drug: placebo;Drug: acyclovir | Genzyme, a Sanofi Company | Not recruiting | 18 Years | 65 Years | Both | 48 | Phase 1 | Germany | |
459 | NCT02286557 | October 2014 | 19 February 2015 | Testing the Effects of Methylphenidate on Multiple Sclerosis | Testing the Effects of Methylphenidate on Cognitive Fatigue in Multiple Sclerosis: a Double-blind, Placebo-controlled, Randomized Clinical Trial | Fatigue in Multiple Sclerosis | Drug: Methelphenidate;Drug: Placebo | Kessler Foundation | Not recruiting | 18 Years | 65 Years | Both | 36 | Phase 2 | ||
460 | NCT02296346 | October 2014 | 26 August 2019 | Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis | A Randomized, Controlled, Open-Label Study to Evaluate the Efficacy of Extracorporeal Photopheresis (ECP) Versus Corticosteroids in the Treatment of Patients With Secondary Progressive Multiple Sclerosis (SPMS) | Secondary Progressive Multiple Sclerosis | Drug: SoluMedrol;Device: Extracorporeal Photopheresis | University of Utah | Mallinckrodt | Not recruiting | 18 Years | 75 Years | All | 13 | N/A | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
461 | EUCTR2011-005249-12-GB | 29/09/2014 | 10 September 2018 | Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients with Relapsing Forms of Multiple Sclerosis | A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients with Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension - TERIKIDS | Multiple Sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Genzyme Corporation | Authorised | Female: yes Male: yes | 165 | Phase 3 | United States;Serbia;Portugal;Estonia;Morocco;Greece;Spain;Ukraine;Lebanon;Ireland;Russian Federation;Israel;France;Macedonia, the former Yugoslav Republic of;Australia;Tunisia;Netherlands;China;Slovenia;Turkey;Lithuania;United Kingdom;Canada;Belgium;Poland;Bulgaria | |||
462 | NCT02232061 | September 29, 2014 | 14 October 2019 | Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod | Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod | Multiple Sclerosis | Drug: Fingolimod | Novartis Pharmaceuticals | Recruiting | N/A | N/A | All | 40 | Phase 4 | Belgium;Germany;Italy | |
463 | EUCTR2013-003600-40-GB | 15/09/2014 | 3 April 2017 | Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects with Multiple Sclerosis (ENHANCE) | A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects with Multiple Sclerosis (ENHANCE) | Multiple Sclerosis MedDRA version: 17.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Fampyra Product Name: Fampridine Product Code: BIIB041 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Current Sponsor code: BIIB041 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use | Biogen Idec Research Limited | Not Recruiting | Female: yes Male: yes | 590 | Phase 3 | United States;Serbia;Finland;Ukraine;Lithuania;Russian Federation;United Kingdom;Switzerland;Italy;Czech Republic;Poland;Bulgaria;Netherlands | |||
464 | EUCTR2014-003209-14-FR | 01/09/2014 | 4 August 2015 | ASSESSMENT OF EARLY CHANGES OBSERVABLE IN DIFFUSION MRI IN RESPONSE TO TYSABRI TREATMENT TO TWO YEARS IN PATIENTS WITH MULTIPLE SCLEROSIS | ASSESSMENT OF EARLY CHANGES OBSERVABLE IN DIFFUSION MRI IN RESPONSE TO TYSABRI TREATMENT TO TWO YEARS IN PATIENTS WITH MULTIPLE SCLEROSIS - TYSADIFF | MULTIPLE SCLEROSIS;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: TYSABRI 300 mg solution à diluer pour perfusion Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 | Hôpitaux Universitaires de Strasbourg | Authorised | Female: yes Male: yes | France | |||||
465 | NCT02045732 | September 2014 | 19 October 2017 | A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) | A Phase 1b, Double-blinded, Placebo-controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (rn168) In Subjects With Multiple Sclerosis (ms) | Multiple Sclerosis | Biological: PF-06342674 0.25 mg/kg;Biological: Placebo;Biological: PF-06342674 1.5 mg/kg;Biological: PF-06342674 6.0 mg/kg | Pfizer | Not recruiting | 18 Years | 55 Years | All | 4 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
466 | NCT02193217 | September 2014 | 2 March 2015 | A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303 | Relapsing-remitting Multiple Sclerosis | Drug: MT-1303-Low;Drug: MT-1303-High;Drug: Fingolimod;Drug: Placebo | Mitsubishi Tanabe Pharma Corporation | Not recruiting | 18 Years | 55 Years | Both | 81 | Phase 1 | United Kingdom | ||
467 | NCT02273635 | September 2014 | 19 February 2015 | Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS | Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis | Primary Progressive Multiple Sclerosis;Multiple Sclerosis, Secondary Progressive | Drug: Andrographolides;Drug: placebo | Innobioscience SpA | Pontificia Universidad Catolica de Chile;University of Chile;Universidad Austral de Chile | Recruiting | 18 Years | 70 Years | Both | 68 | Phase 1/Phase 2 | Chile |
468 | NCT02282878 | September 2014 | 16 December 2017 | The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis | The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis | Multiple Sclerosis | Dietary Supplement: High/Low Sodium Diet | Yale University | Recruiting | 18 Years | 60 Years | All | 25 | N/A | United States | |
469 | NCT02287948 | September 2014 | 15 February 2016 | Wii FIT Balance Board to Recording Balance Parameters in Multiple Sclerosis Subjects | Validation Study for Using Wii FIT Balance Board to Recording Balance Parameters in Healthy Subjects and Multiple Sclerosis Subjects | Postural Balance;Multiple Sclerosis | Device: Nintendo Wii Fit Balance Board | University Hospital of Ferrara | Not recruiting | 18 Years | 80 Years | Both | 40 | N/A | Italy | |
470 | NCT02293967 | September 2014 | 23 March 2015 | Mass Balance Study of MT-1303 | An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C] MT-1303 After a Single Oral Dose to Healthy Male Subjects. | Relapsing-remitting Multiple Sclerosis | Drug: MT-1303 | Mitsubishi Tanabe Pharma Corporation | Not recruiting | 30 Years | 65 Years | Male | 8 | Phase 1 | United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
471 | NCT02777060 | September 2014 | 30 May 2016 | Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures | Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures | Diabetes;Cancer;Multiple Sclerosis;Arthritis;Parkinson's Disease;Cognitive Disorders;Brain Injury;Stroke | Procedure: Exergame;Procedure: Home based balance training | University of Arizona | Recruiting | 18 Years | N/A | Both | 200 | N/A | United States | |
472 | ChiCTR-ICR-15007177 | 2014-08-30 | 18 April 2017 | A Prospective Study on the Efficacy andSafety of Rituximab in Treatment for Neuromyelitis Optica associated Optic Neuritis | A Prospective Study on the Efficacy andSafety of Rituximab in Treatment for Neuromyelitis Optica associated Optic Neuritis | Neuromyelitis Optica associated Optic Neuritis | 1:Intravenous 100mg Rituximab, 1/week*4 ;2:Oral azathioprine (2.5-3 mg/kg bodyweight/day) or mycophenolate mofetil (1000-1500mg/day); | The Ophthalmology Department of the Chinese Peoples Liberation Army Hospital | Recruiting | 18 | 70 | Both | 1:30;2:30; | New Treatment Measure Clinical Study | China | |
473 | NCT02283853 | August 28, 2014 | 16 September 2019 | Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) | Open-Label, Randomized, Multicenter, Multiple-Dose,Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension | Relapsing-Remitting Multiple Sclerosis | Drug: dimethyl fumarate;Drug: Interferon ß-1a | Biogen | Not recruiting | 10 Years | 17 Years | All | 142 | Phase 3 | Belgium;Bulgaria;Canada;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Kuwait;Poland;Serbia;Spain;Sweden;Turkey;United Kingdom;United States;Argentina;Czech Republic;Romania | |
474 | EUCTR2011-005249-12-EE | 13/08/2014 | 28 August 2014 | Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients with Relapsing Forms of Multiple Sclerosis | A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients with Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension - TERIKIDS | Multiple Sclerosis MedDRA version: 17.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Genzyme Corporation | Authorised | Female: yes Male: yes | 165 | United States;Estonia;Greece;Canada;Spain;Belgium;Lebanon;Turkey;Australia;Russian Federation;Israel;China | ||||
475 | NCT02073279 | August 5, 2014 | 17 June 2019 | Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) | Neuromyelitis Optica (NMO);NMO Spectrum Disorder (NMOSD) | Drug: Satralizumab;Drug: Placebo | Hoffmann-La Roche | Chugai Pharmaceutical | Not recruiting | 18 Years | 74 Years | All | 95 | Phase 3 | United States;Bulgaria;Canada;Croatia;Georgia;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Taiwan;Turkey;Ukraine;Bosnia and Herzegovina;Puerto Rico;Singapore |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
476 | NCT02209467 | August 2014 | 17 November 2015 | Balance and Falls in Multiple Sclerosis | Balance and Falls in Multiple Sclerosis: Intervention and Perceptions From Patients and Next of Kins | Multiple Sclerosis | Other: Group balance training | Örebro County Council | Not recruiting | 18 Years | N/A | Both | 52 | N/A | Sweden | |
477 | NCT02218879 | August 2014 | 12 September 2016 | Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS | Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Tecfidera | Yale University | Not recruiting | 18 Years | 60 Years | Both | 7 | N/A | United States | |
478 | EUCTR2014-000092-62-BE | 30/07/2014 | 8 August 2016 | Management of the infusion-associated reactions in RRMS patients treated with Lemtrada | Single arm study to assess comprehensive infusion guidance for the management of the infusion associated reaction (IARs) in Relapsing-Remitting Multiple Sclerosis (RRMS) patients treated with Lemtrada. - EMERALD | Relapsing-remitting multiple sclerosis MedDRA version: 18.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Lemtrada Product Name: Lemtrada Product Code: GZ402673 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: alemtuzumab CAS Number: 216503-57-0 Current Sponsor code: GZ402673 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- | Genzyme Corporation | Not Recruiting | Female: yes Male: yes | 56 | Phase 4 | France;Spain;Belgium;Netherlands;Switzerland | |||
479 | NCT02201108 | July 16, 2014 | 7 October 2019 | Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis | A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension | Multiple Sclerosis | Drug: Teriflunomide;Drug: Placebo | Genzyme, a Sanofi Company | Not recruiting | 10 Years | 18 Years | All | 165 | Phase 3 | United States;Belgium;Bulgaria;Canada;China;Estonia;France;Greece;Israel;Lebanon;Lithuania;Morocco;Netherlands;North Macedonia;Portugal;Russian Federation;Serbia;Slovenia;Spain;Tunisia;Turkey;Ukraine;United Kingdom;Australia;Macedonia, The Former Yugoslav Republic of;Poland | |
480 | NCT02159573 | July 2014 | 13 June 2016 | Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) | A Multicenter, Retrospective, Observational Study Evaluating Real-world Clinical Outcomes in Relapsing-remitting Multiple Sclerosis Patients Who Transition From Tysabri® (Natalizumab) to Tecfidera® (Dimethyl Fumarate) | Relapsing-Remitting Multiple Sclerosis | Biological: natalizumab;Drug: dimethyl fumarate | Biogen | Not recruiting | 18 Years | N/A | Both | 530 | N/A | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
481 | NCT02201849 | July 2014 | 19 February 2015 | A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults | A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral ALKS 8700 in Healthy Adults | Multiple Sclerosis | Drug: Study Drug;Drug: Active Control;Drug: Placebo | Alkermes, Inc. | Not recruiting | 18 Years | 55 Years | Both | 104 | Phase 1 | United States | |
482 | NCT02217982 | July 2014 | 16 December 2017 | Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation | A Pilot Study to Assess Dimethyl Fumarate (Tecfidera) Related GI Symptom Mitigation Via Food Bolus Alteration and Simethicone/Loperamide Administration | Relapsing Remitting Multiple Sclerosis | Drug: Simethicone;Drug: Loperamide;Other: Peanut Butter | Rocky Mountain MS Research Group, LLC | Biogen | Not recruiting | 18 Years | N/A | All | 5 | Phase 4 | United States |
483 | NCT02727907 | July 2014 | 8 August 2016 | Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis | International, Multicenter, Double-blinded, Placebo-controlled, Randomized Study of the Efficacy and Safety of Drugs BCD-033 and Rebif for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis | Drug: BCD-033 (interferon beta 1a);Drug: Rebif (interferon beta 1a);Drug: Placebo | Biocad | Not recruiting | 18 Years | 55 Years | Both | 147 | Phase 2/Phase 3 | Russian Federation | |
484 | EUCTR2013-003126-83-DE | 23/06/2014 | 7 October 2014 | Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator. | A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-ß-1a 30 µg IM Weekly in Subjects with Relapsing Multiple Sclerosis - Efficacy and safety of ONO-4641 versus Interferon-ß-1a in patients with multiple sclerosis | Relapsing multiple sclerosis MedDRA version: 16.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: MSC2430913A or ONO-4641 (to be used as synonyms) Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ceralifimod CAS Number: 891859-12-4 Current Sponsor code: MSC2430913A or ONO-4641 (to be used as synonyms) Other descriptive name: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.05- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Avonex Product Name: Avonex Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: Avonex CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 60- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Intramuscular use Product Code: MSC2430913A or ONO-4641 (to be used as synonyms) Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ceralifimod CAS Number: 891859-12-4 Current Sponsor code: MSC2430913A or ONO-4641 (to be used as synonyms) Other descriptive name: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Merck KGaA | Not Recruiting | Female: yes Male: yes | 1176 | Phase 3 | United States;United Arab Emirates;Belarus;Serbia;Slovakia;Greece;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia;Italy;France;Peru;Denmark;South Africa;Netherlands;Finland;Turkey;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Belgium;Romania;Georgia;Bulgaria;Germany;New Zealand;Sweden | |||
485 | NCT02121444 | June 23, 2014 | 16 December 2017 | BAY86-5046 (Betaseron), Non Interventional Studies | BETAEVAL - The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon® | Multiple Sclerosis | Drug: Interferon beta-1b (Betaferon, BAY 86-5046);Device: BETACONNECT auto-injector. | Bayer | Not recruiting | 18 Years | N/A | All | 151 | N/A | Germany | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
486 | EUCTR2013-002324-16-CZ | 13/06/2014 | 22 October 2018 | Study of efficacy and safety of VAY736 in patients with relapsing-remitting multiple sclerosis | A randomized, partially blind, placebo-controlled, proof-of-concept study to assess the effect of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relapsing-remitting multiple sclerosis | relapsing-remitting multiple sclerosis MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: VAY736 Pharmaceutical Form: Powder for concentrate for solution for infusion Current Sponsor code: VAY736 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 96 | Phase 2 | United States;Czech Republic;Poland;Ukraine;Russian Federation | |||
487 | EUCTR2013-002318-11-SE | 05/06/2014 | 23 October 2017 | Phase 3 Efficacy and Safety Study of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMs). | Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension - CONNECT | Relapsing-Remitting Multiple Sclerosis MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Trade Name: AVONEX Product Name: Avonex Pharmaceutical Form: Injection INN or Proposed INN: Interferon beta-1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: range Concentration number: 7.5-30 | Biogen Idec Research Limited | Authorised | Female: yes Male: yes | 132 | Phase 3 | Serbia;United States;Spain;Turkey;Israel;Italy;United Kingdom;France;Czech Republic;Hungary;Canada;Poland;Belgium;Denmark;Bulgaria;Kuwait;Germany;Sweden | |||
488 | EUCTR2013-002324-16-PL | 04/06/2014 | 12 November 2018 | Study of efficacy and safety of VAY736 in patients with relapsing-remitting multiple sclerosis | A randomized, partially blind, placebo-controlled, proof-of-concept study to assess the effect of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relapsing-remitting multiple sclerosis | relapsing-remitting multiple sclerosis MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: VAY736 Pharmaceutical Form: Powder for concentrate for solution for infusion Current Sponsor code: VAY736 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 96 | Phase 2 | United States;Czech Republic;Poland;Ukraine;Russian Federation | |||
489 | EUCTR2011-005249-12-ES | 03/06/2014 | 28 February 2019 | A two year, randomized, placebo-controlled study to evaluate efficacy, safety, tolerability, and pharmacokinetics of teriflunomide once daily in pediatric patients with relapsing forms of multiple sclerosis | A two year, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate efficacy, safety, tolerability, and pharmacokinetics of teriflunomide administered orally once daily in pediatric patients with relapsing forms of multiple sclerosis - TERIKIDS | Multiple Sclerosis MedDRA version: 16.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Genzyme Corporation | Not Recruiting | Female: yes Male: yes | 165 | Phase 3 | Portugal;United States;Estonia;Slovenia;Greece;Spain;Ireland;Lebanon;Lithuania;Turkey;Israel;Russian Federation;United Kingdom;France;Canada;Belgium;Poland;Australia;Bulgaria;Netherlands;China | |||
490 | NCT01883661 | June 2014 | 19 February 2015 | Safety and Efficacy of BMMNC in Multiple Sclerosis (MS) | Role of Autologous Bone Marrow Derived Mono Nuclear Stem Cell (MNCs) In Patient With Multiple Sclerosis .It is Self Funded (Patients' Own Funding) Clinical Trial | Multiple Sclerosis | Biological: BMMNC | Chaitanya Hospital, Pune | Recruiting | 18 Years | 65 Years | Both | 15 | Phase 1/Phase 2 | India | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
491 | NCT01941004 | June 2014 | 16 December 2017 | Safety and Efficacy of Fingolimod in MS Patients in China | A 12 Month Study, With a 6-month, Double-blind, Randomized, Placebo-controlled, Multi-center Parallel- Groups, Treatment Phase Evaluating Efficacy and Safety of Fingolimod 0.5 mg and a 6-month, Open-label, Treatment Phase, in Chinese Patients With Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Drug: fingolimod;Drug: Placebo (6mos) + open label fingolimod (6 mos) | Novartis Pharmaceuticals | Not recruiting | 18 Years | 50 Years | All | 0 | Phase 3 | ||
492 | NCT02117050 | June 2014 | 19 October 2017 | RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate | RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate. A 24-week, Prospective, Open-label, Multicenter Trial Evaluating Treatment Satisfaction in Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment Change From Tecfidera™ to Rebif® 44 mcg Subcutaneously (sc) Three Times Weekly (Tiw) | Multiple Sclerosis | Drug: Rebif® | EMD Serono | Not recruiting | 18 Years | 65 Years | All | 1 | Phase 4 | United States | |
493 | NCT02133664 | June 2014 | 16 December 2017 | Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis | Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis | Multiple Sclerosis;Cognition | Drug: lipoic acid and omega-3 fatty acids;Drug: Placebo | Oregon Health and Science University | National Multiple Sclerosis Society | Not recruiting | 18 Years | 65 Years | All | 54 | Phase 1/Phase 2 | United States |
494 | NCT02258217 | June 2014 | 16 December 2017 | Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS) | Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS) | Relapsing Remitting Multiple Sclerosis | Drug: Acthar | OhioHealth | Not recruiting | 18 Years | N/A | All | 30 | N/A | United States | |
495 | EUCTR2013-003752-21-GB | 19/05/2014 | 7 January 2019 | A late stage clinical trial to investigate the efficacy and safety of SA237 in patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder | A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of SA237 in patients with neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD) | Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD) MedDRA version: 20.0 Level: LLT Classification code 10029322 Term: Neuromyelitis optica System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: SA237-120/vial Pharmaceutical Form: Solution for injection INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Code: SA237-120 PFS with NSD Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120- | Chugai Pharmaceutical Co. Ltd | Authorised | Female: yes Male: yes | 70 | Phase 3 | France;United States;Hungary;Taiwan;Poland;Spain;Germany;Japan;Italy;United Kingdom | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
496 | JPRN-UMIN000013453 | 2014/05/10 | 7 October 2019 | A multi-center, randomized, double-blind, placebo-controlled trial to determine the efficacy of rituximab against a relapse of neuromyelitis optica spectrum disorders with anti-aquaporin 4 antibody | A multi-center, randomized, double-blind, placebo-controlled trial to determine the efficacy of rituximab against a relapse of neuromyelitis optica spectrum disorders with anti-aquaporin 4 antibody - RIN-1 | Neuromyelitis optica | Rituximab intravenous infusion Placebo | Clinical Research Center, NHO Utano National Hospital | Zenyaku Kogyo Co., Ltd. | Not Recruiting | 16years-old | 80years-old | Male and Female | 40 | Phase 2,3 | Japan |
497 | EUCTR2013-001486-17-DE | 06/05/2014 | 25 April 2016 | TOLERATE - A Study that evaluates the Gastrointestinal Tolerability of DMF in Multiple Sclerosis Patients | A Multicenter, Open-Label, Single-Arm Study to Evaluate Gastrointestinal Tolerability in Subjects with Relapsing-Remitting Multiple Sclerosis Receiving Dimethyl Fumarate (TOLERATE) | Relapsing-Remitting Multiple Sclerosis MedDRA version: 18.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 18.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Tecfidera Product Name: Tecfidera Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- Trade Name: Tecfidera Product Name: Tecfidera Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- | Biogen Idec Research Limited | Not Recruiting | Female: yes Male: yes | Germany | |||||
498 | EUCTR2013-001895-40-IE | 02/05/2014 | 18 January 2016 | A study to evaluate the effect of aspirin on flushing in patients with RRMS treated with Tecfidera | A Phase 4, Randomized, Double-Blind Study with a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects with Relapsing-Remitting Multiple Sclerosis Treated with Tecfidera™ (dimethyl fumarate) delayed-release capsules (ASSURE) - ASSURE | Relapsing-Remitting Multiple Sclerosis MedDRA version: 16.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 16.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Tecfidera Product Name: Tecfidera Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Trade Name: Tecfidera Product Name: Tecfidera Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- Trade Name: Micropirin Pharmaceutical Form: Capsule INN or Proposed INN: ACETYLSALICYLIC ACID CAS Number: 50-78-2 Other descriptive name: ASA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Biogen Idec Research Limited | Not Recruiting | Female: yes Male: yes | 240 | Phase 4 | Ireland;United Kingdom | |||
499 | JPRN-JapicCTI-142447 | 01/5/2014 | 16 July 2019 | Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) | A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Intervention name : BAF312 INN of the intervention : Siponimod Dosage And administration of the intervention : BAF312 will be provided in a dose titration from 0.25 mg to a 2 mg dose. Control intervention name : Placebo Dosage And administration of the control intervention : Matching Placebo administered orally. | Novartis Pharma K.K. | Not Recruiting | 18 | 60 | BOTH | 1530 | Phase 3 | ||
500 | NCT02046629 | May 2014 | 19 February 2015 | A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers | An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Profiles of 14 mg Teriflunomide Tablet in Healthy Chinese Subjects | Multiple Sclerosis | Drug: Teriflunomide HMR1726;Drug: cholestyramine | Sanofi | Not recruiting | 18 Years | 45 Years | Both | 12 | Phase 1 | China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
501 | NCT02064816 | May 2014 | 16 December 2017 | A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis | Multicenter, Open-label, 12 Week, Phase IV Prospective Randomized Study Aimed at Evaluating Whether sc IFN Beta 1a (Rebif®) Administered in the Morning May Affect the Severity of Flu-like Syndrome and Patient-perceived Invisible Symptoms in Subjects With Relapsing Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Rebif® | Merck KGaA | Not recruiting | 18 Years | 60 Years | All | 212 | Phase 4 | Germany | |
502 | NCT02086188 | May 2014 | 11 November 2019 | Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis | Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Multiple Sclerosis (MIRROR) | Multiple Sclerosis | Drug: Mirabegron;Drug: Placebo | Theodore R. Brown, MD MPH | Astellas Pharma Inc | Not recruiting | 18 Years | N/A | All | 28 | Phase 4 | United States |
503 | NCT02143167 | May 2014 | 3 September 2018 | Resistance Training and Amino Pyridine in Multiple Sclerosis | RETRAP - A Double Blind, Randomized, Placebo Controlled Study of the Effect of the Combination of Resistance Training and Prolonged Release Fampridine in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: SR-fampridine;Drug: Placebo | University of Southern Denmark | Region of Southern Denmark;Biogen | Not recruiting | 18 Years | 60 Years | All | 40 | Phase 4 | Denmark |
504 | NCT02579681 | April 30, 2014 | 16 December 2017 | Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 | Single Country Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis Patients Treated With BG00012 | Multiple Sclerosis, Relapsing-Remitting | Drug: dimethyl fumarate | Biogen | Not recruiting | 18 Years | N/A | All | 221 | Phase 3 | Italy | |
505 | EUCTR2014-000296-12-FI | 15/04/2014 | 28 April 2014 | N/A | N/A | Multiple sclerosis MedDRA version: 16.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders | Trade Name: Gilenya Product Name: Fingolimodi Pharmaceutical Form: Capsule, hard | Turku University Hospital | Authorised | Female: yes Male: yes | Finland | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
506 | EUCTR2012-000734-19-ES | 10/04/2014 | 14 April 2014 | Bone marrow cell treatment as treatment of multiple sclerosis | Treatment of autologous mesenchymal stem cells derived from bone marrow as a potential therapeutic strategy for the treatment of multiple sclerosis - EMMES | Multiple Sclerosis MedDRA version: 16.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: XCEL-MC-ALPHA Product Code: XCEL-MC-ALPHA Pharmaceutical Form: Suspension for injection INN or Proposed INN: Autologous adult mesenchymal stem cells from bone marrow expanded and cryopreserved Other descriptive name: Mesenchymal Stem Cells Concentration unit: U unit(s) Concentration type: range Concentration number: 800000-1200000 Pharmaceutical form of the placebo: Suspension for injection Route of administration of the placebo: Intravenous use | Banc de Sang i Teixits | Authorised | Female: yes Male: yes | Spain | |||||
507 | EUCTR2013-002660-17-IT | 09/04/2014 | 11 April 2016 | Long-term follow-up at 10-years of patients enrolled in the fingolimod Phase II program in relapsing multiple sclerosis | Long-term follow-up at 10-years of patients enrolled in the fingolimod Phase II program in relapsing multiple sclerosis - ACROSS | multiple sclerosis MedDRA version: 16.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya Product Name: Fingolmod Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720D Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- | Novartis Farma SpA | Not Recruiting | Female: yes Male: yes | 281 | Phase 2 | France;Portugal;Canada;Finland;Spain;Poland;Denmark;Germany;United Kingdom;Switzerland;Italy | |||
508 | NCT01933802 | April 2014 | 11 June 2018 | Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis | Phase 1 Safety Study of Autologous Bone Marrow-derived Mesenchymal Stem Cell-derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo, Administered Intrathecally in Patients With Multiple Sclerosis | Multiple Sclerosis | Biological: intrathecal administration of autologous MSC-NP | Tisch Multiple Sclerosis Research Center of New York | Not recruiting | 18 Years | 70 Years | All | 20 | Phase 1 | United States | |
509 | NCT01973517 | April 2014 | 17 September 2018 | High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases | 7T MRI Ferumoxytol-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases | Multiple Sclerosis | Drug: Feraheme;Drug: Gadolinium-based contrast | Stanford University | Not recruiting | 18 Years | N/A | All | 0 | Phase 3 | United States | |
510 | NCT02865018 | April 2014 | 22 August 2016 | Neuromyelitis Optica (NMO) & Cetirizine | An Open Label, add-on Trial of Cetirizine for Patients With Neuromyelitis Optica | Neuromyelitis Optica | Drug: cetirizine | Icahn School of Medicine at Mount Sinai | Guthy Jackson Foundation | Not recruiting | 18 Years | 85 Years | Both | 16 | Phase 1/Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
511 | EUCTR2013-002419-87-GB | 18/03/2014 | 28 February 2019 | PROXIMUS (PRotective role of OXcabazepine In MUltiple Sclerosis) | Oxcarbazepine as a neuroprotective agent in MS: phase 2a trial - PROXIMUS - PRotective role of OXcabazepine In MUltiple Sclerosis | Multiple sclerosis MedDRA version: 19.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Trileptal Product Name: Oxcarbazepine Other descriptive name: Trileptal Concentration unit: mg milligram(s) Concentration number: 150- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use | Queen Mary University London | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | United Kingdom | |||
512 | EUCTR2013-002351-15-EE | 13/03/2014 | 7 October 2014 | Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator. | A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-ß-1a 30 µg IM Weekly in Subjects with Relapsing-Remitting Multiple Sclerosis - Efficacy and safety of ONO-4641 versus Interferon-ß-1a in patients with multiple sclerosis | Relapsing remitting multiple sclerosis MedDRA version: 16.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: MSC2430913A or ONO-4641 (to be used as synonyms) Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ceralifimod CAS Number: 891859-12-4 Current Sponsor code: MSC2430913A or ONO-4641 (to be used as synonyms) Other descriptive name: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.05- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Avonex Product Name: Avonex Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: Avonex CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 60- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Intramuscular use Product Code: MSC2430913A or ONO-4641 (to be used as synonyms) Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ceralifmod CAS Number: 891859-12-4 Current Sponsor code: MSC2430913A or ONO-4641 (to be used as synonyms) Other descriptive name: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Merck KGaA | Not Recruiting | Female: yes Male: yes | 1176 | Phase 3 | United States;United Arab Emirates;Portugal;Belarus;Serbia;Estonia;Morocco;Slovakia;Spain;Ukraine;Lebanon;Chile;Russian Federation;Colombia;Italy;France;Jordan;Denmark;Peru;Latvia;Tunisia;Bosnia and Herzegovina;Finland;Turkey;Lithuania;Austria;United Kingdom;Egypt;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Belgium;Romania;Croatia;Georgia;Bulgaria;Germany;Japan;Sweden | |||
513 | EUCTR2013-004616-21-DE | 13/03/2014 | 14 March 2016 | A study to assess immune function and typical disease characteristics in patients with multiple sclerosis, when switching from the medication Natalizumab to the medication Gilenya. | A 32-week, monocentric, exploratory, single arm study to assess immune function and MRI disease activity in patients with relapsing remitting multiple sclerosis (RRMS) transferred from previous treatment with Natalizumab to Gilenya® (Fingolimod) - ToFingo Successor | relapsing remitting multiple sclerosis MedDRA version: 18.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720 Pharmaceutical Form: Capsule, hard INN or Proposed INN: fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Trade Name: Tysabri Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Current Sponsor code: BG00002 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- | Universitätsklinikum Münster | Not Recruiting | Female: yes Male: yes | Germany | |||||
514 | NCT02087813 | March 2014 | 23 April 2019 | Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses | A Single Center Open Label Pilot Study of Alpha1-Antitrypsin: A Novel Treatment to Mitigate Neuromyelitis Optica Attacks | Neuromyelitis Optica | Drug: Alpha1-antitrypsin;Drug: methylprednisolone | Stanford University | Not recruiting | 18 Years | 75 Years | All | 0 | Phase 1 | United States | |
515 | NCT02137109 | March 2014 | 26 October 2015 | Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri | Meta-Analysis of the Safety and Efficacy of Natalizumab in Pediatric Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: natalizumab | Biogen | Not recruiting | N/A | 18 Years | Both | 400 | N/A | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
516 | NCT02208050 | March 2014 | 10 September 2018 | A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis | A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis | Drug: Fampridine;Drug: Placebo | University College Dublin | Not recruiting | 18 Years | 70 Years | All | 66 | Phase 4 | Ireland | |
517 | NCT02028884 | February 20, 2014 | 9 September 2019 | Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD) | A Multicenter, Randomized, Addition to Baseline Treatment, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD) | Neuromyelitis Optica (NMO);NMO Spectrum Disorder (NMOSD) | Drug: Satralizumab;Drug: Placebo;Drug: Baseline Treatment | Hoffmann-La Roche | Chugai Pharmaceutical | Not recruiting | 12 Years | 74 Years | All | 83 | Phase 3 | United States;France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;Ukraine;United Kingdom |
518 | NCT02084121 | February 2014 | 30 September 2019 | Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use) | Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use) | Metachromatic Leukodystrophy | Biological: Enriched Hematopoetic Stem Cell Infusion | University of Louisville | Duke University | Not recruiting | 3 Years | N/A | Male | Phase 4 | United States | |
519 | NCT02166346 | February 2014 | 11 June 2018 | Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) | Double-Blind, Placebo-Controlled Crossover Trial on the Safety and Efficacy of Sustained-Release Dalfampridine in Transverse Myelitis (Re-Launch) | Transverse Myelitis;Neuromyelitis Optica;Idiopathic Transverse Myelitis;Myelitis NOS | Drug: Dalfampridine;Drug: Placebo | Johns Hopkins University | Acorda Therapeutics | Not recruiting | 18 Years | 70 Years | All | 24 | Phase 2 | United States |
520 | NCT02849782 | February 2014 | 20 August 2018 | Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine. | Short and Long Term Fampridine Treatment in Persons With Multiple Sclerosis: Cognitive and Motor Performances | Multiple Sclerosis | Drug: Fampridine | Centre Hospitalier Universitaire de Besancon | Recruiting | 18 Years | 80 Years | All | 98 | Phase 4 | France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
521 | NCT03033355 | February 2014 | 11 June 2018 | Central Nervous System Changes Following BotulinumtoxinA Injection in the Bladder | A Prospective Study of Higher Neural Control Changes Following Intradetrusor Injection of BotulinumtoxinA in Patients With Multiple Sclerosis and Lower Urinary Tract Symptoms. | Multiple Sclerosis;Lower Urinary Tract Symptoms;Neurogenic Bladder;Detrusor, Overactive;Urge Incontinence | Drug: Intradetrusor injection of Botulinum Toxin-A | Rose Khavari, M.D. | The Methodist Hospital System | Recruiting | 18 Years | N/A | Female | 50 | Phase 1 | United States |
522 | EUCTR2012-005450-30-AT | 08/01/2014 | 27 October 2014 | Investigation of neutralising antibodies against interferon-beta in patients with multiple sclerosis, in order to find markers to predict the development of these antibodies and minimize the risk of ineffective therapy | Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment - ABIRISK | Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Avonex Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Rebif Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 44- Trade Name: Betaferon Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1b CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: Extavia Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1b CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: Rebif Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 44- Trade Name: Rebif Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 44- | Medizinische Universität Innsbruck | Authorised | Female: yes Male: yes | 100 | Austria | ||||
523 | JPRN-UMIN000012705 | 2014/01/07 | 2 April 2019 | The efficacy and safety of an anti-interluekin-6 receptor antibody in relapsing-remitting multiple sclerosis | Relapsing-remitting multiple sclerosis | Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 2 years. | Department of Immunology, National Institute of Neuroscience, NCNP | Recruiting | 20years-old | 65years-old | Male and Female | 10 | Not applicable | Japan | ||
524 | NCT01892345 | January 2014 | 1 April 2019 | A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) | Neuromyelitis Optica;Neuromyelitis Optica Spectrum Disorder | Drug: Eculizumab | Alexion Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 143 | Phase 3 | United States;Argentina;Australia;Canada;Colombia;Croatia;Czechia;Denmark;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of;Malaysia;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;Austria;Czech Republic;Singapore | |
525 | NCT02034188 | January 2014 | 16 December 2017 | Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis | Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis | Multiple Sclerosis | Biological: Umbilical cord mesenchymal stem cells | Translational Biosciences | Not recruiting | 18 Years | 55 Years | All | 20 | Phase 1/Phase 2 | Panama | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
526 | NCT02040298 | January 2014 | 25 April 2016 | Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis | A Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Crossover Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Clemastine;Drug: Placebo | University of California, San Francisco | Not recruiting | 18 Years | 60 Years | Both | 50 | Phase 2 | United States | |
527 | EUCTR2013-004626-28-FI | 20/12/2013 | 23 December 2013 | Does targeting of S1P receptors reduce microglial activation in multiple sclerosis? | Does targeting of S1P receptors reduce microglial activation in multiple sclerosis? | Multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders | Trade Name: REBIF Product Name: beetainterferoni -1a Pharmaceutical Form: Solution for injection CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 6- Trade Name: Gilenya Product Name: Fingolimodi Pharmaceutical Form: Capsule, hard CAS Number: 162359-55-9 Other descriptive name: FINGOLIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,5- Trade Name: Avonex Pharmaceutical Form: Solution for injection Trade Name: Betaferon Pharmaceutical Form: Concentrate and solvent for solution for injection Trade Name: Copaxone Pharmaceutical Form: Solution for injection in pre-filled syringe CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Tysabri Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Trade Name: Lemtrada Pharmaceutical Form: Concentrate for solution for infusion CAS Number: 216503-57-0 Other descriptive name: ALEMTUZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12- | Turku University Hospital | Authorised | Female: yes Male: yes | Finland | |||||
528 | NCT02038049 | December 20, 2013 | 4 November 2019 | A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis | A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis | Relapse Remitting Multiple Sclerosis | Drug: VAY736;Drug: Placebo | Novartis Pharmaceuticals | Not recruiting | 18 Years | 55 Years | All | 8 | Phase 2 | United States;Czechia;Ukraine;Czech Republic;Germany;Poland;Russian Federation | |
529 | EUCTR2013-002283-25-CZ | 18/12/2013 | 10 July 2015 | A study To Evaluate the Efficacy, Safety and Tolerability of Plovamer Acetate Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis | A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study To Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis - Efficacy, safety, and tolerability of plovamer acetate | Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1- Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6- Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Copaxone Pharmaceutical Form: Solution for injection INN or Proposed INN: Glatiramer acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- | Merck KGaA | Not Recruiting | Female: yes Male: yes | 550 | Phase 2 | Serbia;United States;Greece;Finland;Spain;Turkey;Colombia;United Kingdom;Italy;Czech Republic;Hungary;Mexico;Poland;Croatia;South Africa;Bulgaria | |||
530 | EUCTR2013-002558-64-IT | 18/12/2013 | 16 October 2017 | improvement of cognitive performance after administration of fampridina in patients with multiple sclerosis | A randomised, placebo-controlled trial investigating the role of fampiridina in improving cognitive function of patients with multiple sclerosis. | MULTIPLE SCLEROSIS MedDRA version: 20.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: fampyra Product Name: FAMPYRA Pharmaceutical Form: Tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Current Sponsor code: CP1/2013 Concentration unit: mg milligram(s) Concentration type: equal Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | dipartimento di neurologia e psichiatria | Not Recruiting | Female: yes Male: yes | 123 | Phase 4 | Italy | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
531 | EUCTR2013-001151-12-DE | 12/12/2013 | 22 October 2018 | EXTENSION STUDY OF ECULIZUMAB IN RELAPSING NEUROMYELITIS OPTICA SUBJECTS | A PHASE III, OPEN-LABEL, EXTENSION TRIAL OF ECU-NMO-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO) | Neuromyelitis Optica MedDRA version: 20.0 Level: LLT Classification code 10029322 Term: Neuromyelitis optica System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: SOLIRIS Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ECULIZUMAB CAS Number: 219685-50-4 Current Sponsor code: h5G1.1-mAb Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- | Alexion Pharmaceuticals, Inc. | Authorised | Female: yes Male: yes | 132 | Phase 3 | United States;United Arab Emirates;Saudi Arabia;Taiwan;Hong Kong;Spain;Russian Federation;Chile;Colombia;Italy;France;Australia;Denmark;Peru;Korea, Republic of;Finland;Turkey;Austria;United Kingdom;Czech Republic;Canada;Argentina;Brazil;Belgium;Singapore;Croatia;Germany;Japan;Sweden | |||
532 | EUCTR2013-002916-28-LV | 12/12/2013 | 28 February 2019 | An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and its Effect on Immune Tolerance in Subjects with Relapsing Multiple Sclerosis | An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and its Effect on Immune Tolerance in Subjects with Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10067063 Term: Progressive relapsing multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ATX-MS-1467 Product Code: MSC2358825A Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: MSC2304479A CAS Number: 1147979-29-0 Current Sponsor code: ATX-MS-01 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 200- INN or Proposed INN: MSC2304480A CAS Number: 1147979-31-4 Current Sponsor code: ATX-MS-04 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 200- INN or Proposed INN: MSC2304481A CAS Number: 1147979-32-5 Current Sponsor code: ATX-MS-06 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 200- INN or Proposed INN: MSC2304482A CAS Number: 1147979-30-3 Current Sponsor code: ATX-MS-07 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 200- | Merck KGaA | Authorised | Female: yes Male: yes | 20 | Phase 2 | Russian Federation;Latvia | |||
533 | NCT02047734 | December 3, 2013 | 15 July 2019 | Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis (Radiance Study) | A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients | Relapsing Multiple Sclerosis | Drug: Ozanimod 0.5 mg;Drug: Ozanimod 1 mg;Drug: Ozanimod placebo;Drug: Interferon ß-1a;Drug: IFN ß-1a placebo | Celgene | Not recruiting | 18 Years | 55 Years | All | 1320 | Phase 3 | United States;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom | |
534 | JPRN-jRCTs031180346 | 02/12/2013 | 7 October 2019 | Treatment with an anti-interleukin-6 receptor antibody for multiple sclerosis | The efficacy and safety of an anti-interluekin-6 receptor antibody in multiple sclerosis | multiple sclerosis;D009103 | Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight. | Takashi Yamamura | Not Recruiting | >= 20age old | <= 65age old | Both | 6 | N/A | none | |
535 | NCT02035514 | December 2013 | 9 January 2017 | Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis | Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis (RRMS) | Biological: Bone marrow autologous mesenchymal stem cells transplantation | Germans Trias i Pujol Hospital | Ministerio de Sanidad, Servicios Sociales e Igualdad | Not recruiting | 18 Years | 50 Years | Both | 9 | Phase 1/Phase 2 | Spain |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
536 | NCT02146534 | December 2013 | 18 March 2019 | Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients | Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients: a Phase IV, Double-blind, Placebo-controlled Study. | Multiple Sclerosis | Drug: extended release fampridine;Drug: Placebo | Clinique Neuro-Outaouais | CogState Ltd. | Not recruiting | 18 Years | N/A | All | 44 | Phase 4 | Canada |
537 | NCT02047097 | November 30, 2013 | 22 July 2019 | Dimethyl Fumarate (DMF) Observational Study | A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM) | Multiple Sclerosis | Drug: dimethyl fumarate | Biogen | Recruiting | 18 Years | N/A | All | 5600 | Phase 4 | United States;Argentina;Australia;Austria;Canada;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Slovakia;Spain;Switzerland;United Kingdom;Czech Republic | |
538 | EUCTR2013-000529-30-GB | 27/11/2013 | 23 December 2013 | prolonged-release oral fampridine in Neuromyelitis Optica (NMO), Pilot feasibility Study | A pilot study to assess efficacy of prolonged-Release oral fampridine on ambulation and visual function in Neuromyelitis Optica - Assessment of fampridine-PR in NMO | Neuromyelitis optica (NMO);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Fampyra Product Name: fampyra 10mg prolonged release tablets Pharmaceutical Form: Prolonged-release tablet | Walton Centre Foundation Trust | Authorised | Female: yes Male: yes | 0 | United Kingdom | ||||
539 | EUCTR2013-002082-19-BE | 25/11/2013 | 8 August 2016 | A clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared to Interferon ß-1a (Avonex, authorised drug) administered once weekly. | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of Laquinimod (0.6 mg/day or 1.2 mg/day) compared to Interferon ß-1a administered Intra Muscular Once Weekly in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) - LIBRETTO | Relapsing remitting multiple sclerosis MedDRA version: 16.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Laquinimod capsules 0.6 mg Product Code: TV-5600 Pharmaceutical Form: Capsule, hard INN or Proposed INN: LAQUINIMOD CAS Number: 248281-84-7 Current Sponsor code: TV-5600 Other descriptive name: Laquinimod Sodium (USAN) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Avonex Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Current Sponsor code: INTERFERON BETA-1A Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30- | Teva Pharmaceutical Industries, Ltd. | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | Finland;Spain;Ireland;Switzerland;United Kingdom;Italy;France;Belgium;Denmark;Norway;Germany;Netherlands;Sweden | |||
540 | EUCTR2013-002283-25-HU | 25/11/2013 | 16 March 2015 | A study To Evaluate the Efficacy, Safety and Tolerability of Plovamer Acetate Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis | A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study To Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis - Efficacy, safety, and tolerability of plovamer acetate | Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1- Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6- Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Copaxone Pharmaceutical Form: Solution for injection INN or Proposed INN: Glatiramer acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- | Merck KGaA | Not Recruiting | Female: yes Male: yes | 550 | Phase 2 | Serbia;United States;Greece;Finland;Spain;Turkey;Colombia;United Kingdom;Italy;Hungary;Czech Republic;Mexico;Poland;Croatia;South Africa;Bulgaria | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
541 | EUCTR2013-001439-34-FI | 18/11/2013 | 13 June 2016 | Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients | A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients - TERI-PRO | Multiple Sclerosis MedDRA version: 19.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Aubagio Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- | Genzyme Corporation | Not Recruiting | Female: yes Male: yes | 1000 | Phase 4 | United States;Greece;Canada;Finland;Belgium;Spain;Austria;Chile;Germany;United Kingdom;Switzerland;Sweden | |||
542 | NCT01939002 | November 2013 | 19 October 2017 | Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-ß) Therapies to Peginterferon Beta-1a (BIIB017) | An Open-Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017 | Relapsing Multiple Sclerosis | Drug: BIIB017;Drug: naproxen | Biogen | Not recruiting | 18 Years | 65 Years | All | 251 | Phase 3 | United States | |
543 | NCT01968902 | November 2013 | 16 December 2017 | Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients | A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Incobotulinumtoxin Type A for the Functional Improvement of Lower Extremity Spasticity in Patients With Multiple Sclerosis | Muscle Spasticity;Multiple Sclerosis | Biological: incabotulinumtoxinA;Biological: Placebo | Multiple Sclerosis Center of Northeastern New York | Merz North America, Inc. | Not recruiting | 18 Years | 65 Years | All | 27 | Phase 4 | United States |
544 | NCT01982942 | November 2013 | 11 June 2018 | Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive;Multiple Sclerosis, Secondary Progressive | Drug: ibudilast;Drug: Placebo oral capsule | MediciNova | National Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS);National Multiple Sclerosis Society | Not recruiting | 21 Years | 65 Years | All | 255 | Phase 2 | United States |
545 | NCT02048358 | November 2013 | 19 February 2015 | Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients | Randomized, Double-blind, Placebo- and Active Comparator- Controlled Crossover Study in Healthy Male Subjects and an Open Label Study in Healthy Subjects and MS Patients to Assess the Safety, Pharmacokinetics and Pharmacodynamics of 2B3-201 | Healthy Volunteers;Multiple Sclerosis | Drug: 2B3-201;Drug: Placebo;Drug: Methylprednisolone hemisuccinate | BBB-Therapeutics B.V. | Not recruiting | 18 Years | 65 Years | Both | 47 | Phase 1 | Netherlands | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
546 | NCT03133403 | November 2013 | 11 June 2018 | Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy | Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study | Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting | Drug: Tecfidera (BG12);Drug: Gilenya;Drug: Tysabri®;Drug: Avonex/Betaseron/Copaxone/Rebif;Procedure: Hematopoietic stem cell transplantation (HSCT) | Sheffield Teaching Hospitals NHS Foundation Trust | Recruiting | 18 Years | 55 Years | All | 5 | Phase 2/Phase 3 | United Kingdom | |
547 | NCT01930708 | October 31, 2013 | 15 July 2019 | A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes | A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting | Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis | Drug: dimethyl fumarate | Biogen | Not recruiting | 18 Years | N/A | All | 1114 | Phase 4 | Austria;Belgium;Canada;Czechia;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;Czech Republic | |
548 | NCT01911767 | October 30, 2013 | 1 April 2019 | Biogen Multiple Sclerosis Pregnancy Exposure Registry | Biogen Idec Multiple Sclerosis Pregnancy Exposure Registry | Multiple Sclerosis;Exposure During Pregnancy | Drug: Dimethyl fumarate;Drug: Peginterferon beta-1a | Biogen | Recruiting | N/A | N/A | Female | 1125 | Phase 2 | United States;Australia;Germany;Ireland;Italy;Spain;United Kingdom;Canada | |
549 | NCT01326715 | October 17, 2013 | 14 October 2019 | Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis | Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis | Multiple Sclerosis | Drug: Mangafodipir (Teslascan) | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | 70 Years | All | 15 | Phase 1 | United States | |
550 | NCT01863888 | October 2013 | 23 March 2015 | Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis | Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis | Drug: teriflunomide HMR1726;Drug: cholestyramine;Drug: charcoal | Sanofi | Not recruiting | 18 Years | 55 Years | Both | 70 | Phase 3 | Belgium;Germany;Netherlands | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
551 | NCT01868048 | October 2013 | 22 August 2016 | Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis. | A Phase 3 Dose Response Study to Assess the Safety and Efficacy of Nabiximols Oromucosal Spray (Sativex) in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis. | Spasticity;Multiple Sclerosis | Drug: Sativex;Drug: Placebo | GW Research Ltd | Not recruiting | 18 Years | N/A | Both | 0 | Phase 3 | ||
552 | NCT01911377 | October 2013 | 12 October 2015 | Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS | The Efficacy of Botulinum Toxin Type A in the Treatment of Allodynic-Type Neuropathic Pain in People With Spinal Cord Injury or Multiple Sclerosis | Neuropathic Pain;Allodynia | Drug: Botulinum Toxin Type A;Drug: Normal Saline for Injection | University of Manitoba | Allergan | Not recruiting | 18 Years | 70 Years | Both | 12 | Phase 2 | Canada |
553 | NCT01950234 | October 2013 | 11 November 2019 | ACTH in Progressive Forms of MS | Treatment of Progressive Forms of Multiple Sclerosis With Pulsed ACTH (Acthar Gel) | Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis;Progressive Relapsing Multiple Sclerosis | Drug: ACTH;Drug: Placebo | University of Minnesota | Mallinckrodt | Not recruiting | 18 Years | N/A | All | 100 | Phase 2 | United States |
554 | NCT01970410 | October 2013 | 11 June 2018 | Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide | Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective? | Multiple Sclerosis | Drug: teriflunomide | Multiple Sclerosis Center of Northeastern New York | Providence Multiple Sclerosis Center | Not recruiting | 21 Years | 60 Years | All | 70 | Phase 4 | United States |
555 | NCT02220244 | October 2013 | 16 December 2017 | Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis | Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study | Multiple Sclerosis | Drug: MD1003 100mg capsule | MedDay Pharmaceuticals SA | Not recruiting | 18 Years | 75 Years | All | 105 | Phase 3 | France;United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
556 | NCT02220933 | October 2013 | 16 December 2017 | Effect of MD1003 in Spinal Progressive Multiple Sclerosis | Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study | Multiple Sclerosis | Drug: MD1003 100mg capsule;Drug: Placebo | MedDay Pharmaceuticals SA | Not recruiting | 18 Years | 75 Years | All | 144 | Phase 3 | France | |
557 | NCT02753088 | October 2013 | 14 November 2016 | Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis | International, Multicentre, Double-blind, Placebo-controlled, Comparative, Randomized Study to Compare Efficacy and Safety of the Generic Drug BCD-063 (CJSC BIOCAD, Russia) and Copaxone®-Teva (Teva Pharmaceutical Industries Limited, Israel) in Patients With Relapsing-remitting Multiple Sclerosis | Relapsing-remitting Multiple Sclerosis | Drug: BCD-063;Drug: Copaxone-Teva;Drug: Placebo | Biocad | Not recruiting | 18 Years | 55 Years | Both | 158 | Phase 3 | ||
558 | EUCTR2012-005324-16-BE | 27/08/2013 | 17 August 2015 | Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis | Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple Sclerosis - TERI-DYNAMIC | multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Current Sponsor code: HMR1726 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- | Genzyme Corporation | Not Recruiting | Female: yes Male: yes | 68 | Belgium;Germany;Netherlands | ||||
559 | EUCTR2013-001409-10-DK | 08/08/2013 | 17 October 2016 | Fampyra and T cell Immunity in Multiple Sclerosis; a study of the Fampyra induced immunomodulatory T cell responses in MS | FATIMS - Fampyra and T cell Immunity in Multiple Sclerosis; a study of the Fampyra induced immunomodulatory T cell responses in MS - FATIMS | Multiple Sclerosis MedDRA version: 14.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Fampyra Product Name: Fampyra Pharmaceutical Form: Tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- | Odense University Hospital | Authorised | Female: yes Male: yes | Phase 4 | Denmark | ||||
560 | JPRN-UMIN000010094 | 2013/08/01 | 2 April 2019 | A pilot study of Elaspol (Sivelestat Sodium) for neuromyelitis optica | neuromyelitis optica | 4.8mg/kg Sivelestat Sodium will administered constantly for 5 days in combination with 3 days intravenous methyl-prednisolone administration to sero-positive neuromyelitis optica patients who relapsed within 72 hours before starting treatment. | Tohoku University Hospital | Not Recruiting | 20years-old | 55years-old | Male and Female | 10 | Phase 1,2 | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
561 | NCT01890655 | August 2013 | 18 April 2016 | Extension Study of MT-1303 | A Phase II, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects With Relapsing-remitting Multiple Sclerosis Who Have Completed the MT-1303-E04 Study | Relapsing-remitting Multiple Sclerosis | Drug: MT-1303-Low;Drug: MT-1303-Middle;Drug: MT-1303-High | Mitsubishi Tanabe Pharma Corporation | Not recruiting | 18 Years | 60 Years | Both | 367 | Phase 2 | Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Lithuania;Poland;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom | |
562 | NCT01903291 | August 2013 | 8 August 2016 | Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS | A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate | Relapsing Forms of Multiple Sclerosis | Drug: dimethyl fumarate | Biogen | Not recruiting | 18 Years | N/A | Both | 333 | N/A | United States | |
563 | NCT01906684 | August 2013 | 19 February 2015 | Comprehensive Analysis of Relapse in Multiple Sclerosis | Comprehensive Analysis of Relapse in Multiple Sclerosis | Multiple Sclerosis | Drug: Acthar Gel | Tanner Foundation for Multiple Sclerosis | Questcor Pharmaceuticals, Inc.;Auburn University MRI Research Center;iReportoire Inc | Not recruiting | 19 Years | 65 Years | Both | 20 | N/A | United States |
564 | NCT01917019 | August 2013 | 16 December 2017 | A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis | A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis Followed by an Open-Label Safety Extension | Multiple Sclerosis, Remittent Progressive;Multiple Sclerosis, Primary Progressive;Relapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Multiple Sclerosis | Drug: Placebo;Drug: BIIB041 (fampridine) | Biogen | Not recruiting | 18 Years | 70 Years | All | 101 | Phase 3 | Japan | |
565 | NCT02141022 | August 2013 | 23 May 2016 | Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya | A Pilot Study of Plasticity-Based and Adaptive Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya | Multiple Sclerosis;Cognitive Deficits;Gilenya Modifying Therapy for MS | Other: plasticity-based computerized cognitive remediation program;Drug: Gileyna | Stony Brook University | Novartis | Not recruiting | 18 Years | 70 Years | Both | 20 | N/A | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
566 | NCT02290444 | August 2013 | 10 December 2018 | Effects of Acthar on Recovery From Cognitive Relapses in MS | Effects of Adrenocorticotropic Hormone (ACTHAR Gel) on Recovery From Cognitive Relapses in Multiple Sclerosis | Multiple Sclerosis | Drug: Adrenocorticotropic Hormone | State University of New York at Buffalo | Not recruiting | 18 Years | 65 Years | All | 60 | Phase 3 | United States | |
567 | NCT02225977 | July 31, 2013 | 3 September 2018 | Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya. | Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya. | Multiple Sclerosis | Drug: Gilenya | University of Southern California | Not recruiting | 18 Years | 65 Years | All | 125 | Phase 3 | United States | |
568 | EUCTR2012-004807-10-DE | 17/07/2013 | 23 July 2018 | Relapse Escalation treatment trial in Optic Neuritis (RESCON): Multi-centre RCT to study the efficacy of plasma exchange (PE) as an escalation treatment strategy in steroid-unresponsive Optic Neuritis | Relapse Escalation treatment trial in Optic Neuritis (RESCON): Multi-centre RCT to study the efficacy of plasma exchange (PE) as an escalation treatment strategy in steroid-unresponsive Optic Neuritis | MS patients who suffer from severe Optic Neuritis without satisfying improvement after treatment with steroids (3-5 days with 1 g daily at least 7 days prior to randomization) and with persisting visual acuity < 0.7, duration of symptoms should be = 4 weeks MedDRA version: 14.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: LLT Classification code 10070425 Term: Multiple sclerosis exacerbation System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Urbason® solubile forte 1000 mg Product Name: Methylprednisolone Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Methylprednisolone CAS Number: 83-43-2 Other descriptive name: METHYLPREDNISOLONE Concentration unit: g gram(s) Concentration type: equal Concentration number: 1- | University Medical Center Hamburg Eppendorf | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | Germany | |||
569 | JPRN-UMIN000011111 | 2013/07/16 | 2 April 2019 | Spinal blood flow and metabolism in neurological diseases | motor neuron disease including ALS, multiple sclerosis, stroke, Parkinson disease, spinocerebellar degeneration, multiple system atrophy | PET scan study with 11C-flumazenil PET scan study with 18F- FDG PET scan study with 15O-H2O | Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences | Recruiting | 20years-old | Not applicable | Male and Female | 70 | Not applicable | Japan | ||
570 | NCT01817166 | July 16, 2013 | 15 July 2019 | Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome | Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years. | Multiple Sclerosis | Drug: Vitamin D;Drug: Placebo;Other: Imaging;Biological: Lumbar puncture;Biological: Blood sampling;Biological: Urine samples | Centre Hospitalier Universitaire de Nimes | Recruiting | 18 Years | 56 Years | All | 316 | Phase 3 | France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
571 | EUCTR2012-005086-12-AT | 05/07/2013 | 11 April 2016 | Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulin | Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis. - PREDICT trial | relapsing multiple sclerosis MedDRA version: 18.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Octagam 50 mg/ml Pharmaceutical Form: Solution for infusion INN or Proposed INN: Human normal immunoglobulin CAS Number: 308067-58-5 Current Sponsor code: Octagam 5% Other descriptive name: IMMUNOGLOBULIN G Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Copaxone 20 mg/ml Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Rebif 44 micrograms Product Name: Rebif 44 micrograms Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: INTERFERON BETA-1a CAS Number: 145258-61-3 Concentration unit: million IU million international units Concentration type: equal Concentration number: 12- Trade Name: Betaferon 250 microgram/ml Product Name: Betaferon 250 microgram/ml Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: INTERFERON BETA-1b CAS Number: 145155-23-3 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: Extavia 250 microgram/ml Product Name: Extavia 250 microgram/ml Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: INTERFERON BETA-1a CAS Number: 145155-23-3 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- | Octapharma AG | Not Recruiting | Female: yes Male: yes | 216 | Phase 3b | Hungary;Poland;Austria;Russian Federation;Bulgaria;Germany | |||
572 | NCT01647880 | July 2013 | 10 December 2018 | MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) | Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis | Multiple Sclerosis | Drug: Verum arm receiving Gilenya®;Drug: Active Comparator receiving Extavia® | Charite University, Berlin, Germany | NeuroCure Clinical Research Center, Charite, Berlin | Not recruiting | 18 Years | 55 Years | All | 15 | Phase 2/Phase 3 | Germany |
573 | NCT01710228 | July 2013 | 9 January 2017 | Alternative Treatment Paradigm for Natalizumab Trial | Alternative Treatment Paradigm for Natalizumab Trial | Multiple Sclerosis (MS) | Drug: methylprednisolone | University of Texas Southwestern Medical Center | Teva Pharmaceutical Industries;The University of Texas Health Science Center, Houston;University of Alabama at Birmingham;Charite University, Berlin, Germany | Not recruiting | 18 Years | 60 Years | Both | 0 | Phase 2 | United States |
574 | NCT01896700 | July 2013 | 11 June 2018 | Methylphenidate to Improve Balance and Walking in MS | Methylphenidate to Improve Balance and Walking in MS | Multiple Sclerosis | Drug: Methylphenidate;Drug: Placebo | Oregon Health and Science University | Portland VA Medical Center | Not recruiting | 20 Years | 65 Years | All | 24 | Phase 2/Phase 3 | United States |
575 | NCT01900093 | July 2013 | 16 December 2017 | Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses | An Open-Label Prospective Proof-Of-Concept Trial to Evaluate the Response to Acthar Gel Therapy in Patients With Multiple Sclerosis (MS) Relapses Who Have Failed To Make an Adequate Recovery After Treatment With High-Dose Intravenous Methylprednisolone | Multiple Sclerosis | Drug: Acthar Gel | Aaron Miller | Mallinckrodt | Recruiting | 18 Years | 65 Years | All | 10 | N/A | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
576 | NCT02048072 | July 2013 | 19 October 2017 | Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS | Funktionelle Evaluation Des Autonomen Nervensystems im Zusammenhang Mit Der Erstmaligen Einnahme Von 0,5mg Fingolimod (Gilenya) Bei Patienten Mit schubförmig Verlaufender Multipler Sklerose | Multiple Sclerosis;Autonomic Nervous System Dysfunction | Drug: Gilenya | Jochen Vehoff | Not recruiting | 18 Years | 60 Years | All | 33 | Phase 4 | Switzerland | |
577 | EUCTR2011-006262-40-CZ | 18/06/2013 | 4 July 2016 | A study to assess the safety and efficacy of BIIB033 in patients with relapsing forms of multiple sclerosis when used concurrently with Avonex® | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects with Relapsing Forms of Multiple Sclerosis When Used Concurrently with Avonex® | Relapsing forms of multiple sclerosis MedDRA version: 19.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BIIB033 Product Code: BIIB033 Pharmaceutical Form: Solution for infusion Current Sponsor code: BIIB033 Other descriptive name: Human anti-LINGO-1 monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Avonex Product Name: AVONEX Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a CAS Number: 145258-61-3 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30- | Biogen Idec Research Limited | Not Recruiting | Female: yes Male: yes | 396 | Phase 2 | Serbia;France;United States;Hungary;Czech Republic;Canada;Poland;Spain;Russian Federation;Netherlands;Italy;United Kingdom | |||
578 | EUCTR2013-001422-25-IT | 11/06/2013 | 26 February 2018 | Study to be conducted only in Italy to evaluate the effect of the treatment with BG00012 on cognitive function in patients with Relapsing Remitting Multiple Sclerosis | Single country study assessing cognition in Relapsing Remitting Multiple Sclerosis patients treated with BG00012 | Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: dimethyl fumarate [DMF] Product Code: BG00012 Pharmaceutical Form: Capsule, hard INN or Proposed INN: dimetilfumarato CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- | Biogen Idec Italia S.r.l. | Authorised | Female: yes Male: yes | 220 | Phase 3 | Italy | |||
579 | JPRN-JapicCTI-132178 | 01/6/2013 | 2 April 2019 | A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis | A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis | Intervention name : AIN457 INN of the intervention : secukinumab Dosage And administration of the intervention : AIN457 will be administered intravenously. Patients will be randomized to AIN457 Low/Middle/High dose. Control intervention name : Placebo Dosage And administration of the control intervention : Matching placebo will be administered intravenously. | Novartis Pharma K.K. | 18 | 55 | BOTH | 380 | Phase 2 | |||
580 | NCT03216915 | June 1, 2013 | 21 January 2019 | Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis | FINGORHYMS - Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: Gilenya®; Novartis Pharmaceuticals Corporation | Universitätsklinikum Hamburg-Eppendorf | Recruiting | 18 Years | N/A | All | 100 | Phase 2 | Germany | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
581 | NCT01621269 | June 2013 | 16 December 2017 | ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon | A 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Fingolimod in the Treatment of Relapsing-remitting Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta | Multiple Sclerosis | Drug: Fingolimod | Novartis Pharmaceuticals | Not recruiting | 18 Years | 65 Years | All | 0 | Phase 4 | Germany | |
582 | NCT01651520 | June 2013 | 16 December 2017 | Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis | Prognosis Value of the Neuronal Damage Detected by Positrons Emission Tomography (PET) With 11C-Flumazenil in Early Multiple Sclerosis. | Multiple Sclerosis | Drug: PET with 11C-Flumazenil | Assistance Publique - Hôpitaux de Paris | Not recruiting | 18 Years | 55 Years | All | 60 | N/A | France | |
583 | NCT01717664 | June 2013 | 8 August 2016 | Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) | A Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of Fixed Dose Combination RHB-104 as Add-On Therapy to Interferon Beta-1a in Patients Treated for Relapsing Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: RHB-104 | RedHill Biopharma Limited | Not recruiting | 18 Years | N/A | Both | 18 | Phase 2 | Israel | |
584 | NCT01777412 | June 2013 | 19 October 2017 | Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations | An Open-label Phase 1b Study of Avastin® (Bevacizumab) for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD). | Neuromyelitis Optica;Neuromyelitis Optica Spectrum Disorder | Drug: Bevacizumab | Johns Hopkins University | Genentech, Inc.;Guthy Jackson Charitable Foundation | Not recruiting | 18 Years | 70 Years | All | 10 | Phase 1 | United States |
585 | NCT01874145 | June 2013 | 19 October 2017 | Safety and Tolerability of Glatiramer Acetate | An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Drug: GA 20 mg/mL;Drug: GA 40 mg/mL | Teva Pharmaceutical Industries | Not recruiting | 18 Years | N/A | All | 209 | Phase 3 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
586 | NCT01895335 | June 2013 | 19 October 2017 | Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients | A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients | Multiple Sclerosis | Drug: Teriflunomide | Sanofi | Not recruiting | 18 Years | N/A | All | 1001 | Phase 4 | United States;Austria;Belgium;Canada;Chile;Finland;France;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom | |
587 | EUCTR2012-003176-39-DE | 31/05/2013 | 11 December 2017 | Daclizumab HYP Extension Study for Subjects with Multiple Sclerosis Who Have Completed 205MS301 | A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301 - EXTEND | Relapsing-remitting Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: DACLIZUMAB HYP Product Code: BIIB019 Pharmaceutical Form: Solution for injection INN or Proposed INN: Daclizumab Current Sponsor code: BIIB019 Other descriptive name: Daclizumab HYP (DAC HYP) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- | Biogen Idec Research Limited | Not Recruiting | Female: yes Male: yes | 1600 | Phase 3 | Serbia;United States;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Switzerland;Italy;India;France;Denmark;Australia;Moldova, Republic of;Finland;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Romania;Georgia;Germany;Sweden | |||
588 | EUCTR2012-004040-30-AT | 24/05/2013 | 27 October 2014 | Natalizumab de-escalation to interferon-beta-1b in patients with relapsing-remitting multiple sclerosis: A multicenter study | Natalizumab de-escalation to interferon-beta-1b in patients with relapsing-remitting multiple sclerosis: A multicenter study | relapse-remitting multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: BETAFERON® (interferon beta-1b) Product Name: Betaferon Pharmaceutical Form: Powder and solution for solution for injection INN or Proposed INN: Betaferon CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- | Ospedale Regionale di Lugano | Authorised | Female: yes Male: yes | 72 | Austria;Switzerland | ||||
589 | NCT01854359 | May 11, 2013 | 19 November 2018 | Idebenone for Primary Progressive Multiple Sclerosis | Open Label Extension Trial of Idebenone for Primary Progressive Multiple Sclerosis | Multiple Sclerosis;Primary Progressive Multiple Sclerosis | Drug: Idebenone | National Institute of Allergy and Infectious Diseases (NIAID) | Not recruiting | 18 Years | N/A | All | 61 | Phase 1/Phase 2 | United States | |
590 | EUCTR2011-005677-23-LT | 10/05/2013 | 7 January 2019 | Safety and efficacy of fingolimod in pediatric patients with multiple sclerosis | A two-year, double-blind, randomized, multicenter, active controlled study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon ß-1a i.m. once weekly in pediatric patients with multiple sclerosis with five-year fingolimod Extension Phase | Relapsing multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya Product Code: FTY720 Pharmaceutical Form: Capsule, hard INN or Proposed INN: fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Avonex Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: interferon beta-1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 60- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Intramuscular use Product Name: fingolimod Product Code: FTY720 Pharmaceutical Form: Capsule, hard INN or Proposed INN: fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Novartis Pharma Service AG | Authorised | Female: yes Male: yes | 190 | Phase 3 | Serbia;Belarus;United States;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Italy;France;Australia;South Africa;Latvia;Netherlands;Turkey;Lithuania;Austria;United Kingdom;Mexico;Canada;Brazil;Poland;Croatia;Romania;Bulgaria;Germany;Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
591 | NCT01838174 | May 2013 | 4 November 2019 | A Trial of Neuroprotection With ACTH in Acute Optic Neuritis | A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis | Multiple Sclerosis | Drug: ACTHAR Gel (ACTH);Drug: IV methylprednisolone (steroids) | University of Colorado, Denver | Mallinckrodt;University of Pennsylvania | Recruiting | 18 Years | 55 Years | All | 100 | Phase 4 | United States |
592 | NCT01845584 | May 2013 | 16 December 2017 | Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. | NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. | Neuromyelitis Optica Spectrum Disorder | Drug: NPB-01 | Nihon Pharmaceutical Co., Ltd | Not recruiting | 20 Years | N/A | All | 7 | Phase 2 | Japan | |
593 | NCT01873417 | May 2013 | 16 December 2017 | Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States | A Multicenter, Open-Label, Single-Arm Study of Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera™ (Dimethyl Fumarate) Delayed-release Capsules | Relapsing Forms of Multiple Sclerosis | Drug: BG00012 (DMF) | Biogen | Not recruiting | 18 Years | N/A | All | 237 | Phase 4 | United States | |
594 | EUCTR2012-004019-29-BE | 29/04/2013 | 21 August 2017 | Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis | A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose-ranging study to evaluate the efficacy and safety of AIN457 in patients with relapsing multiple sclerosis | Relapsing multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Secukinumab Product Code: AIN457 Pharmaceutical Form: Powder for solution for infusion CAS Number: 1229022-83-6 Current Sponsor code: AIN457 Other descriptive name: SECUKINUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Powder for solution for infusion Route of administration of the placebo: Intravenous use | Novartis Pharma AG | Not Recruiting | Female: yes Male: yes | 380 | Phase 2 | Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Czech Republic;Canada;Argentina;Belgium;Poland;Romania;Germany;Japan;Sweden | |||
595 | NCT03198351 | April 25, 2013 | 23 July 2018 | An Observational Study on Teriflunomide-exposed Pregnancies | Teriflunomide Pregnancy Outcome Exposure Registry: An OTIS Autoimmune Diseases in Pregnancy Project | Multiple Sclerosis | Drug: Teriflunomide (HMR1726) | Sanofi | Recruiting | 16 Years | N/A | Female | 325 | Phase 3 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
596 | EUCTR2012-004436-36-DK | 19/04/2013 | 7 November 2016 | Effect of rituximab in secondary progressive multiple sclerosis | A prospective pilotstudy of immunological and radiological effects of intrathecal rituximab in patients with secondary progressive multiple sclerosis | Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: MabThera (Rituximab) Product Name: MabThera Pharmaceutical Form: Injection INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- | Odense University Hospital | Not Recruiting | Female: yes Male: yes | 15 | Phase 2 | Denmark | |||
597 | EUCTR2012-005507-40-IT | 15/04/2013 | 30 June 2014 | Study to provide access to fingolimod to Multiple Sclerosis patients who completed fingolimod phase IIIb studies and who benefited from treatment with fingolimod or do not have suitable alternative treatment options, but do not have access to the reimbursed drug | An open-label, single arm study to provide access to fingolimod to MS patients who completed fingolimod phase IIIb studies and who benefited from treatment with fingolimod or do not have suitable alternative treatment options, but do not have access to the reimbursed drug | Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya Product Code: FTY720 Pharmaceutical Form: Capsule, hard INN or Proposed INN: FINGOLIMOD CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- | NOVARTIS FARMA S.p.A | Not Recruiting | Female: yes Male: yes | Phase 3b | Italy | ||||
598 | EUCTR2012-005113-39-AT | 08/04/2013 | 22 April 2013 | Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve. | A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis - Amiloride Hydrochlorothiazide in acute autoimmune optic neuritis | Optic neuritis is among the most common first symptoms of multiple sclerosis leading to significant atrophy of the optic nerve within a short period of time, thus reflecting neurodegneration.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Amilostad HCT Product Name: Amilostad HCT tablets Pharmaceutical Form: Tablet INN or Proposed INN: AMILORIDE HYDROCHLORIDE, 2 H2O Other descriptive name: Amiloride Hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5.68- INN or Proposed INN: hydrochlorothiazide Other descriptive name: HYDROCHLOROTHIAZIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Universitätsklinik für Neurologie, Medizinische Universität Wien | Authorised | Female: yes Male: yes | Phase 2a | Austria | ||||
599 | EUCTR2012-005082-13-IT | 02/04/2013 | 6 January 2015 | A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects with Relapsing Remitting Multiple Sclerosis | A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects with Relapsing Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: TYSABRI Product Code: AN100226, BG00002 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- | Biogen Idec Research Limited | Not Recruiting | Female: yes Male: yes | 12 | Phase 1 | Italy | |||
600 | NCT01738347 | April 2013 | 16 December 2017 | Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). | Assess Safety, Bio-distribution, and Radiation Dosimetry, and Optimize the Imaging Protocol of GEH120714 (18F) Injection, a Marker of Microglial Activation, in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS) | Relapsing-remitting Multiple Sclerosis (rrMS) | Drug: Arm 1 - GEH120714 (18F) Injection | GE Healthcare | Centre for Probe Development and Commercialization | Not recruiting | 20 Years | 50 Years | All | 30 | Phase 1 | Canada;United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
601 | NCT01808885 | April 2013 | 5 December 2016 | Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta. | A 24-Week, Ph1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study, to Assess the Safety Profile of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta. | Relapsing Remitting Multiple Sclerosis | Drug: olesoxime (TRO19622);Drug: placebo | Hoffmann-La Roche | Hôpital de la Timone;SGS S.A.;STRAGEN Services | Not recruiting | 18 Years | N/A | Both | 44 | Phase 1 | France |
602 | NCT01816100 | April 2013 | 21 December 2015 | The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticity in Multiple Sclerosis Patients | The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticity in Multiple Sclerosis Patients: A Multimodal Neuroimaging Investigation | Multiple Sclerosis | Other: specifically design 6 month resistance training program;Behavioral: 6 months weight resistance and balance program | University of Nebraska | Biogen | Not recruiting | 19 Years | 65 Years | Both | 6 | N/A | United States |
603 | NCT01844232 | April 2013 | 25 May 2015 | One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity | A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity | Multiple Sclerosis;Spasticity | Drug: arbaclofen | Osmotica Pharmaceutical Corp. | Not recruiting | 18 Years | 70 Years | Both | 150 | Phase 3 | United States;Russian Federation;Ukraine | |
604 | NCT01888354 | April 2013 | 19 February 2015 | Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations | Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ) Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations | Multiple Sclerosis (MS) | Drug: H.P. Acthar Gel (repository corticotropin injection) | The University of Texas Health Science Center, Houston | Not recruiting | 18 Years | 55 Years | Both | 25 | Phase 4 | United States | |
605 | NCT01838668 | March 28, 2013 | 3 December 2018 | An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of BG00012 in Subjects From the Asia-Pacific Region and Other Countries With Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis | Drug: Placebo;Drug: dimethyl fumarate | Biogen | Not recruiting | 18 Years | 55 Years | All | 225 | Phase 3 | Czechia;Japan;Korea, Republic of;Poland;Taiwan;Czech Republic | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
606 | NCT01808482 | March 13, 2013 | 16 December 2017 | A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS) | A First Time in Human Study Exploring Preliminary Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Part A: 100 mg/mL GSK2618960;Drug: Part A: matching placebo;Drug: Part B: Dose of GSK2618960 decided from Part A;Drug: Part B: matching placebo;Drug: Part C: Dose of GSK2618960 decided from Part A and B | GlaxoSmithKline | Not recruiting | 18 Years | 55 Years | Male | 16 | Phase 1 | United Kingdom | |
607 | EUCTR2011-002959-34-DK | 11/03/2013 | 17 October 2016 | RETRAP - A study of the effect of combination of resistance training and prolonged-release fampridine on muscle strength in the legs, walking capacity and quality of life in multiple sclerosis patients. | RETRAP - A double blind, randomized, placebo controlled study of the effect of the combination of resistance training and prolonged release fampridine on muscle strength in the lower extremities, walking capacity and quality of life in relapsing remitting multiple sclerosis - RETRAP | Multiple sclerosis MedDRA version: 15.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Fampyra Product Name: Fampyra Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Sønderjylland Hospital, department of neurology | Not Recruiting | Female: yes Male: yes | 125 | Phase 4 | Denmark | |||
608 | EUCTR2012-002639-27-GB | 11/03/2013 | 5 August 2013 | A study to assess long-term safety and effectiveness of MT-1303 in subjects who completed the MT-1303-E04 study. | A phase II, multicentre study to evaluate the long-term safety and efficacy of MT-1303 in subjects with relapsing-remitting multiple sclerosis who have completed the MT-1303-E04 study | Relapsing-remitting multiple sclerosis (RRMS) MedDRA version: 16.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: MT-1303 Product Code: MT-1303 Pharmaceutical Form: Capsule INN or Proposed INN: MT-1303 Current Sponsor code: MT-1303 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Product Name: MT-1303 Product Code: MT-1303 Pharmaceutical Form: Capsule INN or Proposed INN: MT-1303 Current Sponsor code: MT-1303 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.2- Product Name: MT-1303 Product Code: MT-1303 Pharmaceutical Form: Capsule INN or Proposed INN: MT-1303 Current Sponsor code: MT-1303 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.4- | Mitsubishi Tanabe Pharma Corporation (MTPC) | Authorised | Female: yes Male: yes | 400 | Phase 2 | Serbia;Finland;Spain;Ukraine;Lithuania;Turkey;Russian Federation;Italy;United Kingdom;Switzerland;Hungary;Czech Republic;Canada;Poland;Belgium;Croatia;Bulgaria;Latvia;Germany;Sweden;Bosnia and Herzegovina | |||
609 | NCT01714089 | March 2013 | 18 April 2016 | Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis | A Phase II Study Evaluating RNS60 Compared to Interferon Beta-1a (Avonex) for the Treatment of Relapsing Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: RNS60 125 ml;Drug: RNS60 250 ml;Drug: Interferon beta 1a | Revalesio Corporation | Not recruiting | 18 Years | 50 Years | Both | 0 | Phase 2 | United States | |
610 | NCT01768039 | March 2013 | 19 February 2015 | Vitamine D in Multiple Sclerosis | Randomised Double Blind Placebo-controlled Trial of Vitamine D Supplement in Multiple Sclerosis | Multiple Sclerosis | Drug: Vitamin D;Drug: Placebo | Mazandaran University of Medical Sciences | Not recruiting | 18 Years | 50 Years | Both | 240 | Phase 3 | Iran, Islamic Republic of | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
611 | NCT01803867 | March 2013 | 9 March 2015 | An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis | A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS) | Multiple Sclerosis | Drug: rHIgM22 | Acorda Therapeutics | PRA Health Sciences | Not recruiting | 18 Years | 70 Years | Both | 72 | Phase 1 | United States |
612 | NCT01834586 | March 2013 | 11 June 2018 | Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications | Pilot Study of Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications (OUCH) | Multiple Sclerosis | Drug: Anesthetic Topical Adhesive Synera | Brown, Theodore R., M.D., MPH | Not recruiting | 18 Years | N/A | All | 30 | Phase 4 | United States | |
613 | NCT01791244 | February 28, 2013 | 16 December 2017 | A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device | A Phase IV Multicenter Randomized Study to Assess the Impact of a Patient Support Program (MinSupport Plus) on Health Related Quality of Life (HRQoL) and Adherence in Patients With Relapsing Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart Device | Multiple Sclerosis;Relapsing-Remitting | Drug: Rebif® | Merck KGaA | Not recruiting | 18 Years | N/A | All | 93 | Phase 4 | Germany;Sweden | |
614 | EUCTR2011-000985-36-ES | 22/02/2013 | 2 June 2014 | Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as responders and not responders under treatment with Sativex | Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as responders and not responders under treatment with Sativex | Spasticity due to multiple sclerosis identified as responders and not responders under treatment with Sativex MedDRA version: 14.1 Level: LLT Classification code 10041416 Term: Spasticity System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: SATIVEX Product Name: sativex Product Code: N02BG10 Pharmaceutical Form: Oromucosal solution INN or Proposed INN: pending CAS Number: 13956-29-1 Current Sponsor code: pending Other descriptive name: CANNABIDIOL Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.7- | JOSE MANUEL GARCIA DOMINGUEZ | Not Recruiting | Female: yes Male: yes | Spain | |||||
615 | NCT01707992 | February 20, 2013 | 11 June 2018 | The Efficacy, Safety, and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) | A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis | Drug: Laquinimod;Drug: Matching Placebo | Teva Branded Pharmaceutical Products, R&D Inc. | Not recruiting | 18 Years | 55 Years | All | 2199 | Phase 3 | United States;Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Macedonia, The Former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;Belgium;Czech Republic;Kazakhstan;Mexico;Portugal | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
616 | NCT01797965 | February 15, 2013 | 3 December 2018 | Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 | A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301 | Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis | Drug: BIIB019 (Daclizumab) | Biogen | AbbVie | Not recruiting | 18 Years | N/A | All | 1501 | Phase 3 | United States;Argentina;Australia;Brazil;Canada;Czechia;Denmark;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;China;Czech Republic;Finland |
617 | EUCTR2012-000411-91-DE | 13/02/2013 | 4 December 2018 | Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod | Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial - NKZellen-Version1.0 | relapsing-remitting multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya® Product Name: Gilenya® Product Code: Gilenya® Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359-55-9 Current Sponsor code: FINGOLIMOD Other descriptive name: FINGOLIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,5- | Charité - Universitätsmedizin Berlin | Not Recruiting | Female: yes Male: yes | 40 | Phase 4 | Germany | |||
618 | NCT01730547 | February 2013 | 19 February 2015 | Mesenchymal Stem Cells for Multiple Sclerosis | Phase 1/2 Clinical Trial With Autologous Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis | Multiple Sclerosis | Biological: Autologous mesenchymal stem cells | Karolinska Institutet | Recruiting | 18 Years | 50 Years | Both | 15 | Phase 1/Phase 2 | Sweden | |
619 | NCT01772199 | February 2013 | 22 August 2016 | Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis | Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: GSK239512;Drug: Placebo | GlaxoSmithKline | Not recruiting | 18 Years | 50 Years | Both | 131 | Phase 2 | Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom | |
620 | NCT01802489 | February 2013 | 11 June 2018 | Amiloride Clinical Trial In Optic Neuritis | A Double Blind Randomised Control Trial on Neuroprotection of Amiloride in Optic Neuritis | Optic Neuritis;Multiple Sclerosis | Drug: Amiloride;Drug: Placebo | University of Oxford | Multiple Sclerosis Society of Great Britain and Northern Ireland | Not recruiting | 18 Years | 55 Years | All | 46 | Phase 2 | United Kingdom |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
621 | NCT01848327 | February 2013 | 5 February 2018 | Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis | A Randomized Double-Blind Placebo-Controlled Study of Caprylic Triglyceride for Cognitive Impairment in Subjects With Multiple Sclerosis. | Relapsing Remitting MS;Secondary Progressive MS;Primary Progressive MS | Dietary Supplement: Caprylic Triglyceride;Dietary Supplement: Placebo | University of Miami | National Multiple Sclerosis Society;Accera, Inc. | Not recruiting | 18 Years | 59 Years | All | 124 | N/A | United States |
622 | NCT02040116 | February 2013 | 16 December 2017 | Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases | Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases | Multiple Sclerosis | Drug: Rituximab Infusion | Wake Forest University Health Sciences | Not recruiting | 18 Years | 80 Years | All | 19 | Phase 4 | United States | |
623 | EUCTR2012-003627-38-SE | 30/01/2013 | 10 July 2015 | Assessing the Potential Ability of GSK239512 to Remyelinate Brain Lesions in Relapsing Remitting Multiple Sclerosis | Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis MedDRA version: 16.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: GSK2395612 Pharmaceutical Form: Tablet INN or Proposed INN: 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone CAS Number: 720691-69-0 Current Sponsor code: GSK239512 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Code: GSK239512 Pharmaceutical Form: Tablet INN or Proposed INN: 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone CAS Number: 720691-69-0 Current Sponsor code: GSK239512 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Code: GSK239512 Pharmaceutical Form: Tablet INN or Proposed INN: 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone CAS Number: 720691-69-0 Current Sponsor code: GSK239512 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Code: GSK239512 Pharmaceutical Form: Tablet INN or Proposed INN: 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone CAS Number: 720691-69-0 Current Sponsor code: GSK239512 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 80- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | GlaxoSmithKline Research & Development Ltd | Not Recruiting | Female: yes Male: yes | 114 | Czech Republic;Canada;Spain;Ukraine;Bulgaria;Germany;United Kingdom;Sweden | ||||
624 | EUCTR2012-004183-21-GB | 25/01/2013 | 30 April 2019 | Melatonin for Nocturia in patients with Multiple Sclerosis | A randomized, double blind, placebo controlled, cross over trial of Melatonin for the treatment of nocturia in adults with progressive multiple sclerosis, with an open label, single-arm extension study - Melatonin for Nocturia in MS | Nocturia; Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Circadin Product Name: Circadin Product Code: N/A Pharmaceutical Form: Modified-release tablet INN or Proposed INN: Circadin ( INN= Melatonin) CAS Number: 73-31-4 Current Sponsor code: N/A Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | North Bristol NHS Trust | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | United Kingdom | |||
625 | EUCTR2012-004847-61-GB | 16/01/2013 | 4 August 2015 | INSPIRE: Raltegravir (Isentress) Pilot Study in Relapsing MS | A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI - INSPIRE (Isentress Pilot Study in Relapsing MS) | Relapsing Remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: ISENTRESS Product Name: raltegravir Pharmaceutical Form: Film-coated tablet INN or Proposed INN: lactose monohydrate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 26.06- | Queen Mary University of London | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | United Kingdom | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
626 | EUCTR2012-004602-97-ES | 11/01/2013 | 11 June 2018 | ?Vitamin D as add-on treatment for relapsing-remitting multiple sclerosis: an unicentric, randomized, double-blinded, placebo-controlled clinical trial? | ?Vitamin D as add-on treatment for relapsing-remitting multiple sclerosis: an unicentric, randomized, double-blinded, placebo-controlled clinical trial? - VITADEM | RELAPSING-REMITING MULTIPLE SCLEROSIS MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: VITAMINA D3 KERN PHARMA SOLUCIÓN OLEOSA Pharmaceutical Form: Oral drops, solution INN or Proposed INN: COLECALCIFEROL Other descriptive name: COLECALCIFEROL CONCENTRATE (OILY FORM) Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 4000- Pharmaceutical form of the placebo: Oral drops, solution Route of administration of the placebo: Oral use | Javier Olascoaga Urtaza | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | Spain | |||
627 | NCT01802931 | January 7, 2013 | 16 December 2017 | GSK239512 DDI Study | An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK239512 | Multiple Sclerosis | Drug: GSK239512;Drug: ketoconazole | GlaxoSmithKline | Not recruiting | 18 Years | 45 Years | Male | 22 | Phase 1 | Australia | |
628 | EUCTR2012-005076-34-BE | 03/01/2013 | 7 October 2014 | Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters. A cross-over, double-blinded, placebo-controlled study. | Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters. A cross-over, double-blinded, placebo-controlled study. | Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Fampyra Product Name: Fampridine Product Code: BIIB041 Pharmaceutical Form: Prolonged-release tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Cliniques Universitaires Saint-Luc, Neurologie | Authorised | Female: yes Male: yes | Belgium | |||||
629 | NCT01606215 | January 2013 | 26 August 2019 | Stem Cells in Rapidly Evolving Active Multiple Sclerosis | Stem Cells in Rapidly Evolving Active Multiple Sclerosis | Multiple Sclerosis | Drug: Mesenchymal stem cells;Drug: Placebo | Imperial College London | Not recruiting | 18 Years | 50 Years | All | 21 | Phase 1/Phase 2 | United Kingdom | |
630 | NCT01742052 | January 2013 | 26 September 2016 | Dose-finding Study of MT-1303 | A Phase II, Multicentre, Randomised, Double-blind,Parallel Group, Placebo-controlled, Dose-finding Study to Evaluate the Safety and Efficacy of Three Different Oral Doses of MT-1303 Administered for a Period of 24 Weeks in Subjects With Relapsing-remitting Multiple Sclerosis | Relapsing-remitting Multiple Sclerosis | Drug: MT-1303-Low;Drug: MT-1303-Middle;Drug: MT-1303-High;Drug: Placebo | Mitsubishi Tanabe Pharma Corporation | Not recruiting | 18 Years | 60 Years | Both | 415 | Phase 2 | Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Lithuania;Poland;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
631 | NCT01753375 | January 2013 | 19 February 2015 | Role of Vitamin D in Reducing the Relapse Rate in Patients With Multiple Sclerosis | Role of Vitamin D on the Relapse Rate of Multiple Sclerosis | Multiple Sclerosis | Dietary Supplement: Vitamin D3;Dietary Supplement: Placebo | AlJohara M AlQuaiz, M.D. | Not recruiting | 18 Years | 55 Years | Both | 200 | Phase 2 | Saudi Arabia | |
632 | NCT01755871 | January 2013 | 20 June 2016 | Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis | The Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: Fingolimod | Heinrich-Heine University, Duesseldorf | Novartis Pharmaceuticals | Not recruiting | 18 Years | 65 Years | Both | 8 | Phase 4 | Germany |
633 | NCT01759602 | January 2013 | 19 October 2017 | C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation | Phase 1b Study of C1-esterase Inhibitor (Cinryze) With Standard of Care for Acute Treatment of Neuromyelitis Optica Exacerbations | Neuromyelitis Optica | Drug: C1-esterase inhibitor (Cinryze) | Michael Levy | ViroPharma | Not recruiting | 18 Years | 65 Years | All | 10 | Phase 1 | United States |
634 | NCT01779934 | January 2013 | 14 March 2016 | OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis | Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Drug: FTY720 | Novartis Pharmaceuticals | Not recruiting | 28 Years | N/A | Both | 579 | Phase 3 | United States;Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom | |
635 | NCT01665144 | December 20, 2012 | 30 September 2019 | Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) | A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312. | Secondary Progressive Multiple Sclerosis | Drug: BAF312;Drug: Placebo | Novartis Pharmaceuticals | Not recruiting | 18 Years | 60 Years | All | 1652 | Phase 3 | United States;Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;Czech Republic;Egypt | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
636 | EUCTR2012-003056-36-SK | 10/12/2012 | 28 February 2019 | Study of efficacy, safety and tolerability data for BAF312 compared to placebo in patients with secondary progressive multiple sclerosis followed by extended treatment with BAF312 | A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis followed by extended treatment with open-label BAF312 - EXPAND | Secondary progressive multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Siponimod 2 mg tablet Product Code: BAF312A Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Siponimod CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Siponimod 1 mg tablet Product Code: BAF312A Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Siponimod CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Siponimod 0.5 mg tablet Product Code: BAF312A Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Siponimod CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Siponimod 0.25 mg tablet Product Code: BAF312A Pharmaceutical Form: Film-coated tablet | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 1530 | Phase 3 | Portugal;United States;Estonia;Slovakia;Greece;Spain;Ireland;Russian Federation;Israel;Switzerland;Italy;France;Australia;Netherlands;Latvia;China;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Hungary;Canada;Argentina;Poland;Belgium;Romania;Bulgaria;Germany;Japan;Sweden | |||
637 | EUCTR2012-000721-53-SE | 07/12/2012 | 24 September 2018 | An extension trial of intrathecal therapy with monoclonal antibodies in progressive multiple sclerosis | ITT-PMS Extension An extension study of intrathecal therapy with monoclonal antibodies in progressive multiple sclerosis - ITT-PMS Ext | Secondary progressive multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Mabthera Product Name: Mabthera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- | Dept of Neurology, Umeå University Hospital, Umeå, Sweden | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | Sweden | |||
638 | NCT01766063 | December 6, 2012 | 26 February 2018 | Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon | BETASLEEP - SLEEP Quality and Functional Health Status, Fatigue, Comorbidities and Therapeutic Algorithms Among BETAferon® Treated MS Patients | Multiple Sclerosis | Drug: Interferon beta-1b (Betaferon, BAY 86-5046) | Bayer | Not recruiting | 18 Years | N/A | All | 138 | N/A | Germany | |
639 | NCT01272128 | December 2012 | 26 October 2015 | Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study | A Multicenter, Prospective Non-interventional Study to Evaluate the Quality of Life in Belgian Patients With CIS or RRMS in Whom Interferon Beta-1a IM Treatment Has Been Initiated | Multiple Sclerosis | Drug: Interferon beta-1a | Biogen | Not recruiting | 18 Years | N/A | Both | 100 | N/A | Belgium;United States | |
640 | NCT01720849 | December 2012 | 3 August 2015 | Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis | Multiple Sclerosis;EDSS 4-7 | Drug: Fampyra | Vestre Viken Hospital Trust | Recruiting | 18 Years | N/A | Both | 50 | N/A | Norway | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
641 | NCT01764737 | December 2012 | 19 February 2015 | Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS | A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: VX15/2503;Drug: Placebo | Vaccinex Inc. | PRA Health Sciences | Not recruiting | 18 Years | 60 Years | Both | 50 | Phase 1 | United States |
642 | NCT01879202 | December 2012 | 25 May 2015 | Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis | Methylphenidate Modified-release as Treatment of MS-associated Fatigue. A Single-center Randomized Double-blind Placebo-controlled Study. | Multiple Sclerosis;Fatigue | Drug: Methylphenidate modified release;Drug: Maltodextrin | Medical University of Vienna | Recruiting | 18 Years | N/A | Both | 96 | Phase 2 | Austria | |
643 | EUCTR2012-000835-18-SE | 07/11/2012 | 21 September 2015 | A study to evaluate how safe and effective 0.5 mg FTY720 is in delaying disability progression if taken once daily, in patients with PPMS | Open-label, single-arm extension study to the double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis - efficacy and safety of 0.5 mg fingolimod in patients with primary progressive multiple sclerosis | Primary progressive multiple sclerosis. MedDRA version: 16.0 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359- 56-0 Current Sponsor code: FTY720D Other descriptive name: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 700 | United States;Finland;Spain;Turkey;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Australia;Denmark;Netherlands;Germany;Sweden | ||||
644 | EUCTR2012-001965-34-ES | 07/11/2012 | 17 May 2016 | Study to compare the clinical and radiological efficacy of 625 mg vs 1250 mg of oral methylprednisolone in patients with multiple sclerosis in relapse. | Multicenter, randomized, double-blind clinical trial to compare the clinical and radiological efficacy of 625 mg vs 1250 mg of oral methylprednisolone in patients with multiple sclerosis in relapse. | Multiple sclerosis MedDRA version: 15.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Urbason 40 mg Pharmaceutical Form: Capsule CAS Number: 03/03/2375 Other descriptive name: METHYLPREDNISOLONE SODIUM HEMISUCCINATE Concentration unit: mg milligram(s) Concentration type: range Concentration number: 625-1250 Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Servicio de Neurología, HU. Germans Trias i Pujol | Not Recruiting | Female: yes Male: yes | Phase 4 | Spain | ||||
645 | NCT01728922 | November 6, 2012 | 16 December 2017 | Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome | Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome and Healthy Control Participants. An Exploratory Double Blind Placebo Randomised Controlled Study. | Clinically Isolated Syndrome;Multiple Sclerosis | Dietary Supplement: 5000IU vitamin D;Dietary Supplement: 10000IU vitamin D;Other: Placebo | University College Dublin | University of Dublin, Trinity College;St Vincent's University Hospital, Ireland | Not recruiting | 18 Years | 55 Years | All | 64 | Phase 1/Phase 2 | Ireland |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
646 | NCT01679041 | November 2012 | 19 February 2015 | High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment | A Phase II Study of High Dose Chemotherapy With Autologous Hematopoietic Progenitor Cell Transplant for Multiple Sclerosis That Failed at Least Two Lines of Therapy | Multiple Sclerosis | Drug: Alemtuzumab;Drug: Fludarabine;Drug: Cyclophosphamide | Seah Lim M.D. | Not recruiting | 18 Years | 60 Years | Both | 1 | Phase 2 | United States | |
647 | NCT01743651 | November 2012 | 19 February 2015 | Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis | A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis | Spasticity;Multiple Sclerosis | Drug: arbaclofen;Drug: baclofen;Drug: Placebo | Osmotica Pharmaceutical Corp. | Not recruiting | 18 Years | 65 Years | Both | 353 | Phase 3 | United States;Russian Federation;Ukraine | |
648 | NCT01744444 | November 2012 | 19 February 2015 | Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis | Pendular Nystagmus Patients With Multiple Sclerosis | Drug: Memantine;Drug: Gabapentin | Hospices Civils de Lyon | Not recruiting | 18 Years | N/A | Both | 10 | Phase 2 | France | ||
649 | NCT01767493 | November 2012 | 19 February 2015 | Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients | An Open-label, Non-randomized Study to Evaluate the Feasibility of [18F]Florbetapir Positron Emission Tomography (PET) for Assessment of Demyelination in Patients With Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis | Drug: [18F]Florbetapir and PET imaging | Institute for Neurodegenerative Disorders | Biogen Idec | Recruiting | 18 Years | 60 Years | Both | 18 | N/A | United States |
650 | NCT02137707 | November 2012 | 19 November 2018 | Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya | An Investigator-initiated, Multicenter, Phase IV, Open-label Study to Evaluate the Biological Basis for Disease Progression in Relapsing-remitting Multiple Sclerosis Patients Treated in Routine Practice With Gilenya for 2 Years | Multiple Sclerosis-Relapsing-Remitting | Drug: Gilenya | McGill University | Novartis | Not recruiting | 18 Years | 65 Years | All | 135 | Phase 4 | Canada |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
651 | NCT02775110 | November 2012 | 23 May 2016 | Natalizumab Temporary Discontinuation Study | Natalizumab Temporary Discontinuation Study | Multiple Sclerosis | Other: Natalizumab discontinuation | University at Buffalo | Not recruiting | 18 Years | 65 Years | Both | 50 | Phase 4 | United States | |
652 | EUCTR2012-003056-36-HU | 31/10/2012 | 19 November 2018 | Study of efficacy, safety and tolerability data for BAF312 compared to placebo in patients with secondary progressive multiple sclerosis | A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis | Secondary progressive multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Siponimod 2 mg tablet Product Code: BAF312A Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Siponimod CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Siponimod 1 mg tablet Product Code: BAF312A Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Siponimod CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Siponimod 0.5 mg tablet Product Code: BAF312A Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Siponimod CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Siponimod 0.25 mg tablet Product Code: BAF312A Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Siponimod CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Novartis Pharma Services AG | Authorised | Female: yes Male: yes | 1530 | Phase 3 | Portugal;United States;Estonia;Slovakia;Greece;Spain;Ireland;Russian Federation;Israel;Switzerland;Italy;France;Australia;Netherlands;Latvia;China;Lithuania;Turkey;Austria;United Kingdom;Hungary;Czech Republic;Canada;Argentina;Poland;Belgium;Romania;Bulgaria;Germany;Japan;Sweden | |||
653 | EUCTR2012-002470-31-GB | 29/10/2012 | 4 August 2015 | A study to assess safety and effectiveness of the study drug MT-1303 at different dosage strengths | A phase II, multicentre, randomised, double-blind, parallel group, placebo-controlled, dose-finding study to evaluate the safety and efficacy of three different oral doses of MT-1303 administered for a period of 24 weeks in subjects with relapsing-remitting multiple sclerosis | Relapsing-Remitting Multiple Sclerosis MedDRA version: 15.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: MT-1303 Product Code: MT-1303 Pharmaceutical Form: Capsule INN or Proposed INN: MT-1303 Current Sponsor code: MT-1303 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: MT-1303 Product Code: MT-1303 Pharmaceutical Form: Capsule INN or Proposed INN: MT-1303 Current Sponsor code: MT-1303 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.2- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: MT-1303 Product Code: MT-1303 Pharmaceutical Form: Capsule INN or Proposed INN: MT-1303 Current Sponsor code: MT-1303 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.4- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Mitsubishi Tanabe Pharma Corporation (MTPC) | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | Serbia;Finland;Spain;Ukraine;Lithuania;Turkey;Russian Federation;Italy;United Kingdom;Switzerland;Hungary;Czech Republic;Canada;Poland;Belgium;Croatia;Bulgaria;Latvia;Germany;Sweden;Bosnia and Herzegovina | |||
654 | EUCTR2011-004787-30-DE | 26/10/2012 | 30 May 2016 | Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya® | Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya® - MOVING | Multiple sclerosis or clinically isolated syndrom;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya® Product Name: Gilenya® Product Code: Gilenya® Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359-55-9 Current Sponsor code: Gilenya Other descriptive name: FINGOLIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,5- Trade Name: Extavia® Product Name: Extavia® Product Code: Extavia® Pharmaceutical Form: Concentrate and solvent for solution for injection INN or Proposed INN: Interferon beta 1B CAS Number: 145155-23-3 Current Sponsor code: Extavia Other descriptive name: INTERFERON BETA-1B Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 250- | Charite Universitaetsmedizin Berlin | Not Recruiting | Female: yes Male: yes | Phase 3 | Germany | ||||
655 | EUCTR2012-002357-35-GB | 23/10/2012 | 30 April 2019 | Bone marrow stem cells to treat multiple sclerosis | Stem cells in Rapidly Evolving Active Multiple Sclerosis (STREAMS) - Stem cells in Rapidly Evolving Active Multiple Sclerosis (STREAMS) | Multiple Sclerosis;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Autologous Mesenchymal Cell Product Pharmaceutical Form: Suspension for injection in cartridge Pharmaceutical form of the placebo: Suspension for infusion Route of administration of the placebo: Intravenous use | Imperial College London | Not Recruiting | Female: yes Male: yes | 13 | Phase 2 | United Kingdom | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
656 | EUCTR2012-003418-15-AT | 23/10/2012 | 19 November 2012 | Methylphenidate modified release as treatment of MS-associated fatigue. | Methylphenidate modified release as treatment option of MS-associated fatigue. A single-center randomized double-blind placebo-controlled trial. | Fatigue is a very common symptom in multiple sclerosis. Its management comprises nonpharmacologic approaches like exercise, cooling procedures and energy conservation programs and as second step pharmacologic therapy. Until now, Amantadine, Modafinil or antidepressants have been used off-label among others, with some success. Until now, methylphenidate has been successfully used to treat fatigue in HIV and parkinson´s disease, data on its efficacy in MS are not available. ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Ritalin LA 20mg capsules Product Name: Methylphenidate modified release 20 mg Pharmaceutical Form: Capsule, hard INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE CAS Number: 298-59-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Ritalin LA 30mg capsules Product Name: Methylphenidate modified release 30 mg Pharmaceutical Form: Capsule, hard INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE CAS Number: 298-59-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Trade Name: Ritalin LA 40mg capsules Product Name: Methylphenidate modified release 40 mg Pharmaceutical Form: Capsule, hard INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE CAS Number: 298-59-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- | Medizinische Universität Wien | Authorised | Female: yes Male: yes | Austria | |||||
657 | EUCTR2012-002637-11-DE | 15/10/2012 | 11 March 2013 | A 6 months, multicenter study to evaluate the effect of an individualized patient support program on treatment satisfaction in Fingolimod (FTY720)-treated patients with relapsing-remitting multiple sclerosis | A 6 months, randomized, multicenter, parallel-group, open-label study to evaluate the effect of an individualized patient support program on treatment satisfaction in Fingolimod (FTY720)-treated patients with relapsing-remitting multiple sclerosis - STAY | Treatment statisfaction in patients with relapsing remitting Multiple Sclerosis MedDRA version: 15.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720 Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: Fingolimod Hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- | Novartis Pharma GmbH | Not Recruiting | Female: yes Male: yes | Germany | |||||
658 | NCT01578330 | October 2012 | 19 October 2017 | A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 | A 12 -Month, Open-label, Multi-center Pilot Study to Explore the Health Outcomes of FTY720 in RRMS Patients Who Have Previously Been Treated With Other Disease Modifying Therapies (DMT)- Fine | Multiple Sclerosis;Relapsing-Remitting | Drug: Fingolimod | Novartis Pharmaceuticals | Not recruiting | 18 Years | 65 Years | All | 42 | Phase 4 | Turkey | |
659 | NCT01698086 | October 2012 | 11 February 2019 | Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? (MSVR3trial) | Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? | Multiple Sclerosis;Balance;Fatigue;Eye Movement | Other: Vestibular rehabilitation: balance and eye movement exercises | University of Colorado, Denver | National Multiple Sclerosis Society | Not recruiting | 18 Years | 60 Years | All | 88 | N/A | United States |
660 | NCT01895439 | October 2012 | 16 December 2017 | Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis | Phase II Study: Use of Autologus Mesenchymal Stem Cells in Multiple Sclerosis Patients Who do Not Respond to Conventional Treatment | Multiple Sclerosis | Biological: Autologous Mesenchymal Stem Cells | University of Jordan | Not recruiting | 18 Years | 65 Years | All | 13 | Phase 1/Phase 2 | Jordan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
661 | EUCTR2011-001437-16-DE | 19/09/2012 | 25 September 2012 | A 3 year study to determine if optical coherence tomography can be used to measure disease progression in patients with multiple sclerosis | A 3-year, multi-center study to evaluate optical coherence tomography as an outcome measure in patients with multiple sclerosis - | multiple sclerosis MedDRA version: 15.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359-56-0 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Trade Name: Extavia Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta-1b CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: Tysabri Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Copaxone Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Avonex Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta-1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30- | Novartis Pharma Services AG | Authorised | Female: yes Male: yes | 420 | Germany;Switzerland;Netherlands;France;Italy;Austria;Australia;Czech Republic;United Kingdom;Canada;Denmark;Spain;United States;Poland | ||||
662 | EUCTR2012-000635-68-IE | 19/09/2012 | 21 August 2017 | An initial, short-duration study of vitamin D versus an inactive therapy on the ability of the human immune system to counteract the effects of Multiple Sclerosis on the brain and the effects of vitamin D on the immune system in healthy individuals. | Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome or early multiple sclerosis and healthy control participants. An exploratory randomised double blind placebo controlled study - N/A | Multiple Sclerosis MedDRA version: 14.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Vigantol Product Name: N/A Product Code: N/A Pharmaceutical Form: Oral drops, solution Pharmaceutical form of the placebo: Oral drops, solution Route of administration of the placebo: Oral use | University College Dublin | Not Recruiting | Female: yes Male: yes | Phase 2 | Ireland | ||||
663 | NCT01628393 | September 18, 2012 | 17 June 2019 | Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study) | A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients | Relapsing Multiple Sclerosis | Drug: RPC1063;Drug: placebo | Celgene | Not recruiting | 18 Years | 55 Years | All | 258 | Phase 2/Phase 3 | United States;Belgium;Bulgaria;Georgia;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine | |
664 | NCT01413243 | September 2012 | 17 May 2016 | Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome | Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome - A Monocentric, Prospective, Randomized, Double-blind and Placebo-controlled Phase 2 Trial | Multiple Sclerosis | Drug: Trichuris suis ova | Charite University, Berlin, Germany | Not recruiting | 18 Years | 65 Years | Both | 50 | Phase 2 | Germany | |
665 | NCT01624714 | September 2012 | 19 February 2015 | Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects | Phase I Trial Monitoring Efficacy and Safety in Treatment of Alemtuzumab Naive Subjects and Data Collecting and Monitoring of Alemtuzumab Experienced Subjects With Refractory Multiple Sclerosis | Multiple Sclerosis | Drug: Alemtuzumab;Drug: Alemtuzumab immunotherapy | Samuel Forrester Hunter, MD, PhD | Not recruiting | 18 Years | 75 Years | Both | 60 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
666 | NCT01667484 | September 2012 | 25 May 2015 | Adderall XR and Processing Speed in Multiple Sclerosis (MS) | Does Adderall XR Improve Processing Speed in Cognitively Impaired MS Patients? | Impaired Processing Speed;Cognitive Impairment;Multiple Sclerosis | Drug: Adderall XR 5mg;Drug: Adderall XR 10 mg;Drug: Placebo | London Health Sciences Centre | Not recruiting | 18 Years | 59 Years | Both | 70 | Phase 2/Phase 3 | Canada | |
667 | NCT01667497 | September 2012 | 14 September 2015 | Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients? | Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients? A Cross Over Study | Cognitive Fatigue | Drug: Fampridine SR;Drug: Placebo | London Health Sciences Centre | Not recruiting | 18 Years | 64 Years | Both | 60 | Phase 2/Phase 3 | Canada | |
668 | NCT01701856 | September 2012 | 19 February 2015 | Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis | Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis: A Swiss Multicenter Study Prospective, Controlled, Single-arm, Open-label, Multi-centre, Phase IV Study | Relapsing-remitting Multiple Sclerosis | Drug: Interferon beta-1b | Claudio Gobbi | Bayer | Not recruiting | 18 Years | 70 Years | Both | 5 | Phase 4 | Switzerland |
669 | NCT01706055 | September 2012 | 16 December 2017 | Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE) | Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon® | Multiple Sclerosis | Biological: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 18 Years | N/A | All | 629 | N/A | Poland | |
670 | NCT02442570 | September 2012 | 7 September 2015 | A Study to Evaluate Safety and Efficacy of DC-TAB in Multiple Sclerosis | A Phase IIa, Randomized, Double-blind, Placebo-controlled, Exploratory, Dose-ranging Study to Evaluate the Safety, Effectiveness and Pharmacokinetics of Three Courses of DC-TAB Treatment in Patients With Multiple Sclerosis | Multiple Sclerosis | Biological: recombinant human alpha B-crystallin;Other: Placebo comparator | Delta Crystallon BV | Not recruiting | 18 Years | 55 Years | Both | 32 | Phase 2 | Bulgaria | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
671 | NCT02463318 | September 2012 | 16 December 2017 | The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects | Multiple Sclerosis;Oxidative Stress | Drug: Melatonin;Other: Hydrogen peroxide | Tehran University of Medical Sciences | Not recruiting | 20 Years | 40 Years | Female | 34 | N/A | Iran, Islamic Republic of | ||
672 | NCT01633112 | August 9, 2012 | 15 October 2018 | MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone | A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis | Relapsing-remitting Multiple Sclerosis (RRMS) | Drug: fingolimod;Drug: copaxone | Novartis Pharmaceuticals | Not recruiting | 18 Years | 65 Years | All | 1064 | Phase 4 | United States;Argentina;Brazil;Canada;Chile;Mexico;Puerto Rico | |
673 | NCT01582126 | August 2012 | 7 April 2015 | Group Balance Training for People With Multiple Sclerosis | Group Balance Training for People With Multiple Sclerosis | Multiple Sclerosis | Other: Group balance training | Örebro County Council | Uppsala-Örebro Regional Research Council;Norrbacka-Eugenia Foundation | Not recruiting | 18 Years | N/A | Both | 87 | N/A | Sweden |
674 | NCT01597297 | August 2012 | 16 December 2017 | Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis. | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and Balance in Subjects With Multiple Sclerosis | Multiple Sclerosis | Drug: BIIB041 (PR Fampridine);Other: Placebo | Biogen | Not recruiting | 18 Years | 70 Years | All | 132 | Phase 2 | Belgium;Canada;Italy;Netherlands;Sweden;United Kingdom | |
675 | NCT01684761 | August 2012 | 16 December 2017 | Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis | A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis | Autoimmune Diseases of the Nervous System;Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Disease Progression;Brain Atrophy | Biological: Tcelna;Biological: Placebo | Opexa Therapeutics, Inc. | Not recruiting | 18 Years | 60 Years | All | 183 | Phase 2 | United States;Canada | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
676 | EUCTR2011-005475-16-GB | 25/07/2012 | 31 July 2012 | A Phase 1/2 study to test how effective different doses of MEDI-551 is for treating subjects with Relapsing-Remitting Multiple Sclerosis | A Phase 1/2 Randomized, Dose-finding Study of MEDI-551 in Subjects with Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: MEDI-551 Product Code: MEDI-551 Pharmaceutical Form: Concentrate for solution for infusion Current Sponsor code: MEDI-551 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Avonex Product Name: Avonex Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: interferon beta-1a CAS Number: 220581-49-7 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 60- | MedImmune LLC | Authorised | Female: yes Male: yes | 512 | Phase 1/2 | Hungary;Germany;Turkey;Switzerland;Netherlands;France;Ireland;Italy;Austria;Sweden;Israel;Russian Federation;United Kingdom;Czech Republic;Ukraine;Canada;Denmark;Spain;United States;Poland | |||
677 | NCT01639300 | July 2012 | 26 February 2018 | Safety Study of GNbAC1 in Multiple Sclerosis Patients | Randomised Placebo-Controlled Single Blind Study to Investigate Single Ascending Doses of GNbAC1 in Multiple Sclerosis Patients Followed by Open-label Extension With Repeated Doses of GNbAC1 | Multiple Sclerosis | Biological: GNbAC1;Biological: GNbAC1 placebo | GeNeuro Innovation SAS | Not recruiting | 18 Years | 65 Years | All | 10 | Phase 2 | Switzerland | |
678 | NCT01854957 | July 2012 | 19 February 2015 | MEsenchymal StEm Cells for Multiple Sclerosis | MEsenchymal StEm Cells for Multiple Sclerosis (MESEMS) Phase I-II Clinical Trial With Autologous Mesenchymal Stem Cells (MSCs) for the Therapy of Multiple Sclerosis | Multiple Sclerosis | Biological: Autologous Mesenchymal Stem Cells | Antonio Uccelli | Azienda Ospedaliera Universitaria Integrata Verona;Ospedale San Raffaele | Recruiting | 18 Years | 50 Years | Both | 20 | Phase 1/Phase 2 | Italy |
679 | NCT01585298 | June 29, 2012 | 16 December 2017 | STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START) | A 1-week, Open-label, Multi-center Study to Explore Conduction Abnormalities During First Dose Administration of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis | Drug: FTY720 | Novartis Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 6996 | Phase 4 | Germany | |
680 | JPRN-UMIN000009421 | 2012/06/28 | 2 April 2019 | Efficacy and safety of rituximab for intractable immunogenic neurological disorder in children | neuromyelitis optica (NMO), opsoclonus-myoclonus syndrome (OMS) | administration of rituximab | Department of Pediatrics, Kobe Universtiy Graduate School of Medicine | Recruiting | Not applicable | 18years-old | Male and Female | 10 | Not applicable | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
681 | EUCTR2012-000653-32-DE | 27/06/2012 | 2 October 2017 | A study to explore heart function during first dose administration of fingolimod in patients with relapsing-remitting multiple sclerosis | A 1-week, open-label, multi-center study to explore conduction abnormalities during first dose administration of fingolimod in patients with relapsing-remitting multiple sclerosis (START) - START | Conduction abnormalities in patients with relapsing-remitting multiple sclerosis MedDRA version: 18.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720 Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: Fingolimod Hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- | Novartis Pharma GmbH | Not Recruiting | Female: yes Male: yes | Phase 4 | Germany | ||||
682 | EUCTR2012-000518-13-DK | 21/06/2012 | 9 January 2017 | Own mesenchymal stem cells for multiple sclerosis patients | Immunomodulating and neuroprotective properties of autologous multipotent mesenchymal stem cells in patients with multiple sclerosis - A randomised placebo-controlled double-blinded phase II study - COMSCIMS | Multiple sclerosis MedDRA version: 18.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Mesenchymal stem/stromal cells Product Name: Mesenchymal stem cells (MSCs) Pharmaceutical Form: Concentrate for solution for infusion Pharmaceutical form of the placebo: Solution for injection/infusion Route of administration of the placebo: Intravenous use | Prof. Per Soelberg Sørensen | Not Recruiting | Female: yes Male: yes | Phase 2 | Denmark | ||||
683 | NCT01623596 | June 8, 2012 | 15 April 2019 | Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. | A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS) | Relapsing Remitting Multiple Sclerosis | Drug: Fingolimod;Drug: Disease Modifying therapy | Novartis Pharmaceuticals | Not recruiting | 18 Years | 65 Years | All | 881 | Phase 4 | United States;Puerto Rico | |
684 | JPRN-jRCTs031180152 | 04/06/2012 | 7 October 2019 | Tocilizumab in patients with neuromyelitis optica | The safety and efficacy of tocilizumab in patients with neuromyelitis optica: Multicenter study - Tocilizumab in patients with neuromyelitis optica | Neuromyelitis optica;D009471 | Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 6 months. | Takashi Yamamura | Not Recruiting | >= 20age old | <= 65age old | Both | 20 | N/A | none | |
685 | NCT01600716 | June 2012 | 19 October 2017 | Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) | Urinary Incontinence;Multiple Sclerosis;Neurogenic Bladder | Biological: OnabotulinumtoxinA;Drug: Placebo (Normal Saline) | Allergan | Not recruiting | 18 Years | N/A | All | 144 | Phase 3 | United States;Belgium;Canada;Czech Republic;France;Poland;Portugal;Russian Federation | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
686 | NCT01656148 | June 2012 | 3 September 2018 | FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra | Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra | Multiple Sclerosis | Drug: Fampridine-SR | University of Southern Denmark | Region of Southern Denmark;Biogen | Not recruiting | 18 Years | 60 Years | All | 108 | Phase 4 | Denmark |
687 | NCT01712945 | June 2012 | 13 May 2019 | Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis | Keratinocyte Growth Factor - Promoting Thymic Reconstitution and Preventing Autoimmunity After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis | Multiple Sclerosis | Drug: Palifermin;Drug: Alemtuzumab | Cambridge University Hospitals NHS Foundation Trust | Not recruiting | 18 Months | 50 Years | All | 40 | Phase 1/Phase 2 | United Kingdom | |
688 | EUCTR2012-000287-17-IT | 21/05/2012 | 10 February 2014 | functional MRI study to evaluate improvement of hand performance after combined motor exercise and aminopiridine assumption | PROMOTION OF FUNCTIONAL RESTORATION THROUGH PHARMACOLOGICAL MODULATION OF BRAIN PLASTICITY WITH AMINOPYRIDINE IN PATIENTS WITH MULTIPLE SCLEROSIS STUDIED BY FUNCTIONAL MRI | Patients with MS, without relevant medical conditions, with right upper limb impairment assessed by a hand dexterity test will be included.Patients will be in a non-active phase of the disease and under a stable pharmacological treatment.They will not be included if they have received physiotherapy in the previous few months. Healthy volunteers will be recruited if they have no relevant medical condition and no contraindication to perform a MRI scan. MedDRA version: 14.1 Level: LLT Classification code 10028053 Term: MS System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: FAMPYRA Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use | FONDAZIONE SANTA LUCIA | Authorised | Female: yes Male: yes | Italy | |||||
689 | EUCTR2011-004475-36-BG | 19/05/2012 | 14 March 2016 | A Phase IIa, randomized, double-blind, placebo-controlled, exploratory, dose-ranging study to evaluate the safety, effectiveness and pharmacokinetics of three courses of DC-TAB treatment in patients with multiple sclerosis | A Phase IIa, randomized, double-blind, placebo-controlled, exploratory, dose-ranging study to evaluate the safety, effectiveness and pharmacokinetics of three courses of DC-TAB treatment in patients with multiple sclerosis | Relapsing multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: DC-TAB Product Code: DC-TAB Pharmaceutical Form: Solution for injection Current Sponsor code: recombinant human CRYAB Other descriptive name: recombinant human alpha B-crystallin Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 12.5- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use | Delta Crystallon B.V. | Not Recruiting | Female: yes Male: yes | Phase 2a | Bulgaria | ||||
690 | EUCTR2011-005550-57-LV | 15/05/2012 | 25 March 2013 | A clinical study in patients with multiple sclerosis to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml (experimental drug). | A multinational, multicenter, randomized, parallel group, double blind, placebo controlled study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml new formulation administered daily by subcutaneous (SC) injection. - GLOW study | Relapsing-remitting Multiple sclerosis (RRMS) MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: 20mg/0.5ml glatiramer acetate Product Code: 20mg/0.5ml GA Pharmaceutical Form: Solution for injection INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Current Sponsor code: 20 mg/0.5 ml GA Other descriptive name: glatiramer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Teva Pharmaceutical Industries Ltd. | Not Recruiting | Female: yes Male: yes | 1400 | Serbia;United States;Belarus;Estonia;Greece;Ukraine;Lithuania;Russian Federation;Montenegro;Hungary;Czech Republic;Mexico;Macedonia, the former Yugoslav Republic of;Poland;Romania;Croatia;Georgia;Albania;Bulgaria;Germany;Latvia;Moldova, Republic of;Bosnia and Herzegovina | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
691 | JPRN-UMIN000007866 | 2012/05/01 | 2 April 2019 | The safety and efficacy of tocilizumab in patients with neuromyelitis optica: Multicenter Study | neuromyelitis optica | Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 6 years. | Department of Immunology, National Institute of Neuroscience, NCNP | Department of Neurology, Kinki University Faculty of Mediceine | Not Recruiting | 20years-old | 65years-old | Male and Female | 15 | Not applicable | Japan | |
692 | NCT01641120 | May 2012 | 19 October 2017 | Assessing Tolerability of Avonex Intramuscular Injections | Assessing Tolerability of Avonex Intramuscular Injections With a 25 Gauge Needle Versus 30 Gauge Needle | Multiple Sclerosis | Drug: Avonex | Saint Francis Care | Biogen | Not recruiting | 18 Years | 65 Years | All | 20 | N/A | United States |
693 | NCT01718678 | May 2012 | 19 February 2015 | Effect of Melatonin on Multiple Sclerosis Related Fatigue | Study of Melatonin in Treatment of Fatigue in Multiple Sclerosis | Fatigue | Drug: Melatonin;Drug: Placebo | Isfahan University of Medical Sciences | Not recruiting | 18 Years | 55 Years | Both | 44 | Phase 2 | Iran, Islamic Republic of | |
694 | NCT02142205 | May 2012 | 19 February 2015 | Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) | A Prospective, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Efficacy in RUSsian RRMS Patients on One Year Treatment With Natalizumab (TYSabri®). | Relapsing-Remitting Multiple Sclerosis | Biological: BG00002 | Biogen Idec | Biogen Idec International GmbH | Not recruiting | 18 Years | 60 Years | Both | 100 | Phase 4 | Russian Federation |
695 | NCT01491100 | April 30, 2012 | 11 June 2018 | Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis | Study Assessing Cognitive Performance Plus Physical Activity in Patients With Relapsing-Remitting MS Under Treatment With Betaferon® | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 12 Years | 70 Years | All | 1085 | Phase 4 | Albania;Algeria;Argentina;Belgium;Czechia;Egypt;France;Germany;Greece;Hungary;Israel;Kazakhstan;Netherlands;Portugal;Saudi Arabia;Tunisia;Turkey;Bosnia and Herzegovina;Czech Republic;Jordan;Lebanon;Mexico;Poland;Syrian Arab Republic | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
696 | EUCTR2011-005606-30-GB | 25/04/2012 | 1 May 2012 | Preventing patients with multiple sclerosis from developing side effects following treatment with alemtuzumab (Campath-1H). | Keratinocyte Growth Factor - promoting thymic reconstitution and preventing autoimmunity after alemtuzumab (Campath-1H) treatment of multiple sclerosis. CAM-THY - CAM-THY | This trial will test the efficacy of Kepivance in the prevention of new autoimmune diseases in patients who have multiple sclerosis (MS)who are being treated with alemtuzumab. MedDRA version: 14.1 Level: PT Classification code 10058948 Term: Nephritis autoimmune System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1 Level: PT Classification code 10049046 Term: Autoimmune thyroiditis System Organ Class: 10014698 - Endocrine disorders MedDRA version: 14.1 Level: PT Classification code 10061664 Term: Autoimmune disorder System Organ Class: 10021428 - Immune system disorders MedDRA version: 14.1 Level: LLT Classification code 10068004 Term: Autoimmune hyperthyroidism System Organ Class: 10014698 - Endocrine disorders MedDRA version: 14.1 Level: PT Classification code 10050245 Term: Autoimmune thrombocytopenia System Organ Class: 10005329 - Blood and lymphatic system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Kepivance Product Name: Kepivance Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Palifermin CAS Number: 162394-19-6 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Trade Name: MabCampath Product Name: Alemtuzumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Alemtuzumab CAS Number: 216503-57-0 Other descriptive name: anti-CD52 monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- | Cambridge University Hospitals NHS Foundation Trust and University of Cambridge | Authorised | Female: yes Male: yes | 86 | United Kingdom | ||||
697 | NCT01480063 | April 16, 2012 | 17 June 2019 | An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice | A Multicenter, Multinational, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice (LIBERATE) | Multiple Sclerosis | Drug: Fampridine | Biogen | Not recruiting | N/A | N/A | All | 4734 | N/A | Argentina;Canada;Czechia;France;Germany;Ireland;Israel;Lebanon;Netherlands;Norway;Portugal;Spain;United Arab Emirates;Australia;Belgium;Czech Republic;Denmark | |
698 | EUCTR2010-020337-99-NL | 13/04/2012 | 28 February 2019 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis | A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis - OPERA I | Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ocrelizumab 300mg /10ml Product Code: RO4964913 F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for injection Route of administration of the placebo: Intravenous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: range Concentration number: 8.8-22 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) | F.Hoffmann-La Roche | Authorised | Female: yes Male: yes | 800 | Phase 3 | Portugal;United States;Serbia;Estonia;Morocco;Slovakia;Spain;Ukraine;Israel;Chile;Russian Federation;Italy;Switzerland;Australia;Peru;South Africa;Tunisia;Netherlands;Latvia;Finland;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Argentina;Poland;Brazil;Belgium;Bulgaria;Germany;New Zealand | |||
699 | NCT01514370 | April 2012 | 12 September 2016 | Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a | ProspeCtive Study to Evaluate Efficacy, Safety and tOlerability of Dietary supplemeNT of Curcumin (BCM95) in Subjects With Active Relapsing MultIple Sclerosis Treated With subcutaNeous Interferon Beta 1a 44 mcg Three Times a Week (TIW) | Multiple Sclerosis | Drug: IFN beta 1 a + curcumin (BCM 95);Drug: IFN beta-1a + placebo | Merck KGaA | Merck Serono S.P.A., Italy | Not recruiting | 18 Years | 60 Years | Both | 80 | Phase 2 | Italy |
700 | NCT01538225 | April 2012 | 19 February 2015 | Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity | Neurophysiologic Study on Effects of Sativex® on Spasticity in Progressive Multiple Sclerosis | Multiple Sclerosis | Drug: Sativex®;Drug: Placebo | Almirall, S.A. | Not recruiting | 18 Years | N/A | Both | 45 | Phase 3 | Italy | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
701 | NCT01585766 | April 2012 | 29 August 2016 | Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis | A Phase 1 Randomized Study of MEDI-551 in Subjects With Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis, Relapsing Forms | Biological: MEDI-551 IV;Biological: MEDI-551 SC;Drug: Placebo IV;Drug: Placebo SC | MedImmune LLC | Not recruiting | 18 Years | 65 Years | Both | 56 | Phase 1 | United States;Poland;Spain;Ukraine;Czech Republic;United Kingdom | |
702 | NCT01627938 | April 2012 | 19 February 2015 | Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination | A Phase II Proof of Concept Study Evaluating the Reduction of Mitoxantrone-induced Cardiotoxicity and Neurological Outcome in the Combined Use of Mitoxantrone and Dexrazoxane (Cardioxane®) in Multiple Sclerosis (MSCardioPro) | Multiple Sclerosis | Drug: Dexrazoxane (DRZ) plus Mitoxantrone (MX);Drug: Placebo plus Mitoxantrone (MX) | PD Dr. Andrew Chan | Not recruiting | 18 Years | 55 Years | Both | 50 | Phase 2 | Germany | |
703 | EUCTR2011-002561-38-IE | 30/03/2012 | 18 April 2012 | Trial on the effectiveness of Fampridine medication for upper limb function in people with MS. | A double blind, randomized, placebo controlled, crossover study of the effectiveness of oral fampridine in improving upper limb function in progressive multiple sclerosis. | Multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Fampyra Product Name: Fampyra Product Code: SUB0750MIG Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use | St. Vincent's University Hospital | Authorised | Female: yes Male: yes | Ireland | |||||
704 | NCT01404117 | March 2012 | 19 February 2015 | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability | Relapsing Multiple Sclerosis | Drug: Laquinimod 0.6;Drug: Laquinimod 1.2;Other: Glatiramer Acetate or interferon-beta+ Placebo | Teva Pharmaceutical Industries | Not recruiting | 18 Years | 55 Years | Both | 0 | Phase 2 | |||
705 | NCT01436838 | March 2012 | 12 September 2016 | China Betaferon Adherence, Coping and Nurse Support Study | Prospective Study of Betaferon in Adherence, Coping and Nurse Support in Patients of Chinese Origin With Multiple Sclerosis | Multiple Sclerosis, Chronic Progressive | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 18 Years | 75 Years | Both | 110 | N/A | China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
706 | NCT01490502 | March 2012 | 15 July 2019 | Vitamin D Supplementation in Multiple Sclerosis | A Randomized Controlled Trial of Vitamin D Supplementation in Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: Vitamin D3 | Johns Hopkins University | Oregon Health and Science University;University of California, San Francisco;Washington University School of Medicine;Icahn School of Medicine at Mount Sinai;University of Pennsylvania;Yale University;The Cleveland Clinic;University of Rochester;Stanford University;University of Virginia;Swedish Medical Center;Anne Arundel Health System Research Institute;Columbia University;University of Massachusetts, Worcester;Dignity Health | Not recruiting | 18 Years | 50 Years | All | 172 | Phase 3 | United States |
707 | NCT01576354 | March 2012 | 14 December 2015 | Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis | A Phase IIb, Double-blind, Randomized, Mono-center, Placebo-controlled Study With Crossover Design Characterizing the Effects of Prolonged-release Fampridine Treatment on Ambulatory Function in Patients With Multiple Sclerosis Using Detailed Gait Analysis Based on Kinematic and Kinetic Parameters | Multiple Sclerosis | Drug: Prolonged-release Fampridine;Drug: Placebo | University of Zurich | Not recruiting | 18 Years | 65 Years | Both | 70 | Phase 2 | Switzerland | |
708 | NCT01591551 | March 2012 | 19 February 2015 | NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness | NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Relapsing Forms of Multiple Sclerosis Experiencing Fatigue or Sleepiness | Multiple Sclerosis, Relapsing-Remitting | Drug: Natalizumab (Tysabri) | Cornerstone Health Care, PA | Biogen Idec | Not recruiting | 18 Years | 65 Years | Both | 37 | Phase 4 | United States |
709 | EUCTR2011-006043-30-NL | 27/02/2012 | 25 September 2012 | Study to evaluate the effect of oral BAF312 on a monophasic oral contraceptive in healthy female volunteers | An open-label, multiple-dose, two-treatment period study to evaluate the effect of oral BAF312 on the pharmacokinetices and pharmacodynamics of a monophasic oral contraceptive in healthy female volunteers - | healthy volunteers (Multiple sclerosis is the intended indication for BAF312) ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: BAF312 0,25 mg tablet Product Code: BAF312 Pharmaceutical Form: Film-coated tablet CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Product Name: BAF312 1 mg tablet Product Code: BAF312 Pharmaceutical Form: Film-coated tablet CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Product Name: BAF312 4 mg tablet Product Code: BAF312 Pharmaceutical Form: Film-coated tablet CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Trade Name: Microgynon Product Name: Microgynon Pharmaceutical Form: Film-coated tablet INN or Proposed INN: ETHINYLESTRADIOL CAS Number: 57-63-6 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30- CAS Number: 797-63-7 Other descriptive name: LEVONORGESTREL Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.15- | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: no | 24 | Netherlands | ||||
710 | EUCTR2010-023210-31-DE | 24/02/2012 | 30 June 2014 | The aim of the study is to assess the efficacy and safety of intra - detrusor injections of Dysport versus placebo in subjects suffering from neurogenic detrusor overactivity following spinal cord injury or multiple sclerosis. | A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNITS OF DYSPORT IN SUBJECTS SUFFERING FROM NEUROGENIC DETRUSOR OVERACTIVITY FOLLOWING SPINAL CORD INJURY OR MULTIPLE SCLEROSIS | NEUROGENIC DETRUSOR OVERACTIVITY MedDRA version: 15.1 Level: LLT Classification code 10012547 Term: Detrusor hyperreflexia System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Dysport Product Name: Dysport Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: CLOSTRIDIUM BOTULINUM TOXIN TYPE A CAS Number: 93384-43-1 Other descriptive name: BOTULINUM TOXIN TYPE A Concentration unit: U unit(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Intramuscular use | Ipsen Innovation | Not Recruiting | Female: yes Male: yes | 42 | Phase 2A | Czech Republic;Lithuania;Austria;Germany;Italy | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
711 | EUCTR2011-006151-10-DK | 15/02/2012 | 14 April 2014 | FAME - a study of the effect of Fampyra on muscle strength in the lower extremities, walking capacity, coordination in the upper extremitties and cognition in multiple sclerosis patients. | FAME - Fampyra outcome measures study: a study of responsiveness of different outcome measures to Fampyra treatment. - FAME | Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Fampyra Product Name: Fampyra Pharmaceutical Form: Tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Sønderjylland Hospital, department of neurology | Not Recruiting | Female: yes Male: yes | Denmark | |||||
712 | NCT01485003 | February 7, 2012 | 25 February 2019 | Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants | A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients | Relapsing-Remitting Multiple Sclerosis | Biological: natalizumab | Biogen | Not recruiting | 18 Years | 65 Years | All | 231 | Phase 2 | United States | |
713 | NCT01433250 | February 2012 | 19 October 2017 | A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis | An Open Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis | Drug: AIN457 | Novartis Pharmaceuticals | Not recruiting | 18 Years | 55 Years | All | 39 | Phase 2 | Czech Republic;Russian Federation;Ukraine | |
714 | NCT01480076 | February 2012 | 16 December 2017 | Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis | An Open-Label, Multicenter, Multinational Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Quality of Life as Reported by Subjects With Multiple Sclerosis | Multiple Sclerosis | Drug: Fampridine | Biogen | Not recruiting | 18 Years | 75 Years | All | 901 | Phase 4 | Italy;Netherlands;Portugal;United Kingdom;Australia;Belgium;Denmark;France;Germany;United States | |
715 | NCT01497262 | February 2012 | 19 October 2017 | Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis | A 4-month, Open-label, Multi-center Study to Explore the Safety and Tolerability of Fingolimod 0.5 mg in Patients With Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Fingolimod | Novartis Pharmaceuticals | Not recruiting | 18 Years | 65 Years | All | 162 | Phase 3 | Argentina;Brazil;Colombia;Jordan;Malaysia;Mexico;Panama;Peru;Costa Rica | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
716 | NCT01516554 | February 2012 | 19 February 2015 | Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients | A Randomized, Controlled Crossover Trial Evaluating Oral Testosterone in the Treatment of Fatigue in Male Multiple Sclerosis Patients | Multiple Sclerosis;Fatigue | Drug: Testosterone undecanoate;Drug: placebo | Health Sciences Centre, Winnipeg, Manitoba | University of Manitoba;Consortium of Multiple Sclerosis Centers;Manitoba Medical Service Foundation | Not recruiting | 18 Years | 65 Years | Male | 3 | Phase 2 | Canada |
717 | NCT01569451 | February 2012 | 18 June 2018 | Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate | A Double Blinded, Randomized Study Comparing Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy in Patients With Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis | Drug: Rituximab;Drug: Glatiramer Acetate;Other: Placebo | University of Colorado, Denver | Rocky Mountain MS Research Group, LLC | Not recruiting | 18 Years | 55 Years | All | 53 | Phase 2 | United States |
718 | NCT02305264 | February 2012 | 16 December 2017 | Imaging of Intracerebral Inflammation in MS | Imaging of Intracerebral Inflammation in the Progressive Phase of Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis, Primary Progressive | Drug: 18F-DPA-714 and 18F-FDG | Assistance Publique - Hôpitaux de Paris | Recruiting | 18 Years | 65 Years | All | 65 | N/A | France | |
719 | EUCTR2011-002683-24-ES | 30/01/2012 | 26 June 2012 | A clinical trial to test if NU100 is safe and can treat patient with relapsing types of multiple sclerosis | A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis | Relapsing forms of multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: NU100 Pharmaceutical Form: Solution for injection in pre-filled syringe Current Sponsor code: NU100 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Trade Name: Betaferon Product Name: Betaferon Pharmaceutical Form: Powder and solvent for solution for injection CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- | Nuron Biotech, Inc. | Authorised | Female: yes Male: yes | 500 | Phase 3 | Hungary;Russian Federation;Ukraine;Belarus;Georgia;Bulgaria;Spain;Italy;Croatia;Poland | |||
720 | EUCTR2011-003775-11-BE | 12/01/2012 | 7 October 2013 | Fluoxetine therapy for multiple sclerosis | Fluoxetine therapy for multiple sclerosis - FLUOX-PMS | progressive multiple sclerosis MedDRA version: 16.0 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 16.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 16.0 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Fluoxetine Product Name: Fluoxetine Product Code: fluoxetine Pharmaceutical Form: Capsule INN or Proposed INN: Fluoxetine CAS Number: 59333-67-4 Other descriptive name: N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20-40 Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Authorised | Female: yes Male: yes | 120 | Belgium | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
721 | EUCTR2011-003507-38-GB | 06/01/2012 | 28 January 2013 | Long-Term Prolonged-Release Fampridine Treatment and Quality of Life | An Open-Label, Multicenter, Multinational Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Quality of Life as Reported by Subjects with Multiple Sclerosis | Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Fampyra Product Name: Fampridine Product Code: BIIB041 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Current Sponsor code: BIIB041 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- | Biogen Idec Research Limited | Authorised | Female: yes Male: yes | 800 | Sweden;United Kingdom;Italy;Germany;Netherlands;Australia;Denmark;Ireland;Belgium;Portugal;France | ||||
722 | NCT01500408 | January 2012 | 19 February 2015 | Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers | A Randomized, Single-Blind, Crossover Study in Healthy Volunteers to Demonstrate the Bioequivalence of Interferon Beta-1a Manufactured by Two Different Processes | Multiple Sclerosis | Drug: Interferon beta-1a (current approved manufacturing process invloving FBS);Drug: Interferon beta-1a (new process, manufactured without FBS) | Biogen Idec | Not recruiting | 18 Years | 45 Years | Both | 110 | Phase 1 | United States | |
723 | NCT01517282 | January 2012 | 19 October 2017 | Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis | A Randomized, Double-blind, Placebo-controlled Phase Ib Study to Evaluate the Safety and Pharmacokinetics of MOR103, a Human Antibody to GM-CSF, in Patients With Multiple Sclerosis | Multiple Sclerosis | Biological: MOR103;Other: Placebo | MorphoSys AG | Not recruiting | 18 Years | 60 Years | All | 32 | Phase 1/Phase 2 | Germany;Poland;United Kingdom | |
724 | NCT01534182 | January 2012 | 19 October 2017 | Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) | A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of (Fingolimod) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for Multiple Sclerosis (MS) Therapy Change From Previous Disease Modifying Therapy (DMT) | Relapsing Remitting Multiple Sclerosis | Drug: Fingolimod;Drug: Interferon beta - 1a (IFN);Drug: Glatiramer acetate (GA) | Novartis Pharmaceuticals | Not recruiting | 18 Years | 65 Years | All | 298 | Phase 4 | Russian Federation | |
725 | NCT01535664 | January 2012 | 19 October 2017 | An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS) | An Open-label, Proof of Concept Study to Evaluate Multiple Gait and Balance Parameters After Withdrawal of Dalfampridine-ER 10mg in Subjects With MS | Multiple Sclerosis | Other: Withdrawal of dalfampridine-ER 10mg | Acorda Therapeutics | Prometrika, LLC;BCS Consulting, Inc. | Not recruiting | 18 Years | 70 Years | All | 20 | Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
726 | NCT01601119 | January 2012 | 8 June 2015 | Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients | The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients | Relapsing Multiple Sclerosis | Drug: Rebif;Other: Other: Disease modifying therapies (DMT) | Merck KGaA | Merck Serono Limited, UK | Not recruiting | 18 Years | N/A | Both | 545 | N/A | United Kingdom |
727 | NCT01964547 | January 2012 | 19 October 2017 | A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients | A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study of the Effect of Long-term Treatment With Sativex on Cognitive Function and Mood of Patients With Spasticity Due to Multiple Sclerosis | Multiple Sclerosis;Spasticity | Drug: Sativex;Drug: Placebo | GW Pharmaceuticals Ltd. | Not recruiting | 18 Years | N/A | All | 121 | Phase 4 | Czech Republic | |
728 | NCT02280876 | January 2012 | 4 July 2016 | Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS) | Randomized, Comparative, Double Blind Controlled Phase II Clinical Trial, to Evaluate the Efficacy of ApE in Patients With Multiple Sclerosis (MS). | Multiple Sclerosis, Relapsing-Remitting | Drug: 1 - Andrographis paniculata p/st extract;Drug: 2 - Excipients | Universidad Austral de Chile | Comisión Nacional de Investigación Científica y Tecnológica;University of Chile | Not recruiting | 18 Years | 55 Years | Both | 30 | Phase 1/Phase 2 | Chile |
729 | NCT01498887 | December 21, 2011 | 16 December 2017 | Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy | A Multi-centre, Open-label, Non-randomised, Parallel Group Clinical Trial to Assess the Efficacy of Fingolimod in Naive Patients Versus Fingolimod in Patients Previously Treated With Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients With Relapsing-remitting Multiple Sclerosis. | Relapsing Remitting Multiple Sclerosis | Drug: Fingolimod (FTY720) | Novartis Pharmaceuticals | Not recruiting | 18 Years | 50 Years | All | 349 | Phase 4 | Australia;Spain | |
730 | NCT02967380 | December 14, 2011 | 16 December 2017 | Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases | Dynamic Contrast Enhanced Steady State T1-Weighted Perfusion MRI (DCE MRI): Characterization of Intracranial Lesions | Adult Anaplastic (Malignant) Meningioma;Adult Anaplastic Astrocytoma;Adult Anaplastic Ependymoma;Adult Anaplastic Oligodendroglioma;Adult Brain Stem Glioma;Adult Choroid Plexus Neoplasm;Adult Diffuse Astrocytoma;Adult Ependymoblastoma;Adult Ependymoma;Adult Giant Cell Glioblastoma;Adult Glioblastoma;Adult Gliosarcoma;Adult Grade II Meningioma;Adult Medulloblastoma;Adult Mixed Glioma;Adult Oligodendroglioma;Adult Papillary Meningioma;Adult Pineal Gland Astrocytoma;Adult Pineoblastoma;Adult Primary Melanocytic Lesion of Meninges;Adult Supratentorial Primitive Neuroectodermal Tumor;Malignant Adult Intracranial Hemangiopericytoma;Metastatic Malignant Neoplasm in the Brain;Multiple Sclerosis;Recurrent Adult Brain Neoplasm | Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging;Drug: Gadobenate Dimeglumine;Drug: Gadobutrol;Radiation: Gadopentetate Dimeglumine | University of Southern California | National Cancer Institute (NCI) | Not recruiting | 18 Years | N/A | All | 14 | N/A | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
731 | EUCTR2011-003570-89-NL | 02/12/2011 | 19 March 2012 | The effect of interferon beta-1a treatment on adaptability of the brain in patients with MS | The effect of interferon beta-1a treatment on functional adaptation in Multiple Sclerosis (MS) - interferon beta-1a and functional adaptation | Multiple sclerosis MedDRA version: 14.0 Level: PT Classification code 10004504 Term: Beta interferon therapy System Organ Class: 10042613 - Surgical and medical procedures ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Rebif Pharmaceutical Form: Concentrate and solvent for solution for injection INN or Proposed INN: interferon beta-1a Concentration unit: IU international unit(s) Concentration type: range Concentration number: 2400000-12000000 | VU University Medical Center | Authorised | Female: yes Male: yes | Netherlands | |||||
732 | NCT01377870 | December 2011 | 11 June 2018 | Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis | Effect and Side Effect of Mesenchymal Stem Cell in Multiple Sclerosis | Multiple Sclerosis | Biological: intravenous injection of mesenchymal stem cells;Biological: injection of cell free media | Royan Institute | Not recruiting | 18 Years | 55 Years | All | 22 | Phase 1/Phase 2 | Iran, Islamic Republic of | |
733 | NCT01440062 | December 2011 | 10 December 2018 | Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS) | Phase II Study of Efficacy of Vitamin D Supplementation in Multiple Sclerosis | Multiple Sclerosis | Drug: Verum arm receiving Vitamin D oil;Drug: low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day | Charite University, Berlin, Germany | NeuroCure Clinical Research Center, Charite, Berlin | Not recruiting | 18 Years | 65 Years | All | 55 | Phase 2 | Germany |
734 | NCT01470521 | December 2011 | 8 February 2016 | Worms for Immune Regulation of Multiple Sclerosis | Worms for Immune Regulation of Multiple Sclerosis (WIRMS) | Multiple Sclerosis, Relapsing-Remitting | Biological: Hookworm larvae;Biological: Placebo | University of Nottingham | National Multiple Sclerosis Society | Not recruiting | 18 Years | 65 Years | Both | 72 | Phase 2 | United Kingdom |
735 | NCT02006160 | December 2011 | 13 May 2019 | Effects of Dalfampridine on Cognition in Multiple Sclerosis | Effects of Dalfampridine on Cognition in Multiple Sclerosis | Multiple Sclerosis | Drug: dalfampridine;Drug: placebo | State University of New York at Buffalo | Not recruiting | 18 Years | 60 Years | All | 61 | Phase 2/Phase 3 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
736 | NCT01943526 | November 30, 2011 | 11 June 2018 | Ireland Natalizumab (TYSABRI) Observational Program | Ireland Natalizumab (TYSABRI®) Observational Program (iTOP) | Relapsing-Remitting Multiple Sclerosis | Biological: natalizumab | Biogen | Not recruiting | N/A | N/A | All | 191 | Phase 1 | Ireland | |
737 | EUCTR2011-002333-19-DE | 29/11/2011 | 21 September 2015 | Subcutaneous Ofatumumab in Relapsing Remitting Multiple Sclerosis. | A Randomized, Double-blind, Placebo controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months’ administration of Ofatumumab in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) - Ofatumumab sub-cutaneous in RRMS | Relapsing-Remitting Multiple Sclerosis (RRMS) MedDRA version: 15.0 Level: LLT Classification code 10070716 Term: Multiple sclerosis pseudo relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Ofatumumab Product Code: GSK1841157 Pharmaceutical Form: Concentrate for solution for injection INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Current Sponsor code: GSK1841157 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | GlaxoSmithKline Research and Development Limited | Not Recruiting | Female: yes Male: yes | 196 | United States;Czech Republic;Canada;Spain;Denmark;Bulgaria;Russian Federation;Netherlands;Norway;Germany;Italy | ||||
738 | EUCTR2011-002969-38-DE | 08/11/2011 | 24 July 2012 | A 6-month, multicenter, randomized, controlled parallel group study to evaluate the effect of physical training on fatigue in patients with relapsing-remitting multiple sclerosis treated with fingolimod (Gilenya®), followed by a 6 month optional extension phase | A 6-month, multicenter, randomized, controlled parallel group study to evaluate the effect of physical training on fatigue in patients with relapsing-remitting multiple sclerosis treated with fingolimod (Gilenya®), followed by a 6 month optional extension phase - | Fatigue in Patients with relapsing remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720 Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: Fingolimod Hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- | Novartis Pharma GmbH | Authorised | Female: yes Male: yes | Germany | |||||
739 | EUCTR2009-015319-41-DE | 03/11/2011 | 17 May 2016 | Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS) | Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS) - TRIOMS | remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | Product Name: TSO Product Code: TSO Pharmaceutical Form: Oral suspension INN or Proposed INN: Trichuris suis ova (eggs), embryonated, viable Concentration unit: Other Concentration type: equal Concentration number: 2500- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use | Charite Universitätsmedizin Berlin | Not Recruiting | Female: yes Male: yes | Phase 2 | Germany | ||||
740 | NCT01457924 | November 1, 2011 | 11 June 2018 | Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis | A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis | Drug: Ofatumumab 3mg;Drug: Ofatumumab 30mg;Drug: Ofatumumab 60mg;Drug: Placebo | GlaxoSmithKline | Not recruiting | 18 Years | 55 Years | All | 232 | Phase 2 | United States;Bulgaria;Canada;Czechia;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;Czech Republic | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
741 | NCT01451593 | November 2011 | 21 September 2015 | Neuroprotection With Phenytoin in Optic Neuritis | A Phase II Double Blind, Randomized, Placebo Controlled Trial of Neuroprotection With Phenytoin in Acute Optic Neuritis | Optic Neuritis;Multiple Sclerosis | Drug: Phenytoin;Drug: Placebo | University College, London | National Multiple Sclerosis Society;Multiple Sclerosis Society of Great Britain and Northern Ireland | Not recruiting | 18 Years | 60 Years | Both | 92 | Phase 2 | United Kingdom |
742 | NCT01462318 | November 2011 | 16 December 2017 | An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis | A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics of BIIB019, Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Drug: Midazolam;Other: Caffeine;Drug: S-warfarin;Other: Vitamin K;Drug: Omeprazole;Drug: Dextromethorphan;Biological: BIIB019 (Daclizumab) | Biogen | Not recruiting | 18 Years | 65 Years | All | 133 | Phase 3 | United States;Czech Republic;Hungary;Poland;Russian Federation | |
743 | EUCTR2010-020337-99-GB | 20/10/2011 | 22 October 2018 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis | A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis - OPERA I | Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: range Concentration number: 8.8-22 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: ocrelizumab 300mg/10ml Product Code: RO4964913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for injection Route of administration of the placebo: Intravenous use Trade Name: Ocrevus Product Name: ocrelizumab 300mg/10ml Product Code: RO4964913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- | F.Hoffmann-La Roche | Authorised | Female: yes Male: yes | 800 | Phase 3 | Portugal;United States;Serbia;Estonia;Morocco;Slovakia;Spain;Ukraine;Israel;Chile;Russian Federation;Italy;Switzerland;Australia;Peru;South Africa;Netherlands;Tunisia;Latvia;Finland;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Argentina;Poland;Brazil;Belgium;Bulgaria;Germany;New Zealand | |||
744 | EUCTR2010-020315-36-SK | 18/10/2011 | 19 November 2018 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis | A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis - OPERA II | Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: range Concentration number: 8.8-22 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: ocrelizumab 300mg Product Code: RO4964913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for injection Route of administration of the placebo: Intravenous use Trade Name: Ocrevus Product Name: ocrelizumab 300mg Product Code: RO4964913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- | F.Hoffmann-La Roche | Authorised | Female: yes Male: yes | 800 | Phase 3 | United States;Belarus;Slovakia;Spain;Ukraine;Ireland;Turkey;Russian Federation;Colombia;Italy;United Kingdom;France;Czech Republic;Mexico;Canada;Argentina;Belgium;Brazil;Croatia;Peru;Bulgaria;Germany;Sweden;Bosnia and Herzegovina | |||
745 | NCT01285479 | October 15, 2011 | 21 January 2019 | Pregnancy Registry Trial | The Multi-National Pregnancy Fingolimod Exposure Registry in Multiple Sclerosis (Epidemiological Study Protocol FTY720D2404) | Multiple Sclerosis | Drug: Fingolimod | Novartis Pharmaceuticals | Recruiting | N/A | N/A | Female | 500 | Phase 2 | United States;Argentina;Australia;Austria;Belgium;Canada;Cyprus;Czechia;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Spain;Sweden;Switzerland;United Arab Emirates;United Kingdom;Czech Republic | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
746 | NCT01453868 | October 2011 | 19 February 2015 | The Effects of Aerobics Training on Balance in Patients With Multiple Sclerosis | The Effects of Neuromuscular Training on Balance in Patients With Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Other: Non Impact Aerobics;Other: Passive : lecture series | Nelson Mandela Metropolitan University | Recruiting | 20 Years | 60 Years | Both | 60 | Phase 0 | United States | |
747 | NCT01464905 | October 2011 | 19 February 2015 | Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) | A Phase 3, Multicenter, Double-blind,Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of NU100 in Patients With Relapsing Forms of Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Biological: NU100;Biological: Placebo;Biological: rhIFN beta-1b | Nuron Biotech Inc. | Not recruiting | 18 Years | 60 Years | Both | 500 | Phase 3 | Belarus;Bulgaria;Croatia;Georgia;Hungary;Italy;Lebanon;Poland;Russian Federation;Serbia;Spain;Ukraine;India | |
748 | NCT01466114 | October 2011 | 11 November 2019 | Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition | A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition. | Relapsing-remitting Multiple Sclerosis;Secondary-progressive Multiple Sclerosis;Primary-progressive Multiple Sclerosis | Drug: estriol;Other: Placebo;Drug: Norethindrone;Other: Progestin Placebo | University of California, Los Angeles | Recruiting | 18 Years | 55 Years | Female | 64 | Phase 2 | United States | |
749 | EUCTR2011-000888-27-CZ | 21/09/2011 | 24 August 2015 | A clinical trial comparing the efficacy, and safety and tolerability of two disease modifying MS drugs (GTR and Copaxone®) in patients with relapsing remitting multiple sclerosis for 9 months followed by a 15 month GTR treatment part to evaluate efficacy and safety of long-term GTR treatment. | Multi-centre, randomized, double-blind, placebo-controlled, parallel-group, 9 month, equivalence trial comparing the efficacy and safety and tolerability of GTR (Synthon BV) to Copaxone® (Teva) in subjects with relapsing remitting multiple sclerosis followed by an open-label 15 month GTR treatment part evaluating the long-term GTR treatment effects - GATE | Relapsing remitting multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: glatiramer acetate Product Code: GTR Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Current Sponsor code: GTR Other descriptive name: GTR.ace Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Trade Name: Copaxone Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Copaxone Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- | Synthon BV | Not Recruiting | Female: yes Male: yes | 750 | Serbia;United States;Belarus;Estonia;Slovakia;Greece;Spain;Ukraine;Lithuania;Russian Federation;Italy;United Kingdom;Czech Republic;Poland;Romania;Croatia;Bulgaria;Germany | ||||
750 | NCT01412333 | September 20, 2011 | 7 October 2019 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis | A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | Drug: Interferon beta-1a;Drug: Ocrelizumab-matching placebo;Drug: Ocrelizumab;Drug: Interferon beta-1a-matching placebo | Hoffmann-La Roche | Not recruiting | 18 Years | 55 Years | All | 835 | Phase 3 | United States;Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czechia;France;Germany;Ireland;Italy;Mexico;Norway;Poland;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;Czech Republic;Morocco | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
751 | EUCTR2011-002785-20-DE | 19/09/2011 | 28 August 2017 | Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis | Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis - EVIDIMS | Multiple Sclerosis and Clinical isolated Syndrome;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Vigantol® Öl 20.000 I.E./ml Product Name: Vigantol® Öl 20.000 I.E./ml Product Code: Vigantol® Öl 20.000 I.E./ml Pharmaceutical Form: Oral liquid INN or Proposed INN: COLECALCIFEROL CAS Number: 67-97-0 Current Sponsor code: 25OH-Vitamin D Concentration unit: IU/ml international unit(s)/millilitre Concentration type: equal Concentration number: 20.000 - Pharmaceutical form of the placebo: Oral liquid Route of administration of the placebo: Oral use Trade Name: Dekristol®-Tablette 1 (400 IE) Product Name: Dekristol® 400-Tabletten Product Code: Dekristol® 400-Tabletten Pharmaceutical Form: Tablet INN or Proposed INN: COLECALCIFEROL CAS Number: 67-97-0 Other descriptive name: 25OH-Vitamin D Concentration unit: IU/ml international unit(s)/millilitre Concentration type: equal Concentration number: 400- | Charité - Universitätsmedizin Berlin | Not Recruiting | Female: yes Male: yes | Phase 2 | Germany | ||||
752 | EUCTR2010-021219-17-ES | 12/09/2011 | 28 February 2019 | Evaluación de masitinib en esclerosis múltiple | Estudio prospectivo Fase III, multicéntrico, randomizado, doble ciego, de dos grupos paralelos, controlado con placebo y de 96 semanas de duración, para comparar la eficacia y seguridad de masitinib a la dosis de 6 mg/kg/día con placebo en el tratamiento de pacientes con esclerosis múltiple primaria progresiva o esclerosis múltiple secundaria progresiva sin recidiva | Pacientes con esclerosis múltiple primaria progresiva o secundaria progresiva sin recidiva MedDRA version: 14.0 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: masitinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: masitinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | AB Science | Not Recruiting | Female: yes Male: yes | 450 | Phase 3 | France;United States;Czech Republic;Slovakia;Greece;Poland;Spain;Romania;Bulgaria;Germany | |||
753 | NCT01435993 | September 8, 2011 | 16 December 2017 | Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis | A Randomized, Single Blind, Placebo-controlled, Single Ascending Dose/Repeat Dose Cohort Study to Assess Safety, Tolerability, Pharmacokinetics and Immunogenicity of GSK1223249 in Patients With Relapsing Forms of Multiple Sclerosis. | Multiple Sclerosis, Relapsing-Remitting | Drug: GSK1223249;Other: Saline placebo | GlaxoSmithKline | Not recruiting | 18 Years | 60 Years | All | 3 | Phase 1 | Germany;Italy;Norway | |
754 | NCT01324232 | September 2011 | 9 July 2018 | Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis | A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients With Multiple Sclerosis | Central Neuropathic Pain;Multiple Sclerosis | Drug: AVP-923;Drug: Placebo | Avanir Pharmaceuticals | Not recruiting | 18 Years | 85 Years | All | 200 | Phase 2 | United States;Argentina;Czechia;Poland;Spain;Czech Republic;Germany;United Kingdom | |
755 | NCT01360489 | September 2011 | 19 February 2015 | Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS) | An Open Label, 26-Week Study Assessing Arbaclofen Placarbil Safety and Efficacy in Subjects With Spasticity Associated With Multiple Sclerosis With an Addendum Open-Label, 36-Week Study Assessing Arbaclofen Placarbil Safety in Subjects With Spasticity Associated With Multiple Sclerosis | Multiple Sclerosis | Drug: arbaclofen placarbil | XenoPort, Inc. | Not recruiting | 18 Years | 70 Years | Both | 218 | Phase 3 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
756 | NCT01444300 | September 2011 | 19 October 2017 | Dalfampridine for Imbalance in Multiple Sclerosis | Dalfampridine to Improve Imbalance in Multiple Sclerosis: A Pilot Study | Multiple Sclerosis;Fatigue | Drug: Dalfampridine;Drug: Placebo | Oregon Health and Science University | Acorda Therapeutics | Not recruiting | 20 Years | 59 Years | All | 24 | Phase 2 | United States |
757 | NCT01450124 | September 2011 | 30 March 2015 | Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA) | Safety, Tolerability And Mechanism Of Action Of Boswellic Acids In Multiple Sclerosis and Clinically Isolated Syndrome: A MRI-Controlled, Multicenter, Baseline-To-Treatment, 32-Weeks, Open-Label, Phase IIa Trial | Relapsing Remitting Multiple Sclerosis | Drug: Boswellic acids (BOSWELAN) | Universitätsklinikum Hamburg-Eppendorf | Not recruiting | 18 Years | 65 Years | Both | 29 | Phase 2 | Germany | |
758 | EUCTR2011-001442-15-DE | 26/08/2011 | 27 January 2014 | A study to evaluate disease control and safety in patients with RRMS switching from natalizumab to fingolimod | A 32-week, patient- and rater-blinded, randomized, multi-center, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from previous treatment with natalizumab to fingolimod (FTY720) | relapsing remitting multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya Product Name: Gilenya Product Code: FTY720 Pharmaceutical Form: Capsule, hard INN or Proposed INN: fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 142 | Greece;Finland;Spain;Austria;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Australia;Denmark;Germany;Norway;Sweden | ||||
759 | NCT01442194 | August 1, 2011 | 26 August 2019 | Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies | Long-term, Prospective,Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy | Multiple Sclerosis | Drug: other disease-modifying therapy;Drug: Fingolimod | Novartis Pharmaceuticals | Recruiting | N/A | N/A | All | 3620 | N/A | United States;Argentina;Australia;Canada;Chile;Mexico;Puerto Rico | |
760 | NCT01411514 | August 2011 | 28 December 2015 | Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis | Phase IV Study of Oral Prednisone Taper vs. Placebo Following Intravenous Steroids for the Treatment of Acute Relapses in Multiple Sclerosis Within the Ticino Cohort | Multiple Sclerosis | Drug: Prednisone;Drug: Placebo | Claudio Gobbi | Ente Ospedaliero Cantonale, Ticino, Switzerland | Not recruiting | 18 Years | 80 Years | Both | 27 | Phase 4 | Switzerland |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
761 | NCT01420055 | August 2011 | 28 November 2016 | Fingolimod -Response According to Coping - Evaluation | A 4-month, Prospective, Open-label, Multi-center Phase IV Study to Assess Response to Fingolimod Initiation According to Coping Profile in Adult Patients With Highly Active Relapsing Remitting Multiple Sclerosis in France | Multiple Sclerosis, Relapsing-Remitting | Drug: fingolimod | Novartis Pharmaceuticals | Not recruiting | 18 Years | 65 Years | Both | 189 | Phase 4 | France | |
762 | NCT01433497 | August 2011 | 13 May 2019 | Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis | A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis, Primary Progressive;Multiple Sclerosis, Relapse Free | Drug: Masitinib;Drug: Placebo | AB Science | Not recruiting | 18 Years | 75 Years | All | 656 | Phase 3 | Bulgaria;France;Germany;Greece;Poland;Romania;Spain;United States | |
763 | EUCTR2011-001160-21-DE | 18/07/2011 | 4 February 2013 | Study to investigate the immune response to influenza vaccine in patients with multiple sclerosis on teriflunomide | Study to investigate the immune response to influenza vaccine in patients with multiple sclerosis on teriflunomide treatment and using a population of patients with multiple sclerosis as a reference - TERIVA | Multiple sclerosis MedDRA version: 14.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Teriflunomide Product Code: HMR1726D Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Product Name: Teriflunomide Product Code: HMR1726D Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Trade Name: Mutagrip Product Name: Mutagrip Pharmaceutical Form: Injection | sanofi-aventis recherche & developpement | Not Recruiting | Female: yes Male: yes | 120 | Canada;Ukraine;Austria;Russian Federation;Germany | ||||
764 | EUCTR2008-005008-24-GB | 07/07/2011 | 19 March 2012 | Worms for immune regulation of multiple sclerosis - MS and hookworm | Worms for immune regulation of multiple sclerosis - MS and hookworm | Relapsing Multiple Sclerosis MedDRA version: 13.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 13.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders | Product Name: Necator americanus Pharmaceutical Form: Spot-on solution Other descriptive name: Live Necator americanus larvae Concentration unit: U unit(s) Concentration type: equal Concentration number: 25 - Pharmaceutical form of the placebo: Spot-on solution Route of administration of the placebo: Topical use (Noncurrent) | University of Nottingham | Authorised | Female: yes Male: yes | 72 | United Kingdom | ||||
765 | JPRN-UMIN000005889 | 2011/07/01 | 2 April 2019 | The safety and efficacy of tocilizumab in patients with neuromyelitis optica | neuromyelitis optica | Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 6 months. | Department of Immunology, National Institute of Neuroscience, NCNP | Not Recruiting | 20years-old | 65years-old | Male and Female | 3 | Not applicable | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
766 | NCT01103583 | July 2011 | 19 February 2015 | Hydroxyurea in Primary Progressive Multiple Sclerosis | Multiple Sclerosis | Drug: Hydroxyurea;Other: placebo | S. Andrea Hospital | Not recruiting | 18 Years | 60 Years | Both | 33 | Phase 2/Phase 3 | Italy | ||
767 | NCT01417312 | July 2011 | 10 December 2018 | Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients | Multiple Sclerosis, Relapsing-Remitting | Dietary Supplement: Capsules with 160 mg Teavigo (at least 94% EGCG);Dietary Supplement: Placebo | Charite University, Berlin, Germany | Not recruiting | 20 Years | 60 Years | All | 20 | N/A | Germany | ||
768 | NCT01451723 | July 2011 | 19 October 2017 | Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II | Phase 2 Randomized Placebo Controlled Trial of Polyphenon E in MS | Multiple Sclerosis | Drug: Polyphenon E;Other: Placebo | Louisiana State University Health Sciences Center in New Orleans | National Center for Complementary and Integrative Health (NCCIH) | Not recruiting | 18 Years | 60 Years | All | 11 | Phase 2 | United States |
769 | NCT01699555 | July 2011 | 19 February 2015 | First-in-Human Study With GNbAC1 in Healthy Volunteers | Randomized Placebo-Controlled First-in-Human Study With GNbAC1 | Multiple Sclerosis | Biological: GNbAC1;Biological: GNbAC1 placebo | GeNeuro Innovation SAS | Not recruiting | 18 Years | 55 Years | Male | 33 | Phase 1 | ||
770 | EUCTR2011-000926-31-CZ | 29/06/2011 | 17 June 2013 | A long term, 50 week, Phase IV multi-centre study to determine if Sativex has an effect on cognition (thinking ability) when prescribed to patients with spasticity due to MS | A Multicentre, Double-blind, Randomised Parallel Group, Placebo- controlled Study of the Effect of long-term treatment with Sativex on Cognitive Function and Mood of Patients with Spasticity due to Multiple Sclerosis | Spasticity in multiple sclerosis (MS). MedDRA version: 14.1 Level: LLT Classification code 10041416 Term: Spasticity System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Sativex Oromucosal Spray Pharmaceutical Form: Oromucosal spray INN or Proposed INN: N/A CAS Number: 1972-08-3 Other descriptive name: delta-9-tetrahydrocannabinol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 27- INN or Proposed INN: N/A CAS Number: 13956-29-1 Other descriptive name: cannabidiol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Oromucosal spray Route of administration of the placebo: Oromucosal use | GW Pharma Ltd. | Not Recruiting | Female: yes Male: yes | 120 | Phase 4 | Czech Republic | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
771 | EUCTR2010-024000-10-BE | 28/06/2011 | 17 August 2015 | A Study to Evaluate the Effect of Different Doses of TYSABRI on Safety and Efficacy in Relapsing Multiple Sclerosis | A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis - REFINE | Relapsing-Remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: TYSABRI Product Name: Natalizumab for IV Infusion Product Code: AN100226; BG00002 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Current Sponsor code: AN100226; BG00002 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: Natalizumab for Subcutaneous Injection Product Code: AN100226; BG00002 Pharmaceutical Form: Solution for injection INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Current Sponsor code: AN100226; BG00002 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Biogen Idec Limited | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Spain;Belgium;Germany;Italy | |||
772 | EUCTR2011-001280-49-FR | 14/06/2011 | 19 February 2018 | « GRACE : Gilenya® - Réponse Au Coping - Evaluation » Etude clinique menée dans plusieurs centres français, d'une durée de 4 mois, visant à comparer la réponse à l'initiation du traitement par fingolimod (Gilenya®) selon le profil d'anxiété chez des patients adultes présentant une sclérose en plaques rémittente-récurrente très active. | « GRACE : Gilenya® - Réponse Au Coping - Evaluation » Etude multicentrique de phase IV, prospective, en ouvert, d'une durée de 4 mois, visant à comparer la réponse à l’initiation du fingolimod (Gilenya®) selon le profil de « coping » chez des patients adultes présentant une sclérose en plaques rémittente-récurrente très active en France. - GRACE | Sclérose en plaques rémittente-récurrente active MedDRA version: 13.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720 Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,5 - | Novartis Pharma S.A.S | Not Recruiting | Female: yes Male: yes | 250 | Phase 4 | France | |||
773 | NCT01395316 | June 2011 | 16 December 2017 | Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis | Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Alemtuzumab | University of Chicago | Genzyme, a Sanofi Company | Not recruiting | 18 Years | 50 Years | All | 8 | Phase 4 | |
774 | NCT01428726 | June 2011 | 19 February 2015 | A Phase IIa Study of NT-KO-003 for Multiple Sclerosis | A Phase IIa Multicenter Double Blind Study to Evaluate the Efficacy and Safety of Low Doses of Oral NT-KO-003 for the Treatment of Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: NT-KO-003 | Neurotec Pharma | Advancell - Advanced In Vitro Cell Technologies, S.A. | Not recruiting | 18 Years | 55 Years | Both | 99 | Phase 2 | Germany;Spain |
775 | EUCTR2011-001956-12-CZ | 25/05/2011 | 12 December 2016 | Biological Efficacy of Interferon ß Therapy in Patients with Multiple Sclerosis | Monitoring of MxA mRNA Expression as a Marker of Rresponse to Interferon ß Therapy in Patients with Multiple Sclerosis. | To correlate bioactivity of IFNß reflected by level of MxA expression and clinical course of MS To measure expression of MxA protein in patients treated with IFNß depending on NAbs status NAbs positive cohorts will be correlated NAbs titer with level of MxA expression, respectively if the MxA decrease is not preceding NAbs positivity. The MxA induction test will be tested. | Trade Name: Avonex® Product Name: Avonex® Product Code: EU/1/97/033/002 Pharmaceutical Form: Injection Trade Name: Betaferon® Product Name: Betaferon® Product Code: EU/1/95/003/005-010 Pharmaceutical Form: Injection Trade Name: Rebif 22® Product Name: Rebif 22® Product Code: EU/1/98/063/001-003 Pharmaceutical Form: Injection Trade Name: Rebif 44® Product Name: Rebif 44® Product Code: EU/1/98/063/004-006 Pharmaceutical Form: Injection Trade Name: Extavia® Product Name: Extavia® Product Code: EU/1/08/454/001-002, EU/1/08/454/005-007 Pharmaceutical Form: Injection | University Hospital Motol | Not Recruiting | Female: yes Male: yes | Phase 4 | Czech Republic | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
776 | EUCTR2010-024561-43-DK | 24/05/2011 | 5 August 2014 | Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis | Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis | progressive multiple sclerosis MedDRA version: 13.1 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders | Trade Name: Medrol Pharmaceutical Form: Tablet CAS Number: 83-43-2 Other descriptive name: METHYLPREDNISOLONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- | Scleroseklinikken, Rigshospitalet | Not Recruiting | Female: yes Male: yes | 30 | Denmark | ||||
777 | NCT01416363 | May 20, 2011 | 16 December 2017 | Healthy Volunteer Study Using 3 Different Formulations of Firategrast | A Single/Repeat Dose Study With Three Oral Formulations of Firategrast (Immediate Release Tablet, Modified Release Tablet, and Naso-gastric Infusion) in Healthy Male Volunteers | Multiple Sclerosis, Relapsing-Remitting | Drug: Firategrast immediate release tablet;Drug: Firategrast modified release tablet;Drug: Firategrast gastro-retentive solution | GlaxoSmithKline | Not recruiting | 18 Years | 65 Years | Male | 38 | Phase 1 | Australia | |
778 | EUCTR2010-024477-39-LV | 06/05/2011 | 16 November 2015 | A Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis | A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis - ATTAIN | Relapsing Multiple Sclerosis MedDRA version: 17.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: PEGylated Interferon Beta-1a Product Code: BIIB017 Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta 1a Current Sponsor code: BIIB017 Other descriptive name: PEGylated Intereron Beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 125- | Biogen Idec Limited | Not Recruiting | Female: yes Male: yes | 1600 | Serbia;United States;Estonia;Greece;Spain;Ukraine;Chile;Russian Federation;Colombia;India;France;Peru;Latvia;Netherlands;United Kingdom;Czech Republic;Mexico;Canada;Belgium;Poland;Croatia;Romania;Bulgaria;Germany;New Zealand | ||||
779 | EUCTR2010-021978-11-SE | 04/05/2011 | 7 December 2015 | A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Tysabri Product Code: AN100226, BG00002 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Other descriptive name: SUB22282 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use | Biogen Idec Limited | Not Recruiting | Female: yes Male: yes | 856 | United States;Finland;Spain;Ireland;Israel;Russian Federation;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Belgium;Denmark;Netherlands;Germany;Sweden | ||||
780 | NCT01259388 | May 2011 | 11 April 2016 | A Pilot Study of Lithium in Progressive Multiple Sclerosis | A Pilot Trial of Lithium in Progressive Multiple Sclerosis | Multiple Sclerosis | Drug: Lithium Carbonate | VA Office of Research and Development | Not recruiting | 30 Years | 65 Years | Both | 20 | Phase 1/Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
781 | NCT01333358 | May 2011 | 19 February 2015 | Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients | Phase III A Prospective, Longitudinal, Rater-blinded Single-arm Study to Evaluate Alemtuzumab as an Effective Treatment in Stabilizing Overall Neurocognitive Function in RRMS Subjects at Specified Timepoints | Multiple Sclerosis | Drug: Alemtuzumab | Central Texas Neurology Consultants | Genzyme, a Sanofi Company | Not recruiting | N/A | N/A | Both | 30 | Phase 3 | |
782 | NCT01337986 | May 2011 | 19 February 2015 | Ampyra for Optic Neuritis in MS | Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis | Multiple Sclerosis;Optic Neuritis | Drug: Dalfampridine/Placebo;Drug: Placebo/Dalfampridine | Washington University School of Medicine | Acorda Therapeutics | Not recruiting | 18 Years | 55 Years | Both | 53 | Phase 2/Phase 3 | United States |
783 | NCT01357980 | May 2011 | 26 August 2019 | Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis | A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis. | Detrusor Muscle Hyperactivity | Biological: Botulinum toxin type A;Drug: Placebo | Ipsen | Not recruiting | 18 Years | 70 Years | All | 47 | Phase 2 | Czechia;France;Germany;Italy;Poland;Austria;Czech Republic | |
784 | NCT01359566 | May 2011 | 16 December 2017 | Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis | A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis | Multiple Sclerosis | Drug: Arbaclofen placarbil 15 mg BID;Drug: Placebo;Drug: Arbaclofen placarbil 30 mg BID;Drug: Arbaclofen placarbil 45 mg BID | Indivior Inc. | Not recruiting | 18 Years | 70 Years | All | 228 | Phase 3 | United States | |
785 | EUCTR2010-023678-38-IT | 20/04/2011 | 16 February 2015 | High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - ND | High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - ND | patients with multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10028245 | Trade Name: MANTADAN*20CPR 100MG Pharmaceutical Form: Tablet INN or Proposed INN: Amantadine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: AMPYRA Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Ampyra Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use | FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | Not Recruiting | Female: yes Male: yes | Italy | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
786 | EUCTR2011-000150-31-IT | 13/04/2011 | 19 March 2012 | EFFECTS OF GLATIRAMER ACETATE ON TISSUE DAMAGE, CORTICAL FUNCTIONS AND FATIGUE IN MULTIPLE SCLEROSIS: A MORPHO-FUNCTIONAL MRI STUDY. | EFFECTS OF GLATIRAMER ACETATE ON TISSUE DAMAGE, CORTICAL FUNCTIONS AND FATIGUE IN MULTIPLE SCLEROSIS: A MORPHO-FUNCTIONAL MRI STUDY. | Multiple Sclerosis patients MedDRA version: 14.1 Level: HLGT Classification code 10012303 Term: Demyelinating disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: COPAXONE Pharmaceutical Form: Solution for injection INN or Proposed INN: Glatiramer acetate Concentration unit: mg milligram(s) Concentration number: 20- | FONDAZIONE DON CARLO GNOCCHI ONLUS | Authorised | Female: yes Male: yes | Italy | |||||
787 | EUCTR2011-000770-60-IT | 12/04/2011 | 17 June 2013 | “An open-label, multi-center, expanded access study with fingolimod in patients with relapsing-remitting multiple sclerosis for whom no suitable therapy exists” - ND | “An open-label, multi-center, expanded access study with fingolimod in patients with relapsing-remitting multiple sclerosis for whom no suitable therapy exists” - ND | approximately 600 patients with relapsing-remitting MS for whom no suitable therapy exists i.e. where existing therapies have failed. MedDRA version: 14.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: fingolimod Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: other nervous system drugs CAS Number: 162359-56-0 Current Sponsor code: FINGOLIMOD Concentration unit: mg milligram(s) Concentration number: .5- | NOVARTIS FARMA | Not Recruiting | Female: yes Male: yes | 600 | Italy | ||||
788 | NCT01407211 | April 2011 | 19 February 2015 | Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient | The Impact of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by CD4+ T Lymphocyte in Multiple Sclerosis Patients | Relapsing Remitting Multiple Sclerosis | Dietary Supplement: vitamin A | Tehran University of Medical Sciences | Recruiting | 20 Years | 45 Years | Both | 30 | Phase 4 | Iran, Islamic Republic of | |
789 | EUCTR2010-023560-40-SE | 23/03/2011 | 21 October 2013 | Blood stem cell transplantation for patients with relapsiong-remitting multiple sclerosis, in whom standard treatment has failed. | Haematopoetic Stem Cell Therapy for Patients with Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study - MIST | Relapsing-remitting multiple sclerosis MedDRA version: 13.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders | Trade Name: Tysabri Pharmaceutical Form: INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Trade Name: Sendoxan Pharmaceutical Form: Powder for solution for injection CAS Number: 6055192 Other descriptive name: CYCLOPHOSPHAMIDE MONOHYDRATE Trade Name: Thymoglobuline Pharmaceutical Form: Powder for infusion* CAS Number: 0 Other descriptive name: RABBIT HUMAN T LYMPHOCYTE IMMUNOGLOBULIN Trade Name: Neupogen Pharmaceutical Form: Solution for injection Trade Name: Solu-Medrol Pharmaceutical Form: Powder and solvent for dispersion for injection | Uppsala l?ns landsting | Authorised | Female: yes Male: yes | 120 | United States;Canada;Brazil;Sweden | ||||
790 | EUCTR2010-023677-19-IT | 23/03/2011 | 3 April 2012 | Bio-molecular effects of interferon-beta and d-vitamin association - VITAD-2010 | Bio-molecular effects of interferon-beta and d-vitamin association - VITAD-2010 | PATIENT WITH RRMS AND SPMS MedDRA version: 13.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 10029205 - Nervous system disorders | Trade Name: BETAFERON*15CONFEZ 0,25MG/ML+ Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1b Concentration unit: µmole/ml micromole(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: EXTAVIA*SC 15FL 250MCG/ML+15SI Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1b Concentration unit: µg/µl microgram(s)/microlitre Concentration type: equal Concentration number: 250- Trade Name: DIBASE Pharmaceutical Form: Oral drops, solution INN or Proposed INN: Colecalciferol Concentration unit: U/ml unit(s)/millilitre Concentration type: equal Concentration number: 2000- | AZIENDA OSPEDALIERA S. LUIGI GONZAGA | Authorised | Female: yes Male: yes | Italy | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
791 | EUCTR2010-024017-31-IT | 15/03/2011 | 28 August 2014 | A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy - GOLDEN | A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy - GOLDEN | Relapsing Remitting Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 | Product Name: FINGOLIMOD Product Code: FTY720D Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Current Sponsor code: FTY720D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: .5- Trade Name: EXTAVIA Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta-1b Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: AVONEX Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: COPAXONE Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Glatiramer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- | NOVARTIS FARMA | Not Recruiting | Female: yes Male: yes | Italy | |||||
792 | NCT01194570 | March 2, 2011 | 9 September 2019 | A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Drug: Ocrelizumab;Other: Placebo | Hoffmann-La Roche | Not recruiting | 18 Years | 55 Years | All | 732 | Phase 3 | United States;Uruguay;Czech Republic;Germany;Greece;Hungary;Israel;France;Finland;Denmark;Czechia;Canada;Bulgaria;Brazil;Belgium;United Kingdom;Ukraine;Turkey;Switzerland;Spain;Russian Federation;Romania;Portugal;Poland;Peru;Norway;New Zealand;Netherlands;Mexico;Lithuania;Italy;Australia;Austria | |
793 | NCT00813969 | March 2011 | 11 April 2016 | Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS | A Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in Patients With Relapsing Forms of Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Progressive Relapsing Multiple Sclerosis | Biological: Autologous mesenchymal stem cell transplantation | The Cleveland Clinic | University Hospital Case Medical Center | Not recruiting | 18 Years | 55 Years | Both | 24 | Phase 1 | United States |
794 | NCT01328379 | March 2011 | 19 October 2017 | Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis | Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: Dalfampridine-ER 5mg;Drug: Dalfampridine-ER 10mg;Other: Placebo | Acorda Therapeutics | Not recruiting | 18 Years | 70 Years | All | 430 | Phase 3 | United States | |
795 | EUCTR2010-023021-38-SE | 23/02/2011 | 23 November 2015 | Switch To RItuXimab in MS A phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy approach - STRIX-MS | Switch To RItuXimab in MS A phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy approach - STRIX-MS | Relapsing-remitting multiple sclerosis in stable condition while treated with first line injectible disease-modifying drugs (DMDs), eg beta-interferons or glatiramere acetate MedDRA version: 12.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Trade Name: Mabthera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000- | Västerbottens läns landsting | Not Recruiting | Female: yes Male: yes | Phase 2 | Sweden | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
796 | EUCTR2010-023172-12-NL | 15/02/2011 | 14 January 2013 | Efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis and treated with interferon-beta | A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - TERACLES | Multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | sanofi-aventis recherche et development | Not Recruiting | Female: yes Male: yes | 1455 | United States;Portugal;Estonia;Slovakia;Greece;Spain;Chile;Russian Federation;Colombia;Italy;France;Denmark;Australia;Tunisia;Netherlands;Korea, Republic of;Finland;Guatemala;Turkey;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Canada;Argentina;Brazil;Belgium;Germany;Norway;Sweden | ||||
797 | NCT01281657 | February 2011 | 19 February 2015 | Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program | A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program | Multiple Sclerosis | Drug: fingolimod | Novartis | Not recruiting | 18 Years | N/A | Both | 64 | N/A | United States;Canada | |
798 | NCT01310166 | February 2011 | 28 November 2016 | Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis | A 6-month Multicenter, Single-arm, Open-label Study to Investigate Changes in Biomarkers After Initiation of Treatment With 0.5 mg Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis | Relapsing-remitting Multiple Sclerosis | Drug: Fingolimod | Novartis Pharmaceuticals | Not recruiting | 18 Years | 65 Years | Both | 447 | Phase 4 | Germany | |
799 | NCT02073474 | February 2011 | 16 December 2017 | An Observational Post-Marketing Safety Registry of Sativex® | An Observational Post-Marketing Safety Registry Of Patients Who Have Been Prescribed Sativex® | Multiple Sclerosis;Diabetes;Cancer;Neuropathic Pain | Drug: Sativex® | GW Pharmaceuticals Ltd. | Not recruiting | N/A | N/A | All | 978 | N/A | ||
800 | EUCTR2010-022066-28-DE | 18/01/2011 | 30 April 2018 | A 6-month multicenter, single-arm, open-label study to investigate changes in biomarkers after initiation of treatment with 0.5 mg fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis | A 6-month multicenter, single-arm, open-label study to investigate changes in biomarkers after initiation of treatment with 0.5 mg fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis | relapsing remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya Product Name: Gilenya Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: Fingolimod Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- | Novartis Pharma GmbH | Not Recruiting | Female: yes Male: yes | 445 | Phase 3 | Germany | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
801 | EUCTR2010-020338-25-PT | 12/01/2011 | 28 February 2019 | A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis | A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis - Oratorio | Primary Progressive Multiple Sclerosis (PPMS) MedDRA version: 20.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ocrelizumab 300mg/10ml Product Code: Ro 496-4913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Trade Name: OCREVUS Product Name: ocrelizumab 300mg/10ml Product Code: Ro 496-4913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- | F.Hoffmann-La Roche | Authorised | Female: yes Male: yes | 630 | Phase 3 | United States;Portugal;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Switzerland;Italy;France;Peru;Australia;Denmark;Netherlands;Finland;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Poland;Brazil;Belgium;Bulgaria;Norway;Germany;New Zealand | |||
802 | EUCTR2010-022033-28-NL | 10/01/2011 | 6 May 2013 | A study investigating safety, tolerability and efficacy of ECP002A (?9-THC) in Multiple Sclerosis patients suffering from spasticity and pain. | A two-phased, randomized, double blind, placebo-controlled study of ECP002A (?9-THC) to determine safety, tolerability and efficacy in Multiple Sclerosis patients suffering from spasticity and pain. - ECP002A (?9-THC) in MS patients | Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Namisol Product Code: ECP002A Pharmaceutical Form: Tablet INN or Proposed INN: dronabinol CAS Number: 1972-08-03 Current Sponsor code: ECP002A Other descriptive name: Namisol Concentration unit: mg milligram(s) Concentration type: range Concentration number: 1.5-5.0 Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Echo Pharmaceuticals B.V. | Not Recruiting | Female: yes Male: yes | Netherlands | |||||
803 | NCT01071694 | January 2011 | 19 February 2015 | QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea | QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea | Multiple Sclerosis, Relapsing-Remitting | Drug: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046) | Bayer | Not recruiting | 18 Years | N/A | Both | 0 | N/A | Korea, Republic of | |
804 | NCT01454791 | January 2011 | 19 October 2017 | Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate | Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients With Multiple Sclerosis Taking Glatiramer Acetate: A Randomized Controlled Double- Blind Crossover Trial | Multiple Sclerosis | Drug: diclofenac sodium topical gel;Other: Placebo | Brown, Theodore R., M.D., MPH | Teva Neuroscience, Inc. | Not recruiting | 18 Years | N/A | All | 40 | Phase 4 | United States |
805 | NCT01455220 | January 2011 | 16 December 2017 | The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis | The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis | Multiple Sclerosis | Drug: Tysabri ® (Natalizumab) | University of South Florida | Not recruiting | 18 Years | 60 Years | All | 45 | N/A | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
806 | EUCTR2011-001692-39-DE | 9 December 2013 | A study to evaluate the safety and tolerability of the combination of an antidepressive therapy with oral fingolimod in the treatment of relapsing remitting multiple sclerosis patients with mild to moderate depression | A 21-week, multicenter, open label study to evaluate the safety and tolerability profile of the combination of a SSRI or SNRI antidepressive therapy with oral fingolimod in the treatment of RRMS patients with mild to moderate depression | Multiple Sclerosis Depression MedDRA version: 14.1 Level: PT Classification code 10012378 Term: Depression System Organ Class: 10037175 - Psychiatric disorders MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya Product Name: Gilenya Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Trade Name: Venlafaxin Hexal Product Name: Venlafaxin Hexal Pharmaceutical Form: Capsule, hard CAS Number: 99300-78-4 Other descriptive name: VENLAFAXINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Trade Name: Fluoxetin Hexal Product Name: Fluoxetin Hexal Pharmaceutical Form: Tablet INN or Proposed INN: FLUOXETINE HYDROCHLORIDE CAS Number: 59333-67-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Venlafaxin Hexal Product Name: Venlafaxin Hexal Pharmaceutical Form: Capsule, hard CAS Number: 99300-78-4 Other descriptive name: VENLAFAXINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- Trade Name: Fluoxetin Hexal Product Name: Fluoxetin Hexal Pharmaceutical Form: Tablet INN or Proposed INN: FLUOXETINE HYDROCHLORIDE CAS Number: 59333-67-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Trade Name: Gilenya Product Name: Gilenya Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- | Novartis Pharma GmbH | Not Recruiting | Female: yes Male: yes | Germany | ||||||
807 | EUCTR2010-020337-99-LV | 29/12/2010 | 10 September 2018 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis | A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis - OPERA I | Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: range Concentration number: 8.8-22 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: ocrelizumab 300mg/10ml Product Code: RO4964913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for injection Route of administration of the placebo: Intravenous use | F.Hoffmann-La Roche | Authorised | Female: yes Male: yes | 800 | Phase 3 | Hungary;Mexico;Argentina;Czech Republic;United Kingdom;Austria;Lithuania;Finland;Latvia;Tunisia;Netherlands;South Africa;Peru;Australia;Switzerland;Italy;Russian Federation;Chile;Israel;Ukraine;Spain;Slovakia;Morocco;Estonia;Serbia;United States;Portugal;Poland;Brazil;Belgium;Bulgaria;Germany;New Zealand | |||
808 | EUCTR2010-023023-19-IT | 28/12/2010 | 11 April 2016 | A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta-1b in treating the cognitive symptoms associated to relapsing-remitting multiple sclerosis and to assess possible relationship of these effects to regional brain atrophy. - ND | A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta-1b in treating the cognitive symptoms associated to relapsing-remitting multiple sclerosis and to assess possible relationship of these effects to regional brain atrophy. - ND | relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 | Product Name: FINGOLIMOD Product Code: FTY720D Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Current Sponsor code: FTY720D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: .5- Trade Name: EXTAVIA Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta-1b Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 250- | NOVARTIS FARMA | Not Recruiting | Female: yes Male: yes | Germany;Italy | |||||
809 | NCT01466322 | December 22, 2010 | 16 December 2017 | A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. | An Open-label, Randomised, Crossover Study to Assess the Relative Bioavailability of Different 2mg Formulations of GSK2018682(S1P1 Agonist) in Healthy Volunteers | Multiple Sclerosis, Relapsing-Remitting | Drug: GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state | GlaxoSmithKline | Not recruiting | 18 Years | 55 Years | All | 16 | Phase 1 | Australia | |
810 | EUCTR2010-023996-25-BE | 21/12/2010 | 19 August 2013 | The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cerebral axonal energy metabolism and glutamate levels in multiple sclerosis. | The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cerebral axonal energy metabolism and glutamate levels in multiple sclerosis. | Multiple sclerosis (both relapsing remitting and progressive forms) | Product Name: fluoxetine Pharmaceutical Form: Coated tablet CAS Number: 54910-89-3 Other descriptive name: FLUOXETINE Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 20-40 Product Name: Cisapride Pharmaceutical Form: Coated tablet INN or Proposed INN: CISAPRIDE CAS Number: 81098604 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 10-20 Product Name: Prucalopride Pharmaceutical Form: Coated tablet INN or Proposed INN: PRUCALOPRIDE CAS Number: 179474818 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 1-2 | Authorised | Female: yes Male: yes | 32 | Belgium | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
811 | EUCTR2009-017978-21-DE | 20/12/2010 | 28 February 2019 | Long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials | Prospective observational long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials (PREMIERE) - PREMIERE Registry | Multiple Sclerosis patients who have participated in cladribine tablets clinical trials MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Cladribine tablets Product Code: Not applicable Pharmaceutical Form: Tablet INN or Proposed INN: Cladribine CAS Number: 4291-63-8 Current Sponsor code: EMD280922 Other descriptive name: 2-CdA, 2-chloro-2’-deoxy-ß-D-adenosine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- | Merck Serono S.A. - Geneva | Not Recruiting | Female: yes Male: yes | 2175 | Phase 3 | Serbia;Bosnia and Herzegovina;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Romania;Croatia;Korea, Republic of;Tunisia;Latvia;Netherlands;Denmark;Australia;Macedonia, the former Yugoslav Republic of;France;India;Switzerland;Italy;Russian Federation;Lebanon;Ukraine;Spain;Thailand;Greece;Morocco;Estonia;Taiwan;Saudi Arabia;United Arab Emirates;United States;Portugal;Georgia;Bulgaria;Norway;Germany;Sweden | |||
812 | EUCTR2009-017939-18-GB | 15/12/2010 | 19 March 2012 | A Phase 4 randomised, double-blind, placebo controlled, crossover trial Nitrofurantoin Macrocrystals 100 mg twice daily for six weeks in the treatment of overactive bladder symptoms associated with a negative mid stream urine culture and pyuria in patients with Multiple Sclerosis. - Recurrent urine infection in MS | A Phase 4 randomised, double-blind, placebo controlled, crossover trial Nitrofurantoin Macrocrystals 100 mg twice daily for six weeks in the treatment of overactive bladder symptoms associated with a negative mid stream urine culture and pyuria in patients with Multiple Sclerosis. - Recurrent urine infection in MS | Chronic urinary tract infection. MedDRA version: 14.0 Level: LLT Classification code 10059617 Term: Overactive bladder System Organ Class: 10038359 - Renal and urinary disorders | Trade Name: Nitrofurantoin Product Name: Nitrofurantoin Product Code: PL 12762/0049 Pharmaceutical Form: Capsule INN or Proposed INN: Nitrofurantoin CAS Number: 67-20-9 Other descriptive name: Nitrofurantoin Concentration unit: Bq/mg becquerel(s)/milligram Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | UCLH/UCL Biomedical Research Unit | Authorised | Female: yes Male: yes | Phase 4 | United Kingdom | ||||
813 | EUCTR2010-020338-25-FI | 15/12/2010 | 28 February 2019 | A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis | A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis - Oratorio | Primary Progressive Multiple Sclerosis (PPMS) MedDRA version: 20.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ocrelizumab 300 mg Product Code: RO4964913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Ocrevus Product Name: ocrelizumab 300 mg Product Code: RO4964913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- | F.Hoffmann-La Roche | Authorised | Female: yes Male: yes | 630 | Phase 3 | Portugal;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Switzerland;Italy;France;Peru;Australia;Denmark;Netherlands;Finland;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Poland;Brazil;Belgium;Bulgaria;Germany;Norway | |||
814 | NCT01228266 | December 2010 | 19 February 2015 | Mesenchymal Stem Cell Transplantation in MS | Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: a Randomized, Double-blind, Crossover With Placebo Phase II Study | Multiple Sclerosis | Biological: autologous mesenchymal stem cells | Albert Saiz | Instituto de Salud Carlos III | Not recruiting | 18 Years | 50 Years | Both | 9 | Phase 2 | Spain |
815 | NCT01235221 | December 2010 | 19 February 2015 | Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials. | Open-Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine SR in Canadian Subjects With Multiple Sclerosis Who Participated in Acorda Extension Trials | Multiple Sclerosis | Drug: BIIB041 (Fampridine-SR) | Biogen Idec | Acorda Therapeutics | Not recruiting | 18 Years | 70 Years | Both | 38 | Phase 3 | Canada |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
816 | NCT01318421 | December 2010 | 21 December 2015 | A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis | An Open-Label, Long-Term, Follow-Up Study of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis | Drug: ELND002 | Elan Pharmaceuticals | Not recruiting | 18 Years | 65 Years | Both | 12 | Phase 1 | ||
817 | NCT01712373 | December 2010 | 19 February 2015 | Ginseng in Treatment of Fatigue in Multiple Sclerosis | Study of Ginseng in Treatment of Fatigue in Multiple Sclerosis | Fatigue | Drug: Ginseng;Drug: Placebo | Isfahan University of Medical Sciences | Not recruiting | 18 Years | 50 Years | Both | 60 | Phase 2 | Iran, Islamic Republic of | |
818 | NCT00939549 | November 2010 | 1 October 2018 | High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis | Phase II Study of High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: Cyclophosphamide/Glatiramer acetate | Johns Hopkins University | Not recruiting | 18 Years | 70 Years | All | 0 | Phase 2 | United States | |
819 | NCT01236534 | November 2010 | 19 October 2017 | Lubiprostone in Patients With Multiple Sclerosis Associated Constipation | Single-center, Randomized, Double-blind, Placebo-controlled, Parallel-groups Study of Lubiprostone in Patients With Multiple Sclerosis-Associated Constipation | Multiple Sclerosis;Constipation | Drug: Lubiprostone;Drug: Placebo | University of Rochester | Takeda | Not recruiting | 18 Years | N/A | All | 21 | Phase 4 | United States |
820 | NCT01356940 | November 2010 | 19 October 2017 | A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis | A Randomized Controlled Double-blind Cross-over Trial of Dalfampridine ER for Effect on Ambulatory Activity in People With Multiple Sclerosis | Multiple Sclerosis | Drug: dalfampridine ER;Drug: placebo | Brown, Theodore R., M.D., MPH | Acorda Therapeutics | Not recruiting | 18 Years | 75 Years | All | 43 | Phase 4 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
821 | NCT01440101 | November 2010 | 19 October 2017 | Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) | Multicenter Study of BG00002 in Japanese Subjects With RRMS, Consisting of a Multiple-Dose, Open-Label Evaluation of Its Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (Part A) and a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Evaluation of Safety and Efficacy (Part B) | Multiple Sclerosis | Drug: Placebo;Drug: Natalizumab (BG00002) | Biogen | Not recruiting | 18 Years | 65 Years | All | 106 | Phase 2/Phase 3 | Japan;China | |
822 | NCT01667796 | November 2010 | 18 March 2019 | Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health | Pharmacodynamic and Immunologic Effects of Vitamin D Supplementation in Patients With Multiple Sclerosis and Healthy Controls | Multiple Sclerosis, Relapsing-remitting | Dietary Supplement: Vitamin D3 | Johns Hopkins University | University of California, San Francisco;National Multiple Sclerosis Society | Not recruiting | 18 Years | 60 Years | Female | 57 | N/A | United States |
823 | EUCTR2010-020328-23-FI | 21/10/2010 | 4 August 2015 | Supplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. | A three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with 44 µg tiw of Rebif® SOLAR Supplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR | Relapsing-Remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Vigantol Oel Product Name: Vigantol Oil Product Code: 200106 or EMD 28162 Pharmaceutical Form: Oral solution INN or Proposed INN: COLECALCIFEROL CAS Number: 67-97-0 Current Sponsor code: 200109, EMD 28162, 300910 Other descriptive name: Cholecalciferol, Vitamin D3 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use | Merck Serono | Not Recruiting | Female: yes Male: yes | 230 | Phase 2 | Portugal;Estonia;Finland;Lithuania;Austria;Switzerland;Italy;Belgium;Denmark;Norway;Germany;Latvia;Netherlands | |||
824 | NCT01431937 | October 10, 2010 | 16 December 2017 | Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers | A Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Ascending Doses of GSK2018682 (S1P1 Agonist) in Healthy Volunteers | Multiple Sclerosis, Relapsing-Remitting | Drug: GSK2018682;Drug: Placebo | GlaxoSmithKline | Not recruiting | 18 Years | 55 Years | All | 40 | Phase 1 | Australia | |
825 | NCT01005095 | October 2010 | 19 February 2015 | The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis Patients | A One Year Prospective, Randomized, Double Blind Interventional Study to Assess Tolerability, Quality of Life and Immunomodulation With Interferon Beta Combined With Vitamin D in Patients With Relapsing Remitting Multiple Sclerosis | MULTIPLE SCLEROSIS | Dietary Supplement: Vitamin D3 | Carmel Medical Center | Not recruiting | 18 Years | 65 Years | Both | 45 | Phase 4 | Israel | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
826 | NCT01188811 | October 2010 | 19 October 2017 | Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) | Lipoic Acid for Neuroprotection in Secondary Progressive MS | Multiple Sclerosis, Chronic Progressive | Drug: lipoic acid;Drug: Placebo | VA Office of Research and Development | Oregon Health and Science University | Not recruiting | 40 Years | 70 Years | All | 54 | Phase 2/Phase 3 | United States |
827 | NCT01244139 | October 2010 | 16 December 2017 | Safety Study of BIIB033 in Subjects With Multiple Sclerosis | A Randomized, Blinded, Placebo-Controlled, Serial-Cohort, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis | Drug: BIIB033;Drug: Placebo | Biogen | Not recruiting | 18 Years | 60 Years | All | 47 | Phase 1 | United States | |
828 | NCT01279876 | October 2010 | 24 August 2015 | Melatonin in Relapsing-Remitting Multiple Sclerosis Patients | Effects of Melatonin on Clinical and Neuroimaging Indices of Relapsing-Remitting Multiple Sclerosis Patients | Multiple Sclerosis, Relapsing-Remitting | Drug: Melatonin | Tehran University of Medical Sciences | Not recruiting | 20 Years | 45 Years | Both | 25 | Phase 2 | Iran, Islamic Republic of | |
829 | NCT01381354 | October 2010 | 2 July 2018 | Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) | Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) | Multiple Sclerosis | Other: Progressive exercise;Device: Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV;Other: Modified paleolithic diet;Dietary Supplement: Omega 3 fatty acids;Dietary Supplement: Full Spectrum vitamin;Dietary Supplement: Essential - hydroxytyrosol;Dietary Supplement: Maltodextrin fiber supplement;Dietary Supplement: Mineral boost (magnesium);Dietary Supplement: Niacinamide;Dietary Supplement: Methyl B12;Dietary Supplement: Taurine;Dietary Supplement: creatine;Dietary Supplement: thiamine;Dietary Supplement: riboflavin;Dietary Supplement: N acetylcysteine;Dietary Supplement: alpha lipoic acid;Dietary Supplement: L acetyl carnitine;Dietary Supplement: methyl folate;Dietary Supplement: coenzyme Q;Behavioral: meditation;Behavioral: self massage;Behavioral: learning;Dietary Supplement: Coconut oil | University of Iowa | Direct MS Canada;DJO Incorporated;Pinnaclife Inc.;TZ Press, LLC | Not recruiting | 18 Years | 65 Years | All | 38 | Phase 1 | United States |
830 | NCT01416155 | October 2010 | 19 October 2017 | Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis | A Long-Term, Open-Label, Multicenter, Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis | Drug: natalizumab | Biogen | Not recruiting | 18 Years | 65 Years | All | 97 | Phase 2 | Japan;China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
831 | EUCTR2010-018705-11-BE | 13/09/2010 | 17 August 2015 | A SAFETY AND EFFICACY EXTENSION STUDY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS | A SAFETY AND EFFICACY EXTENSION STUDY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS | Relapsing-remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ONO-4641/MSC2430913A Product Code: ONO-4641/MSC2430913A Pharmaceutical Form: Film-coated tablet Current Sponsor code: ONO-4641/MSC2430913A Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.05- Product Name: ONO-4641/MSC2430913A Product Code: ONO-4641/MSC2430913A Pharmaceutical Form: Film-coated tablet Current Sponsor code: ONO-4641/MSC2430913A Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Product Name: ONO-4641/MSC2430913A Product Code: ONO-4641/MSC2430913A Pharmaceutical Form: Film-coated tablet Current Sponsor code: ONO-4641/MSC2430913A Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.15- | Merck Serono S.A. - Geneva | Not Recruiting | Female: yes Male: yes | 376 | United States;Czech Republic;Greece;Canada;Spain;Belgium;Ukraine;Russian Federation;Germany;Japan | ||||
832 | JPRN-JapicCTI-101335 | 01/9/2010 | 2 April 2019 | An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain | An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain (Post Spinal Cord Injury Pain, Post Stroke Pain, And Multiple Sclerosis Pain) | Spinal Cord Diseases, Spinal Cord Injuries, Neuralgia, Pain | Intervention name : pregabalin INN of the intervention : pregabalin Dosage And administration of the intervention : pregabalin capsules 150mg/day, 300mg/day, 450mg/day or 600mg/day BID Control intervention name : null | Pfizer Japan Inc. | 18 | BOTH | 100 | Phase 3 | ||||
833 | NCT01116427 | September 2010 | 19 October 2017 | A Cooperative Clinical Study of Abatacept in Multiple Sclerosis | A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Biological: abatacept;Drug: Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Immune Tolerance Network (ITN) | Not recruiting | 18 Years | 65 Years | All | 65 | Phase 2 | United States;Canada |
834 | NCT01181089 | September 2010 | 19 February 2015 | Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS) | A Multicenter, Randomized, Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF) and Safety in Subjects With Secondary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Biological: Placebo;Biological: Baminercept | Biogen Idec | Not recruiting | 18 Years | 57 Years | Both | 0 | Phase 1/Phase 2 | Canada;United Kingdom | |
835 | NCT01202227 | September 2010 | 19 October 2017 | An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain | An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain (Post Spinal Cord Injury Pain, Post Stroke Pain, And Multiple Sclerosis Pain) | Spinal Cord Diseases;Spinal Cord Injuries;Neuralgia;Pain | Drug: pregabalin | Pfizer | Not recruiting | 18 Years | N/A | All | 104 | Phase 3 | Japan | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
836 | NCT01212094 | September 2010 | 19 October 2017 | Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe) | Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe) | Multiple Sclerosis | Drug: Rituximab;Other: normal saline | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | 65 Years | All | 44 | Phase 1/Phase 2 | United States | |
837 | EUCTR2010-020515-37-FI | 06/08/2010 | 19 November 2018 | Long-term safety and tolerability study of 0.5 mg fingolimod once daily in patients with relapsing forms of multiple sclerosis | A single arm, open-label, multicenter study evaluating the long-term, safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis. | multiple sclerosis MedDRA version: 19.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720D Other descriptive name: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 5000 | Phase 3 | Portugal;United States;Estonia;Slovakia;Greece;Spain;Ireland;Russian Federation;Israel;Italy;Switzerland;France;Jordan;Malaysia;Peru;Australia;Denmark;South Africa;Netherlands;Korea, Republic of;Panama;Finland;Guatemala;Turkey;Austria;United Kingdom;Egypt;Czech Republic;Hungary;Canada;Argentina;Poland;Belgium;Brazil;Romania;Norway;Germany;Sweden | |||
838 | NCT00997438 | August 2010 | 19 October 2017 | Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis | Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis | Multiple Sclerosis | Dietary Supplement: Lipoic Acid | Portland VA Medical Center | Oregon Health and Science University | Not recruiting | 18 Years | N/A | All | 69 | Phase 1 | United States |
839 | NCT01191996 | August 2010 | 19 February 2015 | Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis | A Phase 2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered MIS416 in Patients With Chronic Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis | Biological: MIS416 | Innate Immunotherapeutics | Primorus Clinical Trials;National Multiple Sclerosis Society | Not recruiting | 18 Years | N/A | Both | 34 | Phase 1/Phase 2 | New Zealand |
840 | NCT01216072 | August 2010 | 19 October 2017 | A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis | A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Forms of Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC) | Relapsing Forms of Multiple Sclerosis | Drug: Fingolimod;Drug: Standard MS DMTs | Novartis Pharmaceuticals | Not recruiting | 18 Years | 65 Years | All | 1053 | Phase 4 | United States;Canada;Puerto Rico | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
841 | NCT01337427 | August 2010 | 19 February 2015 | Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis | Optical Coherence Tomography (OCT) in a Multicenter, Randomized,Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: BIIB017 | Johns Hopkins University | Biogen Idec | Not recruiting | 18 Years | 55 Years | Both | 0 | Phase 3 | United States |
842 | EUCTR2009-011888-37-DE | 23/07/2010 | 10 December 2012 | A 1-year, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of zoledronic acid 5 mg (Aclasta®) on bone mineral density in patients with multiple sclerosis followed by a 1-year open-label treatment phase - EXALT | A 1-year, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of zoledronic acid 5 mg (Aclasta®) on bone mineral density in patients with multiple sclerosis followed by a 1-year open-label treatment phase - EXALT | osteoporosis in patients with multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10049088 Term: Osteopenia System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 14.1 Level: PT Classification code 10031282 Term: Osteoporosis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders | Trade Name: Aclasta 5 mg Infusionslösung Product Name: Aclasta Product Code: ZOL446H Pharmaceutical Form: Solution for infusion CAS Number: 165800-06-6 Other descriptive name: ZOLEDRONIC ACID MONOHYDRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | Novartis Pharma GmbH | Not Recruiting | Female: yes Male: yes | Germany | |||||
843 | EUCTR2009-009503-19-BE | 20/07/2010 | 21 August 2017 | A prospective, open label, non-randomised, clinical trial to determine if natalizumab (Tysabri) improves ambulatory measures in relapsing remitting multiple sclerosis (RRMS) patients. - TIMER | A prospective, open label, non-randomised, clinical trial to determine if natalizumab (Tysabri) improves ambulatory measures in relapsing remitting multiple sclerosis (RRMS) patients. - TIMER | Multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Trade Name: Tysabri Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Natalizumab Current Sponsor code: BG00002 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- | Biogen Idec International GmbH | Not Recruiting | Female: yes Male: yes | 200 | Phase 4 | Belgium | |||
844 | EUCTR2010-019028-30-FI | 07/07/2010 | 23 May 2012 | A 3-month blinded, randomized, multicenter, placebocontrolled study to evaluate the effect of treatment with fingolimod on the immune response following seasonal influenza vaccination and tetanus toxoid booster injection in patients with relapsing forms of multiple sclerosis. | A 3-month blinded, randomized, multicenter, placebocontrolled study to evaluate the effect of treatment with fingolimod on the immune response following seasonal influenza vaccination and tetanus toxoid booster injection in patients with relapsing forms of multiple sclerosis. | Relapsing forms of multiple sclerosis. MedDRA version: 12.1 Level: LLT Classification code 10048393 Term: Multiple sclerosis relapse | Product Name: FTY720 Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 120 | Finland;United Kingdom;France;Spain | ||||
845 | NCT01167426 | July 2010 | 19 October 2017 | Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients | An Open-Label, Multicenter Study Evaluating Patient Injection Satisfaction With Two Formulations of Glatiramer Acetate (GA) Using Autoject 2 as the Subcutaneous Injection Delivery Method. | Multiple Sclerosis | Drug: Glatiramer Acetate 20 mg/0.5 mL;Drug: Glatiramer acetate 20 mg/0.5 mL | Teva Neuroscience, Inc. | Not recruiting | 18 Years | N/A | All | 148 | Phase 3 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
846 | NCT01207648 | July 2010 | 19 October 2017 | Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY) | Retrospective Cohort Study of Rebif® Use in Pediatric MS Patients | Multiple Sclerosis | Drug: Rebif® | EMD Serono | Not recruiting | N/A | 18 Years | All | 307 | N/A | United States;Argentina;Canada;France;Italy;Russian Federation;Tunisia;Venezuela | |
847 | NCT01085318 | June 2010 | 19 October 2017 | Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial | A Twenty-four Week, Two Arm, Pilot Trial to Evaluate Remyelination/ Demyelination, Gray Matter Volume and Iron Deposition in the Central Nervous System (CNS) and Immune Status of Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) Treated With Rebif® 44 Mcg Subcutaneously (sc) Three Times a Week (Tiw) Compared to a Healthy Control Group | Multiple Sclerosis | Drug: Rebif | EMD Serono | Not recruiting | 18 Years | 65 Years | All | 38 | Phase 4 | United States | |
848 | NCT01144052 | June 2010 | 19 October 2017 | Natalizumab De-escalation With Interferon Beta-1b | De-escalation After Natalizumab Treatment With Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis | Relapsing-remitting Multiple Sclerosis | Drug: interferon beta-1b;Drug: Natalizumab | Claudio Gobbi | Ospedale Civico, Lugano | Not recruiting | 18 Years | 60 Years | All | 19 | Phase 4 | Switzerland |
849 | NCT01149525 | June 2010 | 16 December 2017 | Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis | A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis | Multiple Sclerosis | Drug: L-Carnitine;Drug: Placebo | University Hospital, Bordeaux | Not recruiting | 18 Years | N/A | All | 59 | Phase 3 | France | |
850 | NCT01156311 | June 2010 | 16 December 2017 | BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis | An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNß) or Glatiramer Acetate (GA) | Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis | Drug: dimethyl fumarate | Biogen | Not recruiting | 18 Years | 55 Years | All | 108 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
851 | NCT01067521 | May 31, 2010 | 16 December 2017 | A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo | A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design | Relapsing Remitting Multiple Sclerosis | Drug: Glatiramer acetate (GA);Other: Placebo | Teva Pharmaceutical Industries, Ltd. | Not recruiting | 18 Years | 55 Years | All | 1404 | Phase 3 | United States;Bulgaria;Croatia;Czechia;Estonia;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Poland;Romania;Russian Federation;South Africa;Ukraine;United Kingdom;Czech Republic;Turkey | |
852 | NCT01047319 | May 27, 2010 | 21 January 2019 | A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis | A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-302 (BRAVO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | Drug: Laquinimod | Teva Pharmaceutical Industries, Ltd. | Not recruiting | N/A | N/A | All | 1047 | Phase 3 | United States;Bulgaria;Croatia;Czechia;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, The Former Yugoslav Republic of;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Ukraine;Czech Republic;Puerto Rico | |
853 | NCT01387217 | May 21, 2010 | 16 December 2017 | GSK2018682 FTIH in Healthy Volunteers | A Single-blind, Placebo-controlled, Two Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of GSK2018682 in Healthy Volunteers | Multiple Sclerosis | Drug: GSK2018682;Drug: Placebo | GlaxoSmithKline | Not recruiting | 18 Years | 55 Years | All | 27 | Phase 1 | Australia | |
854 | NCT01143441 | May 13, 2010 | 11 November 2019 | Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS) | Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS) | Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting | Biological: DAC-HYP | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | 60 Years | All | 48 | Phase 1 | United States | |
855 | NCT01093326 | May 12, 2010 | 16 September 2019 | Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis | Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Ponesimod 10 mg;Drug: Ponesimod 20 mg;Drug: Ponesimod 40 mg | Actelion | Not recruiting | 18 Years | 55 Years | All | 353 | Phase 2 | United States;Austria;Bulgaria;Canada;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;Czech Republic | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
856 | EUCTR2010-019029-32-DE | 06/05/2010 | 22 October 2012 | A 4-month, open-label, multi-center study to explore tolerability and safety and health outcomes of FTY720 in patients with relapsing forms of multiple sclerosis. | A 4-month, open-label, multi-center study to explore tolerability and safety and health outcomes of FTY720 in patients with relapsing forms of multiple sclerosis. | Relapsing multiple sclerosis. MedDRA version: 12.1 Level: LLT Classification code 10048393 Term: Multiple sclerosis relapse | Product Name: FTY720 Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: fingolimod hydrochloride CAS Number: 162359-56-0 Current Sponsor code: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 2400 | Portugal;Slovakia;Greece;Finland;Spain;Ireland;Austria;Italy;United Kingdom;Hungary;Czech Republic;Denmark;Germany;Netherlands;Sweden | ||||
857 | EUCTR2009-017490-38-DE | 03/05/2010 | 24 April 2012 | Randomized Treatment Interruption of Natalizumab - RESTORE | Randomized Treatment Interruption of Natalizumab - RESTORE | Natalizumab is a highly efficacious therapy used in the treatment of patients with relapsing multiple sclerosis (MS). This is a prospective randomized study in subjects with relapsing forms of MS who have been receiving natalizumab treatment for at least 12 months with no MS relapses during these 12 months. MedDRA version: 12.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Trade Name: Tysabri Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Other descriptive name: TYSABRI Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Trade Name: Copaxone Pharmaceutical Form: Solution for injection INN or Proposed INN: GLATIRAMER ACETATE CAS Number: 147245-92-9 Other descriptive name: COPAXONE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: AVONEX Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Other descriptive name: AVONEX Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 60- Trade Name: Urbason Forte Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: METHYLPREDNISOLONE CAS Number: 83-43-2 Other descriptive name: URBASON FORTE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000- | Biogen Idec | Not Recruiting | Female: yes Male: yes | 200 | Germany;Spain | ||||
858 | NCT01006941 | May 2010 | 19 February 2015 | Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study | Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study | Relapsing Multiple Sclerosis | Biological: Trichuris suis ova | Rigshospitalet, Denmark | University of Copenhagen;Statens Serum Institut;Copenhagen University Hospital, Hvidovre;OvaMed GmbH | Not recruiting | 19 Years | 55 Years | Both | 10 | Phase 2 | Denmark |
859 | NCT01076595 | May 2010 | 3 August 2015 | Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period | Prospective Multicenter, Non Interventional Study to Evaluate the Patient's Characteristics Associated With Adherence to Treatment Regimen by Betaferon in the BetaPlus Program | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 18 Years | N/A | Both | 73 | N/A | France | |
860 | NCT01354665 | May 2010 | 19 February 2015 | Depression and Fatigue in MS Patients Treated With Betaferon. | The Short-term Effect of Immunomodulatory Treatment With Interferon Beta-1b (Betaferon) on Fatigue and Depression in First-time Treated Patients With Relapsing-remitting Multiple Sclerosis. | Multiple Sclerosis | Biological: Interferon beta-1b (Betaferon, BAY86-5046) | Bayer | Not recruiting | 18 Years | N/A | Both | 567 | N/A | Poland | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
861 | NCT01842191 | May 2010 | 19 February 2015 | Efficacy of Fish Oil in Multiple Sclerosis | Efficacy of Fish Oil on Serum TNFa, IL-1ß, IL-6, Oxidative Stress Markers in Multiple Sclerosis Treated With Interferon Beta 1-b | Relapsing- Remitting Multiple Sclerosis | Dietary Supplement: Fish Oil;Dietary Supplement: Placebo | Coordinación de Investigación en Salud, Mexico | Not recruiting | 18 Years | 55 Years | Both | 50 | Phase 4 | Mexico | |
862 | EUCTR2009-012500-11-IE | 12/04/2010 | 23 February 2015 | Comparison of Daclizumab HYP and Avonex® in Multiple Sclerosis | Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon ß 1a) in Patients with Relapsing-Remitting Multiple Sclerosis - DECIDE | Relapsing-remitting Multiple Sclerosis MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: DACLIZUMAB HYP Product Code: BIIB019 Pharmaceutical Form: Solution for injection INN or Proposed INN: Daclizumab Current Sponsor code: BIIB019 Other descriptive name: Daclizumab HYP (DAC HYP) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: AVONEX Pharmaceutical Form: Solution for injection Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intramuscular use | Biogen Idec Ltd | Not Recruiting | Female: yes Male: yes | 1800 | Serbia;United States;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Switzerland;Italy;India;France;Australia;Denmark;Moldova, Republic of;Slovenia;Finland;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Romania;Georgia;Germany;Sweden | ||||
863 | EUCTR2009-017003-28-IT | 12/04/2010 | 23 December 2013 | Relationship between IL-6 and TNF-α polymorphism and flu-like syndrome development in multiple sclerosis patients treated with Interferon-beta 1a i.m. Open label multicentre study - Flu-like Symdrome | Relationship between IL-6 and TNF-α polymorphism and flu-like syndrome development in multiple sclerosis patients treated with Interferon-beta 1a i.m. Open label multicentre study - Flu-like Symdrome | multiple sclerosis MedDRA version: 9.1 Level: SOC Classification code 10029205 MedDRA version: 9.1 Level: HLGT Classification code 10012303 MedDRA version: 9.1 Level: HLT Classification code 10052785 MedDRA version: 9.1 Level: LLT Classification code 10063399 | Trade Name: AVONEX Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30- | BIOGEN-DOMPE` SRL | Not Recruiting | Female: yes Male: yes | Italy | |||||
864 | EUCTR2009-016824-29-DK | 06/04/2010 | 19 March 2012 | REsPons på interferon-Alfa hos InterfeRon-ß-neutraliserende antistof-positive patienter med multipel sklerose - REPAIR | REsPons på interferon-Alfa hos InterfeRon-ß-neutraliserende antistof-positive patienter med multipel sklerose - REPAIR | Multiple Sclerosis MedDRA version: 12.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Trade Name: Multiferon Pharmaceutical Form: Solution for injection INN or Proposed INN: HUMAN LEUCOCYTE INTERFERON-ALPHA CAS Number: 0 Current Sponsor code: SWEDISH ORPHAN INTERNATIONAL Other descriptive name: HUMAN LEUCOCYTE INTERFERON-ALPHA Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 6000000- Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Current Sponsor code: Merck Serono Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: range Concentration number: 22-44 Trade Name: Betaferon Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: INTERFERON BETA-1B CAS Number: 145155-23-3 Current Sponsor code: Bayer Other descriptive name: INTERFERON BETA-1B Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 8000000- | Dansk Multipel Sclerose Center | Not Recruiting | Female: yes Male: yes | 10 | Denmark | ||||
865 | NCT01071512 | April 2010 | 16 December 2017 | Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis | Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis | Multiple Sclerosis | Drug: Tysabri | University of Chicago | Biogen | Not recruiting | 18 Years | 60 Years | All | 20 | N/A | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
866 | NCT01181115 | April 2010 | 19 February 2015 | Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) | An Open-Label Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Avonex (Interferon Beta-1a) in Chinese Subjects With Relapsing Multiple Sclerosis | Multiple Sclerosis | Drug: Avonex | Biogen Idec | Not recruiting | 18 Years | 55 Years | Both | 60 | Phase 3 | China | |
867 | EUCTR2009-011470-15-FI | 30/03/2010 | 26 November 2018 | An international study, which is an extension to protocol AC 058B201, with the aim to study how safe and efficacious is the long-term treatment with ponesimod in three different doses in patients with relapsing-remitting multiple sclerosis. | Multicenter, randomized, double-blind, parallel-group extension to study AC 058B201 to investigate the long-term safety, tolerability, and efficacy of 10, 20, and 40 mg/day ponesimod, an oral S1P1 receptor agonist, in patients with relapsing-remitting multiple sclerosis | relapsing-remitting multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Product Name: ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- | ACTELION Pharmaceuticals Ltd | Authorised | Female: yes Male: yes | 353 | Phase 2 | Serbia;United States;Finland;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Romania;Australia;Bulgaria;Netherlands;Germany;Sweden | |||
868 | EUCTR2008-005167-33-DE | 29/03/2010 | 13 June 2016 | Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease - GABATAX | Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease - GABATAX | Patients with cerebellar ataxia with coordination deficits in walking, upper and lower limb movements and oculomtoor coordination deficits are included in the trial. The cause of their atayia is either a degenerative CNS disease (36 patients) such as autosomal dominant Spinocerebellar Ataxia or sporadic ataxia with late onset or inflammatory CNS disease (Multiple Sclerosis; 36 patients). | Trade Name: Neurontin 300 mg hard capsule Product Name: gabapentine 300mg Product Code: GBP Pharmaceutical Form: Capsule, hard INN or Proposed INN: Gabapentin CAS Number: 60142-96-3 Current Sponsor code: 1210 Other descriptive name: GABAPENTIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Charité University Medicine Berlin | Not Recruiting | Female: yes Male: yes | Phase 4 | Germany | ||||
869 | EUCTR2009-014339-19-CZ | 26/03/2010 | 19 March 2012 | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS | Relapsing-remitting Multiple Sclerosis MedDRA version: 12.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Product Code: ONO-4641 Pharmaceutical Form: Film-coated tablet Current Sponsor code: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.05- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: ONO-4641 Pharmaceutical Form: Film-coated tablet Current Sponsor code: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: ONO-4641 Pharmaceutical Form: Film-coated tablet Current Sponsor code: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.15- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | ONO Pharmaceutical Co., Ltd. | Not Recruiting | Female: yes Male: yes | 376 | Germany;Czech Republic;Spain;Greece | ||||
870 | EUCTR2009-011088-35-DE | 24/03/2010 | 19 March 2012 | Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS) - a randomized controlled trial - PACAMUS | Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS) - a randomized controlled trial - PACAMUS | Patients with Multiple Sclerosis (MS) or Clinically isolated syndrome suggestive for MS (CIS) are investigated. The main objective is to conserve data about changes in the VIP/PACAP (vasoactive intestinal polypaptide/pituitary adenylate cyclase activating polypeptide) system in stresses patients who start a immunomodulatory treatment with glatiramer acetate (Copaxone). | Trade Name: Copaxone Product Name: copaxone Product Code: 52069.00.01 Pharmaceutical Form: Solution for injection INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- | Philipps-Universität Marburg | Authorised | Female: yes Male: yes | Germany | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
871 | NCT01024777 | March 2010 | 19 February 2015 | Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis | A Pilot Study to Assess the Relative Safety and Immunology Effects of Low Dose Versus High Dose Cholecalciferol Supplementation in Patients With Multiple Sclerosis | Multiple Sclerosis;Vitamin D Deficiency | Drug: Cholecalciferol | Johns Hopkins University | Not recruiting | 18 Years | 55 Years | Both | 40 | Phase 1 | United States | |
872 | NCT01058005 | March 2010 | 19 October 2017 | Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis | A Multicenter, Randomized, Open-Label, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon Beta-1a) to Natalizumab in Subjects With Relapsing Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: BG00002 (natalizumab);Drug: interferon beta-1a;Drug: glatiramer acetate | Biogen | Elan Pharmaceuticals | Not recruiting | 18 Years | 60 Years | All | 84 | Phase 3 | United States;Australia;Canada;Czech Republic;Finland;France;Hungary;Italy;Latvia;Poland;Slovenia;Spain;Sweden |
873 | NCT01070823 | March 2010 | 17 October 2016 | JC-Virus (JCV) Antibody Program | JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri®: STRATIFY-1 | Multiple Sclerosis | Drug: Tysabri® (natalizumab) | Biogen | United BioSource Corporation;Elan Pharmaceuticals;United BioSource Corporation;Elan Pharmaceuticals | Not recruiting | N/A | N/A | Both | 1096 | N/A | United States |
874 | NCT01070836 | March 2010 | 10 October 2016 | JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab | JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2 | Relapsing Multiple Sclerosis | Drug: natalizumab | Biogen | Not recruiting | N/A | N/A | Both | 35895 | N/A | United States;Puerto Rico | |
875 | NCT01071083 | March 2010 | 19 October 2017 | Treatment Interruption of Natalizumab | Randomized Treatment Interruption of Natalizumab | Relapsing Remitting Multiple Sclerosis | Drug: natalizumab;Drug: interferon beta 1-a;Drug: methylprednisolone;Other: IV placebo;Drug: glatiramer acetate | Biogen | Elan Pharmaceuticals | Not recruiting | 18 Years | 60 Years | All | 175 | Phase 2 | United States;Germany;Spain |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
876 | NCT01077466 | March 2010 | 19 February 2015 | Natalizumab Treatment of Progressive Multiple Sclerosis | Natalizumab Treatment of Progressive Multiple Sclerosis | Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis | Drug: Natalizumab | Rigshospitalet, Denmark | Copenhagen University Hospital, Hvidovre;Biogen Idec;University of Copenhagen;Signifikans ApS | Not recruiting | 19 Years | 55 Years | Both | 24 | Phase 2 | Denmark |
877 | NCT01097668 | March 2010 | 19 October 2017 | ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis | SAFETY AND PROOF OF PRINCIPLE STUDY OF ATX-MS-1467 IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS: OPEN LABEL UPWARD TITRATION OVER FIVE DOSE LEVELS AND USING TWO ROUTES OF ADMINISTRATION (INTRADERMAL AND SUBCUTANEOUS). | Relapsing Remitting Multiple Sclerosis | Biological: ATX-MS-1467 | Apitope Technology (Bristol) Ltd. | Aptiv Solutions;ClinStar, LLC | Not recruiting | 18 Years | 55 Years | All | 43 | Phase 1 | Russian Federation;United Kingdom |
878 | NCT01144351 | March 2010 | 21 December 2015 | A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis | A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis | Drug: ELND002;Drug: Placebo | Elan Pharmaceuticals | Not recruiting | 18 Years | 65 Years | Both | 32 | Phase 1 | United States;Canada | |
879 | NCT01424423 | February 11, 2010 | 16 December 2017 | NOGO-A in Multiple Sclerosis FTIH | A Randomized, Single-blind (Investigator and Subject), Placebo-controlled, Single Ascending Dose Study Exploring the Preliminary Safety, Tolerability, and Pharmacokinetics of GSK1223249 Administered by Intravenous (IV) Infusion to Subjects With Relapsing Forms of Multiple Sclerosis, Not on Disease Modifying Therapy | Multiple Sclerosis | Drug: Placebo;Drug: GSK1223249 | GlaxoSmithKline | Not recruiting | 18 Years | 55 Years | All | 3 | Phase 1 | Australia | |
880 | EUCTR2009-015934-30-FR | 02/02/2010 | 3 April 2017 | étude randomisée en double insu et crossover comparant l’efficacité de la L-carnitine à un placebo dans le traitement de la fatigue dans la sclérose en plaques - FACTSEP | étude randomisée en double insu et crossover comparant l’efficacité de la L-carnitine à un placebo dans le traitement de la fatigue dans la sclérose en plaques - FACTSEP | sclérose en plaque fatigue MedDRA version: 12.0 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Trade Name: levocarnil Product Name: Levocarnil Product Code: na Pharmaceutical Form: Oral solution INN or Proposed INN: L-carnitine Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use | CHU de Bordeaux | Not Recruiting | Female: yes Male: yes | Phase 3 | France | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
881 | EUCTR2009-014857-34-DE | 01/02/2010 | 20 May 2013 | Intra-individual, randomized multicentric comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in patients with Multiple Sclerosis at 3T - Gadovist in MS | Intra-individual, randomized multicentric comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in patients with Multiple Sclerosis at 3T - Gadovist in MS | Patients with clinically definite MS or a clinically isolated episode of CNS involvement and disease dissemination in space, according to the McDonald’s criteria MedDRA version: 12.0 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Trade Name: Gadovist 1.0 mmol/ml Injektionslösung Product Code: V08CA09 Pharmaceutical Form: Solution for injection INN or Proposed INN: GADOBUTROL CAS Number: 138071-82-6 Other descriptive name: GADOBUTROL Concentration unit: mmol/ml millimole(s)/millilitre Concentration type: equal Concentration number: 1.0- Trade Name: Dotarem 0,5mmol/ml, Pharmaceutical Form: Solution for injection INN or Proposed INN: gadoteric acid CAS Number: 92923-44-9 Concentration unit: mmol/ml millimole(s)/millilitre Concentration number: 0,5- | Universitätsklinikum Erlangen | Authorised | Female: yes Male: yes | 50 | Germany | ||||
882 | NCT00988988 | February 2010 | 19 February 2015 | The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections | The Effects of Ethyl-alpha-Guanido-methyl Ethanoate on Skin Reactions Form Glatiramer Acetate | Multiple Sclerosis | Drug: AGEE cream;Drug: 1% Steroid Cream;Drug: topical placebo cream with no active ingredients | University of Nebraska | Teva Pharmaceutical Industries | Not recruiting | 19 Years | 65 Years | Both | 0 | Phase 4 | United States |
883 | NCT01065727 | February 2010 | 19 February 2015 | Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis | Study Impact, on Clinical Outcomes, Quality of Life and Costs of 2 Therapeutic Strategy (Monthly Natalizumab Versus Mitoxantrone Then Immunomodulator) at 3 Years of Follow-up for Aggressive Remitting Multiple Sclerosis | Multiple Sclerosis | Other: mitoxantrone - immunomodulator;Other: natalizumab | Rennes University Hospital | Recruiting | 18 Years | N/A | Both | 250 | N/A | France | |
884 | NCT01073813 | February 2010 | 19 February 2015 | Neuroprotection and Repair in Optic Neuritis | Developing Neuroprotection and Repair Strategies in MS: Phase IIa Randomized, Controlled Trial of Minocycline in Acute Optic Neuritis (ON) | Multiple Sclerosis;Optic Neuritis | Drug: Minocycline | University of Calgary | Neuroscience Canada | Not recruiting | 18 Years | 60 Years | Both | 6 | Phase 2 | Canada |
885 | NCT01414634 | February 2010 | 19 October 2017 | Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells | Establish Tolerance in Multiple Sclerosis With Peptide-coupled, Peripheral Blood Mononuclear Cells - A MRI-controlled, Single Center, Phase I Trial in Relapsing-remitting MS Patients | Multiple Sclerosis, Relapsing-Remitting | Biological: ETIMS | Universitätsklinikum Hamburg-Eppendorf | Not recruiting | 18 Years | 55 Years | All | 9 | Phase 1/Phase 2 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
886 | NCT01417273 | February 2010 | 19 February 2015 | Impact of Vitamin A on Multiple Sclerosis (MS) | Impact of Vitamin A Supplementation on Disease Activity and Progression in Multiple Sclerotic (MS) Patients | Relapsing Remitting Multiple Sclerosis | Dietary Supplement: vitamin A;Drug: Drug: placebo | Tehran University of Medical Sciences | Recruiting | 20 Years | 45 Years | Both | 100 | Phase 4 | Iran, Islamic Republic of | |
887 | NCT01705457 | February 2010 | 19 February 2015 | Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis | Impact of Vitamin A Supplementation on RAR Gene Expression in PBMC Cells in Multiple Sclerotic Patients | Relapsing Remitting Multiple Sclerosis | Drug: Dietary Supplement: vitamin A;Drug: placebo | Tehran University of Medical Sciences | Recruiting | 20 Years | 45 Years | Both | 20 | Phase 4 | Iran, Islamic Republic of | |
888 | EUCTR2009-012431-15-CZ | 21/01/2010 | 19 March 2012 | Možnosti terapeutického ovlivnení neurogenního hyperaktivního detruzoru u pacientu po spinálním poranení a s roztroušenou sklerózou aplikací botulinumtoxinu A. Prospektivní, otevrená studie porovnávající efekt aplikace 300 U Botoxu® pri podání do detruzoru mocového mechýre a subsliznicního podání. Therapeutic Use of Botulinum-A toxin in Neurogenic Detrusor Overactivity in Patient after Spinal Cord Injury and Multiple Sclerosis. A Prospective, Open Study with Comparison of Suburothelial and Intradetrusor Application of 300 U of Botox®. | Možnosti terapeutického ovlivnení neurogenního hyperaktivního detruzoru u pacientu po spinálním poranení a s roztroušenou sklerózou aplikací botulinumtoxinu A. Prospektivní, otevrená studie porovnávající efekt aplikace 300 U Botoxu® pri podání do detruzoru mocového mechýre a subsliznicního podání. Therapeutic Use of Botulinum-A toxin in Neurogenic Detrusor Overactivity in Patient after Spinal Cord Injury and Multiple Sclerosis. A Prospective, Open Study with Comparison of Suburothelial and Intradetrusor Application of 300 U of Botox®. | Studie se zabývá lécbou hyperaktivního neurogeního detruzoru u pacientu, kterí trpí príznaky hyperaktivního mocového mechýre jako dusledek spinálního poranení nebo roztroušené sklerózy. K lécbe se pužívá botulinumotoxin. Ve studii se porovnávaní dve ruzné formy aplikace studjiního léku. | Trade Name: Botox Pharmaceutical Form: Powder and solvent for solution for injection CAS Number: 8000049323 Other descriptive name: BOTULINUM TOXIN TYPE A Concentration unit: U unit(s) | Krajská nemocnice Liberec, a.s. | Authorised | Female: yes Male: yes | 40 | Czech Republic | ||||
889 | EUCTR2009-015318-23-CZ | 21/01/2010 | 19 September 2016 | A study designed to determine safety and efficacy of Daclizumab High Yield Process (DAC HYP) in patients with Multiple Sclerosis Who Have Completed Treatment in a previous study, 205MS202 (SELECTION) | A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS202 (SELECTION) | Relapsing-remitting Multiple Sclerosis MedDRA version: 19.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Daclizumab High Yield Process Product Code: BIIB019 Pharmaceutical Form: Solution for injection INN or Proposed INN: Daclizumab Current Sponsor code: BIIB019 Other descriptive name: Daclizumab HYP (DAC HYP) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- | Biogen Idec Ltd. | Not Recruiting | Female: yes Male: yes | 450 | Phase 2 | Hungary;Czech Republic;Ukraine;Russian Federation;Germany;United Kingdom;India | |||
890 | EUCTR2009-016140-39-ES | 19/01/2010 | 19 March 2012 | MRI in Clinically Isolated Syndromes and relapsing multiple sclerosis after single dose (0.1 mmol/kg) and cumulative dose (0.1 + 0.1 mmol/kg) of GADOVIST at 3.0T Estudio de resonancia magnética 3.0T posterior a la administración de GADOVIST® en dosis única (0.1 mmol/kg) y dosis acumulada (0.1+0.1 mmol/kg) en pacientes con Síndrome Clínico Aislado o recaída de Esclerosis Múltiple. | MRI in Clinically Isolated Syndromes and relapsing multiple sclerosis after single dose (0.1 mmol/kg) and cumulative dose (0.1 + 0.1 mmol/kg) of GADOVIST at 3.0T Estudio de resonancia magnética 3.0T posterior a la administración de GADOVIST® en dosis única (0.1 mmol/kg) y dosis acumulada (0.1+0.1 mmol/kg) en pacientes con Síndrome Clínico Aislado o recaída de Esclerosis Múltiple. | Realce de contraste en resonancia magnética en pacientes con Síndrome Clínico Aislado o recaída de Esclerosis Múltiple con resonancia magnética anormal anterior después de la administración de dosis única y acumulada de GADOVIST® High field strength MRI in patients with clinically isolated syndromes or relapsing MS with abnormal previous MRI after single and double dose of Gadovist® | Trade Name: GADOVIST 1 mmol/ml solución inyectable en jeringa precargada/ cartucho precargado Pharmaceutical Form: Solution for injection INN or Proposed INN: GADOBUTROL Other descriptive name: GADOBUTROL Concentration unit: mmol/kg millimole(s)/kilogram Concentration type: equal Concentration number: 0.2- | Institut Diagnostic per la Imatge | Authorised | Female: yes Male: yes | Spain | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
891 | EUCTR2007-001496-11-GB | 15/01/2010 | 28 February 2019 | The Effects of Tetanus Vaccination on Mediators of Autoimmunity in Patients with Multiple Sclerosis - Multiple Sclerosis Tetanus Vaccine for Reduction of Inflammation-1 | The Effects of Tetanus Vaccination on Mediators of Autoimmunity in Patients with Multiple Sclerosis - Multiple Sclerosis Tetanus Vaccine for Reduction of Inflammation-1 | Multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple Sclerosis | Trade Name: Revaxis Product Name: Revaxis Pharmaceutical Form: Injection* | University of Nottingham | Not Recruiting | Female: yes Male: yes | 46 | Phase 2 | United Kingdom | |||
892 | EUCTR2009-016703-35-DK | 08/01/2010 | 2 September 2013 | Natalizumabbehandling af progressiv multipel sklerose - NAPMS | Natalizumabbehandling af progressiv multipel sklerose - NAPMS | Secondary progressive multiple sclerosis and primary progressive multiple sclerosis MedDRA version: 12.0 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis MedDRA version: 12.0 Level: LLT Classification code 10063401 Term: Primary progressive multiple sclerosis | Trade Name: Tysabri Product Name: Natalizumab Pharmaceutical Form: Intravenous infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Current Sponsor code: Natalizumab Other descriptive name: Tysabri Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- | Dansk Multipel Sclerose Center | Not Recruiting | Female: yes Male: yes | 24 | Denmark | ||||
893 | NCT01031459 | January 2010 | 19 February 2015 | Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial. | An Observational 20-year, Cross-sectional, Long-term Follow up of the Patient Cohort Enrolled in the Pivotal Study of Betaseron® (Interferon Beta-1b) in Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Betaseron (Interferon beta-1b, BAY86-5046) | Bayer | Not recruiting | 18 Years | N/A | Both | 176 | N/A | United States;Canada | |
894 | NCT01101776 | January 2010 | 19 February 2015 | Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. | Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting | Multiple Sclerosis | Drug: Interferon beta-1a (Rebif) | Merck KGaA | Merck Serono Australia Pty Ltd | Not recruiting | 18 Years | N/A | Both | 49 | N/A | Australia |
895 | NCT01364246 | January 2010 | 19 February 2015 | Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica | Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica | Progressive Multiple Sclerosis;Neuromyelitis Optica. | Biological: human umbilical cord mesenchymal stem cells | Shenzhen Beike Bio-Technology Co., Ltd. | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School;The Affiliated Nanjing Brain Hospital of Nanjing University Medical School;Nanjing University Medical College Affiliated Wuxi Second Hospital;Xuzhou Medical College;The Second Hospital of Nanjing Medical University | Recruiting | 18 Years | 60 Years | Both | 20 | Phase 1/Phase 2 | China |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
896 | EUCTR2009-012716-40-EE | 31/12/2009 | 19 March 2012 | The Effect of the Dose of PI-2301 on Efficacy, Safety, and Tolerability, in Subjects with the Relapsing Remitting Form of Multiple Sclerosis: A Phase 2 Randomized, double-blind, four–arm, parallel, placebo-controlled and active descriptive-comparator, 40 week trial | The Effect of the Dose of PI-2301 on Efficacy, Safety, and Tolerability, in Subjects with the Relapsing Remitting Form of Multiple Sclerosis: A Phase 2 Randomized, double-blind, four–arm, parallel, placebo-controlled and active descriptive-comparator, 40 week trial | Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Product Name: PI-2301 Product Code: PI-2301 Pharmaceutical Form: Solution for injection CAS Number: 1026791-66-1 Current Sponsor code: PI-2301 acetate salt Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: PI-2301 Product Code: PI-2301 Pharmaceutical Form: Solution for injection CAS Number: 1026791-66-1 Current Sponsor code: PI-2301 acetate salt Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Copaxone Product Name: Copaxone Pharmaceutical Form: Solution for injection CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- | Peptimmune Inc. | Not Recruiting | Female: yes Male: yes | 350 | Phase 2 | Germany;Czech Republic;Bulgaria;France;Estonia;Poland | |||
897 | EUCTR2008-008554-23-SE | 29/12/2009 | 19 March 2012 | Neutralizing Antibodies to Interferon beta in patients treated with Rebif New Formulation - NAb development with RNF | Neutralizing Antibodies to Interferon beta in patients treated with Rebif New Formulation - NAb development with RNF | IFNß-naïve patients fulfilling Poser or McDonald criteria for CDMS or MS and in whom a decision has been made to initiate treatment with RNF (Rebif New Formulation). MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Trade Name: Rebif Product Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 145258-61-3 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22-44 | The Multiple Sclerosis Research Group, Department of Clinical Neuroscience | Not Recruiting | Female: yes Male: yes | 100 | Sweden | ||||
898 | EUCTR2009-016087-37-ES | 18/12/2009 | 24 April 2012 | Estudio farmacogenético exploratorio, multinacional, multicéntrico y con una sola toma de muestras de sangre del ensayo REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease). A multinational, multicenter, single blood sampling exploratory pharmacogenetic study of the REGARD (the REbif vs Glatiramer Acetate in Relapsing MS Disease) trial - REGARD-PGx | Estudio farmacogenético exploratorio, multinacional, multicéntrico y con una sola toma de muestras de sangre del ensayo REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease). A multinational, multicenter, single blood sampling exploratory pharmacogenetic study of the REGARD (the REbif vs Glatiramer Acetate in Relapsing MS Disease) trial - REGARD-PGx | Esclerosis Múltiple MedDRA version: 12.0 Level: PT Classification code 10028245 Term: Multiple sclerosis | Product Name: Rebif Pharmaceutical Form: Solution for injection Product Name: Copaxone Pharmaceutical Form: Solution for injection | Merck Serono S.A. - Geneva | Not Recruiting | Female: yes Male: yes | 325 | United Kingdom;France;Ireland;Spain;Italy | ||||
899 | NCT00963833 | December 17, 2009 | 16 December 2017 | Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis | Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 12 Years | 16 Years | All | 68 | N/A | Austria;Belgium;Finland;Germany;Israel;United Kingdom;Italy;Portugal | |
900 | EUCTR2009-013284-19-AT | 10/12/2009 | 10 July 2015 | Immune tolerance induction in MS patients with neutralizing antibodies against interferon-beta - HINABS | Immune tolerance induction in MS patients with neutralizing antibodies against interferon-beta - HINABS | multiple sclerosis patients with neutralizing antibodies against interferon-beta | Trade Name: Betaferon Pharmaceutical Form: Intravenous infusion CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: million IU million international units Concentration type: equal Concentration number: 48- | Medical University Innsbruck | Not Recruiting | Female: yes Male: yes | Austria | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
901 | NCT00913510 | December 2009 | 19 October 2017 | Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction | Efficacy of Clean Intermittent Self-catheterization in Combination With Anticholinergic Drugs for Treatment of Bladder Dysfunction in Multiple Sclerosis | Bladder Dysfunction;Multiple Sclerosis | Device: CIC using LoFric Primo;Drug: Anticholinergic medication | Wellspect HealthCare | Not recruiting | 18 Years | N/A | All | 24 | N/A | Belgium;Germany;Netherlands;United Kingdom;France | |
902 | NCT00986960 | December 2009 | 15 July 2019 | Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS) | Effect of Pulsed ACTH add-on Therapy to Weekly Avonex on Remyelination and Neuroregeneration in Patients With Relapsing Remitting Multiple Sclerosis. A 1-year Placebo-controlled, Double-blinded, Randomized Follow-up Study | Multiple Sclerosis | Drug: repository corticotropin injection;Drug: Saline | University at Buffalo | Not recruiting | 18 Years | 65 Years | All | 3 | Phase 2 | United States | |
903 | NCT01037088 | December 2009 | 19 October 2017 | Effects of Vaporized Marijuana on Neuropathic Pain | CCRC: The Analgesic Effect of Vaporized Cannabis on Neuropathic Pain | Neuropathic Pain;Reflex Sympathetic Dystrophy;Peripheral Neuropathy;Post-herpetic Neuralgia;Spinal Cord Injury;Multiple Sclerosis | Drug: Cannabis | University of California, Davis | Center for Medicinal Cannabis Research;VA Northern California Health Care System | Not recruiting | 18 Years | 70 Years | All | 44 | Phase 1/Phase 2 | United States |
904 | NCT02442557 | December 2009 | 25 May 2015 | Safety and Dose-finding Study of DC-TAB in Healthy Subjects | A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and T-cell Tolerizing Effect of DC-TAB in Healthy Volunteers | Multiple Sclerosis | Biological: recombinant human alpha B-crystallin;Other: placebo comparator | Delta Crystallon BV | Not recruiting | 18 Years | 55 Years | Both | 76 | Phase 1 | Netherlands | |
905 | NCT01013350 | November 30, 2009 | 26 August 2019 | Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials | Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials | Multiple Sclerosis | Drug: Cladribine | EMD Serono | Not recruiting | N/A | N/A | All | 1191 | Phase 1/Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
906 | EUCTR2008-004408-29-DE | 27/11/2009 | 19 March 2012 | ESTABLISH TOLERANCE IN MS WITH PEPTIDE-PULSED, PERIPHERAL BLOOD MONONUCLEAR CELLS - A MRI-CONTROLLED, SINGLE CENTER, BASELINE-TO-TREATMENT CROSS-OVER, PHASE I/IIA TRIAL IN RELAPSING-REMITTING MS PATIENTS - ETIMS - - ETIMS | ESTABLISH TOLERANCE IN MS WITH PEPTIDE-PULSED, PERIPHERAL BLOOD MONONUCLEAR CELLS - A MRI-CONTROLLED, SINGLE CENTER, BASELINE-TO-TREATMENT CROSS-OVER, PHASE I/IIA TRIAL IN RELAPSING-REMITTING MS PATIENTS - ETIMS - - ETIMS | relapsing-remitting Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Product Name: ETIMS (EDC-fixed autologous PBMCs coupled with 7 immunodominant myelin peptides in MS patients) Product Code: ETIMS Pharmaceutical Form: Intravenous infusion | University Medical Center Hamburg-Eppendorf | Authorised | Female: yes Male: yes | Phase 1/2A | Germany | ||||
907 | EUCTR2009-013884-21-DE | 18/11/2009 | 24 November 2014 | A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS) | A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS) | Patients with acute exacerbation of Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome MedDRA version: 14.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: PEG-liposomal Prednisolone Sodium Phosphate Product Code: Nanocort Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Prednisolone Sodium Phosphate CAS Number: 125-02-0 Other descriptive name: PREDNISOLONE SODIUM PHOSPHATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 1.0-3.2 Trade Name: Solu-Medrol Pharmaceutical Form: Powder for infusion INN or Proposed INN: METHYLPREDNISOLONE SODIUM SUCCINATE CAS Number: 03/03/2375 Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000- | Enceladus Pharmaceuticals BV | Not Recruiting | Female: yes Male: yes | 90 | Poland;Belgium;Germany | ||||
908 | EUCTR2009-012989-30-GB | 17/11/2009 | 17 October 2016 | A clinical study in subjects with multiple sclerosis who successfully completed the MS-LAQ-301 (ALLEGRO) study, to assess the safety of laquinimod (experimental drug) when taken for a long period of time and how it affects the course of the disease. | A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 (ALLEGRO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis - - | Laquinimod is developed for the treatment of relapsing remitting multiple sclerosis. MedDRA version: 19.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Laquinimod Capsules 0.6 mg Product Code: TV-5600 Pharmaceutical Form: Capsule, hard INN or Proposed INN: laquinimod CAS Number: 248282-07-7 Current Sponsor code: TV-5600 Other descriptive name: ABR-215062 sodium salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- | Teva Pharmaceutical Industries Ltd | Authorised | Female: yes Male: yes | 542 | Phase 3 | Serbia;United States;Estonia;Spain;Ukraine;Lithuania;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Romania;Bulgaria;Georgia;Netherlands;Germany;Sweden | |||
909 | NCT00988052 | November 10, 2009 | 21 January 2019 | A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course | A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-301 (ALLEGRO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing MS | Relapsing Multiple Sclerosis | Drug: Laquinimod | Teva Pharmaceutical Industries, Ltd. | Not recruiting | 18 Years | 55 Years | All | 839 | Phase 3 | United States;Austria;Bulgaria;Canada;Czechia;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;Czech Republic;Latvia | |
910 | NCT01028209 | November 2009 | 15 April 2019 | Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions | Alzheimer Disease;Parkinson Disease;Multiple Sclerosis | Drug: [18F] PBR06 | Institute for Neurodegenerative Disorders | Not recruiting | 18 Years | N/A | All | 12 | Phase 1 | United States | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
911 | NCT01037907 | November 2009 | 19 February 2015 | A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) | A Placebo-controlled Phase IIa Study of Orally Administered BGC20-0134/Pleneva TM (Structured Lipid) in Patients With RRMS | Relapsing Remitting Multiple Sclerosis | Drug: Pleneva TM BGC20-0134;Drug: Placebo | BTG International Inc. | Not recruiting | 18 Years | 65 Years | Both | 173 | Phase 2 | Belgium;France;Germany;Poland;Russian Federation;Spain;Italy | |
912 | NCT01049451 | November 2009 | 16 December 2017 | Pulse ACTH vs. MP for MS | Comparison of Monthly Pulse ACTH (Acthar Gel) Therapy With Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif) | Multiple Sclerosis | Drug: ACTH;Drug: Methylprednisolone | University of Southern California | Not recruiting | 18 Years | 65 Years | All | 23 | Phase 1 | United States | |
913 | NCT01615887 | November 2009 | 19 February 2015 | Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis | Effects of Lisdexamfetamine on Bradyphrenia in Multiple Sclerosis | Multiple Sclerosis | Drug: lisdexamfetamine sulfate;Drug: placebo | State University of New York at Buffalo | Not recruiting | 18 Years | 55 Years | Both | 63 | Phase 2 | United States | |
914 | NCT01719159 | November 2009 | 28 November 2016 | Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis | Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis | Progressive Multiple Sclerosis | Drug: Rituximab | Anders Svenningsson | Västerbotten County Council, Sweden | Not recruiting | 18 Years | 65 Years | Both | 23 | Phase 2 | Sweden |
915 | EUCTR2009-011626-34-SE | 28/10/2009 | 15 May 2012 | A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 24 week period in patients with relapsing-remitting multiple sclerosis - B2201 | A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 24 week period in patients with relapsing-remitting multiple sclerosis - B2201 | Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Product Name: AIN457 Product Code: AIN457 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: not available CAS Number: not availabl Current Sponsor code: AIN457 Other descriptive name: rhumAb to Il-17A (IgG1-k-class) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Powder for solution for infusion Route of administration of the placebo: Intravenous use | Novartis Pharma Services AG | Authorised | Female: yes Male: yes | 88 | Czech Republic;Sweden | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
916 | EUCTR2009-013695-46-FR | 22/10/2009 | 14 March 2016 | ETUDE MULTICENTRIQUE, RANDOMISEE EN DOUBLE AVEUGLE VERSUS PLACEBO EVALUANT L’EFFICACITE D’UN TRAITEMENT ADDITIONNEL PAR CHOLECALCIFEROL (VITAMINE D3) CHEZ DES PATIENTS ATTEINTS DE SCLEROSE EN PLAQUES RECURRENTE (SEP-R) TRAITES PAR INTERFERON BETA 1A 44 µG 3 FOIS PAR SEMAINE PAR VOIE SOUS-CUTANEE - choline | ETUDE MULTICENTRIQUE, RANDOMISEE EN DOUBLE AVEUGLE VERSUS PLACEBO EVALUANT L’EFFICACITE D’UN TRAITEMENT ADDITIONNEL PAR CHOLECALCIFEROL (VITAMINE D3) CHEZ DES PATIENTS ATTEINTS DE SCLEROSE EN PLAQUES RECURRENTE (SEP-R) TRAITES PAR INTERFERON BETA 1A 44 µG 3 FOIS PAR SEMAINE PAR VOIE SOUS-CUTANEE - choline | Sclérose en plaques récurrente (SEP-R) MedDRA version: 12.0 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Trade Name: UVEDOSE 100 000 UI, solution buvable en ampoule Product Name: UVEDOSE 100 000 UI Pharmaceutical Form: Oral solution INN or Proposed INN: COLECALCIFEROL CAS Number: 67-97-0 Concentration unit: IU/ml international unit(s)/millilitre Concentration type: equal Concentration number: 50000- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use | MERCK SERONO s.a.s | Not Recruiting | Female: yes Male: yes | France | |||||
917 | EUCTR2008-005021-11-BE | 14/10/2009 | 12 June 2012 | An open-label, multicenter phase II extension of study 28063 (ATAMS) to obtain long-term follow-up data in patients with relapsing multiple sclerosis treated with atacicept for up to 5 years (ATAMS-Extension) - Atacicept 28063 (RMS) extension study | An open-label, multicenter phase II extension of study 28063 (ATAMS) to obtain long-term follow-up data in patients with relapsing multiple sclerosis treated with atacicept for up to 5 years (ATAMS-Extension) - Atacicept 28063 (RMS) extension study | Relapsing multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Product Name: atacicept Pharmaceutical Form: Solution for injection INN or Proposed INN: atacicept Other descriptive name: TACI-Fc5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Product Name: atacicept Pharmaceutical Form: Solution for injection INN or Proposed INN: atacicept Other descriptive name: TACI-Fc5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Product Name: atacicept Pharmaceutical Form: Solution for injection INN or Proposed INN: atacicept Other descriptive name: TACI-Fc5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- | Merck Serono SA - Geneva, An affiliate of Merck KGaA, Darmstadt, Germany | Not Recruiting | Female: yes Male: yes | 68 | Phase 2 | Czech Republic;Belgium;France;Sweden | |||
918 | NCT00787722 | October 10, 2009 | 15 April 2019 | Hematopoietic Stem Cell Transplant in Devic's Disease | Trial of High Dose Immunosuppressive Therapy With Hematopoietic Stem Cell Support in Devic's Disease | Devic's Disease | Procedure: Hematopoietic Stem Cell Transplantation;Drug: Cyclophosphamide;Drug: G-CSF;Drug: rATG;Drug: Mesna;Drug: Rituximab;Drug: Methylprednisolone | Northwestern University | Not recruiting | 16 Years | 65 Years | All | 13 | Phase 1/Phase 2 | United States | |
919 | EUCTR2008-007459-28-DE | 08/10/2009 | 19 November 2012 | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Product Name: LY2127399 Product Code: LY2127399 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: N/a CAS Number: N/a Current Sponsor code: LY2127399 Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4-120 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use | Eli Lilly and Company | Not Recruiting | Female: yes Male: yes | 245 | France;Czech Republic;Hungary;Finland;Belgium;Denmark;Bulgaria;Germany | ||||
920 | EUCTR2009-011585-28-DE | 08/10/2009 | 4 March 2013 | Early phase clinical trial to evaluate the effectiveness and safety of a new orally administered drug in patients with relapsing-remitting multiple sclerosis | A randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS) | relapsing-remitting multiple sclerosis MedDRA version: 14.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BCG20-0134 Product Code: BCG20-0134 Pharmaceutical Form: Capsule, soft Current Sponsor code: BGC20-0134 Other descriptive name: Glycerol-1,3-didecanoate-2-octadeca-(6Z,9Z,12Z)-trienoate Concentration unit: g gram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use | BTG International Ltd | Not Recruiting | Female: yes Male: yes | 184 | Phase 2a | France;European Union;Spain;Belgium;Russian Federation;Germany | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
921 | NCT01006265 | October 1, 2009 | 16 December 2017 | Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis | Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered for Twenty-four Weeks in Patients With Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis | Drug: ACT-128800 Dose 1;Drug: Placebo;Drug: ACT-128800 Dose 2;Drug: ACT-128800 Dose 3 | Actelion | Not recruiting | 18 Years | 55 Years | All | 464 | Phase 2 | United States;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom | |
922 | NCT00947895 | October 2009 | 11 April 2016 | Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone | Relative Efficacy of Repeat Course of Intravenous methyLprednisolone and Intramuscular ACTH in the Treatment of Acute Relapse of Multiple Sclerosis After Sub Response to Initial Course of Intravenous Methylprednisolone (RECLAIM): a Single Center Pilot Study | Multiple Sclerosis | Drug: Methylprednisolone;Drug: ACTH;Other: IV placebo;Other: IM placebo | Neurologique Foundation, Inc. | Mallinckrodt | Not recruiting | 18 Years | N/A | Both | 30 | Phase 2/Phase 3 | United States |
923 | NCT01225289 | October 2009 | 19 October 2017 | Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients | The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Dietary Supplement: Vitamin A;Drug: Placebo | Tehran University of Medical Sciences | Not recruiting | 20 Years | 45 Years | All | 36 | Phase 4 | Iran, Islamic Republic of | |
924 | NCT02275741 | October 2009 | 10 December 2018 | Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis | Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Biological: prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal) | Dr. med. Micha Loebermann | Not recruiting | 18 Years | 70 Years | All | 226 | Phase 2 | Germany | |
925 | EUCTR2006-001152-12-DE | 14/09/2009 | 11 April 2016 | An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis plus a long-term extension period. | An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis plus a long-term extension period. | Multiple Sclerosis MedDRA version: 16.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | sanofi-aventis recherche & développement | Not Recruiting | Female: yes Male: yes | 780 | France;Estonia;Hungary;Czech Republic;Slovakia;Finland;Lithuania;Denmark;Austria;Bulgaria;Germany;United Kingdom | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
926 | NCT00910598 | September 2009 | 19 February 2015 | Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) | A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS | Multiple Sclerosis | Drug: glatiramer acetate | Amphia Hospital | Sanofi;TEVA Pharmachemie | Recruiting | 18 Years | 55 Years | Both | 60 | Phase 4 | Netherlands |
927 | NCT00981084 | September 2009 | 19 October 2017 | Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS) | The Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis: a Double-Blind Randomized Crossover Study | Multiple Sclerosis | Drug: armodafinil | University of Missouri, Kansas City | University of Kansas | Not recruiting | 18 Years | 60 Years | All | 33 | Phase 2/Phase 3 | United States |
928 | EUCTR2009-013333-24-IT | 03/08/2009 | 19 March 2012 | Multicenter, open-label, 12 weeks Phase IV study to assess adherence to treatment in relapsing multiple sclerosis (RMS) subjects switching from other injectable DMDs using ReBiSmart to self-inject Rebif New Formulation (RNF) In a multi-dose cartriDGE (BRIDGE) - BRIDGE | Multicenter, open-label, 12 weeks Phase IV study to assess adherence to treatment in relapsing multiple sclerosis (RMS) subjects switching from other injectable DMDs using ReBiSmart to self-inject Rebif New Formulation (RNF) In a multi-dose cartriDGE (BRIDGE) - BRIDGE | RELAPSING MULTIPLE SCLEROSIS MedDRA version: 12.0 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Trade Name: REBIF Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- | MERCK SERONO SPA | Not Recruiting | Female: yes Male: yes | Phase 4 | Italy | ||||
929 | NCT00871780 | August 2009 | 16 December 2017 | A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients | A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients TIMER Study | Relapsing Remitting Multiple Sclerosis (RRMS) | Drug: BG00002 (natalizumab) | Biogen | Elan Pharmaceuticals | Not recruiting | 18 Years | 60 Years | All | 224 | Phase 4 | Belgium;Mexico;Poland;Romania;Saudi Arabia;Ukraine;Venezuela |
930 | NCT00930553 | August 2009 | 16 December 2017 | An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab | An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab | Multiple Sclerosis, Relapsing-Remitting | Biological: alemtuzumab | Genzyme, a Sanofi Company | Bayer | Not recruiting | N/A | N/A | All | 1314 | Phase 3 | United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czechia;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;Czech Republic |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
931 | NCT00940719 | August 2009 | 19 February 2015 | Vitamin D3 Supplementation and the T Cell Compartment in Multiple Sclerosis (MS) | The Effects of Vitamin D3 Supplementation on the T Cell Compartment in Multiple Sclerosis; a Pilot Study | Multiple Sclerosis | Dietary Supplement: vitamin D3 | Maastricht University Medical Center | Orbis Medical Centre | Not recruiting | 18 Years | N/A | Both | 15 | N/A | Netherlands |
932 | NCT00970333 | August 2009 | 19 February 2015 | Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions | Evaluation of [18F] FEPPA and PET as a Marker of Inflammation in Subjects With Neurological Conditions | Alzheimer Disease;Parkinson Disease;Multiple Sclerosis | Drug: [18F]-FEPPA | Institute for Neurodegenerative Disorders | Not recruiting | 18 Years | N/A | Both | 3 | Phase 1 | United States | |
933 | EUCTR2009-010661-23-IT | 30/07/2009 | 19 March 2012 | MITOXANTRONE/GLATIRAMER ACETATE COMBINED TREATMENT IN THE THERAPY OF SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS - aMICO STUDY | MITOXANTRONE/GLATIRAMER ACETATE COMBINED TREATMENT IN THE THERAPY OF SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS - aMICO STUDY | subjects affected by secondary-progressive Multiple Sclerosis MedDRA version: 9.1 Level: SOC Classification code 10029205 | Pharmaceutical Form: Solution for injection INN or Proposed INN: Mitoxantrone Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 2- Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Glatiramer acetate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- | AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI | Not Recruiting | Female: yes Male: yes | Italy | |||||
934 | NCT00950248 | July 22, 2009 | 20 August 2018 | Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis (IPPoMS) | Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Drug: Idebenone | National Institute of Allergy and Infectious Diseases (NIAID) | Not recruiting | 18 Years | 65 Years | All | 85 | Phase 1/Phase 2 | United States | |
935 | EUCTR2009-013129-41-NL | 20/07/2009 | 19 March 2012 | A multicenter open label randomized pilot study, to compare retinal nerve fiber layer thickness measured by Optical Coherence Tomography after treatment with daily 20 mg glatiramer acetate subcutaneously or after no treatment, in patients with a clinical isolated syndrome, other than optic neuritis or early relapsing remitting multiple sclerosis patients - OCT | A multicenter open label randomized pilot study, to compare retinal nerve fiber layer thickness measured by Optical Coherence Tomography after treatment with daily 20 mg glatiramer acetate subcutaneously or after no treatment, in patients with a clinical isolated syndrome, other than optic neuritis or early relapsing remitting multiple sclerosis patients - OCT | clinical isolated syndrome MedDRA version: 9.1 Level: LLT Classification code 10028248 Term: Multiple sclerosis-like syndrome | Trade Name: Copaxone Product Name: Copaxone Pharmaceutical Form: Solution for injection CAS Number: 147245929 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- | Amphia Ziekenhuis | Authorised | Female: yes Male: yes | Netherlands | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
936 | EUCTR2008-002626-11-SE | 02/07/2009 | 24 July 2017 | Intrathecal therapy with monoclonal antibodies in severe progressive multiple sclerosis | Intrathecal therapy with monoclonal antibodies in severe progressive multiple sclerosis - PMSIT | Severe progressive multiple sclerosis in which there is no other documented treatment avalilable or allready tested. It is estimated that the prognosis for these patients are poor without any effective treatment MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders | Trade Name: Mabthera Pharmaceutical Form: Concentrate for solution for infusion Other descriptive name: RITUXIMAB | Dept of Neurology | Not Recruiting | Female: yes Male: yes | Phase 2 | Sweden | ||||
937 | NCT00947752 | July 2009 | 16 December 2017 | Safety of New Formulation of Glatiramer Acetate | An Open-Label, Multicenter, Randomized Study Evaluating the Tolerability and Safety of Two Formulations of Glatiramer Acetate (GA) for Subcutaneous Injection | Relapsing Remitting Multiple Sclerosis | Drug: Glatiramer Acetate;Drug: Experimental Glatiramer Acetate | Teva Pharmaceutical Industries | Not recruiting | 18 Years | N/A | All | 147 | Phase 3 | United States | |
938 | NCT00965497 | July 2009 | 19 October 2017 | Escitalopram (Lexapro) for Depression MS or ALS | An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (Lexapro®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis | Major Depression;Multiple Sclerosis;Amyotrophic Lateral Sclerosis | Drug: escitalopram | University of South Carolina | Not recruiting | 18 Years | 70 Years | All | 13 | Phase 3 | United States | |
939 | EUCTR2009-011234-99-DE | 23/06/2009 | 3 February 2014 | A Phase I, sequential group, randomized, double-blind, placebo-controlled study to assess the tolerability and safety of escalating doses of oral laquinimod administered daily in subjects with relapsing remitting multiple sclerosis (RRMS) | A Phase I, sequential group, randomized, double-blind, placebo-controlled study to assess the tolerability and safety of escalating doses of oral laquinimod administered daily in subjects with relapsing remitting multiple sclerosis (RRMS) - MS-LAQ-101 | Laquinimod is developed for the treatment of relapsing remitting multiple sclerosis (RRMS). This study is planned to assess the tolerability and safety of escalating doses of oral laquinimod administered daily in subjects with RRMS. MedDRA version: 15.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Laquinimod Capsules 0.6 mg Product Code: TV-5600 Pharmaceutical Form: Capsule, hard INN or Proposed INN: laquinimod CAS Number: 248282-07-7 Current Sponsor code: TV-5600 Other descriptive name: ABR-215062 sodium salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Laquinimod Capsules 0.3 mg Product Code: TV-5600 Pharmaceutical Form: Capsule, hard INN or Proposed INN: laquinimod CAS Number: 248282-07-7 Current Sponsor code: TV-5600 Other descriptive name: ABR-215062 sodium salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.3- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Teva Pharmaceutical Industries Ltd | Not Recruiting | Female: yes Male: yes | 160 | Phase 1 | Germany | |||
940 | EUCTR2009-011523-31-GB | 23/06/2009 | 19 March 2012 | A study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VAC | A study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VAC | The vaccinations are being used to investigate immunological memory following treatment of multiple sclerosis with the lympho-depleting humanised monoclonal antibody alemtuzumab. MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10046859 Term: Vaccination | Trade Name: Menitorix Pharmaceutical Form: Powder and solvent for solution for injection Trade Name: Pneumovax II Pharmaceutical Form: Solution for injection Trade Name: REVAXIS Pharmaceutical Form: Suspension for injection | R & D, Cambridge University Hospitals | Not Recruiting | Female: yes Male: yes | 60 | United Kingdom | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
941 | EUCTR2008-006333-27-LV | 19/06/2009 | 27 January 2014 | A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple Sclerosis - ADVANCE | A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple Sclerosis - ADVANCE | Relapsing Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Product Name: PEGylated Interferon Beta-1a Product Code: BIIB017 Pharmaceutical Form: Solution for injection Current Sponsor code: BIIB017 Other descriptive name: PEGylated Interferon Beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 63-125 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Biogen Idec LTD | Not Recruiting | Female: yes Male: yes | 1260 | Czech Republic;Estonia;Greece;Spain;Belgium;Bulgaria;Netherlands;Germany;Latvia;United Kingdom | ||||
942 | EUCTR2008-006786-92-CZ | 18/06/2009 | 19 March 2012 | Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosis | Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosis | relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Product Name: ACT-128800 Product Code: ACT-128800 Pharmaceutical Form: Capsule, hard Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: ACT-128800 Product Code: ACT-128800 Pharmaceutical Form: Capsule, hard Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: ACT-128800 Product Code: ACT-128800 Pharmaceutical Form: Capsule, hard Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Actelion Pharmaceuticals Ltd | Authorised | Female: yes Male: yes | 460 | Hungary;Finland;United Kingdom;Czech Republic;Netherlands;Bulgaria;France;Spain;Italy;Austria;Poland;Sweden | ||||
943 | EUCTR2008-007549-29-DK | 09/06/2009 | 19 March 2012 | Trichuris suis Ova Therapy for Relapsing Multiple Sclerosis - a safety study - TRIMS A | Trichuris suis Ova Therapy for Relapsing Multiple Sclerosis - a safety study - TRIMS A | Relapsing Multipel Sclerosis MedDRA version: 12.0 Level: LLT Classification code 10028245 Term: Multiple sclerosis MedDRA version: 12.0 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 12.0 Level: LLT Classification code 10053395 Term: Progressive multiple sclerosis | Product Name: Trichuris suis Ova Product Code: TSO Pharmaceutical Form: Oral suspension INN or Proposed INN: Trichuris suis eggs Current Sponsor code: Trichuris suis eggs Other descriptive name: Trichuris suis eggs Concentration unit: thousand organisms/ml thousand organisms/millilitre Concentration type: range Concentration number: 0,15-0,183 | Danish Multiple Sclerosis Research Center | Not Recruiting | Female: yes Male: yes | 10 | Denmark | ||||
944 | NCT00917839 | June 2009 | 19 February 2015 | The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis | Randomized, Placebo-Controlled Phase II Monocentric Trial for the Neuroprotective Effect of Lamotrigine Plus Interferon Beta 1a 30mcg Once Weekly Intramuscular in Patients With Relapsing-Remitting Multiple Sclerosis. | Relapsing-Remitting Multiple Sclerosis | Drug: lamotrigine | Cantonal Hospital of St. Gallen | Recruiting | 18 Years | 50 Years | Both | 88 | Phase 2 | Switzerland | |
945 | NCT00942214 | June 2009 | 19 February 2015 | Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment | Biomarkers Associated With Response to Natalizumab in Multiple Sclerosis Patients. A Prospective Multicentric Open Label Phase IV Study | Multiple Sclerosis | Drug: Natalizumab | University Hospital, Toulouse | Not recruiting | 18 Years | 55 Years | Both | 300 | Phase 4 | France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
946 | EUCTR2009-011516-37-DK | 29/05/2009 | 8 August 2016 | Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multiple sclerosis - EPO-ProgMS | Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multiple sclerosis - EPO-ProgMS | Multiple Sclerosis, with primary and secondary progressive courses. MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Trade Name: NeoRecormon Pharmaceutical Form: Solution for infusion INN or Proposed INN: Solu-Medrol CAS Number: 2375033 Current Sponsor code: Pfizer Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE Concentration unit: mg milligram(s) Concentration type: equal Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous drip use (Noncurrent) | Danish Multiple Sclerosis Research Centre | Not Recruiting | Female: yes Male: yes | Phase 2 | Denmark | ||||
947 | NCT00799890 | May 2009 | 10 December 2018 | Sunphenon in Progressive Forms of Multiple Sclerosis | Monocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Evaluate the Effect of Sunphenon EGCg (Main Component Epigallocatechin-Gallat) on the Increase of Brain Atrophy in the Cerebral Magnetic Resonance Tomography in a 36-months Treatment Time in Patients With Primary or Secondary Chronic-progressive Multiple Sclerosis | Multiple Sclerosis | Drug: Sunphenon EGCG;Drug: Placebo | Friedemann Paul | TAIYO EUROPE | Not recruiting | 18 Years | 65 Years | All | 60 | Phase 2/Phase 3 | Germany |
948 | NCT00854750 | May 2009 | 19 February 2015 | Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis | Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis | Multiple Sclerosis | Drug: ACTHAR | Elliot Frohman | Questcor Pharmaceuticals, Inc. | Not recruiting | 18 Years | 65 Years | Both | 1 | Phase 4 | United States |
949 | NCT00902135 | May 2009 | 3 August 2015 | Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH) | Betaferon® Injection Management: Non-interventional Study on Personal Digital Assistant (PDA)Supported Effects on Adherence to a Long-term Injection Therapy (BETAPATH) | Relapsing-Remitting Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 18 Years | N/A | Both | 702 | N/A | Germany | |
950 | NCT01075880 | May 2009 | 19 February 2015 | Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® | Post-Authorization Observational Study to Evaluate Cognition and Fatigue in RRMS Patients Treated With Rebif | Multiple Sclerosis, Relapsing-Remitting | Drug: Rebif (Interferon beta-1a) | Merck KGaA | Merck spol.s.r.o., Czech Republic | Not recruiting | 18 Years | 65 Years | Both | 300 | N/A | Czech Republic |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
951 | EUCTR2008-007447-14-IT | 03/04/2009 | 7 January 2013 | GH-IGF-I status and Multiple Sclerosis: clinical implications (a prevalence study). | GH-IGF-I status and Multiple Sclerosis: clinical implications (a prevalence study). | patients with Multiple Sclerosis MedDRA version: 14.1 Level: SOC Classification code 10022891 Term: Investigations System Organ Class: 10022891 - Investigations MedDRA version: 14.1 Level: SOC Classification code 10014698 Term: Endocrine disorders System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: Somatorelin Concentration unit: µg microgram(s) Concentration number: 50- | UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II | Authorised | Female: yes Male: yes | Italy | |||||
952 | NCT00764413 | April 2009 | 19 February 2015 | Chronotherapy in Acute Multiple Sclerosis (MS) Attack | Treatment With Methylprednisolone in Acute Exacerbations of Multiple Sclerosis: Enhanced Effect With Nighttime Treatment? | Multiple Sclerosis | Drug: methylprednisolone;Drug: Sodium chlorid | Sykehuset Innlandet HF | Not recruiting | 18 Years | N/A | Both | 57 | N/A | Norway | |
953 | NCT00881205 | April 2009 | 19 October 2017 | Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment | A 16-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Rivastigmine Patch (10 cm²) on Cognitive Deficits in Patients With Multiple Sclerosis, Followed by a 1-year Open-label Treatment Phase | Multiple Sclerosis;Cognitive Impairment | Drug: Rivastigmine transdermal patch;Drug: Placebo | Novartis Pharmaceuticals | Not recruiting | 18 Years | 65 Years | All | 86 | Phase 4 | Germany | |
954 | NCT00882999 | April 2009 | 26 November 2018 | A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Drug: LY2127399;Drug: Placebo | Eli Lilly and Company | Not recruiting | 18 Years | 64 Years | All | 245 | Phase 2 | United States;Bulgaria;Czechia;France;Germany;Hungary;Israel;Poland;Romania;Russian Federation;Serbia;Slovakia;Ukraine;Belgium;Canada;Czech Republic;Denmark;Finland;Switzerland | |
955 | NCT00904826 | April 2009 | 19 October 2017 | An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica | An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica | Neuromyelitis Optica;Devic's Disease | Drug: Eculizumab | Mayo Clinic | Alexion Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 14 | Phase 1/Phase 2 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
956 | NCT00914290 | April 2009 | 16 December 2017 | A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis | A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis | Spasticity;Multiple Sclerosis | Drug: IPX056;Drug: Baclofen IR;Drug: Placebo IPX056;Drug: Placebo IR | IMPAX Laboratories, Inc. | Not recruiting | 18 Years | N/A | All | 23 | Phase 2 | United States | |
957 | EUCTR2008-006226-34-ES | 25/03/2009 | 10 July 2015 | Estudio multicéntrico, aleatorizado, de grupos paralelos, ciego para el evaluador, que compara la efectividad y seguridad de teriflunomida e interferón beta-1a en pacientes con esclerosis múltiple recidivante ------------------------------------------------------------ A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosisA multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis. - TENERE | Estudio multicéntrico, aleatorizado, de grupos paralelos, ciego para el evaluador, que compara la efectividad y seguridad de teriflunomida e interferón beta-1a en pacientes con esclerosis múltiple recidivante ------------------------------------------------------------ A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosisA multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis. - TENERE | Esclerosis Múltiple ------------------------ Multiple sclerosis | Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Trade Name: REBIF 44 microgramos solución inyectable Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA1A Other descriptive name: INTERFERON BETA1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- | sanofi-aventis recherche et development | Not Recruiting | Female: yes Male: yes | 300 | France;Czech Republic;Hungary;Belgium;Spain;Germany;United Kingdom;Italy | ||||
958 | EUCTR2007-004452-36-GB | 24/03/2009 | 25 September 2012 | A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis using interferon-beta 1a (Rebif®) as an open-label rater-blind calibrator - | Multiple sclerosis MedDRA version: 15.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Teriflunomide Product Code: HMR 1726D Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726D Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Sanofi-aventis recherche & développement | Authorised | Female: yes Male: yes | 1110 | Germany;France;Austria;Australia;Sweden;Czech Republic;Tunisia;Canada;Belarus;Belgium;Greece;United States;Philippines;Poland;Turkey;Netherlands;Chile;United Kingdom;Slovakia;Ukraine;Mexico;Estonia;China;Romania;Spain;Thailand | |||||
959 | NCT00884481 | March 23, 2009 | 19 November 2018 | Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS | A Multi-centre and Prospective Trial to Evaluate the Effects on Multiple Sclerosis Related Fatigue During Treatment With Tysabri in Patients With Relapsing Remitting Multiple Sclerosis Over the Course of 12 Months | Relapsing-Remitting Multiple Sclerosis;Fatigue | Other: Natalizumab | Biogen | Not recruiting | 18 Years | 65 Years | All | 195 | Phase 2 | Austria;Denmark;Norway;Sweden;United States | |
960 | EUCTR2008-008065-35-SE | 13/03/2009 | 24 July 2012 | A multi-centre and prospective trial to evaluate the effects on mul-tiple sclerosis related fatigue during treatment with Tysabri® in patients with relapsing remitting multiple sclerosis over the course of 12 months - TYNERGY | Mutiple sclerosis related fatigue in subjects with relapsing remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10016256 Term: Fatigue | Trade Name: Tysabri Pharmaceutical Form: Intravenous infusion | BiogenIdec A/S | Not Recruiting | Female: yes Male: yes | 200 | Sweden | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
961 | EUCTR2008-004174-40-FR | 06/03/2009 | 19 March 2012 | Imagerie de la démyélinisation dans la sclérose en plaques : une étude en tomographie à émission de positons (TEP) avec le 11C-2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (11C-PIB) - SHADOWTEP | Imagerie de la démyélinisation dans la sclérose en plaques : une étude en tomographie à émission de positons (TEP) avec le 11C-2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (11C-PIB) - SHADOWTEP | Groupe I: volontaires sains Groupe II: patients avec une sclérose en plaques d'évolution rémittente . MedDRA version: 8.1 Level: PT Classification code 10012300 Term: Demyelinating disease (excl multiple sclerosis) | Product Name: 11C-PIB Pharmaceutical Form: Solution for injection INN or Proposed INN: 11C-PIB Concentration unit: MBq megabecquerel(s) Concentration type: equal Concentration number: 740- | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Authorised | Female: yes Male: yes | France | |||||
962 | NCT00818038 | March 2009 | 19 February 2015 | A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function | Phase IV, Proof of Concept Study to Evaluate Tysabri Effectiveness in RRMS Patient Bladder Function | Relapsing-Remitting Multiple Sclerosis | Drug: BG0002 (natalizumab) | Biogen Idec | Not recruiting | 18 Years | 85 Years | Both | 30 | N/A | United States | |
963 | NCT00853762 | March 2009 | 16 December 2017 | Atacicept in Multiple Sclerosis Extension Study, Phase II | An Open-label, Multicenter Phase II Extension of Study 28063 (ATAMS) to Obtain Long-term Follow-up Data in Subjects With Relapsing Multiple Sclerosis Treated With Atacicept for up to 5 Years (ATAMS-Extension) | Relapsing Multiple Sclerosis | Drug: Atacicept 25 mg;Drug: Atacicept 75 mg;Drug: Atacicept 150 mg | EMD Serono | Merck KGaA | Not recruiting | 18 Years | 60 Years | All | 74 | Phase 2 | United States;Australia;Belgium;Canada;Czech Republic;France;Germany;Lebanon;Lithuania;Netherlands;New Caledonia;Russian Federation;Spain;Sweden;Switzerland;Ukraine;United Kingdom |
964 | NCT00879658 | March 2009 | 12 March 2018 | Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis | A Phase II, Double-blind, Randomized, Multi-center, Adaptive Dose-ranging, Placebo-controlled, Parallel-group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis. | Relapsing-remitting Multiple Sclerosis | Drug: BAF312;Drug: Placebo | Novartis Pharmaceuticals | Not recruiting | 18 Years | 55 Years | All | 296 | Phase 2 | United States;Canada;Finland;Germany;Hungary;Italy;Norway;Poland;Russian Federation;Spain;Switzerland;Turkey | |
965 | NCT02021825 | March 2009 | 19 February 2015 | Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders | Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders | Neuromyelitis Optica;Neuromyelitis Optica Spectrum Disorders | Drug: Mitoxantrone | Xuanwu Hospital, Beijing | Recruiting | 18 Years | 55 Years | Both | 50 | Phase 4 | China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
966 | NCT00837785 | February 28, 2009 | 26 February 2018 | A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS | A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: BG00012 | Biogen | Not recruiting | 18 Years | 55 Years | All | 48 | Phase 1 | Germany;United Kingdom | |
967 | EUCTR2008-000256-26-GB | 16/02/2009 | 30 June 2014 | An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferonß-1a (IFNß-1a, Rebif®) therapy in the induction of tolerance to IFNß in MS patients with neutralising antibodies (NAbs) to subcutaneous IFNß-1a (Rebif® or Avonex®) - Tolerance induction with intravenous IFNß-1a | An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferonß-1a (IFNß-1a, Rebif®) therapy in the induction of tolerance to IFNß in MS patients with neutralising antibodies (NAbs) to subcutaneous IFNß-1a (Rebif® or Avonex®) - Tolerance induction with intravenous IFNß-1a | Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Trade Name: Mitoxantrone Product Name: Mitoxantrone Product Code: PL 04515/0127 Pharmaceutical Form: Concentrate for solution for infusion Trade Name: Rebif® Pharmaceutical Form: Solution for injection INN or Proposed INN: Mitoxantrone CAS Number: 70476-82-3 Concentration unit: 1X 100 milligrams/millilitre Concentration type: up to | Queen Mary, University of London | Not Recruiting | Female: yes Male: yes | 15 | Phase 2a | United Kingdom | |||
968 | EUCTR2008-005304-93-GB | 13/02/2009 | 19 March 2012 | A Randomised Control Trial To Evaluate Whether Zoledronate Prevents Bone Loss In Acute Exacerbations Of Multiple Sclerosis - Zoledronate in multiple sclerosis | A Randomised Control Trial To Evaluate Whether Zoledronate Prevents Bone Loss In Acute Exacerbations Of Multiple Sclerosis - Zoledronate in multiple sclerosis | Bone loss in patients with Multiple Sclerosis (MS) who require large short term doses of methylprednisolone for exacerbations of their disease. MedDRA version: 9.1 Level: LLT Classification code 10048393 Term: Multiple sclerosis relapse MedDRA version: 9.1 Level: LLT Classification code 10065687 Term: Bone loss | Trade Name: Aclasta 5mg solution for infusion Product Name: Aclasta Product Code: ZOL446H Pharmaceutical Form: Solution for infusion Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | North Bristol Trust | Not Recruiting | Female: yes Male: yes | United Kingdom | |||||
969 | EUCTR2008-005906-38-FR | 09/02/2009 | 19 March 2012 | Détermination de biomarqueurs associés à la réponse au Natalizumab dans la Sclérose en plaques | Détermination de biomarqueurs associés à la réponse au Natalizumab dans la Sclérose en plaques | sclérose en plaques MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Trade Name: Tysabri Product Name: Tysabri Pharmaceutical Form: Solution for injection | CHU de Toulouse | Authorised | Female: yes Male: yes | 300 | France | ||||
970 | EUCTR2007-002627-32-CZ | 04/02/2009 | 6 January 2015 | efficacy and safety of 0.5 mg fingolimod in patients with primary progressive multiple sclerosis | A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5mg fingolimod administered orally once daily versus placebo in patients with primary progressive multiple sclerosis. | Primary progressive multiple sclerosis. MedDRA version: 17.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359- 56-0 Current Sponsor code: FTY720D Other descriptive name: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 970 | Finland;Spain;Ireland;Turkey;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Australia;Denmark;South Africa;Netherlands;Germany;Sweden | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
971 | NCT03408093 | February 3, 2009 | 2 July 2018 | Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b | Cross-sectional Retrospective Study of Therapeutic Compliance in Patients With Multiple Sclerosis Treated With Interferon Beta-1b | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 18 Years | 100 Years | All | 120 | Phase 1/Phase 2 | ||
972 | NCT00836719 | February 2009 | 19 October 2017 | Safety of Polyphenon E in Multiple Sclerosis Pilot Study | Safety and Neuroprotective Effects of Polyphenon E in Multiple Sclerosis | Multiple Sclerosis | Drug: Polyphenon E | Louisiana State University Health Sciences Center in New Orleans | National Center for Complementary and Integrative Health (NCCIH) | Not recruiting | 18 Years | 65 Years | All | 10 | Phase 1 | United States |
973 | EUCTR2008-001999-67-ES | 30/01/2009 | 26 June 2012 | Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y de 14 semanas de tratamiento para evaluar la eficacia, seguridad y tolerabilidad de Nerispirdina 50 mg, 100 mg y 200 mg en pacientes con Esclerosis Múltiple ___________________________________________________________________ A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients with Multiple Sclerosis | Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y de 14 semanas de tratamiento para evaluar la eficacia, seguridad y tolerabilidad de Nerispirdina 50 mg, 100 mg y 200 mg en pacientes con Esclerosis Múltiple ___________________________________________________________________ A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients with Multiple Sclerosis | Esclerosis Múltiple ______________ Multiple Sclerosis MedDRA version: 11.0 Level: LLT Classification code 10028245 Term: | Product Name: Nerispirdine hydrochloride Product Code: HP184 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Nerispirdine hydrochloride CAS Number: 119229-64-0 Current Sponsor code: HP184 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | sanofi-aventis Recherche & Développement | Authorised | Female: yes Male: yes | 368 | Finland;Germany;France;Spain | ||||
974 | EUCTR2008-005559-46-CZ | 23/01/2009 | 26 August 2013 | An Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis who have completed Treatment in the study 205MS201 (SELECT) | A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT) - SELECTION | Relapsing-remitting Multiple Sclerosis MedDRA version: 14.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: DACLIZUMAB HYP Product Code: BIIB019 Pharmaceutical Form: Solution for injection INN or Proposed INN: Daclizumab with Greek suufix Current Sponsor code: BIIB019 Other descriptive name: Daclizumab HYP (DAC HYP) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: DACLIZUMAB HYP Product Code: BIIB019 Pharmaceutical Form: Solution for injection INN or Proposed INN: Daclizumab with Greek suufix Current Sponsor code: BIIB019 Other descriptive name: Daclizumab HYP (DAC HYP) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- | Biogen Idec Ltd. | Not Recruiting | Female: yes Male: yes | 600 | Hungary;Czech Republic;Poland;Ukraine;Russian Federation;Germany;United Kingdom;India | ||||
975 | EUCTR2008-004753-14-BE | 22/01/2009 | 30 April 2018 | Long-Term Safety and Efficacy Study of Oral BG00012 Monotherapy in Relapsing-Remitting Multiple Sclerosis | A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis - ENDORSE | Relapsing-Remitting Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Dimethyl Fumarate CAS Number: 624497 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- | Biogen Idec Limited | Authorised | Female: yes Male: yes | 1738 | Phase 3 | Serbia;Belarus;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Ireland;Israel;Switzerland;Italy;India;France;Macedonia, the former Yugoslav Republic of;Australia;South Africa;Netherlands;Latvia;Moldova, Republic of;Bosnia and Herzegovina;Guatemala;Austria;United Kingdom;Czech Republic;Mexico;Canada;Poland;Belgium;Romania;Croatia;Bulgaria;Germany;New Zealand | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
976 | EUCTR2008-003098-42-CZ | 06/01/2009 | 19 March 2012 | A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis | A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis | To evaluate the immunogenicity of Avonex® 30 mcg when administered SC to interferon-naïve subjects with relapsing Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Trade Name: AVONEX Pharmaceutical Form: Solution for injection INN or Proposed INN: interferon beta 1a Concentration unit: µg/ml microgram(s)/millilitre Concentration type: not less then Concentration number: 30- | Biogen Idec Ltd | Authorised | Female: yes Male: yes | 150 | Czech Republic | ||||
977 | EUCTR2007-004223-38-GB | 05/01/2009 | 12 June 2012 | A double-blind, randomized, placebo-controlled, multicenter, dose-finding trial of ofatumumab in RRMS patients | A double-blind, randomized, placebo-controlled, multicenter, dose-finding trial of ofatumumab in RRMS patients - Ofatumumab dose-finding in RRMS patients | Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 13.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders | Product Name: Ofatumumab Product Code: HuMax-CD20 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ofatumumab CAS Number: 679818-59-8 Current Sponsor code: HuMax-CD20 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use | GlaxoSmithKline UK | Authorised | Female: yes Male: yes | 57 | Germany;Czech Republic;United Kingdom;Denmark;Sweden | ||||
978 | NCT00666887 | January 2009 | 16 December 2017 | Minocycline in Clinically Isolated Syndromes (CIS) | A Phase III Double-blind, Randomized, Placebo-controlled Trial of Minocycline in Clinically Isolated Syndromes (CIS) and Early Single Relapse Multiple Sclerosis (MS) | Clinically Isolated Syndromes;Early Single Relapse of Multiple Sclerosis | Drug: Minocycline;Drug: Placebo | Dr. Luanne Metz | Multiple Sclerosis Society of Canada | Not recruiting | 18 Years | 60 Years | All | 142 | Phase 3 | Canada |
979 | NCT00828204 | January 2009 | 19 October 2017 | Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects | An Open-Label, Multicenter Study to Evaluate the Safe and Effective Use of the Single-Use Autoinjector With an Avonex® Prefilled Syringe in Multiple Sclerosis Subjects | Multiple Sclerosis | Device: single-use autoinjector with a prefilled liquid Avonex syringe;Device: Avonex prefilled syringe via manual IM injection;Drug: BG9418 (interferon beta-1a) | Biogen | Not recruiting | 18 Years | 65 Years | All | 95 | Phase 3 | United States | |
980 | NCT00841321 | January 2009 | 19 October 2017 | Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis | Ginkgo Biloba for Cognitive Impairment in Multiple Sclerosis | Multiple Sclerosis;Cognitive Ability, General | Drug: Ginkgo biloba;Drug: Placebo | VA Office of Research and Development | Not recruiting | 18 Years | 65 Years | All | 120 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
981 | NCT01031199 | January 2009 | 19 February 2015 | Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers | Open-label, Non-randomized, Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of 140 MBq (ca. 5 mSv) ZK 6032924 (BAY85-8101) for Its Diagnostic Potential in Either Drug-naïve or Specifically (IFN-beta) Pretreated Patients With Multiple Sclerosis (MS) With Acute Relapse or Patients With Clinically Isolated Syndrome (CIS), Compared to Healthy Volunteers | Positron-Emission Tomography;Multiple Sclerosis | Drug: F-18 FEDAA1106 (BAY85-8101) | Bayer | Not recruiting | 20 Years | 55 Years | Both | 16 | Phase 1 | Australia;Sweden | |
982 | EUCTR2009-014724-32-DE | 3 April 2017 | Boswellic Acids in Multiple Sclerosis | SAFETY, TOLERABILITY AND MECHANISM OF ACTION OF BOSWELLIC ACIDS (BA) IN MULTIPLE SCLEROSIS (MS) AND CLINICALLY ISOLATED SYNDROME (CIS): A MRI-CONTROLLED, MULTICENTER, BASELINE-TO-TREATMENT, 32-WEEKS, OPEN-LABEL, PHASE IIA TRIAL IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS OR CLINICALLY ISOLATED SYNDROME - SABA | Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BOSWELAN Product Code: BOSWELAN Pharmaceutical Form: Capsule, soft INN or Proposed INN: BOSWELAN Current Sponsor code: BOSWELAN Other descriptive name: Boswellia serrata extract PS0201Bo capsules Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- | University Medical Center Eppendorf | Not Recruiting | Female: yes Male: yes | Phase 2 | Germany | |||||
983 | EUCTR2009-016442-74-ES | 29 April 2013 | Trasplante autólogo de células madre mesenquimales en esclerosis múltiple: ensayo clínico fase II aleatorizado, enmascarado y cruzado con placebo. | Trasplante autólogo de células madre mesenquimales en esclerosis múltiple: ensayo clínico fase II aleatorizado, enmascarado y cruzado con placebo. | Esclerosis Múltiple MedDRA version: 9 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive | Product Name: Células madre mesenquimales Pharmaceutical Form: INN or Proposed INN: Células madre mesenquimales Current Sponsor code: CMM Concentration unit: EID50 50% Embryo Infective Dose Concentration type: up to Concentration number: 2000000- Route of administration of the placebo: Intravenous use | Fundació Clínic per a la Recerca Biomèdica | Authorised | Female: yes Male: yes | Spain | ||||||
984 | NCT00725985 | December 31, 2008 | 16 December 2017 | Oral Cladribine in Early Multiple Sclerosis (MS) | A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS | Multiple Sclerosis | Drug: Cladribine;Drug: Placebo;Drug: Rebif® new formulation (RNF) | EMD Serono | Not recruiting | 18 Years | 55 Years | All | 617 | Phase 3 | United States;Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Estonia;Finland;France;Georgia;Germany;India;Italy;Korea, Republic of;Lebanon;Macedonia, The Former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;Saudi Arabia | |
985 | EUCTR2008-005125-11-GB | 19/12/2008 | 19 March 2012 | A pilot single-centre randomised controlled trial of recombinant human erythropoietin versus placebo in primary progressive multiple sclerosis. | A pilot single-centre randomised controlled trial of recombinant human erythropoietin versus placebo in primary progressive multiple sclerosis. | Primary progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063401 Term: Primary progressive multiple sclerosis | Trade Name: Neorecormon Product Name: Recombinant Human Erythropoietin Product Code: rhEPO Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: epoetin beta CAS Number: 122312-54-3 Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 30000- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use | Walton Centre for Neurology and Neurosurgery | Not Recruiting | Female: yes Male: yes | United Kingdom | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
986 | EUCTR2007-004051-11-GB | 18/12/2008 | 19 March 2012 | Amiloride Treatment in Multiple Sclerosis - Amiloride in MS | Amiloride Treatment in Multiple Sclerosis - Amiloride in MS | Multiple Sclerosis | Trade Name: Amiloride Product Name: Amiloride Hydrochloride Pharmaceutical Form: Coated tablet | Oxford Racliffe NHS Trust | Not Recruiting | Female: yes Male: yes | 23 | United Kingdom | ||||
987 | EUCTR2008-004954-34-CZ | 12/12/2008 | 27 January 2014 | Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) | Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of converting to MS, treated with Rebif® New Formulation (REFLEXION) - REFLEXION | Subjects of high risk of converting to Multiple Sclerosis or subjects already converted to Multiple Sclerosis. MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Rebif INN or Proposed INN: Interferon-beta 1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Merck Serono S.A. - Geneva, an affiliate of Merck KGaA, Darmstadt, Germany | Not Recruiting | Female: yes Male: yes | 492 | Serbia;Portugal;Estonia;Slovakia;Morocco;Greece;Spain;Lebanon;Russian Federation;Israel;Italy;France;Latvia;Finland;Turkey;Austria;Czech Republic;Canada;Argentina;Belgium;Poland;Romania;Croatia;Bulgaria;Germany | ||||
988 | NCT00819000 | December 2008 | 19 February 2015 | Therapy Optimization in Multiple Sclerosis (MS) | TOP MS is a Study of Multiple Sclerosis Disease Management in Collaboration With Specialty Pharmacies | Multiple Sclerosis | Drug: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b | Teva Neuroscience, Inc. | Not recruiting | 18 Years | N/A | Both | 2878 | N/A | United States | |
989 | NCT00819195 | December 2008 | 19 February 2015 | Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis | Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis | Multiple Sclerosis | Drug: Glatiramer acetate | University of California, San Francisco | National Multiple Sclerosis Society;Teva Neuroscience, Inc. | Not recruiting | 18 Years | 55 Years | Both | 17 | N/A | United States |
990 | EUCTR2007-007759-15-HU | 10/11/2008 | 19 March 2012 | The Effect of the Dose of PI-2301 on Safety, Tolerability, and Pharmacokinetics in Subjects with the Secondary Progressive Form of Multiple Sclerosis A double-blind, placebo-controlled, randomized, multiple ascending dose (MAD) trial | The Effect of the Dose of PI-2301 on Safety, Tolerability, and Pharmacokinetics in Subjects with the Secondary Progressive Form of Multiple Sclerosis A double-blind, placebo-controlled, randomized, multiple ascending dose (MAD) trial | Patients with current diagnosis of SP-MS MedDRA version: 9.1 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis | Product Name: PI-2301 Product Code: CO-14 Pharmaceutical Form: Solution for injection CAS Number: 1026791-33-1 Current Sponsor code: PI-2301 Other descriptive name: CO-14 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | PEPTIMMUNE Inc | Not Recruiting | Female: yes Male: yes | 53 | Hungary | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
991 | NCT00744679 | November 2008 | 19 February 2015 | A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State | An Assessment of the Steady-State Pharmacokinetic and Pharmacodynamic Profile of Tysabri 300 mg Following at Least 12 Monthly Infusions | Multiple Sclerosis | Drug: Natalizumab | Biogen Idec | Elan Pharmaceuticals | Not recruiting | 18 Years | 55 Years | Both | 20 | Phase 4 | United States |
992 | NCT00771043 | November 2008 | 19 February 2015 | A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a | Optical Coherence Tomography as a Measure of Neuroprotection in Patients With Relapsing-Remitting Multiple Sclerosis Receiving Natalizumab or Interferon Beta-1a | Relapsing-Remitting Multiple Sclerosis | Drug: TYSABRI and AVONEX | Biogen Idec | Not recruiting | 18 Years | 55 Years | Both | 50 | Phase 4 | United States | |
993 | EUCTR2008-004579-22-AT | 14/10/2008 | 19 March 2012 | A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg Assay Panel and the B-Cell /Antibody response panel to predict the clinical effect of Octagam 5% in subjects with relapsing/remitting (RR) multiple sclerosis (MS) | A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg Assay Panel and the B-Cell /Antibody response panel to predict the clinical effect of Octagam 5% in subjects with relapsing/remitting (RR) multiple sclerosis (MS) | Subjects with RR Multiple Sclerosis in whom intravenous immunoglobulin (IVIG) treatment is clinically indicated because first-line treatments are contraindicated or not tolerated. | Trade Name: Octagam 5% Product Name: Octagam 5% Pharmaceutical Form: Intravenous infusion INN or Proposed INN: Immunoglobulin CAS Number: 9007-83-4 Concentration unit: % percent Concentration type: equal Concentration number: 5- | Octapharma AG | Not Recruiting | Female: yes Male: yes | 30 | Austria | ||||
994 | NCT00755807 | October 2008 | 19 October 2017 | Duloxetine for Multiple Sclerosis Pain | Duloxetine in Patients With Central Neuropathic Pain Due to Multiple Sclerosis. | Multiple Sclerosis | Drug: Duloxetine Hydrochloride (HCI);Drug: Placebo | Eli Lilly and Company | Not recruiting | 18 Years | N/A | All | 239 | Phase 3 | United States;Belgium;Canada;Poland | |
995 | NCT00784836 | October 2008 | 19 October 2017 | Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients | A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis | Multiple Sclerosis | Drug: BG9418 (interferon beta 1-a) | Biogen | Not recruiting | 18 Years | 60 Years | All | 3 | Phase 3 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
996 | NCT01018485 | October 2008 | 25 May 2015 | The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor | Double-Blind, Randomized, Controlled, Cross-over Comparison of Efficacy and Safety of Botulinum Toxin Type A in the Targeted Treatment of Disabling Tremor in Multiple Sclerosis | Multiple Sclerosis;Tremor | Drug: Botulinum Toxin Type A | Melbourne Health | Eastern Health | Not recruiting | 18 Years | 80 Years | Both | 30 | Phase 3 | Australia |
997 | NCT01080027 | October 2008 | 19 February 2015 | Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) | An International, Multi Centre, Prospective, Observational Study of Safety, Tolerability and Adherence of Patients With Relapsing Remitting Multiple Sclerosis Administered Interferon Beta-1a (Rebif® New Formulation) in Real Life Settings | Multiple Sclerosis, Relapsing Remitting | Drug: Rebif® New Formulation | Merck KGaA | Merck A.E., Greece;Merck OY, Finland;Merck B.V., Netherlands;Merck A.B., Sweden;Merck, S.A., Portugal | Not recruiting | 18 Years | 60 Years | Both | 254 | N/A | Greece |
998 | EUCTR2008-002096-27-PL | 10/09/2008 | 19 March 2012 | A 24-month double-blind, randomized, multicenter, placebocontrolled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis. - N/A | A 24-month double-blind, randomized, multicenter, placebocontrolled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis. - N/A | Relapsing-remitting multiple sclerosis. MedDRA version: 13.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders | Product Name: Fingolimod Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720D Other descriptive name: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Fingolimod Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720D Other descriptive name: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 1080 | United Kingdom;Austria;Poland;Lithuania | ||||
999 | EUCTR2008-002560-34-BE | 02/09/2008 | 19 March 2012 | A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Duloxetine HCl in Patients with Central Neuropathic Pain Due to Multiple Sclerosis - HMFR | A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Duloxetine HCl in Patients with Central Neuropathic Pain Due to Multiple Sclerosis - HMFR | Central neuropathic pain due to Multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10054095 Term: Neuropathic pain | Trade Name: Cymbalta Product Name: Duloxetine Product Code: LY248686 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DULOXETINE CAS Number: 116539594 Current Sponsor code: LY248686 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Gastro-resistant capsule, hard Route of administration of the placebo: Oral use | Eli Lilly and Company | Not Recruiting | Female: yes Male: yes | 238 | Belgium | ||||
1000 | NCT00772525 | September 2008 | 19 February 2015 | Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis | A Double-blind, Placebo-controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients With Multiple Sclerosis | Multiple Sclerosis;Optic Nerve;Neuritis | Drug: Nerispirdine (HP184);Drug: Placebo | Sanofi | Not recruiting | 18 Years | N/A | Both | 31 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1001 | NCT01184833 | September 2008 | 19 February 2015 | Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis | Evaluation of Risk Factors for Premature Discontinuation of Injection Treatment With Betaferon in Patients With Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 18 Years | N/A | Both | 852 | N/A | Poland | |
1002 | NCT01074346 | August 2008 | 19 February 2015 | Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis | A Prospective, Multi-center, Observational Study to Assess the Tolerability of Interferon-beta 1-A (Rebif®) Therapy for Korean Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: Interferon-ß-1a | Merck KGaA | Not recruiting | N/A | N/A | Both | 60 | N/A | Korea, Republic of | |
1003 | NCT00676715 | July 31, 2008 | 7 October 2019 | A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis | Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS | Multiple Sclerosis, Relapsing-Remitting | Drug: Placebo;Drug: Ocrelizumab;Drug: Avonex | Genentech, Inc. | Roche Pharma AG | Not recruiting | 18 Years | 55 Years | All | 220 | Phase 2 | United States;Belgium;Bulgaria;Canada;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;Czech Republic |
1004 | EUCTR2007-003997-24-GB | 08/07/2008 | 18 April 2012 | Long-term extension of the multinational, double-blind, placebo controlled study PDY6045 and PDY6046 to document the safety of teriflunomide when added to treatment with interferon-beta or glatiramer acetate in patients with multiple sclerosis with relapses | Long-term extension of the multinational, double-blind, placebo controlled study PDY6045 and PDY6046 to document the safety of teriflunomide when added to treatment with interferon-beta or glatiramer acetate in patients with multiple sclerosis with relapses | Multiple Sclerosis MedDRA version: 12.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Product Name: Teriflunomide Product Code: HMR 1726D Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Sanofi-Aventis recherche & développement | Not Recruiting | Female: yes Male: yes | 240 | United Kingdom;Spain;Italy;Austria | ||||
1005 | JPRN-UMIN000002725 | 2008/07/01 | 2 April 2019 | Efficacy of ramatroban in multiple sclerosis patients | Multiple sclerosis | Addition of ramatroban to conventional MS therapy | Iou hospital | Not Recruiting | Not applicable | Not applicable | Male and Female | 5 | Not selected | Japan | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1006 | NCT00645749 | July 2008 | 25 February 2019 | Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis | Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Biological: Helminth ova | University of Wisconsin, Madison | National Multiple Sclerosis Society | Not recruiting | 18 Years | 50 Years | All | 17 | Phase 1 | United States |
1007 | NCT00674141 | July 2008 | 19 February 2015 | Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment | Nasal Administration of Dexamethasone for MS Treatment | MS Patient With Relpasing Remitting Attacks | Drug: Dexamethasone soduim phosphate | Hadassah Medical Organization | Not recruiting | 18 Years | N/A | Both | 10 | Phase 1 | Israel | |
1008 | NCT00726648 | July 2008 | 19 February 2015 | CDP323 Biomarker Study | Double-blind, Placebo-controlled, Randomized, Parallel-group Study in Subjects With Relapsing Forms of Multiple Sclerosis to Evaluate the Effects of Different CDP323 Doses on Biomarker Patterns as Well as on Safety and Tolerability. | Relapsing Multiple Sclerosis | Drug: CDP323;Drug: Placebo | UCB Pharma | Biogen Idec | Not recruiting | 18 Years | 65 Years | Both | 71 | Phase 1/Phase 2 | United Kingdom |
1009 | NCT00735007 | July 2008 | 19 October 2017 | 12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis. | International, Multicenter, Single-arm, Open-label, 12-week Phase IIIb Study to Evaluate RebiSmart™ Suitability for Self Injection of Rebif® New Formulation (RNF) in Multidose Cartridges in Patients With Relapsing Form of Multiple Sclerosis (RMS) | Multiple Sclerosis | Drug: Rebif® New Formulation (RNF) using RebiSmartTM | EMD Serono | Not recruiting | 18 Years | 65 Years | All | 106 | Phase 3 | United States;Canada;Germany;Italy;Spain;Sweden | |
1010 | EUCTR2007-001377-28-FR | 11/06/2008 | 19 March 2012 | Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL | Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL | Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously, -- AND who developed adverse events (AEs) corresponding to pre-specified newly diagnosed autoimmune disorders OR who developed severe thrombocytopenia. MedDRA version: 9.1 Level: LLT Classification code 10061664 Term: Autoimmune disorder MedDRA version: 9.1 Level: LLT Classification code 10025139 Term: Lupus erythematosus systemic MedDRA version: 9.1 Level: LLT Classification code 10047888 Term: Wegener's granulomatosis MedDRA version: 9.1 Level: LLT Classification code 10002817 Term: Antiphospholipid syndrome MedDRA version: 9.1 Level: LLT Classification code 10040767 Term: Sjogren's syndrome MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease MedDRA version: 9.1 Level: LLT Classification code 10009900 Term: Colitis ulcerative MedDRA version: 9.1 Level: LLT Classification code 10003827 Term: Autoimmune hepatitis MedDRA version: 9.1 Level: LLT Classification code 10049046 Term: Autoimmune thyroiditis MedDRA version: 9.1 Level: LLT Classification code 10003822 Term: Autoimmune haemolytic anaemia NOS MedDRA version: 9.1 Level: LLT Classification code 10034697 Term: Pernicious anemia MedDRA version: 9.1 Level: LLT Classification code 10028417 Term: Myasthenia gravis MedDRA version: 9.1 Level: LLT Classification code 10018620 Term: Goodpasture's syndrome MedDRA version: 9.1 Level: LLT Classification code 10 | Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Efalizumab Other descriptive name: EFALIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- | Merck Serono International S.A. | Authorised | Female: yes Male: yes | 92 | Phase 4 | Portugal;Germany;Netherlands;France;Austria | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1011 | NCT03577977 | June 1, 2008 | 23 July 2018 | Betaferon Use in Children and Adolescents With Multiple Sclerosis | Retrospective Data Collection on Betaferon Use in Children and Adolescents With Multiple Sclerosis | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, Betaferon, BAY86-5046) | Bayer | Not recruiting | N/A | 18 Years | All | 70 | Phase 1 | Russian Federation | |
1012 | NCT00716066 | June 2008 | 9 September 2019 | Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases | High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases | Autoimmune Disease;Neurologic Autoimmune Disease;Autologous Transplant Autoimmune;Multiple Sclerosis Transplant;MS Stem Cell Transplant;Multiple Sclerosis Stem Cell Transplant;Stiff Person Syndrome;HCT for Neurologic Autoimmune Disorders;CIDP Transplant;Myasthenia Gravis Transplant | Biological: Anti-Thymocyte Globulin;Procedure: Autologous Hematopoietic Stem Cell Transplantation;Drug: Carmustine;Drug: Cytarabine;Drug: Etoposide;Other: Laboratory Biomarker Analysis;Drug: Melphalan;Procedure: Peripheral Blood Stem Cell Transplantation;Drug: Prednisone;Procedure: Syngeneic Bone Marrow Transplantation | Fred Hutchinson Cancer Research Center | National Cancer Institute (NCI) | Recruiting | N/A | 70 Years | All | 40 | Phase 2 | United States |
1013 | NCT00787657 | June 2008 | 26 October 2015 | Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment | Betaferon Prospective Study on Adherence, Coping and Nursing Support | Relapsing Remitting Multiple Sclerosis (RRMS) | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 12 Years | N/A | Both | 1723 | N/A | Argentina;Bahrain;Belgium;Bosnia and Herzegovina;Canada;China;Colombia;Czech Republic;Egypt;Estonia;France;Germany;Iran, Islamic Republic of;Israel;Italy;Jordan;Korea, Republic of;Kuwait;Lebanon;Libyan Arab Jamahiriya;Mexico;Netherlands;New Zealand;Norway;Pakistan;Portugal;Saudi Arabia;Singapore;Slovakia;Slovenia;Sweden;Syrian Arab Republic;Taiwan;United Arab Emirates;United Kingdom;Venezuela | |
1014 | EUCTR2007-007394-22-GB | 22/05/2008 | 19 March 2012 | The role of white and grey matter and meningeal inflammation in multiple sclerosis (MS) and clinically isolated syndromes (CIS) as quantified using [(11)C](R)-PK11195 positron emission tomography (PET) scanning | The role of white and grey matter and meningeal inflammation in multiple sclerosis (MS) and clinically isolated syndromes (CIS) as quantified using [(11)C](R)-PK11195 positron emission tomography (PET) scanning | Multiple Sclerosis MedDRA version: 9.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive | Trade Name: Tysabri Product Name: Tysabri Pharmaceutical Form: Concentrate for solution for infusion | Imperial College London | Authorised | Female: yes Male: yes | United Kingdom | |||||
1015 | EUCTR2007-000888-15-ES | 19/05/2008 | 19 March 2012 | ENSAYO CLÍNICO, MULTICÉNTRICO, CON ASIGNACIÓN ALEATORIA Y DOBLE CIEGO, PARA COMPARAR LA EFICACIA CLÍNICA Y RADIOLÓGICA DE DOSIS EQUIVALENTES DE METILPREDNISOLONA ADMINISTRADAS POR VÍA ORAL O VÍA INTRAVENOSA EN PACIENTES EN BROTE DE ESCLEROSIS MÚLTIPLE - Corticoterapia Oral en Megadosis para el Tratamiento del Brote de Esclerosis Múltiple | ENSAYO CLÍNICO, MULTICÉNTRICO, CON ASIGNACIÓN ALEATORIA Y DOBLE CIEGO, PARA COMPARAR LA EFICACIA CLÍNICA Y RADIOLÓGICA DE DOSIS EQUIVALENTES DE METILPREDNISOLONA ADMINISTRADAS POR VÍA ORAL O VÍA INTRAVENOSA EN PACIENTES EN BROTE DE ESCLEROSIS MÚLTIPLE - Corticoterapia Oral en Megadosis para el Tratamiento del Brote de Esclerosis Múltiple | Pacientes afectos de esclerosis múltiple MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Trade Name: SOLU-MODERIN 1 g Pharmaceutical Form: Intravenous infusion INN or Proposed INN: METHYLPREDNISOLONE CAS Number: 83432 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000- Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Intravenous use Trade Name: URBASON 40 mg comprimidos Pharmaceutical Form: Tablet INN or Proposed INN: METHYLPREDNISOLONE CAS Number: 83432 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Servicio de Neurología | Authorised | Female: yes Male: yes | Spain | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1016 | EUCTR2007-005362-12-FR | 13/05/2008 | 19 March 2012 | Etude comparative de l'imagerie cellulaire et inflammatoire (USPIO (SH U 555 C)) et de l'IRM multimodale 3 tesla dans l'analyse des lésions de la SEP et leur progression. Etude longitudinale sur 3 ans. - USPIO-Mitox | Etude comparative de l'imagerie cellulaire et inflammatoire (USPIO (SH U 555 C)) et de l'IRM multimodale 3 tesla dans l'analyse des lésions de la SEP et leur progression. Etude longitudinale sur 3 ans. - USPIO-Mitox | 1. Multiple Sclerosis 2. Clinically isolated syndromes (at high risk to develop Multiple Sclerosis) MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis MedDRA version: 9.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive MedDRA version: 9.1 Level: LLT Classification code 10028246 Term: Multiple sclerosis aggravated MedDRA version: 9.1 Level: LLT Classification code 10028247 Term: Multiple sclerosis like syndrome MedDRA version: 9.1 Level: LLT Classification code 10028248 Term: Multiple sclerosis-like syndrome MedDRA version: 9.1 Level: LLT Classification code 10048393 Term: Multiple sclerosis relapse MedDRA version: 9.1 Level: LLT Classification code 10053395 Term: Progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063401 Term: Primary progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10064137 Term: Progression of multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10028245 Term: Multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse MedDRA version: 9.1 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis | Product Code: SH U 555 C Pharmaceutical Form: Intravenous infusion Current Sponsor code: ZK 132 281 Concentration unit: mmol/ml millimole(s)/millilitre Concentration type: equal Concentration number: 0.5- | C.H.U. de RENNES | Authorised | Female: yes Male: yes | France | |||||
1017 | EUCTR2007-005363-10-FR | 13/05/2008 | 19 March 2012 | Etude comparative de l'imagerie cellulaire et inflammatoire (USPIO (SH U 555 C)) et de la RMN multimodale dans l'analyse des lésions de sclérose en plaques : étude longitudinale sur 3 ans d'une cohorte de 50 patients après un premier évènement (CIS patients) à haut risque de développer une sclérose en plaques. - USPIO-CIS | Etude comparative de l'imagerie cellulaire et inflammatoire (USPIO (SH U 555 C)) et de la RMN multimodale dans l'analyse des lésions de sclérose en plaques : étude longitudinale sur 3 ans d'une cohorte de 50 patients après un premier évènement (CIS patients) à haut risque de développer une sclérose en plaques. - USPIO-CIS | 1. Multiple Sclerosis 2. Clinically isolated syndromes (at high risk to develop Multiple Sclerosis) MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis MedDRA version: 9.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive MedDRA version: 9.1 Level: LLT Classification code 10028246 Term: Multiple sclerosis aggravated MedDRA version: 9.1 Level: LLT Classification code 10028247 Term: Multiple sclerosis like syndrome MedDRA version: 9.1 Level: LLT Classification code 10028248 Term: Multiple sclerosis-like syndrome MedDRA version: 9.1 Level: LLT Classification code 10048393 Term: Multiple sclerosis relapse MedDRA version: 9.1 Level: LLT Classification code 10053395 Term: Progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063401 Term: Primary progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10064137 Term: Progression of multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10028245 Term: Multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse MedDRA version: 9.1 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis | Product Code: SH U 555 C Pharmaceutical Form: Intravenous infusion Current Sponsor code: ZK 132 281 Concentration unit: mmol/ml millimole(s)/millilitre Concentration type: equal Concentration number: 0.5- | C.H.U. de RENNES | Authorised | Female: yes Male: yes | France | |||||
1018 | EUCTR2007-006338-32-FR | 06/05/2008 | 18 September 2012 | Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis | Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis | Relapsing remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Product Name: Ocrelizumab Product Code: RO4964913/F03 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab Current Sponsor code: RO4964913/F03 Other descriptive name: RhuMab 2H7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Avonex Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30- | Hoffman La Roche Ltd | Authorised | Female: yes Male: yes | 200 | Phase 2 | Finland;Czech Republic;Germany;United Kingdom;Netherlands;Belgium;Denmark;Bulgaria;France;Spain;Italy | |||
1019 | NCT00640328 | May 2008 | 16 December 2017 | Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients | A Double-blind, Randomized, Placebo Controlled, Multicenter, Dose-finding Trial of Ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) Patients | Multiple Sclerosis | Drug: Ofatumumab 100;Drug: Ofatumumab 300;Drug: Ofatumumab 700;Drug: Placebo | GlaxoSmithKline | Not recruiting | 18 Years | 55 Years | All | 38 | Phase 2 | Belgium;Czech Republic;Denmark;Former Serbia and Montenegro;Germany;Poland;Serbia;Sweden;United Kingdom | |
1020 | EUCTR2006-006299-39-NL | 23/04/2008 | 19 March 2012 | A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory Impairment | A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory Impairment | Patients with urinary incontinence due to neurogenic detrusor overactivity as a result of spinal cord injury or multiple sclerosis who have not been adequately managed with anticholinergic therapy and have neurological respiratory impairment. MedDRA version: 8.1 Level: LLT Classification code 10046543 Term: Urinary incontinence | Trade Name: BOTOX® Product Name: BOTOX® Product Code: 9060X Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Botulinum toxin type A CAS Number: 93384-43-1 Current Sponsor code: AGN 191622 Other descriptive name: Botulinum toxin type A Concentration type: equal Concentration number: vials of 100-Allergan units Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Intramuscular use | Allergan | Not Recruiting | Female: yes Male: yes | 135 | Netherlands;France | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1021 | EUCTR2008-001940-38-IT | 22/04/2008 | 19 March 2012 | Functional RMN study to evaluate the prompt and middle term effect of the treatment with Donepezil in patients affected by multiple sclerosis and mild impairment of cognitive function. - ND | Functional RMN study to evaluate the prompt and middle term effect of the treatment with Donepezil in patients affected by multiple sclerosis and mild impairment of cognitive function. - ND | patients affected by multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Trade Name: ARICEPT Pharmaceutical Form: Coated tablet INN or Proposed INN: Donepezil Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Trade Name: ARICEPT Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Donepezil Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- | OSPEDALE S. RAFFAELE | Authorised | Female: yes Male: yes | Italy | |||||
1022 | EUCTR2007-003086-40-FR | 08/04/2008 | 19 March 2012 | A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS) | A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS) | aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis | Product Name: Pixantrone Product Code: BBR 2778 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Pixantrone CAS Number: 144675-97-8 Current Sponsor code: BBR 2778 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- | Fondation Charcot Stichting | Authorised | Female: yes Male: yes | 20 | Phase 1/2 | France | |||
1023 | NCT00605215 | April 2008 | 19 February 2015 | BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon ß-1a (Avonex®) | A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With RRMS to Assess the Efficacy, Safety and Tolerability of Laquinimod Over Placebo in a Double-blind Design and a Reference Arm of Interferon ß-1a (Avonex®) in a Rater-blinded Design. | Multiple Sclerosis | Drug: laquinimod;Drug: placebo;Drug: Interferon ß-1a (Avonex®) | Teva Pharmaceutical Industries | Not recruiting | 18 Years | 55 Years | Both | 1331 | Phase 3 | United States;Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, The Former Yugoslav Republic of;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Ukraine;Latvia;Montenegro;Turkey | |
1024 | NCT00642902 | April 2008 | 19 October 2017 | A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) | A Four-Arm Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study to Evaluate the Safety, Tolerability and Efficacy as Assessed by Frequent MRI Measures of 3 Doses of Atacicept Monotherapy in Subjects With Relapsing Multiple Sclerosis (RMS) Over a 36 Week Treatment Course | Relapsing Multiple Sclerosis | Drug: Atacicept;Drug: Placebo matched to atacicept | EMD Serono | Not recruiting | 18 Years | 60 Years | All | 255 | Phase 2 | United States;Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Lebanon;Lithuania;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Ukraine;United Kingdom | |
1025 | NCT00670449 | April 2008 | 19 October 2017 | An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis | An Extension of the 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis | Drug: Fingolimod | Novartis | Mitsubishi Tanabe Pharma Corporation | Not recruiting | 18 Years | 60 Years | All | 143 | Phase 2 | Japan |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1026 | NCT01414816 | April 2008 | 19 February 2015 | Betaferon® Regulatory Post-Marketing Surveillance | Betaferon® Regulatory Post-Marketing Surveillance | Multiple Sclerosis;Clinically Isolated System | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 12 Years | N/A | Both | 355 | N/A | Korea, Republic of | |
1027 | EUCTR2007-003936-50-ES | 10/03/2008 | 12 June 2012 | Estudio en fase II, multicéntrico, aleatorizado, a doble ciego, con cuatro brazos y controlado frente a placebo, para evaluar, mediante RM frecuentes, la seguridad, tolerabilidad y eficacia de tres dosis de monoterapia con atacicept en sujetos con esclerosis múltiple recidivante (EMR) durante un periodo de tratamiento de 36 semanas. A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks treatment course. - Atacicept frequent MRI study in RMS | Estudio en fase II, multicéntrico, aleatorizado, a doble ciego, con cuatro brazos y controlado frente a placebo, para evaluar, mediante RM frecuentes, la seguridad, tolerabilidad y eficacia de tres dosis de monoterapia con atacicept en sujetos con esclerosis múltiple recidivante (EMR) durante un periodo de tratamiento de 36 semanas. A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks treatment course. - Atacicept frequent MRI study in RMS | Esclerosis múltiple recidivante Relapsing multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Product Name: atacicept Pharmaceutical Form: Solution for injection INN or Proposed INN: atacicept Other descriptive name: TACI-Fc5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 25-150 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Merck Serono International S.A. | Authorised | Female: yes Male: yes | 332 | Phase 2 | United Kingdom;Czech Republic;Netherlands;France;Spain;Austria;Lithuania;Sweden | |||
1028 | EUCTR2007-002179-15-FR | 04/03/2008 | 19 March 2012 | Etude des effets de la méthylprednisolone à fortes doses sur les caractéritiques électrophysiologiques de la fatigabilité à l'effort au cours des poussées de sclérose en plaques - CORTICOFLASH | Etude des effets de la méthylprednisolone à fortes doses sur les caractéritiques électrophysiologiques de la fatigabilité à l'effort au cours des poussées de sclérose en plaques - CORTICOFLASH | Méthylprednisolone administrée aux patients et contrôles à la dose de 1g/j pendant 3 jours, comme prescrit habituellement dans le cadre de leur pathologie. MedDRA version: 8.1 Level: PT Classification code 10028245 Term: Multiple sclerosis | Trade Name: Methylprednisolone Product Name: Methylprednisolone Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Methylprednisolone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Authorised | Female: yes Male: yes | France | |||||
1029 | NCT00429442 | March 2008 | 19 February 2015 | Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis | A Double Blind, Randomised, Placebo Controlled Study Investigating Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis in Patients Treated With Copaxone for at Least 3 Months | Relapsing Remitting Multiple Sclerosis | Drug: Simvastatin;Drug: placebo | Anna Tsakiri | Sanofi | Not recruiting | 18 Years | 60 Years | Both | 0 | Phase 3 | Denmark |
1030 | NCT00616733 | March 2008 | 19 February 2015 | 12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients | An Open-label, Escalating-dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral CS-0777, Administered for 12 Weeks, in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: CS-0777 tablets | Daiichi Sankyo Inc. | Not recruiting | 18 Years | 65 Years | Both | 25 | Phase 1 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1031 | NCT00638196 | March 2008 | 17 August 2015 | Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS | Phase II Study of Linoleic Acid in Relapsing Multiple Sclerosis | Multiple Sclerosis | Drug: Linoleic Acid/Oleic Acid | University of Rochester | Not recruiting | 18 Years | 70 Years | Both | 9 | Phase 1 | United States | |
1032 | EUCTR2008-000490-37-IT | 26/02/2008 | 10 December 2012 | Pharmacological treatment with memantine of oscilloscopy in patients suffering from multiple sclerosis: randomized,double blind placebo controlled study. - ND | Pharmacological treatment with memantine of oscilloscopy in patients suffering from multiple sclerosis: randomized,double blind placebo controlled study. - ND | multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028053 Term: MS | Trade Name: EBIXA Pharmaceutical Form: Oral drops, solution INN or Proposed INN: Memantine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Oral drops, solution Route of administration of the placebo: Oral use | OSPEDALE S. RAFFAELE | Not Recruiting | Female: yes Male: yes | Italy | |||||
1033 | EUCTR2005-002305-23-GB | 05/02/2008 | 19 March 2012 | A pilot study of combination monoclonal antibody treatment in early active relapsing-remitting multiple sclerosis using Campath-1H and its non-binding form, SM3. - SM3 | A pilot study of combination monoclonal antibody treatment in early active relapsing-remitting multiple sclerosis using Campath-1H and its non-binding form, SM3. - SM3 | Relapsing Remitting Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Trade Name: MabCampath ® Product Name: Alemtuzumab Pharmaceutical Form: Solution for infusion INN or Proposed INN: Alemtuzumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- | R&D Addenbrookes Hospital | Authorised | Female: yes Male: yes | United Kingdom | |||||
1034 | NCT00391352 | February 2008 | 19 February 2015 | fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls | A Phase 4, fMRI Study of Treatment Recommendations Comparing Patients Taking IFN-ß-1a 44 mcg Tiw SC (Rebif®) to Controls of Patients Recently Diagnosed With Relapsing Remitting Multiple Sclerosis Currently Naive to Disease-Modifying Therapy. | Relapsing-Remitting Multiple Sclerosis | Drug: IFN-ß-1a (Rebif®) | Waukesha Memorial Hospital | The Cleveland Clinic | Not recruiting | 18 Years | 65 Years | Both | 21 | Phase 4 | United States |
1035 | NCT00630383 | February 2008 | 19 February 2015 | Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis. | Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis. | Multiple Sclerosis | Biological: Live Hookworm Larvae;Other: Histamine | University of Nottingham | Not recruiting | 18 Years | 60 Years | Both | 0 | Phase 2 | United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1036 | EUCTR2007-004122-24-SE | 23/01/2008 | 16 October 2012 | An extension of the 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis. | An extension of the 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis. | Relapsing-remitting multiple sclerosis. MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Pharmaceutical Form: Capsule* INN or Proposed INN: fingolimod hydrochloride CAS Number: 162359-56-0 Current Sponsor code: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- | Novartis Pharma AG | Not Recruiting | Female: yes Male: yes | 1250 | Estonia;Slovakia;Greece;Finland;Ireland;United Kingdom;France;Czech Republic;Hungary;Belgium;Netherlands;Germany;Sweden | ||||
1037 | EUCTR2007-006268-32-IT | 23/01/2008 | 19 March 2012 | EFFICACY AND SAFETYOF BOTULINUM TOXIN THERAPY ON UPPER LIMB SPASTICITY IN INFLAMMATORY AND DEMIELINIZZATING DISEASE OF CENTRAL NERVOUS SYSTEM. - ND | EFFICACY AND SAFETYOF BOTULINUM TOXIN THERAPY ON UPPER LIMB SPASTICITY IN INFLAMMATORY AND DEMIELINIZZATING DISEASE OF CENTRAL NERVOUS SYSTEM. - ND | multiple sclerosis MedDRA version: 9.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive | Trade Name: xeomin Pharmaceutical Form: Solution for injection INN or Proposed INN: xeomin Concentration unit: U unit(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intramuscular use | OSPEDALE S. RAFFAELE | Authorised | Female: yes Male: yes | Italy | |||||
1038 | EUCTR2006-006872-39-GB | 04/01/2008 | 19 March 2012 | A randomised, double-blind, placebo controlled study of AIMSPRO in Multiple Sclerosis - AIMSPRO in MS bladder function | A randomised, double-blind, placebo controlled study of AIMSPRO in Multiple Sclerosis - AIMSPRO in MS bladder function | Overactive Bladder in Secondary Progressive Multiple Sclerosis and the other neurological symptoms associated with Secondary Progressive Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10059617 Term: Overactive bladder MedDRA version: 9.1 Level: LLT Classification code 10012547 Term: Detrusor hyperreflexia | Product Name: AIMSPRO Pharmaceutical Form: Solution for injection Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Daval International Limited | Authorised | Female: yes Male: yes | United Kingdom | |||||
1039 | NCT00464958 | January 2008 | 19 February 2015 | One Year Extension Study To Protocol C2/5/TZ:MS-05 | Long Term Clinical Efficacy and Safety of Novel Sublingual Tizanidine HCl (12 mg) for the Treatment of Spasticity in Patients With Multiple Sclerosis - Open Label Extension Study | Spasticity;Multiple Sclerosis | Drug: sublingual tizanidine 12 mg | Teva GTC | Not recruiting | 20 Years | 65 Years | Both | 10 | Phase 1/Phase 2 | Israel | |
1040 | NCT00536120 | January 2008 | 19 October 2017 | The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis | A Randomized, Open-Label Study to Assess the Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis | Biological: BG00002 (natalizumab);Biological: keyhole limpet hemocyanin (KLH);Biological: tetanus diphtheria toxoid vaccine (Td) | Biogen | Not recruiting | 18 Years | 60 Years | All | 60 | Phase 4 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1041 | NCT00612872 | January 2008 | 15 April 2019 | Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects | Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With Parkinson Disease or Alzheimer Disease and in Healthy Subjects | Parkinson Disease;Alzheimer Disease;Healthy Controls;Multiple Sclerosis | Drug: [123I]CLINDE | Institute for Neurodegenerative Disorders | Not recruiting | 30 Years | 50 Years | All | 46 | Phase 1 | United States | |
1042 | NCT00681538 | January 2008 | 19 October 2017 | A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS) | A Two-phase, Phase 3 Study of the Safety and Efficacy of Sativex, in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis: Phase A - Single-blind Response Assessment; Phase B - Double-blind, Randomised, Placebo Controlled, Parallel Group Study. | Spasticity;Multiple Sclerosis | Drug: Sativex®;Drug: Placebo | GW Pharmaceuticals Ltd. | Not recruiting | 18 Years | N/A | All | 572 | Phase 3 | United Kingdom | |
1043 | NCT00785473 | January 2008 | 19 February 2015 | Can Vitamin D Supplementation Prevent Bone Loss in Persons With Multiple Sclerosis | Can Vitamin D Supplementation Prevent Bone Loss in Persons With MS? A Randomised, Placebo-controlled, Single-centre Study | Multiple Sclerosis, Osteoporosis | Dietary Supplement: cholecalciferol;Dietary Supplement: calcium carbonate | University Hospital of North Norway | Not recruiting | 18 Years | 50 Years | Both | 80 | Phase 4 | Norway | |
1044 | NCT00938366 | January 2008 | 19 October 2017 | Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects | An Open-label, Cross Over Study, to Assess the Interactions of Pantoprazole (Proton Pump Inhibitor) With Oral Cladribine Administered in Subjects With Multiple Sclerosis | Multiple Sclerosis | Drug: Cladribine;Drug: Pantoprazole | Merck KGaA | Merck Serono S.A., Geneva | Not recruiting | 18 Years | 65 Years | All | 18 | Phase 1 | |
1045 | EUCTR2008-000499-25-DE | 26 June 2012 | International, multicenter, single-arm, open-label, 12-week phase IIIb study to evaluate RebiSmartTM suitability for self-injection of Rebif New Formulation (RNF) in multidose cartridges in patients with relapsing form of multiple sclerosis (RMS) - RebiSmartTM in RMS | International, multicenter, single-arm, open-label, 12-week phase IIIb study to evaluate RebiSmartTM suitability for self-injection of Rebif New Formulation (RNF) in multidose cartridges in patients with relapsing form of multiple sclerosis (RMS) - RebiSmartTM in RMS | Relapsing forms of Multiple Sclerosis (RMS) MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Product Name: Rebif New Formulation 44mcg multidose cartridge Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: NA Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 88- | Merck Serono International S.A. | Not Recruiting | Female: yes Male: yes | 100 | Phase 3b | Germany;Spain;Italy;Sweden | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1046 | EUCTR2008-005213-22-DE | 11 April 2016 | SUPREMES - Sunphenon in progressive forms of multiple sclerosis | SUPREMES - Sunphenon in progressive forms of multiple sclerosis - SUPREMES | primary and secondary progressive forms of multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Sunphenon Pharmaceutical Form: Capsule, hard Other descriptive name: Sunphenon EGCg Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Charite Universitätsmedizin Berlin | Not Recruiting | Female: yes Male: yes | Germany | ||||||
1047 | EUCTR2008-005773-35-IT | 2 October 2017 | AUTOLOUGUS STEM CELLS TRANSPLANTATION AFTER LINFOCYTE DEPLETION AS A NEW THERAPY FOR THE AGGRESSIVE AND DRUG RESISTANT FORMS OF MULTIPLE SLEROSIS IN THE ADULTS AND CHILDREN. - AUTOLOUGUS STEM CELLS TRANSPLANTATION IN SM | AUTOLOUGUS STEM CELLS TRANSPLANTATION AFTER LINFOCYTE DEPLETION AS A NEW THERAPY FOR THE AGGRESSIVE AND DRUG RESISTANT FORMS OF MULTIPLE SLEROSIS IN THE ADULTS AND CHILDREN. - AUTOLOUGUS STEM CELLS TRANSPLANTATION IN SM | MULTIPLE SCLEROSIS MedDRA version: 15.1 Level: LLT Classification code 10028053 Term: MS System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: ENDOXAN BAXTER Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Cyclophosphamide Concentration unit: mg/kg milligram(s)/kilogram Concentration number: 40- Trade Name: FLUDARA Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Fludarabine Concentration unit: mg/m2 milligram(s)/square meter Concentration number: 30- Trade Name: THYMOGLOBULINE Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: Antithymocyte immunoglobulin (rabbit) Concentration unit: mg/kg milligram(s)/kilogram Concentration number: 2.5- Trade Name: MABTHERA Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab Concentration unit: mg/m2 milligram(s)/square meter Concentration number: 375.5- | AZIENDA OSPEDALIERA DI PADOVA | Not Available | Female: yes Male: yes | Phase 1 | Italy | |||||
1048 | EUCTR2008-007015-32-DE | 11 March 2013 | A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with multiple sclerosis, followed by a 1-year open-label treatment phase | A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with multiple sclerosis, followed by a 1-year open-label treatment phase | cognitive impairment in Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Trade Name: Exelon transdermales Pflaster Product Name: Exelon Product Code: ENA713 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rivastigmin CAS Number: 123441-03-2 Current Sponsor code: ENA713 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9- Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: Exelon transdermales Pflaster Product Name: Exelon Product Code: ENA713 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rivastigmin CAS Number: 123441-03-2 Current Sponsor code: ENA713 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18- Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: Exelon transdermales Pflaster Product Name: Exelon Product Code: ENA713 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rivastigmin CAS Number: 123441-03-2 Current Sponsor code: ENA713 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9- Trade Name: Exelon transdermales Pflaster Product Name: Exelon Product Code: ENA713 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rivastigmin CAS Number: 123441-03-2 Current Sponsor code: ENA713 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18- | Novartis Pharma GmbH | Not Recruiting | Female: yes Male: yes | Germany | ||||||
1049 | EUCTR2008-008719-25-DE | 1 May 2012 | A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF312 given orally once daily in patients with relapsing-remitting multiple sclerosis | A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF312 given orally once daily in patients with relapsing-remitting multiple sclerosis | Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Product Code: BAF312 Pharmaceutical Form: Film-coated tablet Current Sponsor code: BAF312 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: BAF312 Pharmaceutical Form: Film-coated tablet Current Sponsor code: BAF312 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: BAF312 Pharmaceutical Form: Film-coated tablet Current Sponsor code: BAF312 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: BAF312 Pharmaceutical Form: Film-coated tablet Current Sponsor code: BAF312 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: BAF312 Product Code: BAF312 Pharmaceutical Form: Film-coated tablet Current Sponsor code: BAF312 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 275 | Phase 2 | Hungary;Finland;Germany;Spain;Italy | ||||
1050 | EUCTR2007-001162-32-GB | 24/12/2007 | 26 June 2012 | A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Scleroris Who Have Relapsed On Therapy - CARE MS-II | A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Scleroris Who Have Relapsed On Therapy - CARE MS-II | Relapsing Remitting Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Trade Name: MabCampath ® Product Name: Alemtuzumab Pharmaceutical Form: Solution for infusion INN or Proposed INN: Alemtuzumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- | Genzyme Corporation | Authorised | Female: yes Male: yes | 573 | Phase 3 | Czech Republic;Germany;United Kingdom;Netherlands;Denmark;Belgium;France;Spain;Italy;Poland;Austria;Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1051 | EUCTR2007-000586-38-IT | 21/12/2007 | 23 September 2013 | HIGH-DOSE IMMUNOSUPPRESSION WITH THIOTEPA AND CYCLOPHOSPHAMIDE FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS - ND | HIGH-DOSE IMMUNOSUPPRESSION WITH THIOTEPA AND CYCLOPHOSPHAMIDE FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS - ND | PATIENTS AFFECTED BY MULTIPLE SCLEROSIS MedDRA version: 6.1 Level: HLT Classification code 10052785 | Trade Name: THIOPLEX Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Thiotepa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Trade Name: ENDOXAN BAXTER Pharmaceutical Form: Tablet INN or Proposed INN: Cyclophosphamide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: NEUPOGEN Pharmaceutical Form: Solution for injection INN or Proposed INN: Filgrastim Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 5- | OSPEDALE S. RAFFAELE | Not Recruiting | Female: yes Male: yes | Italy | |||||
1052 | EUCTR2007-005414-40-IT | 21/12/2007 | 3 April 2012 | Efficacy and activity of levetiracetam on Multiple Sclerosis cerebellar symptoms: a multicenters double blind, randomized, placebo-controlled, cross over study - ND | Efficacy and activity of levetiracetam on Multiple Sclerosis cerebellar symptoms: a multicenters double blind, randomized, placebo-controlled, cross over study - ND | Patients with an established and stable Multiple Sclerosis (according to Poser criteria). MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Trade Name: KEPPRA Pharmaceutical Form: Coated tablet INN or Proposed INN: Levetiracetam Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- | AZIENDA SANITARIA N. 3 GENOVESE | Authorised | Female: yes Male: yes | Italy | |||||
1053 | EUCTR2007-001958-99-FI | 18/12/2007 | 19 March 2012 | Collecalciferol as an Add-on Treatment to Subcutaneously-Administred Interferon-beta-1b for Treatment MS | Collecalciferol as an Add-on Treatment to Subcutaneously-Administred Interferon-beta-1b for Treatment MS | Patients with relapsing remitting MS according to the revised Mc Donald's criteria who meet all criteria for inclusion and none criteria of exclusion. MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Trade Name: Dekristol 20000 IE Product Name: Dekristol Pharmaceutical Form: Capsule* INN or Proposed INN: INN COLECALCIFEROL Product Name: Placebo Dekristol SGC 20000 Pharmaceutical Form: Capsule* | Merja Soilu Häninen | Not Recruiting | Female: yes Male: yes | Finland | |||||
1054 | EUCTR2007-001962-34-DE | 12/12/2007 | 1 February 2016 | Klassische Konditionierung immunologischer Reaktionen bei Patienten mit Multipler Sklerose während Mitoxantrontherapie - MIMIK | Klassische Konditionierung immunologischer Reaktionen bei Patienten mit Multipler Sklerose während Mitoxantrontherapie - MIMIK | secondary progressive multiple sclerosis | Trade Name: Ralenova Pharmaceutical Form: Solution for injection INN or Proposed INN: mitoxantrone Current Sponsor code: Mitox Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Intravenous drip use (Noncurrent) | University Medical Center Hamburg Eppendorf | Not Recruiting | Female: yes Male: yes | 5 | Germany | ||||
1055 | NCT00573443 | December 2007 | 16 December 2017 | Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS | A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) | Pseudobulbar Affect (PBA) | Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Drug: Placebo | Avanir Pharmaceuticals | INC Research | Not recruiting | 18 Years | 80 Years | All | 326 | Phase 3 | United States;Argentina;Brazil |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1056 | NCT00623415 | December 2007 | 11 June 2018 | Flupirtine as Oral Treatment in Multiple Sclerosis | Multicentric, Prospective, Double Blind, Randomized/Stratified, Placebo-controlled Pilot-study for Evaluation of Safety and Efficacy of Flupirtine add-on to Interferon-ß1b on Neurodegeneration in Patients With Relapsing Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: Flupirtine;Drug: Placebo | Charite University, Berlin, Germany | Bayer | Not recruiting | 18 Years | 60 Years | All | 30 | Phase 2 | Germany |
1057 | EUCTR2007-000381-20-FI | 16/11/2007 | 25 September 2012 | CLARITY Extension Study | A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY). - CLARITY EXTENSION | Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 13.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders | Product Name: cladribine Product Code: Not Applicable Pharmaceutical Form: Tablet INN or Proposed INN: CLADRIBINE CAS Number: 4291638 Current Sponsor code: EMD280922 Other descriptive name: 2-chloro-2’-deoxyadenosine (2-CdA) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Merck Serono S.A. - Geneva | Not Recruiting | Female: yes Male: yes | 1100 | Phase 3b | Germany;Bulgaria;France;Austria;Australia;Brazil;Czech Republic;Serbia;Canada;Belgium;United States;Croatia;Greece;Poland;Portugal;Turkey;Switzerland;Netherlands;Italy;Morocco;Latvia;Lithuania;Finland;United Kingdom;Russian Federation;Ukraine;Saudi Arabia;Denmark;Estonia;Lebanon | |||
1058 | NCT00595920 | November 2007 | 19 October 2017 | Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis | An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00 | Multiple Sclerosis, Relapsing-Remitting;Clinically Isolated Syndrome | Biological: Tovaxin | Opexa Therapeutics, Inc. | Not recruiting | N/A | N/A | All | 116 | Phase 2 | United States | |
1059 | NCT00688948 | November 2007 | 19 February 2015 | Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS) | A Pilot Study Looking At The Use Of Alfuzosin In The Treatment Of Bladder Dysfunction In Patients With Multiple Sclerosis | Multiple Sclerosis;Bladder Dysfunction | Drug: Alfuzosin | Capital District Health Authority, Canada | Sanofi | Not recruiting | 18 Years | N/A | Both | 20 | Phase 2/Phase 3 | Canada |
1060 | NCT00702468 | November 2007 | 19 October 2017 | Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis | A Placebo Controlled, Parallel Group, Randomised Withdrawal Study of Subjects With Symptoms of Spasticity Due to Multiple Sclerosis Who Are Receiving Long-term Sativex®. | Spasticity;Multiple Sclerosis | Drug: Sativex;Drug: Placebo | GW Pharmaceuticals Ltd. | Not recruiting | 18 Years | N/A | All | 36 | Phase 3 | United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1061 | NCT00937677 | November 2007 | 19 February 2015 | Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study | Effect of Natalizumab (Tysabri®) on Remyelination in Patients With Relapsing-remitting Multiple Sclerosis. A Follow-up Voxel-wise Magnetization Transfer Imaging Study. | Multiple Sclerosis | Drug: Tysabri | University at Buffalo | Biogen Idec | Not recruiting | 18 Years | 65 Years | Both | 85 | N/A | United States |
1062 | EUCTR2008-007162-32-IT | 30/10/2007 | 19 March 2012 | ADVANCED MRI STUDY ON INFLAMMATORY AND DEGENRATIVE DAMAGE IN MULTIPLE SCLEROSIS - RMaIDSM | ADVANCED MRI STUDY ON INFLAMMATORY AND DEGENRATIVE DAMAGE IN MULTIPLE SCLEROSIS - RMaIDSM | Multiple Sclerosis MedDRA version: 9.1 Level: SOC Classification code 10029205 Term: Nervous system disorders | Trade Name: COPAXONE Pharmaceutical Form: Solution for injection INN or Proposed INN: Glatiramer acetate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Trade Name: AVONEX Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: Munit million units Concentration type: equal Concentration number: 6- | ISTITUTO C. MONDINO | Authorised | Female: yes Male: yes | Italy | |||||
1063 | EUCTR2006-001152-12-CZ | 15/10/2007 | 20 February 2017 | An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis plus a long-term extension period. | An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis plus a long-term extension period. | Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | sanofi-aventis recherche & développement | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Belarus;Estonia;Slovakia;Finland;Ukraine;Lithuania;Turkey;Austria;Chile;Russian Federation;United Kingdom;France;Hungary;Czech Republic;Mexico;Canada;Poland;Croatia;Romania;Denmark;Australia;Bulgaria;Germany | |||
1064 | NCT00104143 | October 2007 | 5 September 2016 | A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis. | A Randomized, Double-blind, Placebo Controlled Dose-ranging Study to Determine the Effect on MRI Lesions and Safety of A4I Antagonist in Relapsing Multiple Sclerosis. | Multiple Sclerosis | Drug: A4I Antagonist | Hoffmann-La Roche | Not recruiting | 18 Years | 59 Years | Both | 0 | Phase 2 | Bulgaria;Canada;Czech Republic;Germany;Poland;Russian Federation;Slovakia;Spain;United Kingdom;Finland;United States | |
1065 | NCT00548405 | October 2007 | 16 December 2017 | Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two | A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif®) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy | Multiple Sclerosis, Relapsing-Remitting | Biological: Alemtuzumab 12 mg;Biological: Alemtuzumab 24 mg;Biological: Interferon beta-1a | Genzyme, a Sanofi Company | Bayer | Not recruiting | 18 Years | 55 Years | All | 840 | Phase 3 | United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1066 | NCT00559702 | October 2007 | 19 February 2015 | Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) | A Randomized, Open-Label, Dose-Ranging Study to Evaluate the Pharmacokinetics and Initial Safety of Subcutaneous and Intramuscular Natalizumab in Subjects With Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis | Drug: natalizumab;Other: standard of care | Biogen Idec | Elan Pharmaceuticals | Not recruiting | 18 Years | 65 Years | Both | 76 | Phase 1 | United States |
1067 | NCT00873340 | October 2007 | 19 February 2015 | Physical Disability in Patients Treated With Betaferon | Physical Disability Observational Study in Patients Treated With Betaferon in Daily Practice | Multiple Sclerosis | Drug: Interferon-1beta (Betaseron, BAY86-5046) | Bayer | Not recruiting | 18 Years | N/A | Both | 83 | N/A | Colombia | |
1068 | EUCTR2006-001337-17-DE | 25/09/2007 | 29 May 2012 | Characterisation of multiple sclerosis pathology by “ultra small particles of iron oxide (USPIO)” in comparison with conventional and advanced MRI imaging techniques [Charakterisierung der Multiple Sklerose Pathologie durch “ultra small particles of iron oxide (USPIO)” im Vergleich zu konventionellen und fortgeschrittenen MRT Techniken] - MS_USPIO_MPIP | Characterisation of multiple sclerosis pathology by “ultra small particles of iron oxide (USPIO)” in comparison with conventional and advanced MRI imaging techniques [Charakterisierung der Multiple Sklerose Pathologie durch “ultra small particles of iron oxide (USPIO)” im Vergleich zu konventionellen und fortgeschrittenen MRT Techniken] - MS_USPIO_MPIP | Patients with Multiple Sclerosis (MS, N=90) and patients with a clinically isolated syndrome (ref. to as CIS in literature, i. e. not a clinically definite MS but a syndrome that may occur as first sign of MS early in the course, N=15) are planned to be investigated in the proposed clinical trial. MedDRA version: 8.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Product Name: ultra small particles of iron oxide (USPIO) Product Code: SH U 555 C Pharmaceutical Form: Solution for infusion INN or Proposed INN: SH U 555 C CAS Number: V08CB03 Current Sponsor code: USPIO Other descriptive name: Ultrasmall particles of iron oxide Concentration unit: mmol millimole(s) Concentration type: equal Concentration number: 0.5- | Max-Planck-Institute of Psychiatry | Authorised | Female: yes Male: yes | Germany | |||||
1069 | EUCTR2007-001031-63-CZ | 20/09/2007 | 12 December 2016 | AV650-018: A two-part (double-blind followed by open-label), placebo-controlled, randomized trial to assess the safety, tolerability, and preliminary efficacy of AV650 (tolperisone HCl) in subjects with spasticity associated with multiple sclerosis. | AV650-018: A two-part (double-blind followed by open-label), placebo-controlled, randomized trial to assess the safety, tolerability, and preliminary efficacy of AV650 (tolperisone HCl) in subjects with spasticity associated with multiple sclerosis. | Spasticity associated with multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028335 Term: Muscle spasticity | Trade Name: Tolposan Product Code: AV605 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Tolperisone HC1 CAS Number: 728-88-1 Other descriptive name: Tolpersan Concentration unit: mg milligram(s) Concentration type: range Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Avigen Inc | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Czech Republic;Germany | |||
1070 | EUCTR2007-002138-13-GB | 13/09/2007 | 19 March 2012 | A placebo controlled, parallel group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term GW-1000-02 (Sativex®). | A placebo controlled, parallel group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term GW-1000-02 (Sativex®). | Symptoms of spasticity in multiple sclerosis. | Trade Name: Sativex Product Name: Sativex Product Code: GW-1000-02 Pharmaceutical Form: Oromucosal spray CAS Number: 1972-08-3 Other descriptive name: delta-9-tetrahydrocannabinol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 27- CAS Number: 13956-29-1 Other descriptive name: Cannabidiol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Oromucosal spray Route of administration of the placebo: Oromucosal use | GW Pharma Ltd. | Not Recruiting | Female: yes Male: yes | United Kingdom | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1071 | EUCTR2006-003037-32-LT | 11/09/2007 | 19 March 2012 | A two-arm, randomized, double-blind, control group-compared, multicenter, phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® New Formulation (IFN-beta-1a) in subjects with relapsing remitting multiple sclerosis. - IMPROVE (Investigating MRI Parameters with Rebif® imprOVEd formulation) | A two-arm, randomized, double-blind, control group-compared, multicenter, phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® New Formulation (IFN-beta-1a) in subjects with relapsing remitting multiple sclerosis. - IMPROVE (Investigating MRI Parameters with Rebif® imprOVEd formulation) | Relapsing remitting Multiple Sclerosis MedDRA version: 9.0 Level: PT Classification code 10063399 | Trade Name: Rebif Product Name: Interferon beta-1a FBS-free/HSA-free, RNF Product Code: Not applicable Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon-beta 1a CAS Number: NA Current Sponsor code: Not applicable Other descriptive name: Not applicable Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Merck Serono International SA | Not Recruiting | Female: yes Male: yes | 150 | Phase 3b | Germany;Estonia;Spain;Italy;Lithuania | |||
1072 | EUCTR2006-006347-31-GB | 06/09/2007 | 19 March 2012 | A Phase II randomised placebo controlled clinical trial of Simvastatin in patients with secondary progressive multiple sclerosis | A Phase II randomised placebo controlled clinical trial of Simvastatin in patients with secondary progressive multiple sclerosis | Multiple Sclerosis MedDRA version: 9.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive | Product Name: Encapsulated Simvastatin tablets Product Code: MSTC-001 (MS-STAT) Pharmaceutical Form: Capsule, hard Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Imperial College London | Authorised | Female: yes Male: yes | Phase 2 | United Kingdom | ||||
1073 | EUCTR2007-003226-19-NL | 05/09/2007 | 19 March 2012 | Study Title: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS) - Allegro | Study Title: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS) - Allegro | Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 9.1 Level: PT Classification code 10028245 Term: Multiple sclerosis | Product Name: Laquinimod Capsules 0.6 mg Product Code: TV-5600 Pharmaceutical Form: Capsule* INN or Proposed INN: laquinimod CAS Number: 248282-07-7 Current Sponsor code: TV-5600 Other descriptive name: ABR-215062 sodium salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | Teva Pharmaceutical Industries Ltd | Not Recruiting | Female: yes Male: yes | 1419 | Hungary;Portugal;Germany;Netherlands;Bulgaria;France;Italy;Latvia;Austria;Lithuania;Sweden;United Kingdom;Czech Republic;Estonia;Spain | ||||
1074 | NCT00532532 | September 2007 | 19 February 2015 | Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis | AV650-018: A Two-Part (Double-Blind Followed by Open-Label), Placebo Controlled, Randomized Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of AV650 (Tolperisone HCl) in Subjects With Spasticity Associated With Multiple Sclerosis | Muscle Spasticity | Drug: tolperisone HCl | Avigen | Not recruiting | 18 Years | 70 Years | Both | 150 | Phase 2 | Czech Republic;Germany;Russian Federation;Serbia;Ukraine;Former Serbia and Montenegro | |
1075 | NCT00537082 | September 2007 | 19 October 2017 | Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS) | A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis | Drug: FTY720;Drug: Placebo | Novartis | Mitsubishi Tanabe Pharma Corporation | Not recruiting | 18 Years | 60 Years | All | 171 | Phase 2 | Japan |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1076 | NCT00544037 | September 2007 | 19 February 2015 | BENEFIT Extension Study | Extension Study of the BENEFIT (304747) and BENEFIT Follow-up (305207) Studies to Further Evaluate the Progress of Patients With First Demyelinating Event Suggestive of Multiple Sclerosis | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 23 Years | 50 Years | Both | 283 | N/A | Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Slovenia;Spain;Sweden;Switzerland;Portugal;United Kingdom | |
1077 | NCT00638833 | September 2007 | 19 February 2015 | Memantine Therapy for Multiple Sclerosis | Pilot Clinical Trial With Memantine for Cognitive Deficits in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: Memantine;Drug: Placebo | Clinica Universidad de Navarra, Universidad de Navarra | H. Lundbeck A/S | Not recruiting | 18 Years | 65 Years | Both | 20 | Phase 2 | Spain |
1078 | NCT00937157 | September 2007 | 19 October 2017 | Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA) | Comparison of Standard 1.5 Versus 3T Optimized Protocols in Patients Treated With Glatiramer Acetate. A Conventional and Non-conventional MRI Study | Multiple Sclerosis | Drug: Copaxone | University at Buffalo | Teva Neuroscience, Inc. | Not recruiting | 18 Years | 65 Years | All | 12 | N/A | United States |
1079 | NCT02523703 | September 2007 | 24 August 2015 | Excitotoxicity Markers and the Clinical-radiological Progression After a Demyelinating Event: a Prospective Pilot Study | Multiple Sclerosis | Biological: glutamate and aspartate | University Hospital, Caen | Not recruiting | 18 Years | 60 Years | Both | 36 | N/A | |||
1080 | EUCTR2006-005910-11-CZ | 29/08/2007 | 5 December 2016 | A two-phase Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response assessment; Phase B - double blind, randomised, placebo controlled, parallel group study. | A two-phase Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response assessment; Phase B - double blind, randomised, placebo controlled, parallel group study. | Spacticity in multiple sclerosis (MS) | Product Name: Sativex Product Code: GW-1000-02 Pharmaceutical Form: Oromucosal spray CAS Number: 1972-08-3 Other descriptive name: delta-9-tetrahydrocannabinol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 27- CAS Number: 13956-29-1 Other descriptive name: Cannabidiol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Oromucosal spray Route of administration of the placebo: Oromucosal use | GW Pharma Ltd | Not Recruiting | Female: yes Male: yes | 488 | Phase 3 | Czech Republic;Spain;Germany;Italy;United Kingdom | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1081 | EUCTR2007-001161-14-GB | 24/08/2007 | 12 June 2012 | A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsing-Remitting Multiple Scleroris. - CARE MS-I | A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsing-Remitting Multiple Scleroris. - CARE MS-I | Relapsing Remitting Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Trade Name: MabCampath ® Product Name: Alemtuzumab Pharmaceutical Form: Solution for infusion INN or Proposed INN: Alemtuzumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- | Genzyme Corporation | Not Recruiting | Female: yes Male: yes | 525 | Phase 3 | Czech Republic;Germany;United Kingdom;France;Poland;Sweden | |||
1082 | EUCTR2007-001031-63-DE | 15/08/2007 | 19 March 2012 | AV650-018: A two-part (double-blind followed by open-label), placebo-controlled, randomized trial to assess the safety, tolerability, and preliminary efficacy of AV650 (tolperisone HCl) in subjects with spasticity associated with multiple sclerosis. | AV650-018: A two-part (double-blind followed by open-label), placebo-controlled, randomized trial to assess the safety, tolerability, and preliminary efficacy of AV650 (tolperisone HCl) in subjects with spasticity associated with multiple sclerosis. | Spasticity associated with multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028335 Term: Muscle spasticity | Trade Name: Tolposan Product Code: AV605 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Tolperisone HC1 CAS Number: 728-88-1 Other descriptive name: Tolpersan Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Avigen Inc | Not Recruiting | Female: yes Male: yes | 150 | Germany | ||||
1083 | NCT00530348 | August 2007 | 19 October 2017 | Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One | A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Biological: Alemtuzumab;Biological: Interferon beta-1a | Genzyme, a Sanofi Company | Bayer | Not recruiting | 18 Years | 50 Years | All | 581 | Phase 3 | United States;Argentina;Australia;Brazil;Canada;Croatia;Czech Republic;France;Germany;Mexico;Poland;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;Former Serbia and Montenegro |
1084 | NCT00649792 | August 2007 | 19 October 2017 | Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial | Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial | Multiple Sclerosis | Drug: Fampridine-SR | Acorda Therapeutics | Not recruiting | 18 Years | 70 Years | All | 214 | Phase 3 | United States;Canada | |
1085 | NCT01235455 | August 2007 | 19 February 2015 | Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors | Portuguese BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis (MS) After Conversion to Betaferon by Using Elements of the BetaPlus Program | Relapsing Remitting Multiple Sclerosis (RRMS);Secondary Progressive Multiple Sclerosis (SPMS) | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 18 Years | N/A | Both | 10 | N/A | Portugal | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1086 | EUCTR2006-004893-29-GB | 25/07/2007 | 1 May 2012 | A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis | A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis | Multiple sclerosis | Product Name: teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Sanofi-aventis U.S. Inc. | Authorised | Female: yes Male: yes | 120 | Germany;United Kingdom;Italy;Austria | ||||
1087 | EUCTR2007-000590-37-FR | 17/07/2007 | 19 March 2012 | Etude randomisée, en double aveugle, comparant l’efficacité et la tolérance de la méthylprednisolone administrée à forte dose par voie orale ou par voie intraveineuse dans le traitement des poussées de sclérose en plaques - COPOUSEP | Etude randomisée, en double aveugle, comparant l’efficacité et la tolérance de la méthylprednisolone administrée à forte dose par voie orale ou par voie intraveineuse dans le traitement des poussées de sclérose en plaques - COPOUSEP | Traitement des poussées de sclérose en plaques MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Product Name: METHYLPREDNISOLONE Pharmaceutical Form: Capsule* INN or Proposed INN: METHYLPREDNISOLONE CAS Number: 83432 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: methylprednisolone Product Name: methylprednisolone Pharmaceutical Form: Powder for solution for injection Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Trade Name: methylprednisolone Product Name: methylprednisolone Pharmaceutical Form: Powder for solution for injection Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use | CHU Rennes | Authorised | Female: yes Male: yes | France | |||||
1088 | EUCTR2006-003697-10-BE | 13/07/2007 | 21 August 2017 | A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis - N/A | A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis - N/A | Relapsing-Remitting Multiple Sclerosis MedDRA version: 8.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Product Name: BG00012 Pharmaceutical Form: Capsule, hard CAS Number: 624497 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Copaxone Product Name: Copaxone Pharmaceutical Form: Solution for injection CAS Number: 147245929 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- | Biogen Idec Ltd. | Not Recruiting | Female: yes Male: yes | 1232 | Phase 3 | Estonia;Czech Republic;Greece;Spain;Belgium;Ireland;Bulgaria;Germany;Latvia | |||
1089 | EUCTR2004-000463-94-HU | 03/07/2007 | 19 March 2012 | A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 600mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS). | A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 600mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS). | Relapsing-remitting multiple sclerosis (R-R MS) MedDRA version: 5.1 Level: PT Classification code 10028245 | Product Name: Glatiramer acetate 150mg enteric coated tablets Pharmaceutical Form: Coated tablet INN or Proposed INN: Glatiramer Acetate CAS Number: 147245-92-9 Current Sponsor code: COP-1 Other descriptive name: COP-1/Copolymer-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- | TEVA Pharmaceutical Industries Ltd. | Not Recruiting | Female: yes Male: yes | 25 | Hungary;Italy | ||||
1090 | NCT00467584 | July 2007 | 19 October 2017 | Aspirin for Treatment of Multiple Sclerosis-Related Fatigue | Aspirin for Treatment of Multiple Sclerosis-Related Fatigue | Multiple Sclerosis;Fatigue | Drug: High Dose Aspirin (1300 mg/day);Drug: Low Dose Aspirin (162 mg/day);Drug: Placebo | Mayo Clinic | National Multiple Sclerosis Society | Not recruiting | 18 Years | 65 Years | All | 62 | Phase 3 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1091 | NCT00469378 | July 2007 | 16 December 2017 | Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis | An Open-label Study of Leukocyte Counts in the Cerebrospinal Fluid and Blood of Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment With Firategrast | Multiple Sclerosis | Drug: firategrast | GlaxoSmithKline | Not recruiting | 18 Years | 65 Years | All | 46 | Phase 2 | Belgium;Czech Republic;Denmark;Norway;Sweden | |
1092 | NCT00497952 | July 2007 | 28 January 2019 | Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis | Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis | Multiple Sclerosis | Biological: hematopoetic stem cell infusion | University of Louisville | Not recruiting | 18 Years | 55 Years | All | 3 | Phase 1/Phase 2 | United States | |
1093 | NCT00619307 | July 2007 | 19 October 2017 | Transition to Rebif New Formulation | A Randomized, Multicenter, Two-arm, Open-label, Phase IIIb Study to Evaluate the Satisfaction in Relapsing Multiple Sclerosis Subjects Transitioning to Rebif® New Formulation From Rebif® (Interferon Beta-1a) With Ibuprofen When Necessary (PRN) or as Prophylaxis | Relapsing Multiple Sclerosis | Drug: Rebif New Formulation + prophylactic Ibuprofen;Drug: Rebif New Formulation + ibuprofen PRN | Merck KGaA | Not recruiting | 18 Years | 60 Years | All | 117 | Phase 3 | France;Germany | |
1094 | NCT01158183 | July 2007 | 19 February 2015 | Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis | Real-World Betaseron® Outcomes Study (ROBUST): A Twelve-month, US Prospective, Observational, Open-label, Single-arm, Multi-center Outcomes Study of Interferon ß-1b (Betaseron®) Given Every Other Day for Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: BAY86-5046_Interferon-beta-1b | Bayer | Not recruiting | 18 Years | 65 Years | Both | 226 | N/A | United States | |
1095 | EUCTR2004-002571-16-GB | 29/06/2007 | 4 August 2015 | A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01 | A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01 | Secondary progressive multiple sclerosis MedDRA version: 8.1 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis | Product Name: MBP8298 Synthetic Peptide Product Code: MBP8298 Pharmaceutical Form: Powder for injection* INN or Proposed INN: Dirucotide acetate CAS Number: 781666-30-6 Current Sponsor code: MBP8298 Other descriptive name: MBP8298 Synthetic Peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use | BioMS Technology Corp | Not Recruiting | Female: yes Male: yes | 553 | Estonia;Finland;Spain;Lithuania;Denmark;Latvia;Netherlands;United Kingdom;Sweden | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1096 | NCT00493298 | June 29, 2007 | 30 September 2019 | Tysabri Observational Program | TOP: Tysabri® Observational Program | Relapsing-Remitting Multiple Sclerosis | Drug: natalizumab | Biogen | Not recruiting | 18 Years | 65 Years | All | 6620 | Phase 4 | Argentina;Australia;Belgium;Brazil;Canada;Czechia;Finland;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Portugal;Slovakia;Spain;United Kingdom;Czech Republic;Denmark;Switzerland | |
1097 | EUCTR2006-006323-39-DE | 19/06/2007 | 19 March 2012 | Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MS | Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MS | relapsing-remitting multiple sclerosis ICD classification: G35.1 | Product Name: Sunphenon Pharmaceutical Form: Capsule, hard Other descriptive name: Sunphenon EGCg TM Concentration unit: mg milligram(s) Concentration number: 200- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Charité-Universitätsmedizin Berlin | Not Recruiting | Female: yes Male: yes | 100 | Germany | ||||
1098 | EUCTR2006-005972-42-FR | 12/06/2007 | 19 March 2012 | A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interferon beta-1a) with ibuprofen pro re nata (PRN) or as prophylaxis. - Transition to RNF | A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interferon beta-1a) with ibuprofen pro re nata (PRN) or as prophylaxis. - Transition to RNF | Relapsing multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Trade Name: NA Product Name: Interferon-beta 1a FBS-free/HSA-free, RNF Product Code: NA Pharmaceutical Form: Solution for injection | Merck Serono International SA | Authorised | Female: yes Male: yes | 120 | Phase 3b | Germany;France | |||
1099 | EUCTR2006-003134-14-DE | 04/06/2007 | 19 March 2012 | A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with interferon-beta in subjects with multiple sclerosis | A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with interferon-beta in subjects with multiple sclerosis | Multiple sclerosis | Product Name: teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Sanofi-aventis U.S. Inc. | Not Recruiting | Female: yes Male: yes | 120 | Germany;Spain;Italy | ||||
1100 | NCT00468611 | June 2007 | 19 February 2015 | Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis | A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Drug: MBP8298 | BioMS Technology Corp. | Not recruiting | 18 Years | 65 Years | Both | 510 | Phase 3 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1101 | NCT00480181 | June 2007 | 19 February 2015 | Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis | A Comparative, Single Center, Randomized, Double-blinded, Parallel, Placebo-controlled Study to Evaluate the Efficacy of Nabilone (Cesamet) as Adjunctive Therapy to Gabapentin (Neurontin) in the Management of Neuropathic Pain (NPP) Symptoms in Subjects With Multiple Sclerosis (MS) | Neuropathic Pain;Multiple Sclerosis | Drug: nabilone;Other: placebo | University of Manitoba | Valeant Pharmaceuticals International, Inc. | Not recruiting | 18 Years | 65 Years | Both | 50 | Phase 4 | Canada |
1102 | NCT00490906 | June 2007 | 19 February 2015 | Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis | Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis: A Pilot Study | Multiple Sclerosis;Low Bone Density | Drug: Copaxone;Drug: Interferon-beta 1a;Drug: Interferon-beta 1b | Nancy Hammond, MD | Kansas City Area Life Sciences Institute, Inc. | Not recruiting | 18 Years | N/A | Female | 60 | N/A | United States |
1103 | NCT00574041 | June 2007 | 19 February 2015 | How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose | An Open-Label Study to Examine the Difference in Tolerability Associated With Titration Of Dose on Initiation of Avonex therapY (TODAY) | Relapsing Remitting Multiple Sclerosis | Drug: Interferon beta-1a | Biogen Idec | Not recruiting | 18 Years | N/A | Both | 19 | Phase 4 | Australia | |
1104 | NCT00959218 | June 2007 | 19 February 2015 | Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis | Multi-centre, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Patients With Multiple Sclerosis Associated With Central Neuropathic Pain | Central Neuropathic Pain in Multiple Sclerosis | Drug: Dronabinol;Drug: Placebo | Bionorica Research GmbH | Not recruiting | 18 Years | 70 Years | Both | 240 | Phase 3 | Germany | |
1105 | EUCTR2006-005262-39-DE | 30/05/2007 | 11 February 2013 | Flupirtin as Oral Treatment in MS - FLORIMS | Flupirtin as Oral Treatment in MS - FLORIMS | Relapsing-remitting multiple sclerosis | Trade Name: Trancopal Dolo Product Name: Flupirtin Pharmaceutical Form: Capsule, hard INN or Proposed INN: Flupirtin CAS Number: 56995-20-1 Other descriptive name: Flupirtinmaleat Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Charité-Universitätsmedizin Berlin | Not Recruiting | Female: yes Male: yes | Germany | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1106 | EUCTR2006-007057-42-BE | 29/05/2007 | 28 October 2013 | An open-label study of leukocyte counts in the cerebrospinal fluid and blood of subjects with relapsing forms of multiple sclerosis following treatment with firategrast | An open-label study of leukocyte counts in the cerebrospinal fluid and blood of subjects with relapsing forms of multiple sclerosis following treatment with firategrast | relapsing forms of multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis | Product Name: firategrast (USAN approved name) Product Code: SB-683699 Pharmaceutical Form: Tablet CAS Number: 402567-16-2 Current Sponsor code: SB-683699 Other descriptive name: firategrast (USAN approved name) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- | GlaxoSmithKline Research & Development Ltd | Not Recruiting | Female: yes Male: yes | 45 | Czech Republic;Belgium;Denmark;Sweden | ||||
1107 | EUCTR2007-000236-16-EE | 28/05/2007 | 19 March 2012 | A Double-Blind, Randomized, Placebo- and Active Comparator- Controlled, Parallel Group, Multinational Study to Evaluate the Pharmacokinetics and Pharmacodynamics of IPX056 in Subjects with Established Spasticity Resulting from Multiple Sclerosis | A Double-Blind, Randomized, Placebo- and Active Comparator- Controlled, Parallel Group, Multinational Study to Evaluate the Pharmacokinetics and Pharmacodynamics of IPX056 in Subjects with Established Spasticity Resulting from Multiple Sclerosis | Established Spasticity Resulting from Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10041416 Term: Spasticity | Product Code: IPX056-40 mg Pharmaceutical Form: Capsule* INN or Proposed INN: BACLOFEN CAS Number: 1134470 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Code: IPX056-35 mg Pharmaceutical Form: Capsule* INN or Proposed INN: BACLOFEN CAS Number: 1134470 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 35- Product Code: IPX056-30 mg Pharmaceutical Form: Capsule* INN or Proposed INN: BACLOFEN CAS Number: 1134470 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Product Code: IPX056-20 mg Pharmaceutical Form: Capsule* INN or Proposed INN: BACLOFEN CAS Number: 1134470 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Code: IPX056-10 mg Pharmaceutical Form: Capsule* INN or Proposed INN: BACLOFEN CAS Number: 1134470 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Trade Name: baclofen Product Name: baclofen Product Code: baclofen 20 mg Pharmaceutical Form: Capsule* INN or Proposed INN: BACLOFEN CAS Number: 1134470 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | IMPAX Laboratories, Inc. | Not Recruiting | Female: yes Male: yes | 180 | Estonia;Latvia | ||||
1108 | EUCTR2006-005460-30-IT | 22/05/2007 | 19 March 2012 | POPART?MUS Prevention of Post Partum Relapses with Progestin and Estradiol in Multiple sclerosis - POPART`MUS | POPART?MUS Prevention of Post Partum Relapses with Progestin and Estradiol in Multiple sclerosis - POPART`MUS | Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Trade Name: DEMESTRIL SEPTEM Pharmaceutical Form: Transdermal patch INN or Proposed INN: Estradiol Concentration unit: mg milligram(s) Concentration type: equal Concentration number: .075- Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: LUTENYL Pharmaceutical Form: Tablet INN or Proposed INN: Nomegestrol Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | OSPEDALI CIVILI DI LIONE | Authorised | Female: yes Male: no | 300 | Italy | ||||
1109 | NCT00461396 | May 2007 | 19 February 2015 | Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron | Open-Label, Multicenter, Observational, Phase IV Study to Evaluate the Adherence to Treatment With 250mcg (8MIU) IFNB-1b (Betaseron®) Given Subcutaneous Every Other Day Over a Period of up to 12 Months in Patients With a First Clinical Demyelinating Event Suggestive of Multiple Sclerosis and Patients With Onset of Relapsing-Remitting Multiple Sclerosis (RRMS) Within the Past 12 Months | Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting | Drug: Interferon-1beta (Betaseron, BAY86-5046) | Bayer | Not recruiting | 18 Years | 50 Years | Both | 104 | N/A | United States | |
1110 | NCT00483652 | May 2007 | 19 October 2017 | Study of Fampridine-SR Tablets in Multiple Sclerosis Patients | Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: Fampridine-SR;Drug: Placebo | Acorda Therapeutics | Not recruiting | 18 Years | 70 Years | All | 240 | Phase 3 | United States;Canada | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1111 | NCT00928967 | May 2007 | 19 October 2015 | Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients | Prospective Multicenter, Non-interventional Study to Evaluate the Impact of the Introduction of Interferon Beta-1 b Treatment on Daily Life Activities in Patients at High Risk of Developing Multiple Sclerosis After a First Clinical Demyelinating Event or Having Received a Confirmed Diagnosis of RRMS | Multiple Sclerosis | Drug: Interferon beta-1b, (Betaseron BAY86-5046) | Bayer | Not recruiting | 18 Years | N/A | Both | 67 | N/A | France | |
1112 | EUCTR2008-000955-90-IT | 24/04/2007 | 19 March 2012 | Randomized, single-blind, clinical and MRI study for evaluation of safety and efficacy of N-Acetyl Cysteine (NAC) associated with high-dose beta-Interferon in Relapsing-Remitting (RR) multiple sclerosis patients - renac | Randomized, single-blind, clinical and MRI study for evaluation of safety and efficacy of N-Acetyl Cysteine (NAC) associated with high-dose beta-Interferon in Relapsing-Remitting (RR) multiple sclerosis patients - renac | multiple sclerosis MedDRA version: 9.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive | Product Name: n-acetylcysteine Pharmaceutical Form: Capsule, hard INN or Proposed INN: Acetylcysteine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 600- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | ISTITUTO C. MONDINO | Authorised | Female: yes Male: yes | Italy | |||||
1113 | EUCTR2006-005270-47-FI | 23/04/2007 | 1 May 2012 | International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg or open-label Betaseron/Betaferon 250 µg and (Phase B) open-label Betaseron/Betaferon 500 µg version: final internal approved - Beyond Follow-up | International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg or open-label Betaseron/Betaferon 250 µg and (Phase B) open-label Betaseron/Betaferon 500 µg version: final internal approved - Beyond Follow-up | relapsing multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Trade Name: Betaferon 250µg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta-1b CAS Number: L03 AB 08 Current Sponsor code: ZK 157046 Product Name: Betaferon 500µg Product Code: ZK 157046 Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta-1b CAS Number: L03 AB 08 Current Sponsor code: ZK 157046 | Schering AG | Authorised | Female: yes Male: yes | 1880 | Phase 3b | Hungary;Germany;Netherlands;France;Ireland;Italy;Latvia;Austria;Sweden;Finland;Slovenia;Spain;Greece | |||
1114 | NCT00548769 | April 21, 2007 | 16 December 2017 | Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients | An Open-label, Randomised, Four Period Crossover Study to Investigate the Relative Pharmacokinetic Profiles of Tablets From Three Batches of Firategrast With Different Surface Areas and Two Different Tablet Formulations Containing the Same Batch of Firategrast, Given as Single 900mg Doses to Male and Female Subjects With a Diagnosis of Multiple Sclerosis | Multiple Sclerosis | Drug: Formulation A;Drug: Formulation B;Drug: Formulation C;Drug: Formulation D | GlaxoSmithKline | Not recruiting | 18 Years | 65 Years | All | 37 | Phase 1 | Czechia;Germany;Poland;Czech Republic | |
1115 | NCT00468182 | April 2007 | 25 May 2015 | Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis | Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis | Multiple Sclerosis | Drug: Interferon-beta 1b (Betaseron) | Rutgers, The State University of New Jersey | Bayer | Not recruiting | 18 Years | 60 Years | Both | 24 | Phase 4 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1116 | NCT00472797 | April 2007 | 19 October 2017 | Rebif New Formulation (RNF) Quality of Life (QOL) Study | A Randomized, Multicenter, Two-arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QOL) Measures in Subjects With Relapsing Forms of Multiple Sclerosis (MS) Who Are Transitioning From Rebif® (Interferon Beta-1a) to Rebif New Formulation (RNF) | Relapsing Multiple Sclerosis | Drug: Rebif New Formulation Non Titrated;Drug: Rebif New Formulation Titrated | EMD Serono | Not recruiting | 18 Years | 60 Years | All | 232 | Phase 3 | United States | |
1117 | EUCTR2006-002204-33-BE | 02/03/2007 | 7 October 2014 | Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two doses of CDP323 over 24 weeks with a rater-blind MRI follow-up over 12 weeks. | Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two doses of CDP323 over 24 weeks with a rater-blind MRI follow-up over 12 weeks. | Relapsing forms of multiple slerosis MedDRA version: 9.1 Level: LLT Classification code 10048393 Term: Multiple sclerosis relapse | Product Name: CDP323 Product Code: CDP323 Pharmaceutical Form: Capsule, hard CAS Number: 455264-30-9 Current Sponsor code: CDP323 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | UCB Pharma S.A. | Not Recruiting | Female: yes Male: yes | 317 | Phase 2 | France;Hungary;Finland;Spain;Belgium;Netherlands;Germany;United Kingdom;Sweden | |||
1118 | EUCTR2006-003696-12-BE | 02/03/2007 | 9 October 2012 | A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis - N/A | Relapsing-Remitting Multiple Sclerosis MedDRA version: 8.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Product Name: BG00012 Pharmaceutical Form: Capsule, hard CAS Number: 624497 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Biogen Idec Ltd. | Not Recruiting | Female: yes Male: yes | 1011 | Czech Republic;Germany;United Kingdom;Netherlands;Belgium;Bulgaria;Italy;Greece;Austria;Sweden | |||||
1119 | NCT00451204 | March 2007 | 19 October 2017 | A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) | A Combination Trial of Copaxone Plus Estriol in RRMS | Relapsing Remitting Multiple Sclerosis | Drug: Estriol;Drug: Placebo;Drug: Copaxone | University of California, Los Angeles | Washington University School of Medicine;University of Texas Southwestern Medical Center;Ohio State University;University of Medicine and Dentistry of New Jersey;University of Chicago;University of Utah;Johns Hopkins University;University of Kansas Medical Center;University of Minnesota, MN;Mayo Clinic;University of Colorado, Aurora;University of New Mexico;University of Pennsylvania;Dartmouth-Hitchcock Medical Center;National Multiple Sclerosis Society;National Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | 50 Years | Female | 158 | Phase 2 | United States;Canada |
1120 | NCT01111656 | March 2007 | 19 February 2015 | Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b | SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study (SWABIMS Follow Up-study) | Relapsing-remitting Multiple Sclerosis | Drug: Interferon beta-1b group;Drug: Interferon beta-1b/Atorvastatin group | University Hospital Inselspital, Berne | Viollier AG, Basel, Switzerland;PharmaPart GmbH, Thalwil, Switzerland | Not recruiting | 18 Years | 67 Years | Both | 28 | Phase 2 | Switzerland |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1121 | EUCTR2006-003384-30-SK | 26/02/2007 | 13 March 2017 | A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple Sclerosis | A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple Sclerosis | Multiple Sclerosis | Product Name: NeuroVax 300ug/mL Dose for IM Injection Product Code: IR902 Pharmaceutical Form: Emulsion for injection Current Sponsor code: IR208 Other descriptive name: VB6S5 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: range Concentration number: 75-125 Current Sponsor code: IR401 Other descriptive name: VB13S1 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: range Concentration number: 75-125 Current Sponsor code: IR901 Other descriptive name: VB5S2 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: range Concentration number: 75-125 Pharmaceutical form of the placebo: Emulsion for injection Route of administration of the placebo: Intramuscular use | The Immune Response Corporation | Not Recruiting | Female: yes Male: yes | 200 | Phase 2 | Slovakia | |||
1122 | EUCTR2006-002856-14-DE | 21/02/2007 | 16 September 2013 | Randomised, placebo-controlled, three-arm parallel-group, double-blind, multicentre, national clinical phase II study to evaluate the efficacy, safety, and tolerability of intravenous 3 and 6 g/m² treosulfan given every 6 weeks in patients with secondary progressive and progressive relapsing multiple sclerosis. | Randomised, placebo-controlled, three-arm parallel-group, double-blind, multicentre, national clinical phase II study to evaluate the efficacy, safety, and tolerability of intravenous 3 and 6 g/m² treosulfan given every 6 weeks in patients with secondary progressive and progressive relapsing multiple sclerosis. | Secondary progressive or progressive relapsing multiple sclerosis with signs of disease activity in terms of inflammation MedDRA version: 8.1 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis | Trade Name: Ovastat 1000 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: TREOSULFAN CAS Number: 299752 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Ovastat 5000 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: TREOSULFAN CAS Number: 299752 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5000- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | medac Gesellschaft für klinische Spezialpräparate mbH | Not Recruiting | Female: yes Male: yes | Phase 2 | Germany | ||||
1123 | EUCTR2007-000503-15-IT | 19/02/2007 | 19 March 2012 | Experimental clinical open study, randomized, experimental group vs control group, for the evaluation of tolerability and the effects on magnetic resonance parameters and cognitive functions of memantine in patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta. - NEMESI-MS Neuroprotection by Memantine at Early Stage In Multiple Sclerosis | Experimental clinical open study, randomized, experimental group vs control group, for the evaluation of tolerability and the effects on magnetic resonance parameters and cognitive functions of memantine in patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta. - NEMESI-MS Neuroprotection by Memantine at Early Stage In Multiple Sclerosis | patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta. MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Trade Name: EBIXA Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Memantine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- | AZ. OSPEDALIERA GARIBALDI, S.LUIGI CURRO , ASCOLI TOMASELLI | Authorised | Female: yes Male: yes | Italy | |||||
1124 | NCT00501696 | February 2007 | 19 February 2015 | A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone | A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone on Quality of Life as Measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI54) | Multiple Sclerosis | Drug: 4.5 mg Naltrexone;Drug: Naltrexone | University of California, San Francisco | Not recruiting | 18 Years | 86 Years | Both | 80 | Phase 3 | United States | |
1125 | NCT00870155 | February 2007 | 19 February 2015 | A Study for Patients With Multiple Sclerosis | An Open Label Follow-On Study to Assess the Ongoing Safety of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Drug: dirucotide | Eli Lilly and Company | BioMS Technology Corp. | Not recruiting | 18 Years | 65 Years | Both | 546 | Phase 2/Phase 3 | Canada;Denmark;Estonia;Finland;Germany;Latvia;Netherlands;Spain;Sweden;United Kingdom |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1126 | EUCTR2006-003361-14-GB | 23/01/2007 | 24 July 2012 | Long-term extension of the multinational, double-blind, placebo controlled study EFC6049 (HMR1726D/3001) to document the safety of two doses of teriflunomide (7 and 14 mg) in patients with multiple sclerosis with relapses - | Multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Product Name: teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- | sanofi-aventis recherche & développement | Authorised | Female: yes Male: yes | 1080 | Portugal;Germany;Turkey;Switzerland;Netherlands;France;Norway;Italy;Austria;Sweden;Finland;Russian Federation;United Kingdom;Czech Republic;Ukraine;Canada;Denmark;Estonia;United States;Poland | |||||
1127 | EUCTR2006-004736-79-SK | 19/01/2007 | 13 March 2017 | A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis. | A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis. | To evaluate the efficacy of a selected treatment regimen of ATL 1102 in patients with Relapsing Remitting MS (RRMS) inflammatory lesions using MRI with gadolinium administration compared to placebo. | Product Name: ATL1102 Product Code: ATL1102 Pharmaceutical Form: Solution for injection Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Antisense Therapeutics Ltd. | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | Czech Republic;Slovakia | |||
1128 | EUCTR2006-004255-38-AT | 05/01/2007 | 20 May 2013 | Multi-centre, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of the pain relieving effect of Dronabinol in patients with multiple sclerosis associated with central neuropathic pain | Multi-centre, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of the pain relieving effect of Dronabinol in patients with multiple sclerosis associated with central neuropathic pain | Patients with multiple sclerosis associated with central neuropathic pain MedDRA version: 16.0 Level: LLT Classification code 10054095 Term: Neuropathic pain System Organ Class: 100000004852 | Product Name: dronabinol Product Code: cnp-MS-0601 Pharmaceutical Form: Oral solution INN or Proposed INN: dronabinol CAS Number: 1972-08-3 Current Sponsor code: cnp-MS-0601 Other descriptive name: (-)-trans-delta-9-Tetrahydrocannabinol Concentration unit: % percent Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use | Bionorica research GmbH | Not Recruiting | Female: yes Male: yes | 240 | Austria;Germany | ||||
1129 | NCT00414453 | January 2007 | 19 October 2017 | Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis | Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis (TALENT-MS) | Neuropathic Pain;Chronic Pain;Multiple Sclerosis | Drug: Lidocaine patch 5%;Drug: Extended-release oxycodone;Drug: Placebo extended-release oxycodone pills;Drug: Placebo lidocaine patches | University of Rochester | Endo Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 19 | Phase 4 | United States |
1130 | NCT00423527 | January 2007 | 19 February 2015 | Levetiracetam in Central Pain in Multiple Sclerosis(MS) | Double-blind, Randomised,Placebo-controlled Trial of Levetiracetam in Central Pain in Multiple Sclerosis | Multiple Sclerosis | Drug: levetiracetam | Odense University Hospital | Not recruiting | 18 Years | N/A | Both | 30 | Phase 4 | Denmark | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1131 | NCT00424788 | January 2007 | 19 February 2015 | A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS) | A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS) | Relapsing Forms of Multiple Sclerosis | Procedure: Plasma exchange;Drug: natalizumab treatment | Biogen Idec | Not recruiting | 18 Years | 50 Years | Both | 12 | Phase 0 | United States | |
1132 | NCT00457730 | January 2007 | 19 October 2017 | A Study to Test the Use of Duloxetine for Pain in MS | A Randomized Placebo Controlled Trial of Duloxetine for Central Pain in Multiple Sclerosis | Multiple Sclerosis | Drug: Duloxetine;Drug: Placebo | Brown, Theodore R., M.D., MPH | Eli Lilly and Company | Not recruiting | 18 Years | N/A | All | 38 | Phase 2/Phase 3 | United States |
1133 | EUCTR2006-004318-42-NL | 12/12/2006 | 19 March 2012 | Influence on brain perfusion and metabolism through pharmacologic agents | Influence on brain perfusion and metabolism through pharmacologic agents | Multiple Sclerosis MedDRA version: 8.1 Level: PT Classification code 10028245 Term: Multiple sclerosis | Trade Name: Prepulsid Pharmaceutical Form: Tablet Trade Name: Spiropent Pharmaceutical Form: Tablet | Department of Neurology UMCG | Authorised | Female: yes Male: yes | Netherlands | |||||
1134 | EUCTR2006-002361-39-DE | 01/12/2006 | 19 March 2012 | A 4-week, open-label, multicenter, urodynamic pilot study to explore the efficacy, tolerability and safety of darifenacin (7.5 mg with up-titration to 15 mg) in patients with multiple sclerosis and neurogenic detrusor overactivity | A 4-week, open-label, multicenter, urodynamic pilot study to explore the efficacy, tolerability and safety of darifenacin (7.5 mg with up-titration to 15 mg) in patients with multiple sclerosis and neurogenic detrusor overactivity | Neurogenic overactive bladder disaese in patients with multiple sclerosis MedDRA version: 8.1 Level: LLT Classification code 10059617 Term: Overactive bladder | Trade Name: EMSELEX 7,5 mg Retardtabletten Product Name: Darifenacin Product Code: BAY 79-4998 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Darifenacin Current Sponsor code: Bay 79-4998 Concentration unit: mg milligram(s) Concentration type: equal Trade Name: EMSELEX 15 mg Retardtabletten Product Name: Darifenacin Product Code: BAY 79-4998 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Darifenacin Current Sponsor code: Bay 79-4998 Concentration unit: mg milligram(s) Concentration type: equal | Bayer Vital GmbH | Not Recruiting | Female: yes Male: yes | Germany | |||||
1135 | NCT00358293 | December 2006 | 19 February 2015 | Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity | A Double-Blind, Randomized, Crossover Study to Evaluate the Clinical Efficacy and Safety of Oral Tizanidine HCl (12 mg) Versus Novel Sublingual Tizanidine HCl (12 mg) for the Treatment of Spasticity in MS Patients | Muscle Spasticity | Drug: Tizanidine (sublingual or oral) | Teva GTC | Not recruiting | 20 Years | 65 Years | Both | 20 | Phase 1/Phase 2 | Israel | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1136 | NCT00395317 | December 2006 | 19 February 2015 | Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS) | Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months Administration of SB-683699 in Subjects With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis | Other: Placebo;Drug: Firategrast 150 mg;Drug: Firategrast 300 mg | GlaxoSmithKline | Not recruiting | 18 Years | 65 Years | Both | 343 | Phase 2 | Australia;Austria;Canada;Finland;France;Germany;Italy;Netherlands;New Zealand;Norway;Poland;Russian Federation;Spain;United Kingdom;Lithuania | |
1137 | NCT00411723 | December 2006 | 19 February 2015 | Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis | Phase 1 Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis | Multiple Sclerosis, Chronic Progressive;Multiple Sclerosis, Relapsing-Remitting | Drug: RTL1000 (recombinant T cell receptor ligand);Drug: RTL1000 Placebo | Artielle ImmunoTherapeutics | Not recruiting | 18 Years | 65 Years | Both | 34 | Phase 1 | United States | |
1138 | NCT00428584 | December 2006 | 19 October 2017 | RNF and Betaseron® Tolerability Study | A Randomized, Multicenter, Two Arm, Open Label, Twelve Week Phase IIIb Study to Evaluate the Tolerability of Rebif (New Formulation) (IFN Beta-1a) and Betaseron (IFN Beta-1b) in IFN-naive Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Followed by a Single Arm, Eighty-two Week Minimum, Rebif (New Formulation) Only Safety Extension | Relapsing Remitting Multiple Sclerosis (RRMS) | Drug: New Formulation of rebif - human interferon beta-1a;Drug: Interferon beta -1b | EMD Serono | Pfizer | Not recruiting | 18 Years | 60 Years | All | 129 | Phase 3 | United States |
1139 | NCT00594087 | December 2006 | 19 February 2015 | Eszopiclone for Improving Sleep in Multiple Sclerosis (MS) | Eszopiclone for Improving Sleep Continuity in MS Patients With Sleep Disturbances and Its Impact on Daytime Fatigue | Relapsing Remitting Multiple Sclerosis;Sleep Initiation and Maintenance Disorders;Fatigue | Drug: eszopiclone;Other: placebo | University of Vermont | Not recruiting | 18 Years | 64 Years | Both | 30 | N/A | United States | |
1140 | EUCTR2006-002982-38-BE | 29/11/2006 | 21 August 2017 | A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - Rebif FLEXible dosing in early Multiple Sclerosis (REFLEX) | A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - Rebif FLEXible dosing in early Multiple Sclerosis (REFLEX) | Subjects at high risk of converting to Multiple Sclerosis MedDRA version: 9.0 Level: PT Classification code 10028245 | Trade Name: Rebif Product Name: Interferon-beta 1a FBS-free/HSA free, RNF Product Code: Not Applicable Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon-beta 1a CAS Number: NA Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Merck Serono S.A.-Geneva, an affiliate of Merck KGaA Darmstadt, Germany | Not Recruiting | Female: yes Male: yes | 480 | Phase 3 | Portugal;Estonia;Slovakia;Greece;Finland;Spain;Lithuania;Austria;Italy;France;Czech Republic;Belgium;Denmark;Germany | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1141 | EUCTR2006-000606-23-ES | 23/11/2006 | 29 May 2012 | ?Post-authorization safety study to check the potential association between the safety profile of beta interferon 1a and the body mass index or pharmacodynamics during the titration phase | Post-authorization safety study to check the potential association between the safety profile of beta interferon 1a and the body mass index or pharmacodynamics during the titration phase - PASS-PD del escalado de dosis de Rebif | Not applicalbe MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Rebif 22 y 44 mcg Product Name: Interferon-beta-1a Pharmaceutical Form: Solution for injection CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- | Merck, S.L. | Authorised | Female: yes Male: yes | Spain | |||||
1142 | EUCTR2006-002633-20-NL | 17/11/2006 | 18 April 2012 | Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple Sclerosis | Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis MedDRA version: 8.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Product Name: Firategrast Product Code: SB683699 Pharmaceutical Form: Tablet CAS Number: 402567-16-2 Current Sponsor code: SB683699 Other descriptive name: Firategrast (USAN approved name) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Firategrast Product Code: SB683699 Pharmaceutical Form: Tablet CAS Number: 402567-16-2 Current Sponsor code: SB683699 Other descriptive name: Firategrast (USAN approved name) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | GlaxoSmithKline Research & Development Ltd | Not Recruiting | Female: yes Male: yes | 350 | Finland;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria;Lithuania | ||||
1143 | NCT00370071 | November 2006 | 19 October 2017 | Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis | Open Label Study to Evaluate the Effect, Safety and Tolerability of 250µg (8 MIU) Interferon Beta 1b (Betaferon) Given Subcutaneously Every Other Day (for 24 Weeks) in Patients of Chinese Origin With Multiple Sclerosis | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 16 Years | 55 Years | All | 39 | Phase 3 | China | |
1144 | NCT00436826 | November 2006 | 19 October 2017 | A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) | A Phase II, Multicenter, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Efficacy Study of Add-on Cladribine Tablet Therapy With Interferon-beta (IFN-ß) Treatment in Multiple Sclerosis Subjects With Active Disease | Multiple Sclerosis | Drug: Cladribine;Drug: Placebo;Drug: Interferon-beta (IFN-beta) | EMD Serono | Not recruiting | 18 Years | 65 Years | All | 214 | Phase 2 | United States;Italy;Russian Federation;Spain | |
1145 | NCT00529581 | November 2006 | 19 February 2015 | A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis | A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons With Multiple Sclerosis With Cognitive Impairment | Cognition Disorders;Multiple Sclerosis | Drug: C105 | Cognition Pharmaceuticals, LLC | Not recruiting | 18 Years | 65 Years | Both | 150 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1146 | EUCTR2006-000704-17-GB | 19/10/2006 | 1 May 2012 | A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus interferon ß-1a (Avonex®) administered i.m. once weekly in patients with relapsing-remitting multiple sclerosis with optional Extension Phase - D2302 & E1 | A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus interferon ß-1a (Avonex®) administered i.m. once weekly in patients with relapsing-remitting multiple sclerosis with optional Extension Phase - D2302 & E1 | Relapsing-remitting multiple sclerosis (RRMS) | Product Code: FTY720 Pharmaceutical Form: Capsule* INN or Proposed INN: Fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: Interferon beta-1a Pharmaceutical Form: Solution for injection INN or Proposed INN: interferon beta-1a Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 30/0.5- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intramuscular use Product Code: FTY720 Pharmaceutical Form: Capsule* INN or Proposed INN: Fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.25- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 1275 | Portugal;Hungary;Germany;United Kingdom;Belgium;Spain;Italy;Greece;Austria | ||||
1147 | NCT00516893 | October 2006 | 19 October 2017 | Natalizumab High Titer Immunogenicity and Safety | A Multicenter, Open-Label Immunogenicity and Safety Study of Natalizumab High Titer Material (BG00002-E) in Subjects With Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis | Biological: BG00002-E (natalizumab high titer) | Biogen | Elan Pharmaceuticals | Not recruiting | 18 Years | 55 Years | All | 113 | Phase 2 | United States |
1148 | NCT00781872 | October 2006 | 24 June 2019 | Mesenchymal Stem Cells for the Treatment of MS | Explorative Trial to Investigate the Migration Ability of Mesenchymal Bone Marrow Stem Cells (MSC) in the Central Nervous System (CNS) Following Their Intrathecal Administration in Severe Cases of Multiple Sclerosis (MS) | Multiple Sclerosis | Biological: injection of autologous stem cells | Hadassah Medical Organization | Not recruiting | 35 Years | 65 Years | All | 20 | Phase 1/Phase 2 | ||
1149 | NCT01091727 | October 2006 | 19 February 2015 | Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity | Prospective Randomized Double-blind Trial of Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity and Urinary Incontinence Related to Spinal Cord Injury or Multiple Sclerosis | Neurogenic Detrusor Overactivity | Drug: Botulinum toxin A | Sunnybrook Health Sciences Centre | ethica Clinical Research Inc. | Not recruiting | 18 Years | 75 Years | Both | 57 | Phase 3 | Canada |
1150 | EUCTR2006-001947-70-SK | 14/09/2006 | 13 March 2017 | A Double Blind, Placebo Controlled Multi-Center Pilot Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis | A Double Blind, Placebo Controlled Multi-Center Pilot Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Product Name: MBP8298 Synthetic Peptide Product Code: MBP8298 Pharmaceutical Form: Powder for injection* CAS Number: 781666-30-6 Current Sponsor code: MBP8298 Other descriptive name: MBP8298 Synthetic Peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use | BioMS Technology Corp. | Not Recruiting | Female: yes Male: yes | 215 | Phase 2 | Slovakia | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1151 | EUCTR2004-001286-17-PT | 08/09/2006 | 19 March 2012 | Exploratory trial to evaluate the risk-benefit ratio of the use of mitoxantrone in patients under treatment with high dose interferon-beta-1a for relapsing-remitting or relapsing secondary progresive multiple sclerosis with high activity. - Mitoxantrone in high activity multiple sclerosis | Exploratory trial to evaluate the risk-benefit ratio of the use of mitoxantrone in patients under treatment with high dose interferon-beta-1a for relapsing-remitting or relapsing secondary progresive multiple sclerosis with high activity. - Mitoxantrone in high activity multiple sclerosis | Relapsing-remitting or relapsing secondary progressive multiple sclerosis with high activity MedDRA version: 7.0 Level: PT Classification code 10028245 | Product Name: Mitoxantrone Product Code: N/A Pharmaceutical Form: Solution for infusion | Fundación Española de Esclerosis Múltiple (FEDEM) | Authorised | Female: yes Male: yes | 50 | Portugal | ||||
1152 | EUCTR2005-005751-18-GB | 07/09/2006 | 3 April 2012 | A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies (NAbs) to IFNB-1a (Rebif) - Betaferon NaB Anergy Study | A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies (NAbs) to IFNB-1a (Rebif) - Betaferon NaB Anergy Study | Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system of unknown aetiology. It is the commonest cause of disability in young adults. The prevalence in the UK is approximately 125/100,000 of the population with an annual incidence of 6/100,000. Approximately 80,000 individuals are affected with MS in the UK. | Trade Name: Rebif 44 Product Name: Rebif 44 Product Code: Interferon beta 1a Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta 1a Current Sponsor code: IFNB-1a Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 44- Trade Name: Rebif 22 Product Name: Rebif 22 Product Code: Interferon beta 1a Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta 1a Current Sponsor code: IFNB-1a Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 22- Product Name: Betaferon 500mcg Product Code: Betaferon 500mcg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta 1b Current Sponsor code: IFNB-1b Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 500- | UCL Biomedicine R&D Unit | Not Recruiting | Female: yes Male: yes | 100 | United Kingdom | ||||
1153 | NCT00261326 | September 2006 | 19 February 2015 | Simvastatin Treatment of Patients With Acute Optic Neuritis | Simvastatin Treatment of Patients With Acut Optic Neuritis. A Doubleblind, Randomized and Placebo Controlled Fase III Trial | Optic Neuritis;Multiple Sclerosis | Drug: simvastatin;Drug: placebo | Glostrup University Hospital, Copenhagen | Alpharma ApS | Not recruiting | 18 Years | 59 Years | Both | 64 | Phase 3 | Denmark |
1154 | NCT00381264 | September 2006 | 19 February 2015 | Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis | A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: Cesamet™ (nabilone) | NEMA Research, Inc. | Not recruiting | 18 Years | 75 Years | Both | 23 | Phase 4 | United States | |
1155 | NCT00391079 | September 2006 | 19 October 2017 | Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS | A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Sativex When Added to the Existing Treatment Regimen, in the Relief of Central Neuropathic Pain in Subjects With Multiple Sclerosis | Multiple Sclerosis | Drug: Sativex;Drug: Placebo | GW Pharmaceuticals Ltd. | Not recruiting | 18 Years | N/A | All | 339 | Phase 3 | Canada | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1156 | NCT00398528 | September 2006 | 19 February 2015 | An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis | An fMRI Study of Treatment Optimization Recommendations Comparing Patients Changing Treatment From Glatiramer Acetate 20 mg qd SC (Copaxone®) to IFN-ß-1a 30 Mcg qw IM (Avonex®) to Those Changing From to IFN-ß-1a 30 Mcg qw IM (Avonex®) to Glatiramer Acetate 20 mg qd SC (Copaxone®) in a Multicenter Study of Patients With Relapsing Remitting Multiple Sclerosis Currently on Disease-Modifying Therapy. | Relapsing-Remitting Multiple Sclerosis | Drug: Glatiramer acetate, (Copaxone®);Drug: IFN-ß-1a, (Avonex®) | Neurognostics | Not recruiting | 18 Years | 65 Years | Both | 48 | Phase 4 | United States | |
1157 | NCT00588393 | September 2006 | 19 February 2015 | FolateScan in Autoimmune Disease | Study of the Efficacy and Safety of FolateScan (Technetium TC99m EC20) in Patients With Rheumatoid Arthritis and Other Inflammatory Diseases | Rheumatoid Arthritis;Osteoarthritis;Multiple Sclerosis;Crohn's Disease;Systemic Lupus Erythematosus | Drug: FolateScan (Technetium Tc 99mEC20) | Mayo Clinic | Endocyte | Not recruiting | 18 Years | N/A | Both | 75 | Phase 2 | United States |
1158 | EUCTR2005-005985-35-NL | 29/08/2006 | 19 March 2012 | A 24 week, MRI based, double-blind, randomised, placebo-controlled, modified dose-escalation trial to evaluate the safety, efficacy and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300 and 500 mg administered once daily in patients with relapsing forms of Multiple Sclerosis. | A 24 week, MRI based, double-blind, randomised, placebo-controlled, modified dose-escalation trial to evaluate the safety, efficacy and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300 and 500 mg administered once daily in patients with relapsing forms of Multiple Sclerosis. | Relapsing forms of Multiple Sclerosis MedDRA version: 8.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Product Code: BIRT 2584 XX Pharmaceutical Form: Tablet CAS Number: 688756-00-5 Current Sponsor code: BIRT 2584 XX Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Code: BIRT 2584 XX Pharmaceutical Form: Tablet CAS Number: 688756-00-5 Current Sponsor code: BIRT 2584 XX Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Boehringer Ingelheim | Authorised | Female: yes Male: yes | 320 | Czech Republic;Netherlands;Italy | ||||
1159 | EUCTR2006-001161-42-GB | 29/08/2006 | 3 July 2017 | Multicentre, double-blind, placebo-controlled, dose-ranging study to determine the safety and efficacy of daclizumab HYP (DAC HYP) as a monotherapy treatment in subjects with relapsing-remitting multiple sclerosis. - SELECT | Multicentre, double-blind, placebo-controlled, dose-ranging study to determine the safety and efficacy of daclizumab HYP (DAC HYP) as a monotherapy treatment in subjects with relapsing-remitting multiple sclerosis. - SELECT | Multiple sclerosis (MS) MedDRA version: 8.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis | Product Name: DACLIZUMAB HYP Pharmaceutical Form: Solution for injection Other descriptive name: Daclizumab HYP (DAC HYP) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Biogen Idec Ltd | Not Recruiting | Female: yes Male: yes | 600 | Phase 2 | Czech Republic;Hungary;Germany;United Kingdom;Sweden | |||
1160 | EUCTR2006-003113-40-NL | 18/08/2006 | 19 March 2012 | Dexamethason for the treatment of exacerbations in multiple sclerosis | Dexamethason for the treatment of exacerbations in multiple sclerosis | Multiple Sclerosis MedDRA version: 8.1 Level: PT Classification code 10028245 Term: Multiple sclerosis | Product Name: Dexamethason Pharmaceutical Form: Capsule* INN or Proposed INN: Dexamethasone Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | Department of Neurology UMCG | Authorised | Female: yes Male: yes | 60 | Netherlands | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1161 | EUCTR2006-004937-13-IT | 17/08/2006 | 19 March 2012 | multicentee randomized controlled study of azathioprine versus iterferon beta in relapsing remitting multiple sclerosis - M.A.I.N. trial | multicentee randomized controlled study of azathioprine versus iterferon beta in relapsing remitting multiple sclerosis - M.A.I.N. trial | patients with relapsing remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Trade Name: AZATIOPRINA HEX. 50CPR 50MG BL Pharmaceutical Form: Tablet INN or Proposed INN: Azathioprine CAS Number: 446-86-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: REBIF SC 12SIR 6000000UI 22MCG Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- Trade Name: BETAFERON SC 15F 0,25MG 15SIR Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1b Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 8- Trade Name: REBIF SC 12SIR 12000000UI44MCG Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Trade Name: AVONEX IM 4SIR 30MCG/0,5ML 4AG Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30- | Universita di Firenze | Authorised | Female: yes Male: yes | Italy | |||||
1162 | NCT00337779 | August 2006 | 19 October 2017 | Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA). | A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind Study to Compare the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to That of Glatiramer Acetate Injection 20 mg/ml Administered Once Daily by Subcutaneous Injection in Subjects With Relapsing Remitting (R-R) Multiple Sclerosis (MS) | Relapsing Remitting Multiple Sclerosis | Drug: Glatiramer Acetate (GA) 40 mg;Drug: glatiramer acetate 20 mg | Teva Pharmaceutical Industries | Not recruiting | 18 Years | 55 Years | All | 1155 | Phase 3 | Argentina;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;United Kingdom;United States | |
1163 | NCT00618527 | August 2006 | 19 February 2015 | Combination Therapy Using Cellcept and Rebif in RRMS | Combination Therapy Using Mycophenolate Mofetil (CellCept) and Human Interferon beta1a (Rebif) in Early Treatment of Multiple Sclerosis | Multiple Sclerosis | Drug: mycophenolate mofetil (Cellcept);Drug: human interferon beta 1a (Rebif) | Aaron Boster | EMD Serono;Pfizer | Not recruiting | 18 Years | 65 Years | Both | 31 | Phase 0 | United States |
1164 | NCT00882453 | August 2006 | 19 February 2015 | Physical Activity and Fatigue in Early Multiple Sclerosis (MS) | Betaferon Treatment and Exercise Data Gathering IN Early MS | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 18 Years | N/A | Both | 1739 | N/A | Australia;Austria;Bahrain;Belgium;Canada;Colombia;Czech Republic;Denmark;Egypt;France;Germany;Greece;Indonesia;Israel;Italy;Jordan;Kazakhstan;Korea, Republic of;Kuwait;Lebanon;Mexico;Netherlands;Norway;Oman;Portugal;Slovenia;Spain;Sweden;Switzerland;Taiwan;Thailand;United Arab Emirates;United Kingdom | |
1165 | EUCTR2005-005592-14-DE | 27/07/2006 | 29 May 2012 | Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PROTECT) - Vision Protect | Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PROTECT) - Vision Protect | Multiple sclerosis (MS) is a chronic disease of the central nervous system.Optic neuritis represents one of the most common and frequently the first clinical manifestation of MS. Optic neuritis is mainly characterized by a subacute loss of vision. | Trade Name: Erypo/Erypo FS Product Name: Erypo/Erypo FS Pharmaceutical Form: Injection* INN or Proposed INN: Epoetin alfa Other descriptive name: Epo Concentration unit: IU/ml international unit(s)/millilitre Concentration type: up to Concentration number: 10000- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Trade Name: Urbason solubile forte 1000mg Product Name: Methylprednisolone Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Methylprednisolon-21-hydrogensuccinat, Natriumsalz Concentration unit: mg milligram(s) Concentration type: not less then Concentration number: 1000 mg- | IFSgGmbH, Institute for clinical research | Not Recruiting | Female: yes Male: yes | Germany | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1166 | EUCTR2006-002037-20-HU | 27/07/2006 | 19 March 2012 | A multi-national, multi-centre, randomized, parallel-group, double-blind study to compare the efficacy, tolerability and safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate Injection 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting (RR) Multiple Sclerosis (MS) - FORTE | A multi-national, multi-centre, randomized, parallel-group, double-blind study to compare the efficacy, tolerability and safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate Injection 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting (RR) Multiple Sclerosis (MS) - FORTE | Relapsing-remitting Multiple Sclerosis (RR MS) MedDRA version: 8.1 Level: PT Classification code 10028245 | Product Name: 40 mg glatiramer acetate Product Code: 40 mg GA Pharmaceutical Form: Solution for injection INN or Proposed INN: n.a. CAS Number: 147245-92-9 Current Sponsor code: 40 mg GA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40- Product Name: Copaxone 20 mg/ml Solution for Injection, pre-filled syringe Product Code: 20 mg GA Pharmaceutical Form: Solution for injection INN or Proposed INN: n.a. CAS Number: 147245-92-9 Current Sponsor code: 20 mg GA Other descriptive name: Copaxone Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- | Teva Pharmaceutical Industries, Ltd. | Not Recruiting | Female: yes Male: yes | 980 | Hungary;Germany;Czech Republic;United Kingdom;Belgium;Estonia;Spain;Italy;Latvia;Lithuania | ||||
1167 | NCT00288626 | July 2006 | 16 December 2017 | High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study | A Phase II Study of High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, Melphalan, Thymoglobulin and Autologous CD34+ Hematopoietic Stem Cell Transplant for the Treatment of Poor Prognosis Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Drug: Granulocyte-colony stimulating factor (G-CSF) and prednisone;Drug: Carmustine, etoposide, cytarabine, and melphalan (BEAM);Procedure: Autologous hematopoietic stem cell transplant | National Institute of Allergy and Infectious Diseases (NIAID) | Immune Tolerance Network (ITN) | Not recruiting | 18 Years | 60 Years | All | 25 | Phase 2 | United States |
1168 | NCT00501943 | July 2006 | 19 October 2017 | Neuroprotection With Riluzole Patients With Early Multiple Sclerosis | Neuroprotection With Riluzole in Patients With Early Multiple Sclerosis | Multiple Sclerosis | Drug: Avonex (Interferon beta 1a);Drug: Riluzole;Drug: Placebo | University of California, San Francisco | National Multiple Sclerosis Society;Oregon Health and Science University | Not recruiting | 18 Years | 55 Years | All | 43 | Phase 2 | United States |
1169 | NCT00638027 | July 2006 | 19 October 2017 | Memantine for Spasticity in MS Patients | Memantine for Spasticity in MS Patients | Multiple Sclerosis | Drug: placebo;Drug: memantine | University of Rochester | Forest Laboratories | Not recruiting | 18 Years | 70 Years | All | 21 | Phase 4 | United States |
1170 | NCT00644904 | July 2006 | 19 February 2015 | Safety Trial of High Dose Oral Vitamin D3 With Calcium in Multiple Sclerosis | A Phase I/II Dose-Escalation Trial of Vitamin D3 With Calcium Supplementation in Patients With Multiple Sclerosis | Multiple Sclerosis | Dietary Supplement: Vitamin D3 | University of Toronto | Direct MS-Proactive Charity;Multiple Sclerosis Society of Canada | Not recruiting | 18 Years | 55 Years | Both | 49 | Phase 1/Phase 2 | Canada |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1171 | EUCTR2005-005679-13-IT | 28/06/2006 | 19 March 2012 | An open-label, prospective, multicentric pilot study evaluating safety and symptomatics effects of low dose Naltrexone in patients with primary progressive multiple sclerosis. - ND | An open-label, prospective, multicentric pilot study evaluating safety and symptomatics effects of low dose Naltrexone in patients with primary progressive multiple sclerosis. - ND | multiple sclerosis MedDRA version: 6.1 Level: PT Classification code 10053395 | Pharmaceutical Form: Capsule, hard INN or Proposed INN: Naltrexone CAS Number: 16676-29-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- | OSPEDALE S. RAFFAELE | Authorised | Female: yes Male: yes | 40 | Italy | ||||
1172 | EUCTR2005-001567-55-DE | 23/06/2006 | 18 April 2012 | A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of Multiple Sclerosis | A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of Multiple Sclerosis | This study is performed in patients with relapsing forms of Multiple Sclerosis. Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS), thought to be mediated by autoreactive T cells. Daclizumab is a genetically engineered humanized IgG1 monoclonal antibody that binds specifically to CD25 (alpha chain of the IL-2 receptor) and achieves immunosuppression at least in part by competitive antagonism of IL-2-induced T cell proliferation. | Product Name: Daclizumab Pharmaceutical Form: Solution for injection INN or Proposed INN: Daclizumab Other descriptive name: Anti-CD25 Humanized Monoclonal Antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Protein Design Labs, Inc. | Not Recruiting | Female: yes Male: yes | 270 | Phase 2 | United Kingdom;Germany;Spain | |||
1173 | EUCTR2005-004061-41-GB | 01/06/2006 | 28 February 2019 | TYSABRI Long Term Re-Dosing Study | An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 or C-1802 and a Dosing Suspension Safety Evaluation - STRATA | Multiple sclerosis (MS) MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: TYSABRI 300 mg concentrate for solution for infusion Product Name: NATALIZUMAB Product Code: BG00002 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Natalizumab Current Sponsor code: BG00002 Other descriptive name: Recombinant humanized anti-alpha 4 integrin antibody Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- | BIOGEN IDEC LTD | Not Recruiting | Female: yes Male: yes | 458 | Phase 3 | Greece;Finland;Spain;Ireland;Turkey;Austria;Italy;United Kingdom;Switzerland;France;Hungary;Czech Republic;Canada;Poland;Belgium;Australia;Denmark;Germany;New Zealand;Sweden | |||
1174 | NCT00342381 | June 2006 | 19 February 2015 | Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation | Fatigue in Multiple Sclerosis: Evaluated With 3 Tesla MRI and Transcranial Magnetic Stimulation | Multiple Sclerosis;Fatigue | Drug: 3,4-diaminopyridine;Drug: Placebo | University of Aarhus | The Danish Multiple Sclerosis Society | Not recruiting | 18 Years | 55 Years | Both | 120 | Phase 2 | Denmark |
1175 | NCT00355134 | June 2006 | 19 October 2017 | Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis | 24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase | Multiple Sclerosis | Drug: Fingolimod;Drug: Placebo | Novartis | Not recruiting | 18 Years | 55 Years | All | 1083 | Phase 3 | United States;Australia;Austria;Canada;Poland;Romania;Turkey;United Kingdom;Lithuania | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1176 | NCT00648908 | June 2006 | 19 October 2017 | Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial | Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis Who Participated in the MS-F203 Trial | Multiple Sclerosis | Drug: Fampridine-SR | Acorda Therapeutics | Not recruiting | 18 Years | 70 Years | All | 269 | Phase 3 | United States;Canada | |
1177 | EUCTR2006-000397-71-DK | 16/05/2006 | 19 March 2012 | Double-blind, randomised, placebo-controlled trial of levetiracetam for central neuropathic pain in patients with multiple sclerosis - levetiracetam for central neuropathic pain in patients with multiple sclerosis | Double-blind, randomised, placebo-controlled trial of levetiracetam for central neuropathic pain in patients with multiple sclerosis - levetiracetam for central neuropathic pain in patients with multiple sclerosis | Trade Name: Keppra Product Name: Levetiracetam Product Code: ucb L059 Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Søren H. Sindrup, Department of Neurology, Odense University Hospital | Not Recruiting | Female: yes Male: yes | 30 | Denmark | |||||
1178 | NCT00245622 | May 2006 | 19 February 2015 | Autologous T Cell Vaccine (TCV) for Multiple Sclerosis | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous Tovaxin in Subjects With CIS or RR-MS | Relapsing-Remitting Multiple Sclerosis | Biological: Tovaxin Autologous T cell vaccine;Biological: Placebo | Opexa Therapeutics, Inc. | Not recruiting | 18 Years | 55 Years | Both | 150 | Phase 2 | United States | |
1179 | NCT00324506 | May 2006 | 19 February 2015 | Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis | A Randomized, Open-label, Parallel-Group Multicenter Study to Determine the Safety/Efficacy of Mycophenolate Mofetil in Mono & Combination Therapy With Interferon Beta 1a in Patients With Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Mycophenolate Mofetil (CellCept) | University of Texas Southwestern Medical Center | Aspreva Pharmaceuticals | Not recruiting | 18 Years | 55 Years | Both | 43 | Phase 2 | United States |
1180 | NCT00331747 | May 2006 | 19 February 2015 | Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate | Three Dimensional Gait Evaluation in Relapsing Remitting Multiple Sclerosis Patients Treated With Glatiramer Acetate | Multiple Sclerosis | Drug: Glatiramer acetate | Sheba Medical Center | Recruiting | 18 Years | N/A | Both | 20 | N/A | Israel | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1181 | NCT00340834 | May 2006 | 16 December 2017 | Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase | A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase | Multiple Sclerosis | Drug: Fingolimod 1.25 mg;Drug: Fingolimod 0.5 mg;Drug: Interferon ß-1a 30 µg | Novartis | Not recruiting | 18 Years | 55 Years | All | 1292 | Phase 3 | United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Portugal;Spain;Switzerland;United Kingdom;Puerto Rico | |
1182 | NCT02517788 | May 2006 | 17 August 2015 | Phase I BP Interferon (IFN) Beta-004 | Comparative Pharmacokinetic Profile of Interferon Beta-1a (Bioferon®) Administered as Single i.v. Doses in HSA-free Formulation and HSA+ Solution and as Multiple s.c. Doses in Healthy Subjects | Multiple Sclerosis, Relapsing-Remitting | Drug: Interferon beta-1a HSA-free biosimilar;Drug: Interferon beta-1a HSA+ biosimilar;Drug: Interferon beta-1a original | Centre Hospitalier Universitaire Vaudois | BioPartners GmbH | Not recruiting | 18 Years | 45 Years | Both | 24 | Phase 1 | |
1183 | EUCTR2006-002562-19-IT | 21/04/2006 | 19 March 2012 | Immunoablation with Cyclophosphamide at high dosage and Rabbit antithymoglobulin followed by autologous hematopoietic stem cell transplantation in severe multiple sclerosis - LIGHT | Immunoablation with Cyclophosphamide at high dosage and Rabbit antithymoglobulin followed by autologous hematopoietic stem cell transplantation in severe multiple sclerosis - LIGHT | VERIFICARE Patients with multiple sclerosis, age between 18 and 50 MedDRA version: 6.1 Level: PT Classification code 10028245 | Trade Name: L04AA04 - IMMUNOGLOBULINA ANTITIMOCITARIA (DI CONIGLIO) IMMUNOGLOBULINA DI CONIGLIO ANTITIMOCITI UMANI THYMOGLOBULINE Product Name: Thymoglobuline Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: Antithymocyte Current Sponsor code: LIGHT Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Trade Name: Endoxan - ciclofosfamide Product Name: Endoxan Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: Cyclophosfamide Current Sponsor code: LIGHT Concentration unit: g gram(s) Concentration type: equal Concentration number: 1- | Dipartimento di Neuroscienze Oftalmologia e Genetica DINOG - Universita di Genova | Authorised | Female: yes Male: yes | 12 | Italy | ||||
1184 | EUCTR2005-005265-11-GB | 03/04/2006 | 19 March 2012 | A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sclerosis. This will be followed by a 12 week open label treatment phase and then a 4 week randomised withdrawal phase (Part B) for a subset of subjects | A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sclerosis. This will be followed by a 12 week open label treatment phase and then a 4 week randomised withdrawal phase (Part B) for a subset of subjects | Relief of central neuropathic pain in subjects with multiple sclerosis (MS) | Product Name: Sativex Product Code: GW-1000-02 Pharmaceutical Form: Oromucosal spray CAS Number: 1972-08-3 Other descriptive name: delta-9-tetrahydrocannabinol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 27- CAS Number: 13956-29-1 Other descriptive name: Cannabidiol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Oromucosal spray Route of administration of the placebo: Oromucosal use | GW Pharma Ltd | Authorised | Female: yes Male: yes | 312 | Czech Republic;United Kingdom;France | ||||
1185 | EUCTR2005-001540-23-SE | 03/03/2006 | 19 March 2012 | A Scandinavian, randomized, rater-blinded study of single and double-dose (2x250 mcg e.o.d.) Betaferon in patients with early secondary progressive multiple sclerosis. - BECAUSE - Betaferon in Early SPMS - SCAndinavian study on USE of double dose | A Scandinavian, randomized, rater-blinded study of single and double-dose (2x250 mcg e.o.d.) Betaferon in patients with early secondary progressive multiple sclerosis. - BECAUSE - Betaferon in Early SPMS - SCAndinavian study on USE of double dose | Early Secondary Progressive Multiple Sclerosis | Trade Name: Betaferon Product Name: Betaferon Pharmaceutical Form: Powder for solution for injection Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 2x250- Trade Name: Betaferon Product Name: Betaferon Pharmaceutical Form: Powder and solvent for solution for injection Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 250- | Schering Nordiska AB | Not Recruiting | Female: yes Male: yes | 160 | Denmark;Sweden | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1186 | NCT00291148 | March 2006 | 19 February 2015 | Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain | A Comparative Single Center, Randomized Neuropathic Pain Assessment Study Involving Patients With Clinically Definite Multiple Sclerosis (MS) Receiving Treatment With Either Pregabalin or Paroxetine | Neuropathic Pain;Multiple Sclerosis | Drug: paroxetine;Drug: pregabalin;Drug: Paroxetine | University of Manitoba | Not recruiting | 18 Years | 65 Years | Both | 75 | Phase 3 | Canada | |
1187 | NCT00297232 | March 2006 | 19 October 2017 | Natalizumab (Tysabri) Re-Initiation of Dosing | An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, C-1803, or C-1808 and a Dosing Suspension Safety Evaluation | Relapsing-Remitting Multiple Sclerosis | Drug: Natalizumab | Biogen | Not recruiting | 18 Years | N/A | All | 1094 | Phase 3 | Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;Austria | |
1188 | NCT00306592 | March 2006 | 16 December 2017 | Natalizumab Re-Initiation of Dosing | An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, or C-1803 and a Dosing Suspension Safety Evaluation | Multiple Sclerosis, Relapsing-Remitting | Biological: BG00002 (natalizumab) | Biogen | Elan Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 404 | Phase 3 | United States;Canada |
1189 | NCT00317941 | March 2006 | 19 October 2017 | Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif | The AVANTAGE Study - A Randomized, Multicenter, Phase IV, Open-label Prospective Study Comparing Injection Site Reaction and Injection Site Pain in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) or After a First Demyelinating Event Suggestive of MS Newly Started on Interferon Beta-1b (Betaferon®) or Interferon Beta-1a (Rebif®). | Relapsing-remitting Multiple Sclerosis | Drug: Betaferon/Betaseron;Drug: Rebif | Bayer | Not recruiting | 18 Years | 55 Years | All | 220 | Phase 4 | France | |
1190 | EUCTR2004-004403-37-DE | 27/02/2006 | 19 March 2012 | Eine monozentrische, randomisierte, kontrollierte Studie zur Untersuchung von Interferon-beta zur Behandlung der Multiplen-Sklerose (MS)-assoziierten und primären Uveitis intermedia im Vergleich zur Standardtherapie A monocentric, randomised, controlled trial for the investigation of Interferon-beta in the treatment of multiple-slerosis (MS)-associated and primary uveitis intermedia compared to the standardized treatment - TEAM-Studie | Eine monozentrische, randomisierte, kontrollierte Studie zur Untersuchung von Interferon-beta zur Behandlung der Multiplen-Sklerose (MS)-assoziierten und primären Uveitis intermedia im Vergleich zur Standardtherapie A monocentric, randomised, controlled trial for the investigation of Interferon-beta in the treatment of multiple-slerosis (MS)-associated and primary uveitis intermedia compared to the standardized treatment - TEAM-Studie | Uveitis intermedia with inflammatory macula edema with or without associated Multiple Sclerosis | Product Name: Rebif Pharmaceutical Form: Cutaneous solution INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- Product Name: Rebif Pharmaceutical Form: Cutaneous solution INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Product Name: Metex Pharmaceutical Form: Cutaneous liquid INN or Proposed INN: Methotrexat Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- | Universitätsklinikum Heidelberg | Authorised | Female: yes Male: yes | Germany | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1191 | EUCTR2005-004334-41-GB | 10/02/2006 | 17 October 2016 | An extended clinical study in subjects with multiple sclerosis who successfully completed the LAQ/5062 and LAQ/5063 study, to assess the safety of laquinimod (experimental drug) when taken for a long period of time and how it affects the course of the disease. | An active extension of LAQ/5062 study. A multinational, multicenter, randomized, double-blind, parallel-group study, to evaluate the safety, tolerability and efficacy of two doses (0.3 mg and 0.6 mg) of laquinimod, orally administered in relapsing remitting (R-R) multiple sclerosis (MS) subjects (study LAQ/5063 active double-blind phase) followed by an open label phase of laquinimod 0.6 mg daily (LAQ/5063 OL). | Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 19.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Laquinimod Capsules 0.6 mg Product Code: TV-5600 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Laquinimod CAS Number: 248282-07-7 Current Sponsor code: TV-5600 Other descriptive name: ABR-215062 sodium salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- | Teva Pharmaceutical Industries Ltd | Authorised | Female: yes Male: yes | 105 | Phase 2 | Hungary;Czech Republic;Poland;Spain;Russian Federation;Israel;Germany;Italy;United Kingdom | |||
1192 | NCT00382629 | February 2006 | 19 February 2015 | BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis | BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: BHT-3009 0.5 mg;Drug: BHT-3009 1.5 mg;Drug: Placebo | Bayhill Therapeutics | Not recruiting | 18 Years | 55 Years | Both | 252 | Phase 2 | ||
1193 | NCT00492765 | February 2006 | 19 February 2015 | Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis | A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment IM Administered Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Interferon-beta-1a;Drug: Simvastatin;Drug: Placebo | Biogen Idec | Not recruiting | 18 Years | 55 Years | Both | 380 | Phase 4 | Denmark | |
1194 | EUCTR2005-005263-29-GB | 31/01/2006 | 18 April 2012 | Multiple Sclerosis and Extract of Cannabis (MUSEC): A randomised, double-blind, placebo-controlled phase III trial to determine the efficacy and safety of a standardised oral extract of Cannabis sativa for the symptomatic relief of muscle stiffness and pain in Multiple Sclerosis. - MUSEC study | Multiple Sclerosis and Extract of Cannabis (MUSEC): A randomised, double-blind, placebo-controlled phase III trial to determine the efficacy and safety of a standardised oral extract of Cannabis sativa for the symptomatic relief of muscle stiffness and pain in Multiple Sclerosis. - MUSEC study | Multiple Sclerosis | Product Name: Cannador Pharmaceutical Form: Capsule, soft Current Sponsor code: Standardised Cannabis Extract Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use | Gesellschaft fuer klinische Forschung e.V. (Society for Clinical Research) | WELEDA AG | Authorised | Female: yes Male: yes | 300 | Phase 3 | United Kingdom | ||
1195 | EUCTR2005-004289-18-FI | 26/01/2006 | 19 March 2012 | A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline) | A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline) | Relapse Remitting Multiple Sclerosis MedDRA version: 8.0 Level: PT Classification code 10063399 | Product Name: Minocycline 100 mg Film-coated Tablets Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Minocycline Hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Merck AB | Not Recruiting | Female: yes Male: yes | 320 | Finland;Sweden | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1196 | EUCTR2005-003903-35-GB | 19/01/2006 | 3 April 2012 | : The Role of Keppra in the Treatment of Tremor in Multiple Sclerosis | : The Role of Keppra in the Treatment of Tremor in Multiple Sclerosis | Multiple Sclerosis | Trade Name: Keppra 250mg Pharmaceutical Form: INN or Proposed INN: Levetiracetam Concentration unit: mg milligram(s) Concentration type: range Concentration number: 250mg bd-1500mg bd Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Keppra 500mg Product Name: Keppra ® Pharmaceutical Form: Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Newcastle-upon-Tyne Hospitals NHS Trust | Authorised | Female: yes Male: yes | United Kingdom | |||||
1197 | EUCTR2005-003930-16-SE | 19/01/2006 | 19 March 2012 | A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis - SIMCOMBIN | A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis - SIMCOMBIN | Patients with definite relapsing-remitting multiple sclerosis who have never received treatment with interferons or glatiramer acetate, who meet all the criteria for inclusion and none of the exclusion criteria. Patients will be recruited from the outpatient clinics of the participating neurological departments among patients who are eligible for treatment with interferon-beta-1a. MedDRA version: 7.0 Level: PT Classification code 10028425 | Product Name: Simvastatin Alternova Pharmaceutical Form: Coated tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 40- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use | Biogen Idec A/S | Not Recruiting | Female: yes Male: yes | 380 | Finland;Sweden | ||||
1198 | EUCTR2005-005211-21-FI | 17/01/2006 | 19 March 2012 | A long term follow up of relapsing remitting multiple sclerosis patients who have been treated with intereron beta -1b (Betaferon) at least 5 years | A long term follow up of relapsing remitting multiple sclerosis patients who have been treated with intereron beta -1b (Betaferon) at least 5 years | Remitting relapsing multiple sclerosis (RRMS) is one of the most common diseases of the central nervous system. The cause of MS is not yet known but it is a result of damage to myelin. Symptoms vary widely and include blurred vision, weak limbs, tingling sensations, unsteadiness and fatigue. | Trade Name: Betaferon Product Name: Betaferon Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Beta-1b interferoni Concentration unit: µg/ml microgram(s)/millilitre | Schering Oy | Not Recruiting | Female: yes Male: yes | 80 | Finland | ||||
1199 | NCT00280592 | January 2006 | 19 February 2015 | Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients | Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients. | Multiple Sclerosis;Urinary Tract Infections;Bladder Dysfunction | Drug: Cranberry;Drug: Placebo | Rennes University Hospital | Pierre Fabre Laboratories;Ministry of Health, France | Not recruiting | 18 Years | 70 Years | Both | 171 | Phase 3 | France |
1200 | NCT00289978 | January 2006 | 19 October 2017 | Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis | A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis | Relapsing-remitting Multiple Sclerosis | Drug: Fingolimod 1.25 mg;Drug: Fingolimod 0.5 mg;Drug: Placebo | Novartis | Not recruiting | 18 Years | 55 Years | All | 1272 | Phase 3 | Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Israel;Lithuania;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Sweden;Switzerland;Turkey;United Kingdom;Italy | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1201 | NCT00818103 | January 2006 | 19 February 2015 | Characteristic Study on Chinese Patients With Multiple Sclerosis | Characteristic Study on Chinese Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: atorvastatin;Drug: ß-interferon;Drug: EPO | Sun Yat-sen University | Third Affiliated Hospital, Sun Yat-Sen University | Recruiting | N/A | 65 Years | Both | 600 | N/A | China |
1202 | EUCTR2006-006465-16-DE | 9 May 2016 | Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis - rhGH in MS | Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis - rhGH in MS | Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis | Trade Name: Genotropin Product Name: Genotropin Pharmaceutical Form: Solution for injection INN or Proposed INN: human recombinant growth hormone CAS Number: 12629-01-5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5-12 | University of Leipzig | Not Recruiting | Female: yes Male: yes | Phase 2 | Germany | |||||
1203 | EUCTR2005-000365-19-SE | 19/12/2005 | 19 March 2012 | A 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis - D2301 | A 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis - D2301 | Relapsing-remitting multiple sclerosis (RRMS) | Product Code: FTY720 Pharmaceutical Form: Capsule* CAS Number: 162359-56-0 Current Sponsor code: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5, 1.25- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 1250 | Hungary;Finland;Germany;Czech Republic;United Kingdom;Estonia;Ireland;Greece;Lithuania;Sweden | ||||
1204 | NCT00241254 | December 2005 | 19 February 2015 | Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis | A Double-blind, Two-arm, Multicenter, Randomized Trial to Evaluate Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Recent Secondary Progressive Multiple Sclerosis: P.R.OM.E.S.S Study | Multiple Sclerosis, Chronic Progressive | Drug: Cyclophosphamide (drug);Drug: Methylprednisolone (drug) | University Hospital, Bordeaux | Ministry of Health, France | Not recruiting | 18 Years | 65 Years | Both | 138 | Phase 3 | France |
1205 | NCT00676156 | December 2005 | 19 February 2015 | A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis | A Pilot Trial to Study the Pharmacokinetics of Oral Lipoic Acid (LA) and Immunological Effects of LA in Multiple Sclerosis | Multiple Sclerosis | Drug: oral lipoic acid (LA);Drug: lipoic acid (LA) with fish oil and LA without fish oil;Drug: R lipoic acid | Oregon Health and Science University | National Center for Complementary and Integrative Health (NCCIH) | Not recruiting | 18 Years | 80 Years | Both | 40 | Phase 1 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1206 | NCT01142466 | December 2005 | 19 October 2017 | A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone | Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone | Multiple Sclerosis, Relapsing-Remitting | Drug: Interferon beta-1a (Rebif) | Merck KGaA | Gesellschaft für Therapieforschung mbH | Not recruiting | 18 Years | 60 Years | All | 30 | Phase 4 | |
1207 | EUCTR2005-003410-15-SE | 21/11/2005 | 19 March 2012 | A twelve-month double-blind placebo-controlled cross-over study of the effect ofAricept treatment on cognitive dysfunction in multiple sclerosis. - Aricept in MS | A twelve-month double-blind placebo-controlled cross-over study of the effect ofAricept treatment on cognitive dysfunction in multiple sclerosis. - Aricept in MS | Multiple sclerosis is a devastating inflammation in the central nervous system and it can often give cognitive dysfunction, affecting memory, mental concentration. Lately it has been shown that the cognitive dysfunction has a big impact on life quality. Immunomodulatory medication can only partially limit the bouts but there is no effective cure at the moment. There is little options to treat the effects on higher functions for the moment. | Trade Name: Aricept 5 mg filmdragerade tabletter Product Name: Aricept 5 mg Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Donepezil Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Aricept 10 mg filmdragerade tabletter Product Name: Aricept 10 mg Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Donepezil Concentration unit: mg/l milligram(s)/litre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Neurology Unit | Not Recruiting | Female: yes Male: yes | 20 | Sweden | ||||
1208 | NCT00273364 | November 16, 2005 | 15 April 2019 | Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study | Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study | Multiple Sclerosis | Procedure: Hematopoietic Stem Cell Therapy;Drug: Standard treatment with a conventional drug | Northwestern University | Uppsala University;Sheffield Teaching Hospitals NHS Foundation Trust;University of Sao Paulo | Not recruiting | 18 Years | 55 Years | All | 110 | Phase 2 | United States |
1209 | EUCTR2005-001008-37-SE | 01/11/2005 | 19 March 2012 | Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy - Interferon beta dose and antibody | Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy - Interferon beta dose and antibody | Multiple sclerosis | Trade Name: Rebif® Product Name: Rebif® Product Code: Not applicable Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Current Sponsor code: Not applicable Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22, 44- | Sahlgrenska University Hospital | Authorised | Female: yes Male: yes | 100 | Sweden | ||||
1210 | NCT00270816 | November 2005 | 18 January 2018 | Interferon ß-1b Treatment by Cyclical Administration | Effect of Cyclical Administration of Interferon ß-1b in Multiple Sclerosis - Comparison With Normal Dose. | Multiple Sclerosis | Drug: Interferon-ß-1b;Drug: Interferon ß-1b | S. Andrea Hospital | Italian Multiple Sclerosis Foundation | Not recruiting | 18 Years | 55 Years | All | 60 | Phase 2/Phase 3 | Italy |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1211 | NCT00242268 | October 2005 | 19 February 2015 | A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: Simvastatin | Alabama Neurology Associates, PC | Biogen Idec | Recruiting | 18 Years | 55 Years | Both | 30 | Phase 3 | United States | |
1212 | EUCTR2005-001949-42-GB | 08/09/2005 | 24 April 2012 | A randomised controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis - Neuroprotection with lamotrigine in multiple sclerosis | A randomised controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis - Neuroprotection with lamotrigine in multiple sclerosis | Multiple sclerosis | Product Name: Lamotrigine extended release tablets Product Code: N/A Pharmaceutical Form: Modified-release tablet INN or Proposed INN: Lamotrigine CAS Number: N/A Current Sponsor code: N/A Other descriptive name: N/A Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 400- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | University College London | Authorised | Female: yes Male: yes | United Kingdom | |||||
1213 | NCT00220506 | September 2005 | 19 February 2015 | Fatigue Treatment Using Provigil | Fatigue Treatment Using Provigil in Patients With Relapsing Remitting Multiple Sclerosis | All Multiple Sclerosis Patients | Drug: Provigil | Sheba Medical Center | Recruiting | 18 Years | 55 Years | Both | 50 | N/A | Israel | |
1214 | NCT00754832 | September 2005 | 19 October 2017 | American Ginseng Treatment for Multiple Sclerosis Related Fatigue | A Double-blinded, Placebo-controlled Crossover Pilot Study of American Ginseng Treatment for Multiple Sclerosis Related Fatigue | Multiple Sclerosis | Drug: American ginseng extract HT-1001;Drug: placebo | Oregon Health and Science University | National Multiple Sclerosis Society | Not recruiting | 18 Years | 70 Years | All | 56 | Phase 2 | United States |
1215 | NCT01074619 | September 2005 | 19 February 2015 | Study on Cognitive Disorders of Multiple Sclerosis | Effects of Memantine on Cognitive Disorders of Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Memantine;Drug: Placebo | University Hospital, Caen | Ministry of Health, France;H. Lundbeck A/S | Not recruiting | 18 Years | 60 Years | Both | 90 | Phase 3 | France |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1216 | EUCTR2005-006071-12-IT | 31/08/2005 | 19 March 2012 | Evaluation of efficacy, safety and tolerability of an ADd-on therapy with Cianocabalamine Vitamin B12 plus Calcium levofolinate in relapsing-remitting multiple sclerosis patients Already in treatment with Nterferon beta over a period of 24 months for a better lonterm outComE - ADVANCE | Evaluation of efficacy, safety and tolerability of an ADd-on therapy with Cianocabalamine Vitamin B12 plus Calcium levofolinate in relapsing-remitting multiple sclerosis patients Already in treatment with Nterferon beta over a period of 24 months for a better lonterm outComE - ADVANCE | MULTIPLE SCLEROSIS MedDRA version: 6.1 Level: PT Classification code 10028245 | Trade Name: EPARMEFOLIN 30 CPR 0,1/0,5MG Pharmaceutical Form: Coated tablet INN or Proposed INN: CALCIO FOLINATO DC.IT CAS Number: 1492-18-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: .5- INN or Proposed INN: CIANOCOBALAMINA FU DC.IT CAS Number: 68-19-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: .5- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use Trade Name: LEVOFOLENE 4 MG 30 CPR Pharmaceutical Form: Tablet INN or Proposed INN: Calcium levofolinate CAS Number: 80433-71-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | AZIENDA OSPEDALIERA SAN CAMILLO FORLANINI | Not Recruiting | Female: yes Male: yes | 276 | Italy | ||||
1217 | EUCTR2005-001340-22-GB | 12/08/2005 | 24 April 2012 | BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS | BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS | Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarded as the predominant autoantigen. BHT-3009 is a 3.5 kb bacterial plasmid expression vector containing the coding sequences for full length human myelin basic protein (hMBP). | Product Name: BHT-3009 Product Code: BHT-3009 Pharmaceutical Form: Solution for injection Current Sponsor code: BHT-3009 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.5- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intramuscular use | Bayhill Therapeutics | Authorised | Female: yes Male: yes | 252 | Finland;Czech Republic;United Kingdom | ||||
1218 | EUCTR2005-001776-13-DE | 05/08/2005 | 19 March 2012 | Efficacy of Levetiracetam in the treatment of spasticity in MS: a ranomized double blind cross over study | Efficacy of Levetiracetam in the treatment of spasticity in MS: a ranomized double blind cross over study | Multiple Sclerosis | Product Name: Levetiracetam Pharmaceutical Form: Capsule, hard Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Organisation name was not entered | Authorised | Female: yes Male: yes | 24 | Germany | ||||
1219 | NCT00239993 | August 2005 | 16 December 2017 | A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone® | An Open-Label, Randomized, Single Cross-over Study of Warm Compress Versus Usual Injection Site Preparation on Local Injection Site Reactions Among Persons With MS Who Perform Daily Injections of Copaxone®. | Multiple Sclerosis | Drug: glatiramer acetate;Procedure: Warm compress prior to injection of glatiramer acetate | Teva Neuroscience, Inc. | Not recruiting | 18 Years | 55 Years | All | 50 | Phase 4 | United States | |
1220 | NCT00915577 | August 2005 | 19 February 2015 | Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe | An Open-Label, Multicenter Study to Determine Subject Satisfaction in Using the Single-Use Autoinjector With a Pre-Filled Liquid AVONEX® Syringe in Multiple Sclerosis Subjects | Multiple Sclerosis | Drug: Interferon beta-1a;Device: Single-use autoinjector | Biogen Idec | Not recruiting | 18 Years | 65 Years | Both | 74 | Phase 3 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1221 | EUCTR2004-004903-39-GB | 26/07/2005 | 1 May 2012 | A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis. - UNKEMPT | A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis. - UNKEMPT | Early, active relapsing remitting Multiple Sclerosis (RRMS) | Trade Name: Mitoxantrone Product Name: Mitoxantrone Pharmaceutical Form: Trade Name: Copaxone Product Name: Glatiramer Acetate Pharmaceutical Form: Injection* Trade Name: Rebif 44 Product Name: Interferon Beta 1a Pharmaceutical Form: Injection* | The Walton Centre for Neurology and Neurosurgery | Authorised | Female: yes Male: yes | 60 | United Kingdom | ||||
1222 | EUCTR2005-001009-25-IT | 16/07/2005 | 7 January 2013 | Efficacy, safety and tolerability of Atorvastatin 40 mg in patients with Relapsing-remitting multIple sclerosis in treAtment with INterferoN-betA. - ARIANNA | Efficacy, safety and tolerability of Atorvastatin 40 mg in patients with Relapsing-remitting multIple sclerosis in treAtment with INterferoN-betA. - ARIANNA | Multiple sclerosis treatment MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: TORVAST*10CPR 10MG Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Atorvastatin CAS Number: 134523-03-8 Concentration unit: mg milligram(s) Concentration number: 40- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: TORVAST*10CPR 10MG Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Atorvastatin Concentration unit: mg milligram(s) Concentration number: 10- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | DR DIMENSIONE RICERCA | Not Recruiting | Female: yes Male: yes | Italy | |||||
1223 | EUCTR2005-001026-89-DE | 14/07/2005 | 7 January 2013 | Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple sclerosis after mitoxantrone - Deescalation to Rebif® after Mitoxantrone therapy (REMAIN study) | Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple sclerosis after mitoxantrone - Deescalation to Rebif® after Mitoxantrone therapy (REMAIN study) | Relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS) with relapses MedDRA version: 7.1 Level: LLT Classification code 10028245 | Trade Name: Rebif Product Name: Rebif 8,8 µg, Rebif 22µg Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1 a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 8,8 or 22- Trade Name: Rebif Product Name: Rebif 44 µg Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1 a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- | Serono GmbH | Not Recruiting | Female: yes Male: yes | 100 | Phase 4 | Germany | |||
1224 | NCT00122954 | July 2005 | 16 December 2017 | Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis | Fish Oil as an Adjunct Therapy for Depression in Multiple Sclerosis | Multiple Sclerosis;Depression | Drug: Fish oil concentrate;Drug: Placebo | Oregon Health and Science University | National Center for Complementary and Integrative Health (NCCIH) | Not recruiting | 18 Years | 85 Years | All | 39 | Phase 1/Phase 2 | United States |
1225 | NCT00202423 | July 2005 | 19 February 2015 | Use of Cannabinoids in Patients With Multiple Sclerosis | fMRI and Neurophysiological Study Protocol on Cannabinoids in Multiple Sclerosis | Multiple Sclerosis | Drug: Sativex | S. Andrea Hospital | University of Roma La Sapienza | Recruiting | 18 Years | 60 Years | Both | 20 | Phase 2 | Italy |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1226 | NCT01142518 | July 2005 | 19 February 2015 | An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone | A Prospective Analysis of MS Patients After Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment | Relapsing-Remitting Multiple Sclerosis | Drug: Interferon beta 1a | Merck KGaA | Not recruiting | N/A | N/A | Both | 86 | N/A | ||
1227 | NCT00127075 | June 2005 | 19 February 2015 | POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis | POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis | Multiple Sclerosis | Drug: nomegestrol acetate;Drug: estradiol;Drug: placebo | Hospices Civils de Lyon | Not recruiting | 18 Years | 50 Years | Female | 300 | Phase 3 | France | |
1228 | NCT00202397 | June 2005 | 19 February 2015 | Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia | Phase 2 Study of Riluzole Effects on Patients With Chronic Cerebellar Ataxia | Hereditary Ataxia;Multiple Sclerosis;Cerebellar Ataxia | Drug: Riluzole;Other: placebo | S. Andrea Hospital | Not recruiting | 18 Years | 80 Years | Both | 40 | Phase 2 | Italy | |
1229 | NCT00463710 | June 2005 | 19 February 2015 | Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With MS | Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis | Multiple Sclerosis | Drug: Avonex® monotherapy (6.0 MIU administered i.m. each week) | State University of New York at Buffalo | Biogen Idec | Not recruiting | 18 Years | 65 Years | Both | 150 | Phase 4 | United States |
1230 | NCT01450488 | June 2005 | 18 December 2018 | Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis | A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Activity of Oral AB1010 Administered at 2 Dose Levels to Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis | Multiple Sclerosis | Drug: masitinib | AB Science | Not recruiting | 18 Years | 60 Years | All | 35 | Phase 2 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1231 | EUCTR2004-005148-28-FI | 26/05/2005 | 1 May 2012 | A phase III, randomised, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral Cladribine in subjects with relapsing remitting multiple sclerosis - Oral Cladribine versus Placebo in RRMS | A phase III, randomised, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral Cladribine in subjects with relapsing remitting multiple sclerosis - Oral Cladribine versus Placebo in RRMS | Relapsing-remitting multiple sclerosis (RRMS) MedDRA version: 7.0 Level: PT Classification code 10028245 | Product Name: Cladribine Product Code: Not Applicable Pharmaceutical Form: Tablet INN or Proposed INN: Cladribine Other descriptive name: 2-chloro-2'-deoxyadenosine, 2CdA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Merck Serono International S.A. | Not Recruiting | Female: yes Male: yes | 1290 | Phase 3 | Finland;Germany;Czech Republic;United Kingdom;Denmark;Estonia;Italy;Latvia;Lithuania | |||
1232 | EUCTR2005-000171-18-FI | 12/05/2005 | 19 March 2012 | A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3066A2-210-WW - N/A | A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3066A2-210-WW - N/A | Multiple Sclerosis (Relapsing-remitting MS and Secondary progressive MS with relapses) | Product Name: Temsirolimus Tablets Product Code: CCI-779 Pharmaceutical Form: Coated tablet INN or Proposed INN: Temsirolimus Current Sponsor code: CCI-779 Other descriptive name: WAY-130799 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- | Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development | Not Recruiting | Female: yes Male: yes | 180 | Finland | ||||
1233 | NCT00094172 | May 2005 | 16 December 2017 | Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patients With Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis (ITN020AI) | Multiple Sclerosis | Drug: Atorvastatin;Drug: Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Immune Tolerance Network (ITN) | Not recruiting | 18 Years | 55 Years | All | 82 | Phase 2 | United States;Canada |
1234 | NCT00127530 | May 2005 | 19 October 2017 | Study of Oral Fampridine-SR in Multiple Sclerosis | Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis | Multiple Sclerosis | Drug: Fampridine-SR;Drug: Placebo | Acorda Therapeutics | Not recruiting | 18 Years | 70 Years | All | 301 | Phase 3 | United States;Canada | |
1235 | NCT00942591 | May 2005 | 19 February 2015 | Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b | Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b.SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis. | Multiple Sclerosis | Drug: Interferon beta 1b;Drug: Atorvastatin | University Hospital Inselspital, Berne | CRO: PharmaPart AG, Bahnhofstrasse 20, P.O. Box 173, CH-8800 Thalwil;Laboratory: Viollier AG Spalenring 145 / 147 Postfach 4002 Basel | Not recruiting | 18 Years | 55 Years | Both | 77 | Phase 2 | Switzerland |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1236 | NCT01142453 | May 2005 | 19 February 2015 | An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients | Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in MS Patients. Case Series for Adjustment of Treatment Strategy and Its Monitoring | Relapsing-Remitting Multiple Sclerosis | Drug: Interferon beta 1a | Merck KGaA | Gesellschaft für Therapieforschung mbH | Not recruiting | N/A | N/A | Both | 231 | N/A | |
1237 | NCT01199640 | May 2005 | 19 February 2015 | Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis | A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis | Multiple Sclerosis | Drug: MLN1202 | Millennium Pharmaceuticals, Inc. | Not recruiting | 18 Years | N/A | Both | 50 | Phase 2 | ||
1238 | NCT02515695 | May 2005 | 17 August 2015 | Phase I BP Interferon (IFN) Beta-001 | Bioavailability, Pharmacokinetic and Pharmacodynamic Profile of Interferon Beta-1a (Bioferon®) Administered i.v. and s.c. as Single Doses to Healthy Subjects | Multiple Sclerosis, Relapsing-Remitting | Drug: Interferon beta-1a | Centre Hospitalier Universitaire Vaudois | BioPartners GmbH | Not recruiting | 18 Years | 45 Years | Both | 12 | Phase 1 | |
1239 | EUCTR2004-002567-24-CZ | 04/04/2005 | 19 March 2012 | A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis - Not appilcable | A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis - Not appilcable | The purpose of this study is to investigate the safety, PK parameters, PD responses, and clinical responses of multiple dose administration of MLN1202 in patients with relapsing remitting multiple sclerosis (RRMS). | Product Name: MLN1202 Product Code: MLN1202 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Not yet available Current Sponsor code: Not yet available Other descriptive name: Not yet available Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- | Millennium Pharmaceuticals, Inc. | Not Recruiting | Female: yes Male: yes | 160 | Phase 2a | Hungary;United Kingdom;Czech Republic | |||
1240 | NCT00109161 | April 2005 | 19 February 2015 | Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis | A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis | Drug: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody) | PDL BioPharma, Inc. | Not recruiting | 18 Years | 55 Years | Both | 270 | Phase 2 | United States;Canada | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1241 | NCT00213135 | April 2005 | 19 October 2017 | A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) | A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis, Relapsing-Remitting | Drug: Cladribine 5.25 mg/kg;Drug: Cladribine 3.5 mg/kg;Other: Placebo | EMD Serono | Not recruiting | 18 Years | 65 Years | All | 1326 | Phase 3 | Canada;Switzerland | |
1242 | NCT00668343 | April 2005 | 19 February 2015 | Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo | Relapsing Remitting Multiple Sclerosis | Drug: simvastatin;Drug: placebo | Tehran University of Medical Sciences | Not recruiting | 15 Years | 60 Years | Both | 80 | Phase 3 | Iran, Islamic Republic of | ||
1243 | EUCTR2004-002509-63-CZ | 11/03/2005 | 19 March 2012 | A double blind, randomised, placebo controlled, parallel group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis - N/A | A double blind, randomised, placebo controlled, parallel group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis - N/A | Spasticity due to Multiple Sclerosis (MS) | Product Name: Sativex Product Code: GW-1000-02 Pharmaceutical Form: Oromucosal spray Other descriptive name: delta-9-tetrahydrocannabinol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 27- Other descriptive name: cannabidiol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Oromucosal spray Route of administration of the placebo: Oromucosal use | GW Pharma Ltd | Not Recruiting | Female: yes Male: yes | 284 | United Kingdom;Czech Republic | ||||
1244 | EUCTR2004-003799-13-LT | 08/03/2005 | 1 May 2012 | A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis. - Rebif® New Formulation in RMS | A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis. - Rebif® New Formulation in RMS | Relapsing form of MS ; diagnosis of MS is in accordance with the McDonald criteria MedDRA version: 7.0 Level: PT Classification code 10028245 | Product Name: Interferon-beta-1a FBS-free/HSA free, RNF Product Code: Not applicable Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon-beta-1a CAS Number: 9008-11-1 Other descriptive name: G2-SFM (IFN-beta-1a from clone 484-39,FBS-free process) Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- | Serono International SA | Not Recruiting | Female: yes Male: yes | 230 | Phase 3b | United Kingdom;Spain;Ireland;Sweden;Lithuania | |||
1245 | NCT00146159 | March 2005 | 19 February 2015 | Study Evaluating Mitoxantrone in Multiple Sclerosis | A Double-Blind, Three-Armed, Randomized Phase-III-Study, to Compare the Efficacy, Tolerability and Safety of Three Doses of Mitoxantrone in the Treatment of Patients With Secondary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Drug: Mitoxantrone | Wyeth is now a wholly owned subsidiary of Pfizer | Not recruiting | 18 Years | 55 Years | Both | 336 | Phase 3 | Germany | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1246 | NCT01599234 | March 2005 | 19 October 2017 | A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis | A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Sativex, in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis. | Multiple Sclerosis | Drug: Sativex;Drug: Placebo | GW Pharmaceuticals Ltd. | Not recruiting | 18 Years | N/A | All | 337 | Phase 3 | United Kingdom | |
1247 | EUCTR2004-003761-33-ES | 17/02/2005 | 19 March 2012 | Unicenter double-blind, cross-over, randomised, placebo controlled clinical trial to evaluate efficacy of vardenafil in subjects with E.D. and multiple sclerosis (M.S.) - EMDE | Unicenter double-blind, cross-over, randomised, placebo controlled clinical trial to evaluate efficacy of vardenafil in subjects with E.D. and multiple sclerosis (M.S.) - EMDE | Erectile Dysfunction | Trade Name: Levitra Product Name: Vardenafil (hidrocloride) Pharmaceutical Form: Buccal tablet INN or Proposed INN: VARDENAFILO HIDROCLORURO Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Buccal tablet Route of administration of the placebo: Oral use Trade Name: Levitra Product Name: Vardenafil (hidrocloride) Pharmaceutical Form: Buccal tablet INN or Proposed INN: VARDENAFILO HIDROCLORURO Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Buccal tablet Route of administration of the placebo: Oral use Trade Name: Levitra Product Name: Vardenafil (hidrocloride) Pharmaceutical Form: Buccal tablet INN or Proposed INN: VARDENAFILO HIDROCLORURO Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Buccal tablet Route of administration of the placebo: Oral use | Unidad de Neuroinmunología | Authorised | Female: Male: yes | 28 | Spain | ||||
1248 | EUCTR2004-004130-14-AT | 17/02/2005 | 22 April 2013 | A multicenter, randomized, rater-blind study to compare the efficacy and safety of natalizumab (300 mg IV every four weeks) with Interferon beta-1a (44 mcg SC three times a week) in subjects with relapsing multiple sclerosis previously treated with Interferon beta-1a (22 or 44 mcg SC three times a week). | A multicenter, randomized, rater-blind study to compare the efficacy and safety of natalizumab (300 mg IV every four weeks) with Interferon beta-1a (44 mcg SC three times a week) in subjects with relapsing multiple sclerosis previously treated with Interferon beta-1a (22 or 44 mcg SC three times a week). | Male and female subjects with relapsing multiple sclerosis previously treated with interferon beta-1a (22 mcg or 44 mcg, SC three times a week). | Product Name: Natalizumab Product Code: Not Applicable Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: natalizumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Rebif 44 micrograms Product Name: Rebif 44 micrograms Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- | Biogen Idec GmbH | Not Recruiting | Female: yes Male: yes | 1050 | Austria | ||||
1249 | EUCTR2004-003943-28-HU | 14/02/2005 | 8 May 2012 | A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the efficacy, tolerability and safety of two doses of laquinimod orally administered in relapsing remitting (R-R) multiple sclerosis (MS) subjects | A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the efficacy, tolerability and safety of two doses of laquinimod orally administered in relapsing remitting (R-R) multiple sclerosis (MS) subjects | Relapsing Remitting Multiple Sclerosis MedDRA version: 5.1 Level: PT Classification code 10028245 | Product Name: Laquinimod Tablets 0.3 mg Product Code: ABR-215062 sodium salt Pharmaceutical Form: Tablet INN or Proposed INN: laquinimod CAS Number: 248282-07-7 Current Sponsor code: ABR-215062 sodium salt Other descriptive name: PNU-215062 sodium salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.3- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Teva Pharmaceutical Industries Ltd | Not Recruiting | Female: yes Male: yes | 265 | Hungary;Germany;United Kingdom;Czech Republic;Spain;Italy | ||||
1250 | EUCTR2004-003799-13-SE | 03/02/2005 | 1 May 2012 | A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis. - Rebif® New Formulation in RMS | A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis. - Rebif® New Formulation in RMS | Relapsing form of MS ; diagnosis of MS is in accordance with the McDonald criteria MedDRA version: 7.0 Level: PT Classification code 10028245 | Product Name: Interferon-beta-1a FBS-free/HSA free, RNF Product Code: Not applicable Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon-beta-1a CAS Number: 9008-11-1 Other descriptive name: G2-SFM (IFN-beta-1a from clone 484-39,FBS-free process) Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- | Serono International SA | Not Recruiting | Female: yes Male: yes | 230 | Phase 3b | United Kingdom;Spain;Ireland;Lithuania;Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1251 | NCT00190268 | February 2005 | 19 February 2015 | Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis | Multicentric Study, Comparative, Randomized, in Double Knowledge of the Effectiveness (Versus Placebo) of a Salt Of 3,4 - Diaminopyridine in the Treatment of Tiredness During the Multiple Sclerosis | Multiple Sclerosis | Drug: 3,4-diaminopyridine | Assistance Publique - Hôpitaux de Paris | Not recruiting | 18 Years | 60 Years | Both | 126 | Phase 3 | France | |
1252 | EUCTR2004-004519-43-CZ | 12/01/2005 | 1 May 2012 | Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis | Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | Product Code: RO0506997 Pharmaceutical Form: Film-coated tablet Current Sponsor code: RO0506997 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: RO0506997 Pharmaceutical Form: Film-coated tablet Current Sponsor code: RO0506997 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: RO0506997 Pharmaceutical Form: Film-coated tablet Current Sponsor code: RO0506997 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | F. Hoffmann-La Roche Ltd | Authorised | Female: yes Male: yes | 200 | Phase 2 | Germany;United Kingdom;Czech Republic;Spain | |||
1253 | NCT00110396 | January 2005 | 19 October 2017 | Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis | A Multicentre, Single Arm, Open-Label, Phase IIIB Study to Evaluate the Safety and Antigenicity of Rebif® (Interferon-beta-1a) in Subjects With Relapsing Forms of Multiple Sclerosis | Multiple Sclerosis | Biological: Interferon-beta-1a FBS-free/HSA-free | EMD Serono | Pfizer | Not recruiting | 18 Years | 60 Years | All | 260 | Phase 3 | United States |
1254 | NCT00139789 | January 2005 | 19 February 2015 | A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis | A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis | Multiple Sclerosis | Drug: Kemstro | UCB Pharma | Not recruiting | 18 Years | 65 Years | Both | 60 | Phase 3 | United States | |
1255 | NCT00203047 | January 2005 | 19 October 2017 | Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate | A Multi-Centered, Randomized, Double-Blind, Placebo Controlled Study Assessing the Add-on Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated With Glatiramer Acetate (GA) | Relapsing Remitting Multiple Sclerosis | Drug: Glatiramer Acetate;Drug: Placebo;Drug: Prednisone | Teva Pharmaceutical Industries | Not recruiting | 18 Years | 55 Years | All | 414 | Phase 4 | Canada;United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1256 | NCT00206635 | January 2005 | 19 February 2015 | Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis | A Long-term Follow up of Patients Enrolled in the Pivotal Study of Betaseron® (Interferon Beta 1b) in Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 33 Years | N/A | Both | 432 | N/A | United States;Canada;United Kingdom | |
1257 | NCT00211887 | January 2005 | 19 October 2017 | Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx | A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients With Relapsing-Remitting Multiple Sclerosis (CombiRx) | Relapsing Remitting Multiple Sclerosis | Drug: Interferon beta 1-a;Drug: glatiramer acetate;Other: placebo | Fred Lublin | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | 60 Years | All | 1008 | Phase 3 | United States;Canada |
1258 | NCT01142492 | January 2005 | 19 February 2015 | A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®) | Postmarketing Surveillance Study on the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis With Interferon Beta 1a (Rebif®) | Relapsing-Remitting Multiple Sclerosis | Drug: Interferon beta-1a | Merck KGaA | Not recruiting | N/A | N/A | Both | 403 | N/A | ||
1259 | NCT01201343 | January 2005 | 19 October 2017 | Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients | Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients | Multiple Sclerosis, Relapsing, Remitting | Drug: Interferon beta-1a | Merck KGaA | Merck Serono S.A.S, France | Not recruiting | 18 Years | N/A | All | 79 | Phase 4 | |
1260 | NCT00097188 | December 2004 | 19 February 2015 | A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis | A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (Mabthera/Rituxan) in Adults With Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis | Drug: rituximab | Genentech, Inc. | Not recruiting | 18 Years | 55 Years | Both | 104 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1261 | NCT00200655 | December 2004 | 9 May 2016 | Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis | Safety and Efficacy of Pravastatin in Relapsing-remitting MS: a Double Blind Placebo Controlled Study | Relapsing-remitting Multiple Sclerosis | Drug: Pravastatin;Drug: Placebo | Nantes University Hospital | Not recruiting | 18 Years | 45 Years | Both | 40 | Phase 3 | France | |
1262 | NCT00203099 | December 2004 | 19 February 2015 | Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine | A Pilot, Multicenter, Open-label, One-group Study to Explore the Efficacy, Tolerability and Safety of the Combination of Glatiramer Acetate (GA) and N-Acetylcysteine (NAC) in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS) | Relapse Remitting Multiple Sclerosis | Drug: Glatiramer Acetate, N-Acetylcysteine | Teva Pharmaceutical Industries | Not recruiting | 18 Years | 50 Years | Both | 18 | Phase 2 | Canada | |
1263 | NCT00360906 | December 2004 | 19 February 2015 | Omega-3 Fatty Acid Treatment in Multiple Sclerosis | Omega-3 Fatty Acid Treatment in Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Drug: Triomar™ (omega-3 fatty acids) | Haukeland University Hospital | The Multiple Sclerosis National Competence Centre;The Norwegian Multiple sclerosis Society;Pronova BioPharma;Serono Nordic;Amersham Health | Not recruiting | 18 Years | 55 Years | Both | 100 | Phase 2/Phase 3 | Norway |
1264 | NCT00869726 | December 2004 | 19 February 2015 | A Study for Patients With Secondary Progressive Multiple Sclerosis | A Double-Blind, Placebo Controlled Multicentre Study To Evaluate The Efficacy And Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Drug: dirucotide;Drug: Placebo | Eli Lilly and Company | BioMS Technology Corp. | Not recruiting | 18 Years | 65 Years | Both | 596 | Phase 2/Phase 3 | Canada;Denmark;Estonia;Finland;Germany;Latvia;Netherlands;Spain;Sweden;United Kingdom |
1265 | EUCTR2004-000555-42-NO | 22/11/2004 | 14 August 2012 | A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses - TEMSO | A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses - TEMSO | Multiple sclerosis | Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Sanofi-aventis US, Inc | Not Recruiting | Female: yes Male: yes | 1080 | Portugal;Czech Republic;United Kingdom;Denmark;Estonia;Norway;Italy;Sweden | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1266 | EUCTR2004-001601-10-IT | 19/11/2004 | 19 March 2012 | MULTICENTTRIC, NATIONAL, SINGLE BLIND,CONTROLLED IN PARALLEL GROUP TO EVALUATE THE SAFETY AND EFFICACY OF THE SEQUENTIAL COMBINATION OF MITOXANTRONE AND BETA INTERFERON REBIF 44 mcg X 3 TIMES WEEKLY IN PATIENTS AFFECTED BY MULTIPLE SCLEROSIS, IN THE FIRST STEP OF THE DISEASE | MULTICENTTRIC, NATIONAL, SINGLE BLIND,CONTROLLED IN PARALLEL GROUP TO EVALUATE THE SAFETY AND EFFICACY OF THE SEQUENTIAL COMBINATION OF MITOXANTRONE AND BETA INTERFERON REBIF 44 mcg X 3 TIMES WEEKLY IN PATIENTS AFFECTED BY MULTIPLE SCLEROSIS, IN THE FIRST STEP OF THE DISEASE | MULTIPLE SCLEROSIS TREATMENT MedDRA version: 6.1 Level: SOC Classification code 10029205 | Trade Name: NOVANTRONE*INF 2MG/ML 5ML Pharmaceutical Form: Solution for injection INN or Proposed INN: Mitoxantrone CAS Number: 70476-82-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Trade Name: REBIF*SC 12SIR 12000000UI44MCG Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- | OSPEDALE S. RAFFAELE | Authorised | Female: yes Male: yes | 266 | France;Italy | ||||
1267 | EUCTR2004-000145-38-CZ | 16/11/2004 | 19 March 2012 | A Phase 2, Double-blind, Placebo-controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects with Relapsing-remitting Multiple Sclerosis. | A Phase 2, Double-blind, Placebo-controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects with Relapsing-remitting Multiple Sclerosis. | Relapse-remitting Multiple Sclerosis (RRMS) Classification code 10048393 | Product Name: Human monoclonal antibody (CNTO 1275) to interleukin-12p40 Product Code: CNTO 1275 Pharmaceutical Form: Powder for solution for injection Current Sponsor code: CNTO 1275 Other descriptive name: Anti-IL-12; Human anti-IL-12 Mab; Human anti-IL-12 IgG1 Mab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Subcutaneous use | Centocor B.V. | Authorised | Female: yes Male: yes | 250 | Phase 2 | Hungary;United Kingdom;Czech Republic | |||
1268 | NCT00101959 | November 2004 | 19 February 2015 | Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects | An Implementation Study of Treatment Optimization Recommendations Comparing Subjects Continuing Treatment With IFN-ß-1a 30 Mcg qw IM (Avonex®) or Glatiramer Acetate 20 mg qd SC (Copaxone®) to Those Randomized to IFN-ß-1a 44 Mcg Tiw SC (Rebif®), in a Multicenter Study of Subjects With Relapsing Remitting Multiple Sclerosis Currently on Disease-Modifying Therapy | Relapsing-Remitting Multiple Sclerosis | Drug: Rebif | EMD Serono | Not recruiting | 18 Years | 60 Years | Both | 0 | Phase 4 | United States | |
1269 | NCT00151294 | November 2004 | 19 February 2015 | The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis | A Double-Blind, Placebo-Controlled Investigation Into the Safety and Efficacy of Escitalopram for Depression in Multiple Sclerosis | Depression;Multiple Sclerosis | Drug: escitalopram oxalate antidepressant | Weill Medical College of Cornell University | Forest Laboratories | Not recruiting | 18 Years | N/A | Both | 20 | Phase 4 | United States |
1270 | EUCTR2004-000759-40-IT | 22/10/2004 | 19 March 2012 | A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 15 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis. | A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 15 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis. | Subject with relapsing remitting Multiple Sclerosis. Subject must have at least one documented relapse within one year prior to screening visit. MedDRA version: 6.1 Level: PT Classification code 10028245 | Product Name: glatiramer acetate Product Code: TV-5010 Pharmaceutical Form: Solution for injection INN or Proposed INN: Glatiramer acetate Current Sponsor code: TV - 5010 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- | TEVA | Not Recruiting | Female: yes Male: yes | 25 | Italy | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1271 | NCT00137176 | October 2004 | 19 February 2015 | EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis | EARLY IFNb-1a (Rebif) and Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis | Multiple Sclerosis | Drug: Rebif | University of North Carolina, Chapel Hill | Not recruiting | 18 Years | 60 Years | Both | 30 | N/A | United States | |
1272 | NCT00168701 | October 2004 | 19 February 2015 | Efficacy and Safety of BG00012 in MS | Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis | Drug: BG00012 | Biogen Idec | Not recruiting | 18 Years | 55 Years | Both | 260 | Phase 2 | Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Sweden;Switzerland;Turkey;United Kingdom | |
1273 | NCT00240032 | October 2004 | 19 February 2015 | A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®. | A Double-Blind, Randomized, Placebo Controlled Study of An Oral Antihistamine on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone® Using Autoject® 2 for Glass Syringe. | Multiple Sclerosis | Drug: glatiramer acetate injection with oral cetirizine hydrochloride;Drug: glatiramer acetate with placebo | Teva Pharmaceutical Industries | Not recruiting | 18 Years | N/A | Both | 80 | Phase 4 | United States | |
1274 | EUCTR2005-000393-47-IT | 22/09/2004 | 19 March 2012 | Effect of Cannabis Based Medicine Extract Sativex on brain function as assessed by fMRI and neurophysiologic evaluation in patients with Multiple Sclerosis a double blind, randomised, placebo-controlled, crossover study. | Effect of Cannabis Based Medicine Extract Sativex on brain function as assessed by fMRI and neurophysiologic evaluation in patients with Multiple Sclerosis a double blind, randomised, placebo-controlled, crossover study. | Treatment of spasticity in patients with Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis | Trade Name: Cannabis Based Medicine Extract (Sativex) Pharmaceutical Form: Oromucosal spray Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.7- | AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | Not Recruiting | Female: yes Male: yes | Italy | |||||
1275 | EUCTR2004-000663-99-SE | 10/09/2004 | 19 March 2012 | Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis. | Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis. | MS is a chronic disease of the CNS. It's a disease of young adults, primarily women, with disease onset typically occuring between the ages of 20 and 40. Although etiology is uncertain, evidence points to MS being an autoimmune disease directed against protein components of myelin. The majority of patients with MS start out with a clinical course characterised by episodes or attacks (relapses) of neurologic dysfunction, which occurs over many years. | Product Name: second-generation fumaric acid Product Code: BG00012 Pharmaceutical Form: Capsule, hard INN or Proposed INN: dimethyl fumarate CAS Number: 62008-21 Current Sponsor code: dimethyl fumarate Other descriptive name: dimethyl fumarate Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Biogen Idec Inc. | Biogen Idec Ltd | Not Recruiting | Female: yes Male: yes | 260 | Hungary;Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1276 | EUCTR2004-000073-64-FI | 03/09/2004 | 19 March 2012 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Effects of L-000124467 on Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis as Measured by MRI. Satunnaistettu, kaksoissokkoutettu ja lumekontrolloitu rinnakkaisryhmin etenevä tutkimus, jossa tutkitaan L-000124467 -lääkkeen kliinistä tehoa, turvallissuutta ja siedettävyyttä aaltomaista MS-tautia sairastavilla potilailla MRI menetelmällä. - - | A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Effects of L-000124467 on Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis as Measured by MRI. Satunnaistettu, kaksoissokkoutettu ja lumekontrolloitu rinnakkaisryhmin etenevä tutkimus, jossa tutkitaan L-000124467 -lääkkeen kliinistä tehoa, turvallissuutta ja siedettävyyttä aaltomaista MS-tautia sairastavilla potilailla MRI menetelmällä. - - | Aaltomainen MS-tauti | Product Code: L-000124467 Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Merck & Co., Inc./Suomen MSD Oy | Not Recruiting | Female: yes Male: yes | 120 | Finland | ||||
1277 | NCT00097331 | September 2004 | 20 April 2015 | Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis | A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Investigate the Efficacy and Safety of Three Months Administration of SB-683699 (150 - 1200mg Twice Daily) in Subjects With Relapsing Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: SB683699 | GlaxoSmithKline | Not recruiting | 18 Years | 65 Years | Both | 261 | Phase 2 | Belgium;Germany;Poland;Russian Federation;Spain;United States;Canada;France;Italy;Romania | |
1278 | NCT00146068 | September 2004 | 19 February 2015 | EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis | Phase IV Double-Blind Randomized Study to Evaluate Safety and Efficacy of Interferon Beta-1a (Avonex) Plus Simvastatin (Zocor) Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis Over a One Year Period | Multiple Sclerosis | Drug: Avonex/Zocor | University of North Carolina | Not recruiting | 18 Years | 60 Years | Both | 30 | Phase 4 | United States | |
1279 | NCT00315367 | September 2004 | 19 February 2015 | A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties | A Double-Blind, Crossover Trial of Aricept® in Memory-Impaired Patients With Multiple Sclerosis: A Phase IV Demonstration of Functional MRI (fMRI) as a Surrogate Marker of Brain Activity Associated With Improvement in Memory Function | Relapsing-Remitting Multiple Sclerosis | Drug: Donepezil HCI (drug) | Neurognostics | Not recruiting | 18 Years | 65 Years | Both | 26 | Phase 4 | United States | |
1280 | EUCTR2004-000762-13-IT | 31/08/2004 | 3 September 2012 | A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis. | A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis. | Subject with relapsing remitting Multiple Sclerosis. Subject must have at least one documented relapse within one year prior to screening visit. MedDRA version: 15.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Glatiramer acetate Product Code: TV-5010 Pharmaceutical Form: Solution for injection INN or Proposed INN: Glatiramer acetate Current Sponsor code: TV-5010 Concentration unit: mg milligram(s) Concentration number: 30- | TEVA ITALIA srl | Authorised | Female: yes Male: yes | 7 | Italy | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1281 | NCT00220922 | August 2004 | 19 February 2015 | A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®. | An Open-Label, Randomized, Single Cross-Over Study of Isopropyl Alcohol Wipes Versus No Injection Site Preparation on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone® | Multiple Sclerosis | Procedure: Alcohol Wipes vs. No Alcohol Wipes | Teva Neuroscience, Inc. | Not recruiting | 18 Years | N/A | Both | 50 | Phase 4 | United States | |
1282 | NCT00239655 | August 2004 | 8 August 2016 | A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED) | A Randomized, Double-Blind Placebo Controlled, Parallel Groups Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by MRI | Relapsing-Remitting Multiple Sclerosis | Drug: MK0812 | Merck Sharp & Dohme Corp. | Not recruiting | 18 Years | 55 Years | Both | 120 | Phase 2 | Canada;Finland;Germany;United Kingdom;United States | |
1283 | EUCTR2004-000047-18-SE | 27/07/2004 | 19 March 2012 | An open-label, multicenter extension study to evaluate the safety and tolerability of natalizumab in subjects with multiple sclerosis who have completed studies C-1801, C-1802, or C-1803. | An open-label, multicenter extension study to evaluate the safety and tolerability of natalizumab in subjects with multiple sclerosis who have completed studies C-1801, C-1802, or C-1803. | Male and female subjects with multiple sclerosis who have completed natalizumab studies C-1801, C-1802, or C-1803 | Product Name: natalizumab Product Code: AN100226 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: natalizumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- | Biogen Idec Ltd. | Not Recruiting | Female: yes Male: yes | 1900 | Sweden | ||||
1284 | EUCTR2004-000337-12-HU | 23/07/2004 | 19 March 2012 | A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of subcutaneously administered r-hIFN beta-1a (Rebif) using clone 484-39 in the treatment of subjects with Relapsing Remitting Multiple Sclerosis - EMEA Post Approval Commitment New Clone Study | A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of subcutaneously administered r-hIFN beta-1a (Rebif) using clone 484-39 in the treatment of subjects with Relapsing Remitting Multiple Sclerosis - EMEA Post Approval Commitment New Clone Study | MS with 2 or more relapses within the last 2 years MedDRA version: 7.0 Level: PT Classification code 10028245 | Trade Name: Rebif Product Code: Not applicable Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a CAS Number: 9008-11-1 Current Sponsor code: IFN-beta Other descriptive name: Recombinant human interferon beta Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- Trade Name: Rebif Product Name: Rebif Product Code: Not applicable Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a CAS Number: 9008-11-1 Current Sponsor code: IFN-beta Other descriptive name: Recombinant human interferon beta Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- | Serono International SA | Authorised | Female: yes Male: yes | 400 | Phase 4 | Hungary | |||
1285 | EUCTR2004-000462-13-HU | 12/07/2004 | 19 March 2012 | A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 300mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS). | A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 300mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS). | Relapsing-remitting multiple sclerosis (R-R MS) MedDRA version: 5.1 Level: PT Classification code 10028245 | Product Name: Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets Pharmaceutical Form: Coated tablet INN or Proposed INN: Glatiramer Acetate CAS Number: 147245-92-9 Current Sponsor code: GA Other descriptive name: COP-1/Copolymer-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- | TEVA Pharmaceutical Industries Ltd. | Not Recruiting | Female: yes Male: yes | 25 | Hungary;Italy | ||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1286 | NCT00103974 | July 2004 | 19 February 2015 | Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis | A Phase I Trial of Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis | Multiple Sclerosis | Biological: BHT-3009-01 | Bayhill Therapeutics | Not recruiting | 18 Years | 65 Years | Both | 30 | Phase 1 | United States;Canada | |
1287 | NCT00202995 | July 2004 | 19 February 2015 | Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS | A Multi-Center, Randomized, Single-Blind, Parallel Group Study to Compare the Efficacy, Tolerability and Safety, of Copaxone® to That of High Dose Interferon (Betaseron® or Rebif®) in the Treatment of Relapsing Multiple Sclerosis Patients | Relapsing Remitting Multiple Sclerosis | Drug: Glatiramer Acetate;Drug: Betaseron;Drug: Rebif | Teva Pharmaceutical Industries | Not recruiting | 18 Years | 50 Years | Both | 91 | Phase 4 | United States;Canada | |
1288 | NCT00207727 | July 2004 | 19 October 2017 | A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis | A Phase II, Double-blind, Placebo-Controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40(CNTO1275) in Subjects With Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis | Drug: CNTO 1275 | Centocor, Inc. | Centocor BV | Not recruiting | 18 Years | 65 Years | All | 249 | Phase 2 | Australia;Canada;Czech Republic;Hungary;Poland;United Kingdom;United States |
1289 | NCT00223301 | July 2004 | 19 February 2015 | Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis | A One-Year Prospective, Randomized, Placebo-Controlled, Double-Blind, Phase II/III Safety Trial of Combination Therapy With IFN Beta-1a (Avonex) and Mycophenolate Mofetil (Cellcept) in Early Multiple Sclerosis | Multiple Sclerosis | Drug: Mycophenolate Mofetil (cellcept) | University of Texas Southwestern Medical Center | Roche Pharma AG;Biogen Idec | Not recruiting | 21 Years | 45 Years | Both | 24 | Phase 2/Phase 3 | United States |
1290 | EUCTR2004-000374-31-IT | 09/06/2004 | 19 March 2012 | A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-Ranging Study to Investigate the Efficacy and Safety of Three Months administration of SB 683699 (150 - 1200mg twice daily) in Subjects with Relapsing Multiple Sclerosis | A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-Ranging Study to Investigate the Efficacy and Safety of Three Months administration of SB 683699 (150 - 1200mg twice daily) in Subjects with Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | Trade Name: ALTRI FARMACI DEL SISTEMA NERVOSO Product Name: NA Product Code: aSB-683699 Pharmaceutical Form: Tablet Current Sponsor code: SB683699 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- | GLAXO SMITHKLINE | Not Recruiting | Female: yes Male: yes | Italy | |||||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1291 | NCT00087529 | June 2004 | 19 October 2017 | A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis | A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis | Multiple Sclerosis | Drug: placebo;Drug: rituximab | Genentech, Inc. | Not recruiting | 18 Years | 65 Years | All | 439 | Phase 2/Phase 3 | Canada;United States | |
1292 | NCT00203112 | June 2004 | 19 February 2015 | Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline | A Multi-Centered, Randomized, Double-Blind, Placebo-Controlled, Parallel Study Assessing the Add-on Effect of Minocycline in Relapsing-Remitting Multiple Sclerosis (RR-MS) Subjects Treated With Glatiramer Acetate (GA). | Relapse Remitting Multiple Sclerosis | Drug: glatiramer acetate with minocycline;Drug: Glatiramer acetate with placebo | Teva Pharmaceutical Industries | Not recruiting | 18 Years | 50 Years | Both | 44 | Phase 2 | Canada | |
1293 | NCT01142557 | June 2004 | 19 February 2015 | An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis | Therapy of the Chronic Multiple Sclerosis With Interferon-beta 1a (Rebif®) | Multiple Sclerosis | Drug: Interferon beta-1a (Rebif) | Merck KGaA | Gesellschaft für Therapieforschung mbH | Not recruiting | N/A | N/A | Both | 522 | N/A | Germany |
1294 | NCT00367484 | May 2004 | 19 October 2017 | Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis | Multicentre, Single Arm, Open, Phase IV Study To Evaluate Immunogenicity And Safety Of Subcutaneous r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In The Treatment Of Relapsing Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Biological: Rebif® (clone 484-39) | Merck KGaA | Not recruiting | 18 Years | 60 Years | All | 460 | Phase 4 | ||
1295 | NCT00493077 | May 2004 | 19 February 2015 | Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy | A Swedish Multi-Centre, Prospective, Open Label Study: Safety of Avonex Treatment in Multiple Sclerosis Patients Who Are NAB Positive on Previous s.c Interferon Beta Therapy | Multiple Sclerosis | Drug: low immunogenic interferon-beta-1a | Biogen Idec | Not recruiting | 18 Years | 55 Years | Both | 3 | Phase 4 | Sweden | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1296 | NCT00682929 | April 14, 2004 | 11 June 2018 | Cannabis for Spasticity in Multiple Sclerosis | Cannabis for Spasticity in Multiple Sclerosis: A Placebo-Controlled Study | Multiple Sclerosis | Drug: Inhaled Cannabis;Drug: Oral THC;Drug: Oral Placebo;Drug: Inhaled placebo | University of California, Davis | National Multiple Sclerosis Society | Not recruiting | 21 Years | N/A | All | 41 | Phase 1/Phase 2 | United States |
1297 | NCT00086671 | April 2004 | 19 February 2015 | Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS) | A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12 Antibody ABT-874 in Subjects With Multiple Sclerosis With a 24-Week Double-Blind, Active Extension Phase | Multiple Sclerosis | Drug: ABT-874/Human monoclonal antibody against IL-12;Drug: Placebo | AbbVie (prior sponsor, Abbott) | Not recruiting | 18 Years | 60 Years | Both | 215 | Phase 2 | United States;Canada;Germany;Netherlands;United Kingdom | |
1298 | NCT00217295 | April 2004 | 19 February 2015 | A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis | A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis. | Multiple Sclerosis | Drug: Avonex and Topamax | Multiple Sclerosis Institute | Recruiting | 18 Years | 55 Years | Both | 30 | Phase 2 | United States | |
1299 | NCT00300716 | April 2004 | 22 October 2019 | Trial of Memantine for Cognitive Impairment in Multiple Sclerosis | Double Blind Placebo Controlled Pilot Trial of Memantine for Cognitive Impairment in Multiple Sclerosis | Multiple Sclerosis;Cognition Disorders | Drug: Memantine | Oregon Health and Science University | Forest Laboratories;University of Southern California;University of Texas Southwestern Medical Center;MS-Hub Seattle | Not recruiting | 18 Years | 65 Years | All | 82 | Phase 2/Phase 3 | United States |
1300 | NCT01233245 | April 2004 | 19 February 2015 | BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program | BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program | Relapsing Remitting MS (RRMS);Secondary Progressive MS (SPMS) | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 18 Years | N/A | Both | 1077 | N/A | Czech Republic;France;Germany;Iran, Islamic Republic of;Israel;Italy;Jordan;Korea, Republic of;Lebanon;Netherlands;Portugal;Saudi Arabia;Spain;Taiwan;Turkey | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1301 | NCT00078338 | March 2004 | 19 February 2015 | Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis | Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis | Relapsing-remitting Multiple Sclerosis | Drug: Human interferon beta-1a and glatiramer acetate | EMD Serono | Pfizer | Not recruiting | 18 Years | 60 Years | Both | 764 | Phase 4 | United States;Argentina;Austria;Brazil;France;Germany;Italy;Netherlands;Russian Federation;Spain;Switzerland;United Kingdom |
1302 | NCT00168714 | February 2004 | 19 February 2015 | Pregnancy Exposure Registry for Avonex (Interferon Beta-1a) | Avonex Pregnancy Exposure Registry | Prenatal Exposure Delayed Effects;Multiple Sclerosis;Pregnancy | Drug: BG9418 (interferon beta-1a) | Biogen Idec | Not recruiting | N/A | N/A | Female | 329 | N/A | United States | |
1303 | NCT00501748 | January 2004 | 19 February 2015 | Safety and Tolerability of Rituximab in Neuromyelitis Optica | Open Label Study of Safety and Tolerability of Rituximab in Neuromyelitis Optica, Recurrent Transverse Myelitis and Recurrent Bilateral Simultaneous Optic Neuritis | Neuromyelitis Optica | Drug: Rituximab | University of California, San Francisco | Genentech, Inc. | Not recruiting | 12 Years | 86 Years | Both | 20 | Phase 1 | United States |
1304 | NCT00666224 | January 2004 | 19 October 2017 | Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome | A Multinational, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Effect of Early Glatiramer Acetate Treatment in Delaying the Conversion to Clinically Definite Multiple Sclerosis (CDMS) of Subjects Presenting With Clinically Isolated Syndrome (CIS) | Multiple Sclerosis | Drug: Glatiramer Acetate (DB);Drug: Placebo;Drug: Glatiramer Acetate (OL) | Teva Pharmaceutical Industries | Not recruiting | 18 Years | 45 Years | All | 481 | Phase 3 | Argentina;Australia;Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;New Zealand;Norway;Romania;Spain;Sweden;United Kingdom;United States | |
1305 | NCT00246324 | December 2003 | 11 June 2018 | Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis | An Open Label Trial of Safety and Efficacy of Combination Therapy With Interferon-B-1a and Oral Doxycycline in Patients With Relapsing-remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis | Drug: Interferon beta 1a, oral doxycycline | Louisiana State University Health Sciences Center Shreveport | Biogen | Not recruiting | 18 Years | 55 Years | All | 16 | Phase 4 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1306 | NCT00276172 | December 2003 | 19 February 2015 | Open-Label Natalizumab Safety Extension Study | An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Natalizumab in Subjects With Multiple Sclerosis Who Have Completed Studies C-1801, C-1802, or C-1803 | Multiple Sclerosis | Drug: Natalizumab | Biogen Idec | Not recruiting | 18 Years | N/A | Both | 1615 | Phase 3 | United States | |
1307 | NCT00099502 | November 2003 | 19 February 2015 | BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients | International, Randomized, Multicenter, Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of at Least 104 Weeks: 1. Double-Blinded Safety, Tolerability, and Efficacy of Betaseron/ Betaferon 250 µg (8 MIU) and Betaseron/-Betaferon 500 µg (16 MIU), Both Given Subcutaneously Every Other Day, and 2. Rater-Blinded Safety, Tolerability, and Efficacy of Betaseron/-Betaferon s.c. Every Other Day With Copaxone 20 mg s.c. Once Daily. | Multiple Sclerosis, Relapsing-Remitting | Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046);Drug: Copaxone | Bayer | Not recruiting | 18 Years | 55 Years | Both | 2244 | Phase 3 | United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;Switzerland;Ukraine | |
1308 | NCT00228397 | November 2003 | 19 February 2015 | Study Evaluating CCI-779 in Relapsing Multiple Sclerosis | A Multicenter, Randomized, Double-blind, Long-term Extension Study to Determine the Safety, Tolerability, and Preliminary Efficacy of CCI-779 in Subjects With Relapsing Multiple Sclerosis. | Multiple Sclerosis, Relapsing-Remitting | Drug: CCI-779 | Wyeth is now a wholly owned subsidiary of Pfizer | Not recruiting | N/A | N/A | Both | 221 | Phase 2 | ||
1309 | NCT00654927 | November 2003 | 19 October 2017 | Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis | Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: Fampridine-SR b.i.d. (Twice Daily) | Acorda Therapeutics | Not recruiting | 18 Years | 70 Years | All | 177 | Phase 3 | United States;Canada | |
1310 | NCT00071838 | October 30, 2003 | 16 December 2017 | Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis | Zenapax (Daclizumab) Admin to Pts With Multiple Sclerosis (ZAP MS): Effect of Intravenously Admin Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (Daclizumab) on Inflammatory Activity in the Central Nervous System | Multiple Sclerosis, Relapsing-Remitting | Drug: Daclizumab | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | 65 Years | All | 16 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1311 | NCT00242177 | October 2003 | 29 July 2019 | Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability | Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability | Multiple Sclerosis, Relapsing-Remitting | Drug: ACTOS (Pioglitazone) | University of Illinois at Chicago | Takeda Pharmaceuticals North America, Inc. | Not recruiting | 18 Years | 65 Years | All | 30 | Phase 1 | United States |
1312 | NCT00296205 | October 2003 | 19 February 2015 | Phase II High-Dose Cyclophosphamide for Multiple Sclerosis | Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis | Multiple Sclerosis | Drug: Cyclophosphamide | Stony Brook University | Not recruiting | 18 Years | 75 Years | Both | 25 | Phase 2 | United States | |
1313 | NCT00493116 | October 2003 | 19 February 2015 | Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta | A Multi-Centre, Open Label Study to Investigate the Recovery of IFN-beta Efficacy in Relapsing-Remitting Multiple Sclerosis Patients With Neutralising IFN-beta Antibodies and Reduced Bioavailability | Relapsing-Remitting Multiple Sclerosis | Drug: Interferon-beta-1a;Drug: methylprednisolone | Biogen Idec | Not recruiting | 18 Years | 55 Years | Both | 20 | Phase 4 | Australia;New Zealand | |
1314 | NCT00616187 | October 2003 | 11 June 2018 | Atorvastatin in Relapsing-Remitting Multiple Sclerosis | Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: interferon beta treatment to add-on atorvastatin treatment;Drug: untreated to atorvastatin treatment | Charite University, Berlin, Germany | German Research Foundation;German Federal Ministry of Education and Research;Pfizer | Not recruiting | 18 Years | 55 Years | All | 41 | Phase 2 | |
1315 | NCT00418145 | September 2003 | 16 December 2017 | Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks | Oral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA) | Multiple Sclerosis | Drug: megadose oral methylprednisolone;Drug: IV methylprednisolone | Fred Lublin | National Multiple Sclerosis Society;Pfizer | Not recruiting | 18 Years | 50 Years | All | 16 | Phase 3 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1316 | NCT00202982 | August 2003 | 19 February 2015 | A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose | A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy, Tolerability and Safety of 40 mg of Copaxone in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients | Relapse-Remitting Multiple Sclerosis | Drug: glatiramer acetate 20 mg;Drug: glatiramer acetate 40 mg | Teva Pharmaceutical Industries | Not recruiting | 18 Years | 50 Years | Both | 90 | Phase 2 | United States | |
1317 | NCT00276341 | August 2003 | 18 December 2018 | Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis | Efficacy of EGb 761® 120mg Twice a Day Versus Placebo on Cognitive Impairment in Patients With Multiple Sclerosis. A Randomised, Double-blind, Multicentre, Parallel Groups Placebo Controlled Phase III Study. | Multiple Sclerosis, Relapsing-Remitting | Drug: EGb 761® (Tanakan®) | Ipsen | Not recruiting | 18 Years | N/A | All | 240 | Phase 3 | France | |
1318 | NCT00913250 | August 2003 | 19 February 2015 | A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers | A Randomized, Single-Blind, Crossover Study in Healthy Volunteers to Demonstrate the Bioequivalence of AVONEX® (Interferon Beta-1a) Solutions for Injection Produced by a Serum-Containing Manufacturing Process and by a Serum-Free Manufacturing Process | Multiple Sclerosis | Drug: Serum containing Avonex;Drug: Serum Free Avonex | Biogen Idec | Not recruiting | 18 Years | 45 Years | Both | 96 | Phase 1 | ||
1319 | NCT00079495 | July 2003 | 19 February 2015 | Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS) | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of NBI-5788 in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis | Drug: NBI-5788 | Neurocrine Biosciences | Immune Tolerance Network (ITN) | Not recruiting | 18 Years | 55 Years | Both | 150 | Phase 2 | |
1320 | NCT00097760 | June 2003 | 19 February 2015 | Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis | Safety Study of Natalizumab in Combination With Glatiramer Acetate (GA) | Multiple Sclerosis, Relapsing-Remitting | Drug: Natalizumab;Drug: Placebo | Biogen Idec | Elan Pharmaceuticals | Not recruiting | 18 Years | 55 Years | Both | 110 | Phase 2 | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1321 | NCT00112034 | June 2003 | 19 February 2015 | AVONEX® Combination Trial - ACT | A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX Compared With AVONEX in Combination With Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects With Relapsing Remitting MS Who Have Breakthrough Disease on AVONEX Monotherapy. | Multiple Sclerosis, Relapsing-Remitting | Drug: Methotrexate;Drug: IV methylprednisolone | Biogen Idec | Not recruiting | 18 Years | 55 Years | Both | 350 | Phase 4 | United States | |
1322 | NCT00142402 | June 2003 | 19 February 2015 | Modafinil in Multiple Sclerosis | Modafinil for Improving New Learning and Memory in Multiple Sclerosis | Multiple Sclerosis | Drug: Modafinil | Kessler Foundation | National Multiple Sclerosis Society | Not recruiting | 18 Years | 60 Years | Both | 20 | N/A | United States |
1323 | NCT00203073 | June 2003 | 19 February 2015 | A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis. | A Multi-Center, Randomized, Open Label Study To Evaluate Safety, Tolerability And Efficacy Of Treatment With Mitoxantrone; Pre-Treatment With Glatiramer Acetate (GA) Versus Treatment With GA Alone In Relapsing Forms Of Multiple Sclerosis. | Relapsing Remitting Multiple Sclerosis | Drug: glatiramer acetate 20 mg;Drug: glatiramer acetate 20 mg, with mitoxantrone | Teva Pharmaceutical Industries | Not recruiting | 18 Years | 55 Years | Both | 40 | Phase 2 | United States;Canada | |
1324 | NCT00220493 | June 2003 | 19 February 2015 | Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients | Clinical Study Protocol: Evaluation of the Efficiency of Ritalin in Multiple Sclerosis Patients | Relapsing Remitting Multiple Sclerosis;Multiple Sclerosis, Chronic Progressive | Drug: Ritalin | Sheba Medical Center | Recruiting | 25 Years | 65 Years | Both | 80 | Phase 1 | Israel | |
1325 | NCT00235989 | June 2003 | 19 October 2017 | Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis | An Open-label Extension Study of the Double-blind, Randomized, Parallel Group, Multicenter Phase 2 Study 307000A to Further Evaluate the Safety and Tolerability of Betaseron® 500 mcg Subcutaneously Every Other Day and Betaseron® 250 mcg Subcutaneously Every Other Day in Patients With Relapsing-remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis, Relapsing-Remitting | Drug: Interferon beta 1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 18 Years | 55 Years | All | 63 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1326 | NCT00267319 | June 2003 | 19 February 2015 | FOCUS Fatigue Outcome in Copaxone USers | Fatigue Outcomes of Copaxone Users in Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Glatiramer acetate | Sanofi | Not recruiting | 18 Years | N/A | Both | 111 | Phase 4 | Czech Republic | |
1327 | NCT00278655 | June 2003 | 19 October 2017 | Hematopoietic Stem Cell Therapy for Patients With Multiple Sclerosis | Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Interferon Therapy: A Phase II Multi-Center Trial | Multiple Sclerosis | Biological: Hematopoietic stem cell transplantation | Northwestern University | Not recruiting | 18 Years | 50 Years | All | 21 | Phase 1/Phase 2 | United States | |
1328 | NCT00095329 | May 2003 | 3 October 2016 | Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor | A Phase I/II, Open-Label Pilot Trial to Evaluate the Safety of Rapamune (Sirolimus) in Patients With Multiple Sclerosis | Multiple Sclerosis (MS) - Relapsing-remitting | Biological: sirolimus | National Institute of Allergy and Infectious Diseases (NIAID) | Autoimmunity Centers of Excellence | Not recruiting | 18 Years | 58 Years | Both | 14 | Phase 1/Phase 2 | United States |
1329 | NCT00333138 | May 2003 | 16 December 2017 | Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis | Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Safety, Tolerability and Effect on MRI Lesion Parameters of FTY720 vs Placebo in Patients With Relapsing Multiple Sclerosis Including 18 Month Extension Phase | Multiple Sclerosis | Drug: FTY720;Drug: Placebo | Novartis | Not recruiting | 18 Years | 60 Years | All | 281 | Phase 2 | Canada;Denmark;Finland;France;Germany;Italy;Poland;Portugal;Spain;Switzerland;United Kingdom | |
1330 | NCT00206648 | March 2003 | 19 February 2015 | An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS | A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron 250 µg Subcutaneously Every Other Day With Avonex 30 µg Intramuscularly Once Per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated With Avonex | Multiple Sclerosis, Relapsing-Remitting | Drug: Betaferon/Betaseron | Bayer | Not recruiting | 18 Years | 60 Years | Both | 271 | Phase 4 | United States;Canada | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1331 | NCT00260741 | March 2003 | 19 February 2015 | Cannabis for Spasticity in Multiple Sclerosis | Cannabis for Spasticity in Multiple Sclerosis: A Placebo-Controlled Study | Multiple Sclerosis | Drug: Smoked Cannabis | Center for Medicinal Cannabis Research | Not recruiting | 21 Years | N/A | Both | 60 | Phase 1/Phase 2 | United States | |
1332 | NCT00492466 | March 2003 | 19 February 2015 | Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies | A Multicentre, Open Label, Non-Comparative Trial Investigating the Recovering of INF-Beta Efficacy in Breakthrough Relapsing-Remitting Multiple Sclerosis Patients With Neutralizing Interferon-Beta Antibodies | Relapsing-Remitting Multiple Sclerosis | Drug: Interferon-beta-1a;Drug: methylprednisolone | Biogen Idec | Not recruiting | 18 Years | 55 Years | Both | 14 | Phase 4 | Finland | |
1333 | NCT00053417 | February 2003 | 19 October 2017 | Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis | Double-Blind, Placebo-Controlled, 20-Week, Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis | Multiple Sclerosis | Drug: Placebo;Drug: 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP);Drug: 15 mg fampridine-SR (4-aminopyridine, 4-AP);Drug: 20 mg fampridine-SR (4-aminopyridine, 4-AP) | Acorda Therapeutics | Not recruiting | 18 Years | 70 Years | All | 206 | Phase 2 | United States;Canada | |
1334 | NCT00298662 | February 2003 | 19 February 2015 | Combination Therapy of Betaseron-Prograf in Multiple Sclerosis | A Pilot Safety and Tolerability Open-Label Study of Interferon Beta-1b in Combination With Tacrolimus in Patients Suffering From Multiple Sclerosis Who Have Failed Treatment With Approved Disease Modifying Agents | Multiple Sclerosis | Drug: Interferon beta-1b and Tacrolimus | Clinique de sclérose en plaques et neuromusculaire de l'Outaouais | Not recruiting | 18 Years | 55 Years | Both | 30 | Phase 2 | Canada | |
1335 | NCT00076934 | January 2003 | 16 December 2017 | Safety of RG2077 in Patients With Multiple Sclerosis | A Phase I Study: Safety of RG2077 (CTLA4-IgG4m) in Patients With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting | Drug: RG2077 (CTLA4-IgG4m) | National Institute of Allergy and Infectious Diseases (NIAID) | Immune Tolerance Network (ITN);Repligen Corporation | Not recruiting | 18 Years | 55 Years | All | 20 | Phase 1 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1336 | NCT00176592 | January 2003 | 19 February 2015 | Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI | Phase IV, Rater-blinded, Randomized Study, Comparing 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-remitting(RR) or CIS Forms of ms Using 3 Tesla(3T) Magnetic Resonance Imaging (MRI) With Triple-dose Gadolinium | Multiple Sclerosis | Drug: Betaseron;Drug: Copaxone | Stuart D Cook MD | Not recruiting | 18 Years | 55 Years | Both | 93 | Phase 4 | United States | |
1337 | NCT00210301 | January 2003 | 19 February 2015 | Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS | Combination Therapy (Provigil + Avonex) in the Treatment of Attention Problems in Patients With Relapsing-Remitting MS | Relapsing-Remitting Multiple Sclerosis | Drug: Provigil (modafinil) | Institute for Clinical Research | Recruiting | 20 Years | 65 Years | Both | 60 | N/A | United States | |
1338 | NCT00912860 | January 2003 | 19 February 2015 | Immunogenicity and Safety Study of Serum-Free Avonex | A Multicenter, Open-Label Immunogenicity and Safety Study of a Serum-Free Pre-Formulated Solution of AVONEX (Interferon Beta-1a) Administered Intramuscularly to Patients With Relapsing/Remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Interferon beta-1a | Biogen Idec | Not recruiting | 18 Years | 60 Years | Both | 155 | Phase 2 | ||
1339 | NCT00050232 | December 2002 | 8 August 2016 | Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients | Multiple Sclerosis | Drug: AVP-923 | Avanir Pharmaceuticals | Not recruiting | 18 Years | 68 Years | Both | 96 | Phase 3 | United States | ||
1340 | NCT00050778 | December 2002 | 19 October 2017 | A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis | A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Biological: Interferon beta-1a;Biological: Alemtuzumab 12 mg;Biological: Alemtuzumab 24 mg | Genzyme, a Sanofi Company | Bayer | Not recruiting | 18 Years | 50 Years | All | 334 | Phase 2 | United States;Croatia;Poland;Russian Federation;United Kingdom |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1341 | NCT00220779 | December 2002 | 19 October 2017 | Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis | Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Different Dose Regimens of IGIV Chromatography (IGIV-C), 10% Treatment on Relapses in Patients With Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified;Drug: Albumin (Human) 25%, United States Pharmacopeia (USP) | Grifols Therapeutics Inc. | Not recruiting | 18 Years | 55 Years | All | 128 | Phase 2 | United States;Austria;Canada;Czech Republic;Germany;Greece;Hungary;Israel;Poland;Slovakia;Sweden;United Kingdom | |
1342 | NCT00893217 | November 2002 | 19 February 2015 | BEYOND Pilot Study | Double-blind, Randomized, Parallel Group, Multicenter Study of the Safety and Tolerability of Betaseron 500 Mcg Subcutaneously Every Other Day and Betaseron 250 Mcg Subcutaneously Every Other Day for at Least 12 Weeks in Patients With RRMS | Multiple Sclerosis;Relapsing-Remitting | Drug: Betaseron (Interferon beta-1b, BAY86-5046) | Bayer | Not recruiting | 18 Years | 55 Years | Both | 71 | Phase 2 | United States | |
1343 | NCT00913666 | November 2002 | 19 February 2015 | Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers | A Pilot Multi-Center, Open-Label, Assessor Blinded, Prospective Profiling Study in MS Subjects Treated With AVONEX®, MS Subjects Naïve to Treatment, and Healthy Control Subjects | Multiple Sclerosis | Drug: Interferon beta-1a (Avonex) | Biogen Idec | Not recruiting | 18 Years | 65 Years | Both | 121 | Phase 4 | ||
1344 | NCT00185211 | August 2002 | 19 October 2017 | BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study | Open-label, Multi-center Phase III Extension of the Double-blind, Placebo-controlled BENEFIT Study (no. 92012/304747) to Obtain Long-term Follow-up Data of Patients With Clinically Definite Multiple Sclerosis (MS) and Patients With a First Demyelinating Event Suggestive of MS Treated With 8 MIU (250 µg) Interferon Beta-1b (Betaferon® / Betaseron®) Given Subcutaneously Every Other Day for at Least 36 Months. | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | Not recruiting | 18 Years | 48 Years | All | 468 | Phase 3 | Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom | |
1345 | NCT00599274 | August 2002 | 19 February 2015 | Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis | A Multicenter, Prospective and Retrospective, Long-Term Observational Study of AVONEX® and Rebif® to Determine the Efficacy, Tolerability, and Safety in Subjects With Relapsing Multiple Sclerosis (MS) | Multiple Sclerosis | Drug: Interferon beta-1a | Biogen Idec | Not recruiting | 18 Years | 50 Years | Both | 136 | N/A | United States;Australia;Austria;Canada | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1346 | NCT00678795 | August 2002 | 19 October 2017 | A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis | A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Cannabis Based Medicine (CBM) Extract, in Patients Suffering Detrusor Overactivity Associated With Multiple Sclerosis. | Detrusor Overactivity;Multiple Sclerosis | Drug: Sativex®;Drug: Placebo | GW Pharmaceuticals Ltd. | Not recruiting | 18 Years | N/A | All | 135 | Phase 3 | United Kingdom | |
1347 | NCT00587691 | July 2002 | 16 December 2017 | Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis | An Open-Label, Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive | Biological: Tovaxin Autologous T Cell Vaccine | Opexa Therapeutics, Inc. | Not recruiting | 18 Years | 65 Years | All | 16 | Phase 1/Phase 2 | United States | |
1348 | NCT00047580 | June 2002 | 21 December 2015 | Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity. | A Multicenter, Open-Label, Randomized, 4-Way Crossover Trial of the Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex (Tizanidine Hydrochloride) Tablets Taken Under Fed and Fasted Conditions in Patients With Moderate to Severe Spasticity | Multiple Sclerosis;Muscle Spasticity;Spinal Cord Injury;Stroke | Drug: tizanidine hydrochloride capsule | Elan Pharmaceuticals | Not recruiting | 18 Years | N/A | Both | 120 | Phase 3 | United States | |
1349 | NCT00711646 | June 2002 | 19 October 2017 | A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis. | A Double Blind, Randomised, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Cannabis Based Medicine 1:1 THC:CBD Compared With Placebo for the Treatment of Spasticity in Patients With Multiple Sclerosis. | Spasticity;Multiple Sclerosis | Drug: Sativex®;Drug: Placebo | GW Pharmaceuticals Ltd. | Not recruiting | 18 Years | N/A | All | 189 | Phase 3 | United Kingdom | |
1350 | NCT00037115 | May 2002 | 11 June 2018 | Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. | An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results. | Demyelinating Disorders;Multiple Sclerosis;Optic Neuritis;Myelitis;Neuritis | Drug: interferon beta 1a;Drug: methotrexate;Drug: methylprednisolone | MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute | Consultants in Neurology | Not recruiting | 18 Years | 50 Years | All | 0 | Phase 4 | United States |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1351 | NCT00151801 | May 2002 | 19 February 2015 | Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients | Safety and Tolerability of Oral Two-Doses Estroprogestins Associated With Interferon-Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis | Drug: estroprogestins;Drug: interferon-beta 1a | S. Andrea Hospital | Recruiting | 18 Years | 40 Years | Female | 200 | Phase 2 | Italy | |
1352 | NCT00228228 | May 2002 | 19 February 2015 | TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis | T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis | Multiple Sclerosis | Biological: T cell vaccination | Sheba Medical Center | Recruiting | 15 Years | 50 Years | Both | 80 | Phase 3 | Israel | |
1353 | NCT01448252 | May 2002 | 19 February 2015 | T Cell Vaccination in Patients With Progressive Multiple Sclerosis | Autologous T Cell Vaccination With Line Specific for 9 Myelin Peptides in Patients With Progressive / Relapsing Multiple Sclerosis | Multiple Sclerosis | Biological: multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides);Biological: T cell vaccination | Hadassah Medical Organization | Not recruiting | 18 Years | 60 Years | Both | 30 | Phase 1/Phase 2 | Israel | |
1354 | NCT00405353 | April 2002 | 19 February 2015 | Testosterone Treatment for Multiple Sclerosis | Testosterone Treatment for Multiple Sclerosis: A Preliminary Trial | Multiple Sclerosis | Drug: Androgel 100mg gel | University of California, Los Angeles | National Multiple Sclerosis Society | Not recruiting | 18 Years | 65 Years | Male | 10 | Phase 1/Phase 2 | United States |
1355 | NCT01604265 | March 2002 | 19 October 2017 | A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis | A Double Blind, Randomised, Parallel Group, Placebo Controlled Study of Sativex in the Treatment of Central Neuropathic Pain in Multiple Sclerosis. | Multiple Sclerosis;Neuropathic Pain | Drug: Placebo;Drug: Sativex | GW Pharmaceuticals Ltd. | Not recruiting | 18 Years | N/A | All | 66 | Phase 3 | United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1356 | NCT01606176 | March 2002 | 19 October 2017 | A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin | A Multi Centre Randomised, Double Blind, Placebo Controlled, Parallel Group Comparison of the Effects of Cannabis Based Medicine Standardised Extracts Over 4 Weeks, in Patients With Chronic Refractory Pain Due to Multiple Sclerosis or Other Defects of Neurological Function. | Pain;Multiple Sclerosis | Drug: GW-1000-02;Drug: Placebo | GW Pharmaceuticals Ltd. | Not recruiting | 18 Years | N/A | All | 70 | Phase 3 | United Kingdom | |
1357 | NCT00067327 | February 2002 | 19 February 2015 | Treatment of Multiple Sclerosis Using Over the Counter Inosine | Treatment of Multiple Sclerosis Using Over the Counter Inosine | Multiple Sclerosis, Relapsing-Remitting | Drug: Inosine | National Center for Complementary and Integrative Health (NCCIH) | Not recruiting | 18 Years | 60 Years | Both | 30 | Phase 2 | United States | |
1358 | NCT01606137 | February 2002 | 19 October 2017 | A Study of the Long-term Safety of Sativex Use | A Long-term, Open Label, Safety and Tolerability Study of Cannabis Based Medicine Extract in Patients Who Have Participated in a GW Clinical Study Using Cannabis Based Medicine. | Multiple Sclerosis;Spasticity;Pain | Drug: GW-1000-02 | GW Pharmaceuticals Ltd. | Not recruiting | 18 Years | N/A | All | 507 | Phase 3 | United Kingdom | |
1359 | NCT00030966 | January 2002 | 19 February 2015 | Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab, When Added to Avonex® (Interferon Beta-1a), in Subjects With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Natalizumab;Drug: Placebo | Biogen Idec | Elan Pharmaceuticals | Not recruiting | 18 Years | 55 Years | Both | 1200 | Phase 3 | United States;Austria;Belgium;France;Germany;Israel;Italy |
1360 | NCT00228163 | January 2002 | 7 April 2015 | Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses | Extension of Protocol HMR1726D/2001, A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses | Multiple Sclerosis | Drug: teriflunomide (HMR1726) | Sanofi | Not recruiting | 18 Years | 65 Years | Both | 147 | Phase 2 | Canada;France | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1361 | NCT00027300 | November 2001 | 16 December 2017 | Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Natalizumab;Drug: Placebo | Biogen | Elan Pharmaceuticals | Not recruiting | 18 Years | 50 Years | All | 900 | Phase 3 | United States;Belgium;Canada;Czech Republic;France;Germany;Netherlands;United Kingdom |
1362 | NCT00035529 | November 2001 | 19 February 2015 | A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis | A Phase II,Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Preliminary Efficacy, Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Placebo;Drug: BMS 188667 (Abatacept) | Bristol-Myers Squibb | Not recruiting | 18 Years | 55 Years | Both | Phase 2 | United States | ||
1363 | NCT00039988 | November 2001 | 3 October 2016 | Treatment of Multiple Sclerosis With Copaxone and Albuterol | Treatment of Multiple Sclerosis With Copaxone (Glatiramer Acetate) and Albuterol | Autoimmune Diseases;Multiple Sclerosis | Drug: Glatiramer acetate;Drug: Albuterol;Drug: Albuterol placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Autoimmunity Centers of Excellence | Not recruiting | 18 Years | 55 Years | Both | 40 | N/A | United States |
1364 | NCT00202410 | November 2001 | 19 February 2015 | Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis | Phase 2-3 Use of Bacille Calmette-Guèrin (BCG) Vaccine in Patients With a First Clinical Demyelinating Episode: a Multicenter, Randomized, Single Blind Study. | Multiple Sclerosis | Biological: Bacille of Calmette-Guerin;Other: placebo | S. Andrea Hospital | Multiple Sclerosis Italian Foundation (FISM);Istituto Superiore di Sanità | Not recruiting | 18 Years | N/A | Both | 80 | Phase 2/Phase 3 | Italy |
1365 | NCT00248378 | September 2001 | 19 February 2015 | Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis | Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis | Multiple Sclerosis | Drug: Smoked Cannabis | Center for Medicinal Cannabis Research | Not recruiting | 18 Years | N/A | Both | 30 | Phase 1/Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1366 | NCT00304291 | August 2001 | 19 February 2015 | A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) | A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) | Neuromyelitis Optica;Myelitis, Transverse;Demyelinating Autoimmune Diseases, CNS;Autoimmune Diseases of the Nervous System | Drug: Mitoxantrone | State University of New York at Buffalo | EMD Serono | Not recruiting | 18 Years | 55 Years | Both | 5 | Phase 4 | United States |
1367 | NCT00037102 | July 2001 | 11 June 2018 | Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis | An Open Label Study of the Safety and Efficacy of Combination Therapy With AVONEX and Bi-Monthly High Dose Intravenous Methotrexate With Leucovorin Rescue in the Treatment of Multiple Sclerosis | Multiple Sclerosis | Drug: interferon beta 1a;Drug: methotrexate | MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute | Consultants in Neurology;Biogen | Not recruiting | 18 Years | 60 Years | All | 16 | Phase 4 | United States |
1368 | NCT01610687 | July 2001 | 19 October 2017 | A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis | A Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension | Multiple Sclerosis;Spasticity | Drug: GW-1000-02 | GW Pharmaceuticals Ltd. | Not recruiting | 18 Years | N/A | All | 137 | Phase 3 | United Kingdom | |
1369 | NCT00043264 | June 2001 | 19 February 2015 | Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis | Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis | Multiple Sclerosis | Drug: Rifampin;Drug: Azithromycin | National Center for Research Resources (NCRR) | National Multiple Sclerosis Society | Not recruiting | 18 Years | 65 Years | Both | 40 | Phase 2 | United States |
1370 | NCT01610700 | May 2001 | 19 October 2017 | An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients | Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension | Multiple Sclerosis | Drug: GW-1000-02;Drug: Placebo | GW Pharmaceuticals Ltd. | Not recruiting | 18 Years | N/A | All | 160 | Phase 3 | United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1371 | NCT01610713 | May 2001 | 19 October 2017 | An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis | Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension | Multiple Sclerosis | Drug: GW-1000-02 | GW Pharmaceuticals Ltd. | Not recruiting | 18 Years | N/A | All | 154 | Phase 3 | United Kingdom | |
1372 | NCT00017628 | April 2001 | 19 February 2015 | Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: cyclophosphamide;Drug: filgrastim;Drug: methylprednisolone;Procedure: Autologous Stem Cell Transplantation | Northwestern Memorial Hospital | Not recruiting | N/A | 59 Years | Both | 20 | Phase 1 | United States | ||
1373 | NCT01487096 | April 2001 | 19 February 2015 | Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses | A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses | Multiple Sclerosis | Drug: Teriflunomide;Drug: Placebo (placebo for teriflunomide) | Sanofi | Not recruiting | 18 Years | 65 Years | Both | 179 | Phase 2 | Canada;France | |
1374 | NCT00011375 | February 2001 | 19 February 2015 | Rolipram to Treat Multiple Sclerosis | Safety, Tolerability & Effects of Rolipram on Inflammatory Activity in the Central Nervous System in Multiple Sclerosis. A Phase II, Open Label Crossover Trial Using MRI as an Outcome Measure | Multiple Sclerosis | Drug: Rolipram | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 52 | Phase 2 | United States | |
1375 | NCT00179478 | February 2001 | 16 December 2017 | Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis | Controlled High-risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance (CHAMPIONS10) | Multiple Sclerosis;Optic Neuritis;Transverse Myelitis;Acute Brainstem/Cerebellar Syndrome | Drug: interferon beta 1a 30 ug IM once weekly | Beth Israel Deaconess Medical Center | Biogen | Not recruiting | 18 Years | N/A | All | 155 | Phase 4 | United States;Canada |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1376 | NCT01863069 | January 2001 | 19 February 2015 | Avonex®: Safety, Blood Levels and Effects | A Single-centre Study to Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of a New Inhaled Formulation of AVONEX® (Interferon Beta-1a) in Healthy Volunteers | Multiple Sclerosis (MS) | Drug: Interferon beta 1a;Drug: (IM) AVONEX® | Trio Medicines Ltd. | Biogen Idec | Not recruiting | 18 Years | 45 Years | Both | 77 | Phase 1 | United Kingdom |
1377 | NCT00292266 | November 1999 | 19 February 2015 | A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS) | An Open Label, Randomized, Multicenter, Comparative, Parallel Group Study of Rebif® 44 Mcg Administered Three Times Per Week by Subcutaneous Injection, Compared With Avonex® 30 Mcg Administered Once Per Week by Intramuscular Injection in the Treatment of Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Rebif®;Drug: Avonex® | EMD Serono | Merck Serono International SA | Not recruiting | 18 Years | 55 Years | Both | 677 | Phase 3 | |
1378 | NCT00534261 | November 1999 | 19 February 2015 | Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? | Evaluation of the Correlation Between the MS Functional Composite Index and Two Quality of Life Scales (MS54 and AMS Quality of Life) in Relapsing MS Patients Treated With Interferon Beta-1a (AVONEX®) | Relapsing Remitting Multiple Sclerosis | Drug: Interferon beta-1a | Biogen Idec | Not recruiting | 18 Years | 70 Years | Both | 284 | Phase 4 | Belgium;Luxembourg;United Kingdom | |
1379 | NCT00001934 | September 1999 | 19 February 2015 | Zenapax to Treat Multiple Sclerosis | Effect of the Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (IL-2R-Alpha; Zenapax(Registered Trademark)) on Inflammatory Activity in the CNS in MS in a Baseline-to-Treatment, Cross-Over, MRI-Controlled Single Center Phase I/II Trial | Multiple Sclerosis | Drug: Zenapax | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | 65 Years | Both | 22 | Phase 2 | United States | |
1380 | NCT00010842 | September 1999 | 19 February 2015 | Natural Antioxidants in the Treatment of Multiple Sclerosis | Natural Antioxidants in the Treatment of Multiple Sclerosis | Multiple Sclerosis | Drug: Ginkgo biloba;Drug: Alpha-lipoic acid;Drug: Vitamin E/Selenium;Drug: Essential fatty acids | National Center for Complementary and Integrative Health (NCCIH) | Not recruiting | N/A | N/A | Both | Phase 1/Phase 2 | United States | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1381 | NCT00062972 | September 1999 | 16 December 2017 | Improving Memory in Patients With Multiple Sclerosis | Interventions to Improve Memory in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: donepezil;Drug: glucose | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | U.S. Department of Education | Not recruiting | 18 Years | 56 Years | All | 0 | Phase 3 | United States |
1382 | NCT00473213 | September 1999 | 19 February 2015 | Optimizing IFN Beta - 1B Dose | Optimizing IFN Beta - 1B Dose | Multiple Sclerosis | Drug: Interferon Beta 1 | University of Turin, Italy | Dimensione Ricerca s.r.l. | Not recruiting | 18 Years | 50 Years | Both | 217 | Phase 3 | |
1383 | NCT00915460 | September 1999 | 19 February 2015 | Open-Label Safety Extension Study of Avonex | An Open-Label Safety Extension Study of AVONEX® (Interferon Beta-1a) Treatment in Subjects Who Completed Biogen Studies C95-812, C96-823, or C97-830 | Multiple Sclerosis | Drug: Interferon beta-1a (Avonex) | Biogen Idec | Not recruiting | N/A | N/A | Both | 408 | Phase 4 | ||
1384 | NCT00219908 | July 1999 | 19 February 2015 | Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis | Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis: Induction Treatment With Mitoxantrone Followed by Long-Term Treatment With Interferon-beta1b | Relapsing-Remitting Multiple Sclerosis | Drug: Mitoxantrone | Rennes University Hospital | Bayer;Wyeth is now a wholly owned subsidiary of Pfizer;Farmades, Italy | Not recruiting | 18 Years | 45 Years | Both | 124 | Phase 2 | France;Italy |
1385 | NCT00006060 | April 1999 | 19 February 2015 | Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: standard gadolinium contrast | National Center for Research Resources (NCRR) | University of Pennsylvania | Recruiting | 20 Years | 70 Years | Both | 100 | N/A | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1386 | NCT00040482 | April 1999 | 19 February 2015 | High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis | Intensive Immunosuppression Followed by Rescue With CD34 Selected, T Cell Depleted, Leukopheresis Products in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: Cyclophosphamide;Drug: ATG;Drug: MESNA;Procedure: Radiation therapy | Baylor College of Medicine | The Methodist Hospital System;Center for Cell and Gene Therapy, Baylor College of Medicine | Not recruiting | 18 Years | 60 Years | Both | 10 | Phase 2 | United States |
1387 | NCT00220428 | July 1998 | 19 February 2015 | T-Cell Vaccination in Multiple Sclerosis (MS) | The Effect of T-Cell Vaccination in Multiple Sclerosis - Phase I/II Safety and Efficacy Trial | Multiple Sclerosis | Biological: T-Cell Vaccination | Sheba Medical Center | Recruiting | 16 Years | 60 Years | Both | 20 | Phase 1/Phase 2 | Israel | |
1388 | NCT00001781 | February 1998 | 19 February 2015 | Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS) | Open-Label Baseline vs. Treatment Trial Evaluating the Safety, Tolerability and Effect on MRI Lesion and Immunology Parameters of CGP 77116 in Patients With Multiple Sclerosis Mark | Multiple Sclerosis | Drug: CGP 77116 | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 25 | Phase 2 | United States | |
1389 | NCT01257958 | February 1998 | 12 October 2015 | Vitamin D Pilot Study in Patients With Multiple Sclerosis | Vitamin D Pilot Study in Patients With Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: 19 nor vitamin d | University of Wisconsin, Madison | Not recruiting | 18 Years | 45 Years | Both | Phase 1 | United States | ||
1390 | NCT00014755 | December 1997 | 19 February 2015 | Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: filgrastim;Drug: prednisone;Procedure: peripheral blood stem cell transplantation;Procedure: irradiation | Fred Hutchinson Cancer Research Center | Not recruiting | 18 Years | 60 Years | Both | 35 | Phase 1 | United States | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1391 | NCT00001669 | July 1997 | 19 February 2015 | A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients | A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients | Multiple Sclerosis | Drug: rhIGF-1 (CEP-151) | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | N/A | N/A | Both | 15 | Phase 2 | United States | |
1392 | NCT00004816 | July 1995 | 19 February 2015 | A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: monoclonal antibody M-T412 | National Center for Research Resources (NCRR) | Stanford University | Not recruiting | 21 Years | 75 Years | Both | 25 | Phase 1 | ||
1393 | NCT00203021 | March 26, 1994 | 18 December 2018 | Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness. | Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone® | Multiple Sclerosis | Drug: Glatiramer acetate | Teva Branded Pharmaceutical Products, R&D Inc. | Not recruiting | 18 Years | N/A | All | 208 | Phase 4 | United States | |
1394 | NCT00004744 | February 1993 | 19 February 2015 | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis | Multiple Sclerosis | Drug: immune globulin | National Institute of Neurological Disorders and Stroke (NINDS) | Mayo Clinic | Not recruiting | 18 Years | 60 Years | Both | 76 | Phase 3 | ||
1395 | NCT00004814 | October 1991 | 19 February 2015 | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis | Drug: copolymer 1 | National Center for Research Resources (NCRR) | University of Maryland | Not recruiting | 18 Years | 45 Years | Both | 250 | Phase 3 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
1396 | NCT00000146 | July 1988 | 19 February 2015 | Optic Neuritis Treatment Trial (ONTT) | Multiple Sclerosis;Optic Neuritis | Drug: Methylprednisolone;Drug: Prednisone | National Eye Institute (NEI) | Not recruiting | 18 Years | 46 Years | Both | Phase 3 | United States | |||
1397 | NCT00000147 | July 1988 | 19 February 2015 | Longitudinal Optic Neuritis Study (LONS) | Multiple Sclerosis;Optic Neuritis | Drug: Methylprednisolone;Drug: Prednisone | National Eye Institute (NEI) | Not recruiting | 18 Years | 46 Years | Both | N/A | United States | |||
1398 | JPRN-JapicCTI-050031 | 23 April 2019 | Intrathecal Baclofen therapy with the implanted pump system for Spastic Palsy (Post-marketing clinical trial extended phase 3 after NDA approval) | Intrathecal Baclofen therapy with the implanted pump system for Spastic Palsy (Post-marketing clinical trial extended phase 3 after NDA approval) | [Spinal cord Origin] Spinal cord Injury, Multiple sclerosis, Spinocerebellar degeneration, Circulatory disorder of the spinal, Ossification of the posterior longitudinal ligament [Cerebral Origin] Cerebral palsy, Traumatic head injury | Intervention name : Baclofen Dosage And administration of the intervention : Intertheacal injection | DAIICHI SANKYO COMPANY, LIMITED | BOTH | Phase 4 |